cphi10q093014.htm

0001010549-14-000619.txt : 20141114 0001010549-14-000619.hdr.sgml : 20141114 20141114160554 ACCESSION NUMBER: 0001010549-14-000619 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20140930 FILED AS OF DATE: 20141114 DATE AS OF CHANGE: 20141114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CHINA PHARMA HOLDINGS, INC. CENTRAL INDEX KEY: 0001106644 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 731564807 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34471 FILM NUMBER: 141224046 BUSINESS ADDRESS: STREET 1: 2ND FLOOR, NO. 17, JINPAN ROAD STREET 2: HAIKOU CITY: HAINAN PROVINCE STATE: F4 ZIP: 570216 BUSINESS PHONE: 8689866811730 MAIL ADDRESS: STREET 1: 2ND FLOOR, NO. 17, JINPAN ROAD STREET 2: HAIKOU CITY: HAINAN PROVINCE STATE: F4 ZIP: 570216 FORMER COMPANY: FORMER CONFORMED NAME: TS ELECTRONICS INC DATE OF NAME CHANGE: 20030818 FORMER COMPANY: FORMER CONFORMED NAME: SOFTSTONE INC DATE OF NAME CHANGE: 20030128 FORMER COMPANY: FORMER CONFORMED NAME: SOFTSTONE INC /DE/ DATE OF NAME CHANGE: 20010808 10-Q 1 cphi10q093014.htm CHINA PHARMA HOLDINGS cphi10q093014.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended September 30, 2014

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the transition period from ____________ to ____________

Commission File Number 001-34471

CHINA PHARMA HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Nevada	73-1564807
(State or other jurisdiction of	(IRS Employer Identification No.)
incorporation or organization)

Second Floor, No. 17, Jinpan Road

Haikou, Hainan Province, China 570216

(Address of principal executive offices) (Zip Code)

+86- 898-6681-1730 (China)

(Issuer's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check One):

Large accelerated filer o	Accelerated filer o
Non-accelerated filer o (Do not check if a smaller reporting company)	Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: 43,579,557 shares of Common Stock, $.001 par value, were outstanding as of November 10, 2014.

CHINA PHARMA HOLDINGS, INC. AND SUBSIDIARIES

TABLE OF CONTENTS

PART I FINANCIAL INFORMATION

Page

Item 1.	Financial Statements	2

	Condensed Consolidated Balance Sheets as of September 30, 2014 and December 31, 2013 (Unaudited)	3

	Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) for the Three and Nine Months Ended September 30, 2014 and 2013 (Unaudited)	4

	Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2014 and 2013 (Unaudited)	5

	Notes to Condensed Consolidated Financial Statements (Unaudited)	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	23

Item 4.	Controls and Procedures	23

PART II OTHER INFORMATION

Item 6.	Exhibits	24

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

The accompanying unaudited condensed consolidated balance sheets, statements of operations and comprehensive income, and statements of cash flows and the related notes thereto, have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and in conjunction with the rules and regulations of the Securities and Exchange Commission. Accordingly, they do not include all of the disclosures required by U.S. GAAP for complete financial statements. The financial statements reflect all adjustments, consisting only of normal, recurring adjustments, which are, in the opinion of management, necessary for a fair presentation for the interim periods.

The accompanying financial statements should be read in conjunction with the financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2013.

The results of operations for the nine-month period ended September 30, 2014 are not necessarily indicative of the results to be expected for the entire fiscal year or any other period.

CHINA PHARMA HOLDINGS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)

	September 30,		December 31,
	2014		2013
ASSETS
Current Assets:
Cash and cash equivalents	$	4,269,037	$	5,993,139
Banker's acceptances		116,047		336,003
Trade accounts receivable, less allowance for doubtful
accounts of $27,912,179 and $13,301,622, respectively		30,642,878		45,147,602
Other receivables, less allowance for doubtful
accounts of $70,004 and $43,064, respectively		516,095		175,739
Advances to suppliers		9,040,464		7,626,716
Inventory, less allowance for obsolescence
of $4,670,853 and $8,027,126, respectively		19,014,172		24,677,120
Total Current Assets		63,598,693		83,956,319

Advances for purchases of intangible assets		41,653,862		41,701,505
Property and equipment, net of accumulated depreciation of
$5,951,165 and $5,264,350, respectively		33,869,491		30,241,337
Intangible assets, net of accumulated amortization of
$4,075,696 and $3,812,992, respectively		1,410,482		1,711,793
TOTAL ASSETS	$	140,532,528	$	157,610,954

LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities:
Trade accounts payable	$	3,131,988	$	1,877,437
Accrued expenses		214,740		323,651
Other payables		1,293,273		1,312,361
Advances from customers		1,773,478		2,228,238
Other payables - related parties		1,354,567		1,354,567
Current portion of construction loan facility		1,625,118		-
Short-term notes payable		4,875,353		4,909,662
Total Current Liabilities		14,268,517		12,005,916
Non-current Liabilities:
Construction loan facility		11,375,825		12,484,183
Long-term deferred tax liability		232,866		176,414
Total Liabilities		25,877,208		24,666,513
Stockholders' Equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized;
no shares issued or outstanding		-		-
Common stock, $0.001 par value; 95,000,000 shares authorized;
43,579,557 shares and 43,579,557 shares outstanding, respectively		43,580		43,580
Additional paid-in capital		23,590,204		23,590,204
Retained earnings		71,535,109		88,896,276
Accumulated other comprehensive income		19,486,427		20,414,381
Total Stockholders' Equity		114,655,320		132,944,441
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	140,532,528	$	157,610,954

The accompanying notes are an integral part of these condensed consolidated financial statements.

CHINA PHARMA HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE INCOME (LOSS)
(Unaudited)

	For the Three Months						For the Nine Months
	Ended September 30,						Ended September 30,
	2014			2013			2014			2013
Revenue	$	5,566,543		$	8,116,599		$	18,802,602		$	24,392,311
Cost of revenue		4,057,480			5,863,587			12,215,756			17,837,989
Inventory obsolescence		-			15,747			-			3,735,820

Gross profit		1,509,063			2,237,265			6,586,846			2,818,502

Operating expenses:
Selling expenses		745,976			921,851			2,193,823			2,435,592
General and administrative expenses		422,729			372,568			1,229,488			1,536,831
Research and development expenses		181,796			352,599			2,528,230			1,384,263
Bad debt expense		3,940,144			3,277,780			15,280,588			7,910,583
Losses from natural disaster		2,275,593			-			2,275,593			-
Total operating expenses		7,566,238			4,924,798			23,507,722			13,267,269

Subsidy income		65,086			-			65,086			-

Loss from operations		(5,992,089	)		(2,687,533	)		(16,855,790	)		(10,448,767	)

Other income (expense):
Interest income		8,824			2,228			47,435			4,830
Interest expense		(325,244	)		(89,238	)		(495,054	)		(263,732	)
Net other expense		(316,420	)		(87,010	)		(447,619	)		(258,902	)

Loss before income taxes		(6,308,509	)		(2,774,543	)		(17,303,409	)		(10,707,669	)
Income tax benefit (expense)		(19,215	)		472,512			(57,758	)		1,129,506
Net loss		(6,327,724	)		(2,302,031	)		(17,361,167	)		(9,578,163	)
Other comprehensive income - foreign currency
translation adjustment		33,366			880,315			(927,954	)		3,918,978
Comprehensive (loss) income	$	(6,294,358	)	$	(1,421,716	)	$	(18,289,121	)	$	(5,659,185	)
Loss per share:
Basic	$	(0.15	)	$	(0.05	)	$	(0.40	)	$	(0.22	)
Diluted	$	(0.15	)	$	(0.05	)	$	(0.40	)	$	(0.22	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

CHINA PHARMA HOLDINGS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)

	For the Nine Months
	Ended September 30,
	2014			2013
Cash Flows from Operating Activities:
Net loss	$	(17,361,167	)	$	(9,578,163	)
Depreciation and amortization		1,014,221			1,039,716
Bad debt expense		15,280,588			7,910,583
Deferred income taxes		57,758			(1,129,506	)
Inventory obsolescence reserve		-			3,311,926
Changes in assets and liabilities:
Trade accounts receivable		(3,029,386	)		1,077,182
Other receivables		(342,012	)		(452,500	)
Advances to suppliers		(1,468,882	)		(642,850	)
Inventory		7,671,072			4,138,431
Trade accounts payable		1,338,724			376,312
Accrued taxes payable		(34,638	)		(2,486,073	)
Other payables and accrued expenses		(90,108	)		42,847
Advances from customers		(439,740	)		90,159
Net Cash Provided by Operating Activities		2,596,430			3,698,064

Cash Flows from Investing Activities:
Advances for purchases of intangible assets		(244,073	)		(496,634	)
Purchases of property and equipment and
construction in process		(4,638,265	)		(9,267,088	)
Net Cash Used in Investing Activities		(4,882,338	)		(9,763,722	)

Cash Flows from Financing Activities:
Proceeds from construction term loan		604,756			6,437,906
Net Cash Provided by Financing Activity		604,756			6,437,906

Effect of Exchange Rate Changes on Cash		(42,950	)		103,542
Net (Decrease) Increase in Cash and Cash Equivalents		(1,724,102	)		475,790
Cash and Cash Equivalents at Beginning of Period		5,993,139			4,029,708
Cash and Cash Equivalents at End of Period	$	4,269,037		$	4,505,498

Supplemental Cash Flow Information:
Cash paid for interest	$	943,251		$	324,117
Cash paid for income taxes		-			2,472,099

Supplemental Noncash Investing and Financing Activities:
Accounts payable for purchases of property and equipment	$	69,378		$	136,742
Accounts receivable collected with banker's acceptances		1,955,808			6,256,327
Inventory purchased with banker's acceptances		2,173,689			2,810,462
Advances for purchases of equipment paid with banker's acceptances		-			2,555,419
Advances for purchases of intangibles paid with banker's acceptances		-			715,445

The accompanying notes are an integral part of these condensed consolidated financial statements.

CHINA PHARMA HOLDINGS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 1 - BASIS OF PRESENTATION

Organization and Nature of Operations – China Pharma Holdings, Inc., a Nevada corporation, owns 100% of Onny Investment Limited (“Onny”), a British Virgin Islands corporation, that in turn owns 100% of Hainan Helpson Medical & Biotechnology Co., Ltd (“Helpson”), a corporation organized under the laws of the People's Republic of China (the “PRC”). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the “Company”.

The Foreign Investment Industrial Catalogue (the “Catalogue”) jointly issued by the China’s Ministry of Commerce and the National Development and Reform Commission (as the latest version is the year 2012 version, effective January 30, 2012) classified various industries/businesses into three different categories: (i) encouraged for foreign investment; (ii) restricted to foreign investment; and (iii) prohibited from foreign investment. For any industry/business not covered by any of these three categories, they will be deemed industries/businesses permitted for foreign investment. A typical foreign investment ownership restriction in the pharmaceutical industry is that a foreign investment enterprise (the “FIE”) shall not have the whole or majority of its equity interests owned by a foreign owner if the FIE establishes more than 30 branch stores and distributes a variety of brands in those franchise stores, which is not the case of the Company’s business.

Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located throughout the PRC. The Company believes Helpson’s business is not subject to any ownership restrictions prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson from Helpson’s three former shareholders on May 25, 2005 by entry into an Equity Transfer Agreement with such three parties on May 25, 2005. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishing of Enterprises with Foreign Investment in the PRC on the same day and its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.

The Company has and continues to acquire well-accepted medical formulas to add to its diverse portfolio of Western and Chinese medicines.

Consolidation and Basis of Presentation – The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and are expressed in United States dollars. The accompanying consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

Helpson’s functional currency is the Chinese Renminbi. Helpson’s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson’s financial statements are included in accumulated other comprehensive income, which is a component of stockholders’ equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is a party to the transaction are included in the results of operations.

Reclassification - The Company has made certain reclassifications to the condensed consolidated statement of operations and cash flows for the three and nine months ended September 30, 2013 to conform to the presentation for the three and nine months ended September 30, 2014. These reclassifications had no effect on the condensed consolidated balance sheets, results of operations or cash flows as of or for the three and nine months ended September 30, 2013.

Condensed Financial Statements – The accompanying unaudited condensed consolidated financial statements were prepared pursuant to the rules and regulations of the United States Securities and Exchange Commission (the “Commission”). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Management of the Company (“Management”) believes the following disclosures are adequate to make the information presented not misleading. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2013 filed with the Commission on March 20, 2014.

CHINA PHARMA HOLDINGS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

These unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) that, in the opinion of Management, are necessary to present fairly the consolidated financial position and results of operations of the Company for the periods presented. Operating results for the nine months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014.

Accounting Estimates - The preparation of financial statements in conformity with U.S. GAAP requires Management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

Basic and Diluted Loss per Common Share - Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per share is calculated to give effect to any potentially issuable dilutive common shares. There were no potentially dilutive common shares outstanding for all periods presented.

The following table is a presentation of the numerators and denominators used in the calculation of basic and diluted (loss) earnings per share:

	For the Three Months						For the Nine Months
	Ended September 30,						Ended September 30,
	2014			2013			2014			2013
Net loss	$	(6,327,724	)	$	(2,302,031	)	$	(17,361,167	)	$	(9,578,163	)
Basic weighted-average common shares outstanding		43,579,557			43,579,557			43,579,557			43,579,557
Effect of dilutive securities:
Warrants		-			-			-			-
Options		-			-			-			-
Diluted weighted-average common shares outstanding		43,579,557			43,579,557			43,579,557			43,579,557
Basic loss per share	$	(0.15	)	$	(0.05	)	$	(0.40	)	$	(0.22	)
Diluted loss per share	$	(0.15	)	$	(0.05	)	$	(0.40	)	$	(0.22	)

NOTE 2 – LOSSES FROM NATURAL DISASTER

On July 18, 2014, the Company’s manufacturing facilities and inventory sustained storm damage from a powerful tropical typhoon that hit Haikou on that date. The losses are comprised of $2,015,248 of inventory related costs and $260,345 of facilities damage costs. The Company received minor insurance compensation as only the building of new plant was insured and the damage to it was minor.

The Company assessed whether any asset impairment had occurred as a result of the storm. Based on the assessment, no impairment was considered necessary. In addition, the Company assessed whether the damage caused by the tropical typhoon resulted in exposure to environmental remediation liability. Based on the assessment, the Company determined that no such exposure has occurred.

NOTE 3 – INVENTORY

Inventory consisted of the following:

	September 30,			December 31,
	2014			2013
Raw materials	$	19,571,419		$	28,259,707
Work in process		-			853,602
Finished goods		4,113,606			3,590,937
		23,685,025			32,704,246
Obsolescence reserve		(4,670,853	)		(8,027,126	)
Total Inventory	$	19,014,172		$	24,677,120

NOTE 4 - PROPERTY AND EQUIPMENT

Property and equipment consisted of the following:

CHINA PHARMA HOLDINGS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

	September 30,			December 31,
	2014			2013
Permit of land use	$	457,743		$	460,964
Building		10,033,988			2,494,623
Plant, machinery and equipment		16,393,856			6,671,620
Motor vehicle		150,611			151,670
Office equipment		246,553			229,210
Construction in progress		12,537,905			25,497,600
Total		39,820,656			35,505,687
Less: accumulated depreciation		(5,951,165	)		(5,264,350	)
Property and Equipment, net	$	33,869,491		$	30,241,337

Construction in progress consists primarily of the construction of a new production facility and the acquisition of related equipment and capitalized interest during the construction period. During the nine months ended September 30, 2014, an aggregate of approximately $17.16 million was reclassified from construction in progress to their respective property and equipment category as the assets were placed in service and depreciation commenced.

A reconciliation of total interest cost incurred to interest expense as recognized in the consolidated statement of operations is as follows:

	For the Three Months				For the Nine Months
	Ended September 30,				Ended September 30,
	2014		2013		2014		2013
Total interest cost incurred	$	330,995	$	89,238	$	952,836	$	263,732
Interest cost capitalized		5,751		-		457,782		-
Interest expense	$	325,244	$	89,238	$	495,054	$	263,732

Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:

Asset		Life - years
Permit of land use		40 - 70
Building		20 - 49
Plant, machinery and equipment		10
Motor vehicle		5 - 10
Office equipment		3-5

For the three months ended September 30, 2014 and 2013, depreciation expense was $321,020 and $210,182. For the nine months ended September 30, 2014 and 2013, depreciation expense was $724,509 and $640,550.

NOTE 5 - INTANGIBLE ASSETS

Intangible assets represent the cost of medical formulas approved for production by the China Food and Drug Administration (“CFDA”) in China. During the nine months ended September 30, 2014, the Company did not obtain CFDA production approval for any medical formula and therefore there were no costs reclassified from advances to medical formulas.

Approved medical formulas are amortized from the date CFDA approval is obtained over their individually identifiable estimated useful life, which ranges from ten to thirteen years. It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. For the three and nine months ended September 30, 2014 and 2013, amortization expense relating to intangible assets was $96,382 and $131,585, $289,712 and $399,166, respectively. Medical formulas typically do not have a residual value at the end of their amortization period.

CHINA PHARMA HOLDINGS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

The Company evaluates each approved medical formula for impairment at the date of CFDA approval, when indications of impairment are present and at the date of each financial statement. The Company’s evaluation is based on an estimated undiscounted net cash flow model, considering currently available market data for the related drug and the Company’s estimated market share. If the carrying value of the medical formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over the discounted estimated future net cash flows. As a result of the evaluation, the Company has determined that each medical formula continues to provide benefits to the Company and no impairment was recognized during the nine months ended September 30, 2014 or 2013.

As of September 30, 2014 and December 31, 2013, intangible assets consisted solely of CFDA approved medical formulas as follows:

	September 30,			December 31,
	2014			2013
Gross carrying amount	$	5,486,178		$	5,524,785
Accumulated amortization		(4,075,696	)		(3,812,992	)
Net carrying amount	$	1,410,482		$	1,711,793

NOTE 6 – ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS

In order to expand the number of medicines manufactured and marketed by the Company, it has entered into contracts with independent laboratories for the purchase of medical formulas. Although CFDA approval had not been obtained for certain medical formulas as of the dates of the respective contracts, the objective of the contracts is for the Company to purchase CFDA-approved medical formulas once the CFDA approval process is completed. Some of the medical formulas currently in the CFDA approval process also come with patents. As of September 30, 2014, the Company had received the title to two unexpired patents that relate to medical formulas currently in the CFDA approval process.

Prior to entering into the contracts, the laboratories typically have completed all required researches and developments to determine the medical formula for and the method of production of the generic medicines. The application to the CFDA for production approval must be made by the facilities that will manufacture the related products. As a result, a contract typically provides that the Company purchases the medical formula from the laboratory and the laboratory is required to assist the Company in applying for and obtaining the production approval from the CFDA.

A typical CFDA approval process for the production of a generic medical product involves a number of steps that generally require three to five years to complete. If the medical formula is purchased at the point when the generic medical product receives the CFDA’s approval for a clinical study, which is very typical for the Company, the clinical study that follows will usually take one and a half to three years to complete. After completing the clinical study, results are submitted to the CFDA and a production approval application would be filed. In most cases, it takes between eight to eighteen months from preparing and submitting the production approval application until obtaining CFDA’s approval. Upon approving, the CFDA would issue a production certificate and the Company can start producing and promoting the generic medical product. Therefore, it is expected to take five years from the dates of the medical formula contracts until acquiring CFDA’s approval. However, the actual time needed could be even longer due to the updated criteria in the drug registration process.

Under the terms of the contracts, the laboratories are required to assist the Company in obtaining production approval for the medical formulas from the CFDA. Management monitors the status of each medical formula on a regular basis in order to assess whether the laboratories are performing adequately under the contracts. If a medical product is not approved by the CFDA, as evidenced by their issuance of a denial letter, or if the laboratory breaches the contract, the laboratory is obliged under the contract to provide a refund of the full payment to the Company. alternatively, the Company can require the application of those payments to another medical formula with the same laboratory. As a result of the refund right, the Company is ultimately purchasing an approved medical product. Accordingly, payments made prior to the issuance of production approval by the CFDA are recorded as advances for purchases of intangible assets.

CHINA PHARMA HOLDINGS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

To date, no formula has failed to receive CFDA production approval nor has the Company been informed or become aware of any formula that may fail to receive such approval. However, there is no assurance that the medical products will receive production approval and if the Company does not receive such approval, it will enforce its contractual rights to receive the refund from the laboratory or have the payments applied to another medical formula with the same laboratory.

At September 30, 2014, the Company was obliged to pay laboratories and others approximately $5.19 million upon completion of various phases of contracts to provide CFDA production approval of medical formulas.

NOTE 7 – RELATED PARTY TRANSACTIONS

Total advances owing to a board member were $1,354,567 as of September 30, 2014 and December 31, 2013 and are recorded as “other payables – related parties” on the accompanying condensed consolidated balance sheets. The advances bear interest at a rate of 1.0% per year. Total interest expense of $10,159 and $10,159 was recognized for the nine months ended September 30, 2014 and 2013, respectively.

NOTE 8 – NOTES PAYABLE

On November 1, 2013 the Company entered into a revolving line of credit with a bank in the amount of RMB 30,000,000. Advances on the line of credit are due one year from the date of the advance and are collateralized by certain land use rights, buildings and accounts receivable and bear interest at an annual rate of 6.6% (based upon 110% of the PRC government’s current short term rate of 6.00%). The Company’s Chief Executive Officer and Chair of the board of directors personally guaranteed the line of credit. The Company is in the process of obtaining an extension of the line of credit with the bank, and anticipates this to be completed during the fourth quarter.

The outstanding balance due under the revolving line of credit was RMB 30,000,000 as of September 30, 2014 and December 31, 2013 ($4,875,353 as of September 30, 2014 and $4,909,662 as of December 31, 2013). The Company has no additional amounts available to it under this line of credit. This amount has been classified as short-term notes payable in the accompanying condensed consolidated balance sheets at September 30, 2014 and December 31, 2013.

NOTE 9 – CONSTRUCTION LOAN FACILITY

The Company obtained a construction loan facility in the amount of RMB 80,000,000 (approximately $13.0 million at September 30, 2014) from a construction loan facility dated June 21, 2013. The loan facility is for an eight-year term, which commenced on the initial draw-down date of July 11, 2013, and is from the same bank that currently provides the line of credit as discussed in Note 8. The proceeds of the loan were used for and are collateralized by the construction of the Company’s new production facility and the included production line equipment and machinery. The loan currently bears interest at 7.205% based upon 110% of the PRC government’s eight-year term rate effective on the actual draw-down date, and is subjected to annual adjustments based on 110% of the floating rate for the same type of loan on the anniversary from the draw-down date and its subsequent anniversary dates. The loan requires interest only payments for the first two years. Beginning July 11, 2015, the balance of the principal will be due in annual installments over the next six years through July 11, 2021. At September 30, 2014, the Company had no additional amounts available to it under this facility.

Fair Value of Notes Payable and Construction Loan Facility – Based on the borrowing rates currently available to the Company for bank loans with similar terms and maturities, the carrying amounts of notes payable and the construction loan facility outstanding as of September 30, 2014 and December 31, 2013 approximated their fair value because of either the immediate or short-term maturity of these financial instruments or because the underlying instruments bear interest rates that approximated current market rates.

NOTE 10 - INCOME TAXES

Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax laws or rates are recognized in operations in the period that includes the enactment date.

CHINA PHARMA HOLDINGS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

Undistributed earnings of Helpson, the Company’s foreign subsidiary, since its acquisition, amounted to approximately $76.9 million at September 30, 2014. Those earnings, as well as the investment in Helpson of approximately $23.3 million, are considered to be indefinitely reinvested and, accordingly, no U.S. federal or state income taxes have been provided thereon. Upon distribution of those earnings in the form of dividends or otherwise, the Company would be subject to U.S. federal and state income taxes (net of an adjustment for foreign tax credits) and withholding taxes payable to the PRC. Determination of the amount of unrecognized deferred U.S. income tax liability is not practicable because of the complexities associated with its hypothetical calculation; however, unrecognized foreign tax credits may be available to reduce a portion of the U.S. tax liability.

Under current tax law in the PRC, the Company is and will be subject to the following enterprise income tax rates:

		Enterprise Income
Year		Tax Rate
2014		15%
2015		15%
2016		15%
Thereafter		25%

The provision for income taxes consisted of the following:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2014		2013			2014		2013
Current	$	-	$	-		$	-	$	-
Deferred		19,215		(472,512	)		57,758		(1,129,506	)
Total income tax expense (benefit)	$	19,215	$	(472,512	)	$	57,758	$	(1,129,506	)

The Company has net operating loss carryforwards for PRC tax purposes of approximately $10.16 million at September 30, 2014, of which approximately $6.83 million and $3.33 is available to offset future taxable income through 2018 and 2019, respectively.

In assessing the realizability of deferred tax assets, Management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized. Management considers projected future taxable income and tax planning strategies in making this assessment. Based upon an assessment of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets are deductible or can be utilized, Management believes it is not likely the Company will realize all of the benefits of the deferred tax assets as of September 30, 2014 and December 31, 2013. Therefore, the Company has provided for a valuation allowance against its deferred tax assets of $6,450,846 and $4,915,960 as of September 30, 2014 and December 31, 2013, respectively.

The Company has also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable.

NOTE 11 – FAIR VALUE MEASUREMENTS

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value, a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs other than Level 1 including quoted prices for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can be corroborated by observable market data. Level 3 – Unobservable inputs supported by little or no market activity for financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.

CHINA PHARMA HOLDINGS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

The Company uses fair value to measure the value of the banker’s acceptance notes it holds. The banker’s acceptance notes are recorded at cost which approximates fair value. The Company held the following assets recorded at fair value as of September 30, 2014 and December 31, 2013:

			Fair Value Measurements at
			Reporting Date Using
Description	September 30, 2014		Level 1		Level 2		Level 3
Banker's acceptance notes	$	116,047	$	-	$	116,047	$	-
Total	$	116,047	$	-	$	116,047	$	-

			Fair Value Measurements at
			Reporting Date Using
Description	December 31, 2013		Level 1		Level 2		Level 3
Banker's acceptance notes	$	336,003	$	-	$	336,003	$	-
Total	$	336,003	$	-	$	336,003	$	-

NOTE 12 - STOCKHOLDERS' EQUITY

Preferred and Common Stock – The total number of authorized shares is 95,000,000 shares of common stock and 5,000,000 shares of preferred stock. The preferred stock may be issued in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely by the Company’s Board of Directors.

Stock and Stock Options – On November 12, 2010, the Company’s Board of Directors adopted, and on December 22, 2010, its stockholders approved the Company’s 2010 Incentive Plan (the “Plan”), which gave the Company the ability to grant stock options, restricted stock, stock appreciation rights and performance units to its employees, directors and consultants, or those who will become employees, directors and consultants of the Company and/or its subsidiaries. The Plan currently allows for equity awards of up to 4,000,000 shares of common stock. Through September 30, 2014, there were 175,000 shares of restricted stock granted and outstanding under the Plan.

There were no securities issued from the Plan during the nine months ended September 30, 2014 and at September 30, 2014 there was no unrecognized compensation expense related to securities granted under the Plan.

NOTE 13 – CONTINGENCIES

Economic environment - Substantially all of the Company's operations are conducted in the PRC, and therefore the Company is subject to special considerations and significant risks not typically associated with companies operating in the United States of America. These risks include, among others, the political, economic and legal environments and fluctuations in the foreign currency exchange rate. The Company's results from operations may be adversely affected by changes in the political and social conditions in the PRC, and by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely affect the Company’s operations.

In addition, all of the Company's revenue is denominated in the PRC's currency of Renminbi (RMB), which must be converted into other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval of the PRC government.

CHINA PHARMA HOLDINGS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

NOTE 14 – CONCENTRATIONS

At September 30, 2014, one customer accounted for 16.6% of accounts receivable. At December 31, 2013, two customers accounted for 14.5% and 11.2% of accounts receivable.

For the nine months ended September 30, 2014, one customer accounted for 16.7% of sales. For the nine months ended September 30, 2013, no customer accounted for more than 10% of sales.

For the nine months ended September 30, 2014 and 2013, purchases from one supplier accounted for 31.8% and 20.6% of raw material purchases, respectively.

NOTE 15 – SUBSEQUENT EVENTS

In November 2014 the Company received the manufacturing certificate from the CFDA relating to the Company’s new manufacturing facility. This certificate enables the Company to commence production in the new facility in accordance with the new Good Manufacturing Practice standards promulgated by the CFDA effective March 1, 2011.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The statements contained in this report with respect to our financial condition, results of operations and business that are not historical facts are forward-looking statements. Forward-looking statements can be identified by the use of forward-looking terminology, such as "anticipate", "believe", "expect", "plan", "intend", "seek", "estimate", "project", "could", "may" or the negative thereof or other variations thereon, or by discussions of strategy that involve risks and uncertainties. Management wishes to caution the readers of the forward-looking statements that any such statements that are contained in this report reflect our current beliefs with respect to future events and involve known and unknown risks, uncertainties and other factors, including, but not limited to, economic, competitive, regulatory, technological, key employees, and general business factors affecting our operations, markets, growth, services, products, licenses and other factors, some of which are described in this report and some of which are discussed in our other periodic filings with the Securities and Exchange Commission. These forward-looking statements are only estimates or predictions. No assurances can be given regarding the achievement of future results, as actual results may differ materially as a result of risks facing our company, and actual events may differ from the assumptions underlying the statements that have been made regarding anticipated events.

These risk factors should be considered in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may issue. All written and oral forward looking statements made in connection with this report that are attributable to our company or persons acting on our behalf are expressly qualified in their entirety by these cautionary statements. Given these uncertainties, we caution investors not to unduly rely on our forward-looking statements. We do not undertake any obligation to review or confirm analysts’ expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this report or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

Business Overview & Recent Developments

The Chinese Food and Drug Administration (“CFDA”) promulgated Good Manufacturing Practices for Pharmaceutical Products (2010 revised version) (the “new GMP”) on February 12, 2011, which became effective on March 1, 2011. The new GMP outlines the basic principles and standards for the manufacturing of pharmaceutical products and the management of quality controls in the manufacturing process in the PRC. Pursuant to those mandatory requirements, the upgrading of our two sterilization production lines - liquid injectable and dry powder injectable product lines were required to be completed by the end of 2013. As of January 1, 2014, we had suspended such two production lines due to the failure to meet the GMP upgrading deadline. However, construction of the new main building has been completed, and two new sterilization production lines have been installed, and during the third quarter were in testing and commissioning. In November 2014 the CFDA completed their process of the GMP certification for our new facility and issued the GMP certificate to enable us to commence manufacturing our liquid injectable and dry powder injectable product lines. We have commenced the operation on the two product lines as of the date of this report.

We anticipate we will begin upgrading our existing sterilization facility to meet new GMP standards and therefore expand our capacity in this product category during the next year.

On July 18, 2014, a once-in-forty-year 16 grade super typhoon Rammasun hit Haikou. This typhoon caused considerable damage to our manufacturing facilities and inventory. Part of the warehouse was flooded; some damage was caused to our new facility while the water and electricity supply was suspended for several days causing a brief halt to our production activities. We have taken emergency measures to restore and recover post-typhoon. The Company’s losses from natural disaster were approximately $2.3 million (RMB14.2 million) for the nine months ended September 30, 2014. The Company received insurance compensation of $0.01 million as only the new plant building was insured and the damage to it was minor. The old plant has restored to the operational mode at the end of July.

The products in our pipeline have experienced delays. The CFDA has increased the approval criteria and lengthened the process which requires additional supplemental materials and trials, higher cost, and longer approval time for all our products. Started from the year of 2013, we commenced leading formulation screening, new technology exploration and technical criteria improvement activities. We expect this new model will improve our exploration channels for the pipeline products.

The status of our pipeline products remains the same as we reported in our Annual Report on Form 10-K for the year ended December 31, 2013.

In the three months ended September 30, 2014, we continued to execute our prudent marketing strategy to implement a more stringent screening on existing and potential distributors and hospital customers in terms of the speed of payment in order to gradually improve our trade turnover, especially in terms of the collection of our accounts receivable. This strategy temporarily impacts our sales in the current period by limiting our credit sales.

Market Trends

The Chinese pharmaceutical market shows features of rapid expansion, fierce competition, low concentration, and is greatly influenced by government policies. According to Biao Dian Medical Information Co., Ltd. under the CFDA Southern Institute of Economic Research, the annual growth rate of Chinese healthcare market went beyond 20% during 2009-2011 due to the advancement of Healthcare Reform; however, this rate dropped below 20% in 2012 due to the limiting use of antibiotics and strengthening drug-price-control policies issued that year; and this rate further dropped to 15.64% in 2013 due to the impact of continuous drug-price-control policy, anti-commercial bribery, and the new GMP requirement.

A series of changes in the market position of the different categories of medication occurred along with the changes in disease spectrum and prescription habits: the decrease in the systemic use of anti-infection drugs in hospitals became the most significant trend. The market share of anti-infection drugs decreased to 15.3% in 2013, which represented a decrease of roughly 9% from 24.5% in 2007 per “China Pharmaceutical Market Development Blue Book (2014)” ("the “Blue Book”), which was mainly due to a better understanding of antibiotic abuse problems, policy instruction of price cutting in antibiotics, and the release of “Clinical Use of Antibiotics Hierarchical Management Approach”. Meanwhile, the market shares of central nerve system category (CNS) and digestive category increased slightly to 14.5% and 14.1% in 2013 from 13.3% and 12.5% in 2007 per the “Blue Book”. It is notable that Traditional Chinese Medicine (“TCM”) had better performance compared to chemical medicines in the above two categories, which decelerated the sales increase for the latter. All the changes mentioned above had impacted most of our existing products.

In July 2014, National Health Commission of PRC rearranged “New Rural Cooperative Medical System” (“NRCMS”) for the year 2014, which stated the key projects this year as follows: improving funding level, promoting insurance for major diseases, adjusting payment policy, and strengthening fund supervision. It clearly stipulated that the NRCMS fund surplus accumulated this year cannot exceed 25% of the total financing. We believe that at least more than RMB13 billion of new funds will be spent in order to achieve this standard, which could effectively mitigate the adversity of “healthcare payment control”. This change in industrial environment might bring positive impacts to the collection of our accounts receivables because our government-backed hospital clients could potentially benefit from such funding from the government.

Results of Operations for the Three Months Ended September 30, 2014

Revenue

Revenue for the three months ended September 30, 2014 was $5.5 million, a decrease of 31% from $8.1 million for the three months ended September 30, 2013. This was mainly due to the production suspension of our injectable production lines this year.

We suspended production of our dry powder injectable and liquid injectable products at our two old production lines as of January 1, 2014 due to the failure to meet the GMP upgrading deadline. Expecting that this shutdown would affect our sales in 2014, we had gradually increased inventory levels of certain products in advance in order to support the market demand for these products. As mentioned above, we received the GMP certificate from the CFDA this November and we have commenced manufacturing liquid injectable and dry powder injectable products.

Set forth below are our revenues by product categories in millions USD for the three months ended September 30, 2014 and 2013:

Product Category	Three Months Ended September 30,		Net Change	% Change
Product Category	2014	2013	Net Change	% Change
Anti-Viro/ Infection & Respiratory	$3.61	$4.20	-$0.59	-14%
CNS Cerebral & Cardio Vascular	$1.17	$1.80	-$0.63	-35%
Digestive Diseases	$0.29	$0.80	-$0.51	-64%
Other	$0.50	$1.30	-$0.80	-62%

“Anti-Viro/Infection &Respiratory” category decreased by $0.59 million to $3.16 million in the third quarter in 2014 compared to $4.20 million in the same period in 2013, which was mainly due to the sales decrease in Andro-grapholide caused by the less supply to the distributors who sold Andro-grapholide with big sum of account receivables.

The decrease in revenue was in our “CNS Cerebral & Cardio Vascular” product category, which generated $1.17 million in sales revenue in the third quarter of 2014 compared to $1.80 million in the same period a year ago, decreased by $0.63 million. This decrease was mainly due to having injectables as the main product in this category. The suspension of the injectables production lines since the beginning of this year has negatively impacted our sales performance.

Sales of the “Digestive Diseases” decreased by $0.51 million to $0.29 million in the third quarter in 2014 compared to $0.80 million in the same period in 2013, mainly due to the decrease in sales of Compound Ammonium Glycyrrhetate injectable and Tiopronin, which were affected primarily by market volatility.

Our “Other” category generated $0.5 million of sales in the third quarter in 2014, compared to $1.30 million in the same period last year, a decrease of $0.8 million. This decrease was mainly due to the decrease in sales of an injectable product Vitamin B6 in this category caused by the production line suspension mentioned above.

In the three months ended September 30, 2014, revenue breakdown by product category showed some changes. Sales of the “Anti-Viro / Infection & Respiratory” products category represented 65% of total sales in the three months ended September 30, 2014, compared to 52% in the same period last year. The “CNS, Cerebral & Cardio Vascular” category represented 21% of total revenue in the three months ended September 30, 2014 and 22% in the same period last year. The “Digestive Diseases” category represented 5% of total revenue in three months ended September 30, 2014 and 10% in the same period last year. The “Other” category represented 9% and 16% of revenues in three months ended September 30, 2014 and 2013, respectively.

Cost of Revenue

For the three months ended September 30, 2014, our cost of revenue was $4.0 million, or 73% of total revenue, which represented a decrease of $1.8 million from $5.8 million, or 73% of total revenue, in the third quarter of 2013. The decrease in cost of revenue in the third quarter of 2014 was mainly due to the decrease in purchasing prices of certain raw materials due to market fluctuations.

Gross Profit and Gross Margin

Gross profit for the three months ended September 30, 2014 was $1.5 million, a decrease of $0.7 million, from gross profit of $2.2 million in the same period of 2013. Our gross profit margin in the third quarter of 2014 was 27% compared to 28% in the same period of 2013. Looking forward, we expect pricing pressures on most products, while our new products have and will support the overall gross margin. For instance, Candesartan, the product we launched last November, is sold at a price that supports our gross margin.

Selling Expenses

Our selling expenses for the three months ended September 30, 2014 were $0.7 million, compared to $0.9 million in the same period last year. Selling expenses accounted for 13% of the total revenue in the third quarter 2014 compared to 11% in the same period in 2013. Due to many adjustments in our selling processes under healthcare reform policies, despite the decrease in sales, we still require comparable personnel and expenses to maintain our revenue and collection of accounts receivable.

General and Administrative Expenses

Our general and administrative expenses for the three months ended September 30, 2014 were $0.42 million, an increase of $0.05 million from $0.37 million in the same period of 2013. General and administrative expenses accounted for 8% and 5% of our total revenues in the three months ended September 30, 2014 and 2013, respectively.

Research and Development Expense

Our research and development expenses for the three months ended September 30, 2014 and 2013 were $0.18 million and $0.35 million, respectively. The change in research and development expense was mainly due to the decreases of costs related to testing of the new production lines.

Bad Debt Expense

Our bad debt expenses for the three months ended September 30, 2014 and 2013 were $3.9 million and $3.2 million, respectively. The increase in bad debt expenses was mainly due to the increase in the aged accounts receivable.

In general, our normal credit or payment terms extended to customers are 90 days. This has not changed in recent years. Due to the peculiarity of the Chinese pharmaceutical market environment, deferred payments to pharmaceutical companies by state-owned hospitals and local medicine distributors are a normal phenomenon. Our customers are primarily pharmaceutical distributors who sell products to mostly government-backed hospitals. Therefore, the age of our receivables from our customers tends to be old. Although these customers typically pay after the due date of the receivables, since the majority of hospitals in China are backed by the government, Management believes that the deferred payments from the state-owned hospitals are relatively secured.

The amount of accounts receivable that were past due (or the amount of accounts receivable that were more than 90 days old) was $30.6 million and $45.1 million as of September 30, 2014 and December 31, 2013, respectively. The following table illustrates our accounts receivable aging distribution in terms of percentage of total accounts receivable as of September 30, 2014 and December 31, 2013.

	September 30,			December 31,
	2014			2013
1 - 90 Days		8	%		8.0	%
90 - 180 Days		4.6	%		7.4	%
180 - 360 Days		5.8	%		23.3	%
360 - 720 Days		38.4	%		61.3	%
> 720 Days		43.2	%		0.0	%
Total		100.0	%		100.0	%

Our bad debt allowance estimate is currently calculated as the sum of 3.5% of accounts receivable that are less than 365 days old, 10% of accounts receivable that are between 365 days and 720 days old and 100% of accounts receivable that are greater than 720 days old.

In order to collect cash to support the construction of our new plant to meet the policy requirements for new GMP upgrading, we have shifted to prudent sales strategies in the recent two years. This strategy strengthened the preference on sales of customers with good credit performance, while reduced the supplement to customers with poor credit record. On one hand, this strategy contributed to the recovery of funds; on the other hand, it negatively impacted our sales and indirectly prolonged the payment from the estranged customers due to their lack of incentive to pay their accounts receivable faster than if they otherwise would have the prospects of having larger supplies from the Company. These two factors resulted in increased proportion of our older-aged accounts receivable balance.

Management has paid high attention to this issue. During the third quarter of 2014, we offered two of our largest customers a discount of 30% for payments made on their outstanding balance of accounts receivable. As a result, we recognized additional bad debt expense of approximately $0.53 million for the three and nine months ended September 30, 2014. In addition, Management evaluated the collection conditions and further considered taking a series of targeted measures to promote collection of older-aged accounts receivable in the fourth quarter.

Losses from Natural Disaster

We suffered losses of $2,275,593 relating to a tropical typhoon during the three months ended September 30, 2014 as discussed more fully in Note 2 to the condensed consolidated financial statements. There was no comparable expense in the prior year period.

Loss from Operations

Our operating loss for the three months ended September 30, 2014 was $6 million, compared to operating loss of $2.7 million in the same period in 2013. The increase in operating loss was primarily due to the decrease in sales, the increase in bad debt expense and the losses from natural disaster recognized during the three months ended September 30, 2014.

Income Tax Expense (Benefit)

For the three months ended September 30, 2014 and 2013, our income tax rate was 15%. Income tax expense was $0.02 million for the three months ended September 30, 2014, and income tax benefit was $0.4 million for the three months ended September 30, 2013. The income taxes recognized for the three months ended September 30, 2014 and 2013 were related to net changes in long-term deferred tax assets and liabilities. We renewed our "National High-Tech Enterprise" status ("National HT Status") from the PRC government in the third quarter of 2013. With this designation, for the years ended December 31, 2014, 2015 and 2016, we will continue to enjoy a preferential tax rate of 15% which is notably lower than the statutory income tax rate of 25%.

Net Loss

Net loss for three months ended September 30, 2014 and 2013 were $6.3 million and $2.3 million, respectively. The increase in net loss was primarily due to the decrease in sales, the increase in bad debt expense and the losses from natural disaster recognized for the three months ended September 30, 2014.

For the three months ended September 30, 2014, loss per basic and diluted common share was $0.15, compared to loss per basic and diluted share of $0.05 for the same period in 2013.

The number of basic and diluted weighted-average outstanding shares used to calculate loss per share was 43,579,557 for the three months ended September 30, 2014 and 2013, respectively.

Nine Months Ended September 30, 2014 and 2013

Revenue

For the nine months ended September 30, 2014, our sales revenue decreased by $5.6 million, or 23%, to $18.8 million from $24.4 million in the corresponding period of 2013.

Set forth below are our revenues by product categories in millions USD for each of the nine months ended September 30, 2014 and 2013.

Product Category	Nine Months Ended September 30,		Net Change	% Change
Product Category	2014	2013	Net Change	% Change
Anti-Viro/ Infection & Respiratory	$12.70	$12.90	($0.20)	-2%
CNS Cerebral & Cardio Vascular	$3.07	$5.90	($2.83)	-48%
Digestive Diseases	$1.06	$2.60	($1.54)	-59%
Other	$1.92	$2.90	($0.98)	-34%

During the nine months 2014, our overall sales revenue decreased by 23% on a year-over-year basis led by the CNS Cerebral & Cardio Vascular and Digestive categories. Sales in the Anti-Viro/ Infection & Respiratory category reached $12.7 million, a decrease of $0.2 million, or 2%, compared to $12.90 million in the same period last year, CNS Cerebral & Cardio Vascular category decreased by $2.83 million, or 48%, to $3.07 million from $5.09 million due to the suspension of our injectable production lines. Sales in Digestive category decreased by $1.54 million, or 59%, to $1.06 million from $2.60 million, which was mainly due to the sales decrease of injectable products in this category. Sales of the “Other” category decreased by $0.98 million, or 34%, to $1.92 million from $2.90 million. The decrease was mainly due to the production suspension of our injectable production lines this year.

Gross Margin and Gross Profit

Gross profit for the nine months ended September 30, 2014 was $6.6 million, compared to $2.8 million in the same period of 2013. Gross profit margin for the nine months ended September 30, 2014 and 2013 were 35% and 12% respectively. Without the effect of inventory obsolescence for the nine months ended September 30, 2013, management estimates that our gross profit would have been approximately $6.5 million, and gross margin would have been 27%. The increase in gross profit margin was mainly due to market fluctuation and sales price increases in certain products; in addition, more high-margin products were sold in the first nine months of 2014 compared to the same period a year ago.

Selling Expenses

Our selling expenses for the nine months ended September 30, 2014 were $2.2 million, a decrease of 10%, compared to $2.4 million for the nine months ended September 30, 2013. Selling expenses were approximately 12% of revenue in the first half of 2014 compared to 10% during the comparable period a year ago.

General Administrative Expenses

Our general and administrative expenses for the nine months ended September 30, 2014 were $1.2 million, a decrease of $0.3 million, or 20%, compared to $1.5 million for the same period in 2013. This decrease was mainly due to a financial consulting fee incurred in the first half of 2013 for the preparation of the construction loan facility.

Research and Development Expense

Our research and development expenses for the nine months ended September 30, 2014 and 2013 were $2.5 million and $1.4 million, respectively. The change in research and development expenses was mainly due to the costs related to testing of the new production lines.

Bad Debt Expense

Our bad debt expense for the nine months ended September 30, 2014 was $15.3 million, compared to $7.9 million for the same period in 2013. Please see additional discussion of bad debt and accounts receivables in the section above named "Bad Debt Expense".

We recognize bad debt expense per actual write-offs as well as the changes of allowance for doubtful accounts. To the extent that our current allowance for doubtful accounts is higher than that of the previous period, we recognize a bad debt expense for the difference between the two periods; when the current allowance is lower than that of the previous period, we recognize a bad debt benefit for the difference. The allowance for doubtful accounts was $27.9 million and $13.3 million as of September 30, 2014 and December 31, 2013, respectively. Therefore, the changes in the allowance for doubtful accounts during the nine months ended September 30, 2014 and 2013 were as follows:

	For the Nine Months Ended
	September 30,
	2014				2013
Balance, beginning of period		$	13,301,622		$	4,429,945
Bad debt expense (benefit)			15,280,588			7,910,583
Charged to reserve – collection discount			(531,382	)		-
Foreign currency translation adjustment			(138,649	)		7,206
Balance, end of period		$	27,912,179		$	4,268,356

Losses from Natural Disaster

We suffered losses of $2,275,593 relating to a tropical typhoon during the nine months ended September 30, 2014 as discussed more fully in Note 2 to the condensed consolidated financial statements. There was no comparable in expense in the prior year period.

Loss from Operations

Our operating loss for the nine months ended September 30, 2014 was approximately $16.85 million, compared to $10.45 million for the same period in 2013, which represented a deterioration of $6.40 million. The deterioration in operating income performance was primarily due to lower revenue, higher bad debt and R&D expense and losses from natural disaster in the current period compared to the corresponding period one year ago.

Net Loss

Our net loss for the nine months ended September 30, 2014 and 2013 was $17.4 million and $9.6 million, respectively. The deterioration in net income performance was primarily due to lower revenue, higher bad debt expense, increased R&D expense and losses from natural disaster in the current period as compared to the corresponding period one year ago.

Liquidity and Capital Resources

Our principal sources of liquidity are cash generated from operations and short-term bank loans. Our cash and cash equivalents were $4.3 million, which represents 3% of our total assets as of September 30, 2014, as compared to $6.0 million, which represents 4% of our total assets as of December 31, 2013. All of the $4.3 million of cash and cash equivalents at September 30, 2014 is considered to be reinvested indefinitely in Helpson and is not expected to be available for payment of dividends, for other payments to our parent company or to its shareholders. As of September 30, 2014, we had a principal balance of $4.9 million in short-term bank loans. This loan was due on November 1, 2014. Management is in the process of obtaining an extension, and anticipates this to be completed during the fourth quarter. In addition, we entered into an eight-year construction loan facility with a bank on September 21, 2013. The total loan facility amount is RMB80,000,000 (approximately $13 million), which had been fully utilized through May 7, 2014. The cash flow generated from operating activities was used to fund the remaining construction of our GMP upgrading project. The current portion of the construction loan facility is $1.6 million as of September 30, 2014. Both the short term bank loan and the construction loan facility are from the same bank.

Based on our current operating plan, management believes that our cash provided by operations will be sufficient to meet our operating capital needs and our anticipated capital expenditures, including expenditures for new formula acquisitions and GMP upgrading related construction and equipment, for the next twelve months. However, if events or circumstances change and we do not meet our operating plan as expected, we may be required to seek additional capital and/or to reduce certain discretionary spending, which could have a material adverse effect on our ability to achieve our business objectives. Notwithstanding the foregoing, when we regard market conditions are most advantageous, we may seek additional financing as necessary for expansion purposes, which may include debt and/or equity financing. There can be no assurance that any additional financing will be available on acceptable terms, if at all.

Operating Activities

Net cash provided by operating activities was $2.6 million in the nine months ended September 30, 2014 compared to $3.7 million for the same period in 2013.

At September 30, 2014, our accounts receivable was $30.6 million, a decrease of $14.5 million from $45.1 million at December 31, 2013. The decrease was due to our enhanced collection efforts as well as the increased allowance for doubtful accounts at September 30, 2014 compared to December 31, 2013.

At September 30, 2014, total inventory was $19.0 million, a decrease of $5.67million from $24.7 million at December 31, 2013. This decrease was mainly due to the damage from typhoon, decreased purchases of raw materials for injectable products and additional inventory needs from R&D expense for trial productions at the new facility.

Investing Activities

During the nine months ended September 30, 2014, net cash used in investing activities decreased to $4.9 million from $9.8 million during the same period in 2013. The investment spending for the nine months ended September 30, 2014 was mainly for the GMP upgrading related construction and equipment. The decrease of $4.9 million in investing activities for the nine months ending September 30, 2014 as compared to the same period of 2013 relates to the decreased costs on construction of the new facility and equipment installation.

Financing Activities

There was $0.6 million cash flow provided from financing activities in the nine months ended September 30, 2014 and $6.4 million for the same period in 2013. The large number of financing activities that occurred in the nine months of 2013 related to the construction loan facility described under the first paragraph in this section entitled “Liquidity and Capital Resources”.

According to relevant PRC laws, companies registered in the PRC, including our PRC subsidiary, Helpson, are required to allocate at least ten percent (10%) of their after-tax net income, as determined under accounting standards and regulations in the PRC, to statutory surplus reserve accounts until the reserve account balances reach fifty percent (50%) of the companies’ registered capital prior to their remittance of funds out of the PRC. Allocations to these reserves and funds can only be used for specific purposes and are not transferrable to the parent company in the form of loans, advances or cash dividends. As of September 30, 2014 and December 31, 2013, the net assets of Helpson were $109,560,000 and $127,626,000, respectively. Due to the restriction on dividend distribution to overseas shareholders, the amount of Helpson’s net assets designated for general and statutory capital reserves, and thus could not be transferred to our parent company as cash dividends, were $8,182,770 and $8,182,770 (50% of registered capital) at September 30, 2014 and December 31, 2013, respectively. Since the amount that Helpson must set aside for the statutory surplus fund only accounts for 7.5% and 6.4%, respectively, of its total net assets, this reserve does not have a major impact on our liquidity. There were no allocations to the statutory surplus reserve accounts during the nine months ended September 30, 2014.

The PRC government also imposes controls on the conversion of RMB into foreign currencies and the remittance of currencies out of the PRC. Our businesses and assets are primarily denominated in RMB. All foreign exchange transactions take place either through the People’s Bank of China or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the People’s Bank of China. Approval of foreign currency payments by the People’s Bank of China or other regulatory institutions requires submitting a payment application form together with applicable invoices and signed contracts. These currency exchange control procedures imposed by the PRC government authorities may restrict the ability of Helpson, our PRC subsidiary, to transfer its net assets to our parent company through loans, advances or cash dividends.

Off Balance Sheet Arrangements

As of September 30, 2014, we did not have any off-balance sheet arrangements.

Commitments

At September 30, 2014, we were obligated to pay laboratories and others approximately $5.19 million over approximately the next four years upon completion of the various phases of contracts to provide CFDA production approval of medical formulas.

Critical Accounting Policies

Management's discussion and analysis of its financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles. Our financial statements reflect the selection and application of accounting policies which require management to make significant estimates and judgments. The discussion of our critical accounting policies contained in Note 1 to our consolidated financial statements, “Organization and Significant Accounting Policies”, is incorporated herein by reference.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, we are not required to provide information required by this item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our Chief Executive Officer and interim Chief Financial Officer, evaluated the effectiveness of our “disclosure controls and procedures” (as defined in the Securities Exchange Act of 1934 (the “Exchange Act”) Rules 13a-15(e) or 15d-15(e)) as of the end of the period covered by this quarterly report. Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act (a) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and (b) is accumulated and communicated to management, including our Chief Executive Officer and interim Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their objectives as described above. Based on this evaluation, our Chief Executive Officer and interim Chief Financial Officer concluded that as of the end of the period covered by this report, our disclosure controls and procedures were effective.

Changes in Internal Controls over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 or 15d-15 that occurred during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II OTHER INFORMATION

Item 6. Exhibits

The exhibits required by this item are set forth in the Exhibit Index attached hereto.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: November 14, 2014	CHINA PHARMA HOLDINGS, INC. By: /s/ Zhilin Li Name: Zhilin Li Title: President and Chief Executive Officer (principal executive officer)
Date: November 14, 2014	By: /s/ Zhilin Li Name: Zhilin Li Title: Interim Chief Financial Officer (principal financial officer and principal accounting officer)

EXHIBIT INDEX

No. Description

31.1 - Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2 - Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1 - Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.INS* - XBRL Instance Document

101.SCH* - XBRL Taxonomy Extension Schema Document

101.CAL* - XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF* - XBRL Taxonomy Extension Definition Linkbase Document

101.LAB* - XBRL Taxonomy Extension Label Linkbase Document

101.PRE* - XBRL Taxonomy Extension Presentation Linkbase Document

* Furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise not subject to liability under these sections.

EX-31.1 2 cphi10qex311093014.htm cphi10qex311093014.htm

Exhibit 31.1

CERTIFICATION OF

PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

I, Zhilin Li certify that:

1.	I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):

a) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 14, 2014

/s/ Zhilin Li

Name: Zhilin Li

Title: Chief Executive Officer

(principal executive officer)

EX-31.2 3 cphi10qex312093014.htm cphi10qex312093014.htm

Exhibit 31.2

CERTIFICATION OF

PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

I, Zhilin Li, certify that:

1.	I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 14, 2014

/s/ Zhilin Li

Name: Zhilin Li

Title: Interim Chief Financial Officer

(principal financial officer and principal accounting officer)

EX-32.1 4 cphi10qex321093014.htm cphi10qex321093014.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned hereby certifies, in her capacity as Chief Executive Officer and interim Chief Financial Officer of China Pharma Holdings, Inc. (the “Company”), for the purposes of 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of her knowledge:

(1) The Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2014 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 14, 2014

/s/ Zhilin Li

Name: Zhilin Li

President and Chief Executive Officer

(principal executive officer)

/s/ Zhilin Li

Name: Zhilin Li

Title: Interim Chief Financial Officer

(principal financial officer and principal

accounting officer)

This certification accompanies each Report pursuant to § 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of §18 of the Securities Exchange Act of 1934, as amended.

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.INS 5 cphi-20140930.xml

4269037

5993139

116047

336003

30642878

45147602

516095

175739

7626716

19014172

24677120

63598693

83956319

41653862 41701505

33869491

30241337

1410482

1711793

140532528

157610954

3131988

1877437

214740

323651

1293273

1312361

1773478

2228238

1354567

1625118

4875353

4909662

14268517

12005916

11375825

12484183

232866

176414

25877208

24666513

43580

23590204

71535109

88896276

19486427

20414381

114655320

132944441

140532528

157610954

27912179

13301622

70004 43064 4670853 8027126

5951165

5264350

4075696

3812992

0.001

5000000

0.001

95000000

43579557

5566543

8116599

18802602

24392311

4057480

5863587

12215756

17837989

15747

1509063

2237265

6586846

2818502

745976

921851

2193823

2435592

422729

372568

1229488

1536831

181796 352599 2528230 1384263

3940144

3277780

15280588

7910583

2275593 2275593

7566238

4924798

23507722

13267269

65086 65086

-5992089

-2687533

-16855790

-10448767

8824

2228

47435

4830

-325244

-89238

-495054

-263732

-316420

-87010

-447619

-258902

-6308509

-2774543

-17303409

-10707669

-19215

472512

-57758

1129506

-6327724

-2302031

33366

880315

-927954

3918978

-6294358

-1421716

-18289121

-5659185

-0.15

-0.05

-0.40

-0.22

-0.15

-0.05

-0.40

-0.22

9040464

-17361167

-9578163

3735820

-17361167

-9578163

1014221

1039716

15280588 7910583

57758

-1129506

3311926

-3029386

1077182

-342012

-452500

-1468882

-642850

7671072

4138431

1338724

376312

-34638

-2486073

-90108

42847

-439740

90159

2596430

3698064

-244073

-496634

4638265

9267088

-4882338

-9763722

604756

6437906

604756

6437906

-42950

103542

-1724102

475790

5993139 4029708 4269037 4505498

943251

324117

2472099

69378 136742 1955808 6256327 2173689 2810462 2555419 715445

NOTE 1 - BASIS OF PRESENTATION   Organization and Nature of Operations China Pharma Holdings, Inc., a Nevada corporation, owns 100% of Onny Investment Limited (Onny), a British Virgin Islands corporation, that in turn owns 100% of Hainan Helpson Medical & Biotechnology Co., Ltd (Helpson), a corporation organized under the laws of the People's Republic of China (the PRC). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.   The Foreign Investment Industrial Catalogue (the Catalogue) jointly issued by the Chinas Ministry of Commerce and the National Development and Reform Commission (as the latest version is the year 2012 version, effective January 30, 2012) classified various industries/businesses into three different categories: (i) encouraged for foreign investment; (ii) restricted to foreign investment; and (iii) prohibited from foreign investment. For any industry/business not covered by any of these three categories, they will be deemed industries/businesses permitted for foreign investment. A typical foreign investment ownership restriction in the pharmaceutical industry is that a foreign investment enterprise (the FIE) shall not have the whole or majority of its equity interests owned by a foreign owner if the FIE establishes more than 30 branch stores and distributes a variety of brands in those franchise stores, which is not the case of the Companys business.   Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located throughout the PRC. The Company believes Helpsons business is not subject to any ownership restrictions prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson from Helpsons three former shareholders on May 25, 2005 by entry into an Equity Transfer Agreement with such three parties on May 25, 2005. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishing of Enterprises with Foreign Investment in the PRC on the same day and its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.   The Company has and continues to acquire well-accepted medical formulas to add to its diverse portfolio of Western and Chinese medicines.   Consolidation and Basis of Presentation The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and are expressed in United States dollars. The accompanying consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.   Helpsons functional currency is the Chinese Renminbi. Helpsons revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpsons financial statements are included in accumulated other comprehensive income, which is a component of stockholders equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is a party to the transaction are included in the results of operations.   Reclassification - The Company has made certain reclassifications to the condensed consolidated statement of operations and cash flows for the three and nine months ended September 30, 2013 to conform to the presentation for the three and nine months ended September 30, 2014. These reclassifications had no effect on the condensed consolidated balance sheets, results of operations or cash flows as of or for the three and nine months ended September 30, 2013.   Condensed Financial Statements The accompanying unaudited condensed consolidated financial statements were prepared pursuant to the rules and regulations of the United States Securities and Exchange Commission (the Commission). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Management of the Company (Management) believes the following disclosures are adequate to make the information presented not misleading. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2013 filed with the Commission on March 20, 2014.      These unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) that, in the opinion of Management, are necessary to present fairly the consolidated financial position and results of operations of the Company for the periods presented. Operating results for the nine months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014.   Accounting Estimates - The preparation of financial statements in conformity with U.S. GAAP requires Management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.   Basic and Diluted Loss per Common Share - Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per share is calculated to give effect to any potentially issuable dilutive common shares. There were no potentially dilutive common shares outstanding for all periods presented.   The following table is a presentation of the numerators and denominators used in the calculation of basic and diluted (loss) earnings per share:   <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%'> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="6" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> For the Three Months</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="6" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> For the Nine Months</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="6" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Ended September 30,</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="6" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Ended September 30,</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2014</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2013</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2014</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2013</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:52%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Net loss</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (6,327,724</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (2,302,031</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (17,361,167</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (9,578,163</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:52%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Basic weighted-average common shares outstanding</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 43,579,557</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 43,579,557</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 43,579,557</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 43,579,557</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:52%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Effect of dilutive securities:</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:52%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Warrants</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:52%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Options</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:52%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Diluted weighted-average common shares outstanding</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 43,579,557</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 43,579,557</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 43,579,557</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 43,579,557</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:52%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Basic loss per share</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (0.15</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (0.05</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (0.40</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (0.22</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:52%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Diluted loss per share</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (0.15</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (0.05</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (0.40</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (0.22</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td></tr></table>

NOTE 3 INVENTORY   Inventory consisted of the following:    <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="80%" style='width:80%'> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:70%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> September 30,</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> December 31,</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:70%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2014</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2013</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:70%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Raw materials</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 19,571,419</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 28,259,707</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:70%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Work in process</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 853,602</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:70%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Finished goods</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 4,113,606</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 3,590,937</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:70%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 23,685,025</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 32,704,246</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:70%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Obsolescence reserve</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (4,670,853</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (8,027,126</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:70%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Total Inventory</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 19,014,172</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 24,677,120</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr></table></div>

NOTE 4 - PROPERTY AND EQUIPMENT   Property and equipment consisted of the following:     <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="85%" style='width:85%'> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:70%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> September 30,</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> December 31,</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:70%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2014</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2013</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:70%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Permit of land use</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 457,743</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 460,964</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:70%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Building</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 10,033,988</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2,494,623</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:70%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Plant, machinery and equipment</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 16,393,856</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 6,671,620</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:70%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Motor vehicle</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 150,611</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 151,670</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:70%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Office equipment</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 246,553</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 229,210</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:70%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Construction in progress</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 12,537,905</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 25,497,600</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:70%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Total</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 39,820,656</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 35,505,687</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:70%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Less: accumulated depreciation</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (5,951,165</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (5,264,350</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:70%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Property and Equipment, net</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 33,869,491</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 30,241,337</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr></table></div>   Construction in progress consists primarily of the construction of a new production facility and the acquisition of related equipment and capitalized interest during the construction period. During the nine months ended September 30, 2014, an aggregate of approximately $17.16 million was reclassified from construction in progress to their respective property and equipment category as the assets were placed in service and depreciation commenced.    A reconciliation of total interest cost incurred to interest expense as recognized in the consolidated statement of operations is as follows:   <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%'> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="6" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> For the Three Months</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="6" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> For the Nine Months</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="6" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Ended September 30,</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="6" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Ended September 30,</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2014</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2013</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2014</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2013</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:52%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Total interest cost incurred</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 330,995</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 89,238</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 952,836</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 263,732</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:52%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Interest cost capitalized</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 5,751</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 457,782</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:52%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Interest expense</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 325,244</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 89,238</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 495,054</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 263,732</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr></table>   Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:   <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="50%" style='width:50%'> <tr> <td valign="top" width="33%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:33%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Asset</td> <td valign="top" width="2%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:2%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="top" width="13%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  Life - years</td></tr> <tr> <td valign="top" width="33%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:33%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Permit of land use</td> <td valign="top" width="2%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:2%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="top" width="13%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:13%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 40 - 70</td></tr> <tr> <td valign="top" width="33%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:33%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Building</td> <td valign="top" width="2%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:2%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="top" width="13%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:13%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 20 - 49</td></tr> <tr> <td valign="top" width="33%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:33%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Plant, machinery and equipment</td> <td valign="top" width="2%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:2%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="top" width="13%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:13%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 10</td></tr> <tr> <td valign="top" width="33%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:33%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Motor vehicle</td> <td valign="top" width="2%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:2%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="top" width="13%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:13%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 5 - 10</td></tr> <tr> <td valign="top" width="33%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:33%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Office equipment</td> <td valign="top" width="2%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:2%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="top" width="13%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:13%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 3-5</td></tr></table></div>   For the three months ended September 30, 2014 and 2013, depreciation expense was $321,020 and $210,182.  For the nine months ended September 30, 2014 and 2013, depreciation expense was $724,509 and $640,550.

NOTE 5 - INTANGIBLE ASSETS   Intangible assets represent the cost of medical formulas approved for production by the China Food and Drug Administration (CFDA) in China. During the nine months ended September 30, 2014, the Company did not obtain CFDA production approval for any medical formula and therefore there were no costs reclassified from advances to medical formulas.   Approved medical formulas are amortized from the date CFDA approval is obtained over their individually identifiable estimated useful life, which ranges from ten to thirteen years.  It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. For the three and nine months ended September 30, 2014 and 2013, amortization expense relating to intangible assets was $96,382 and $131,585, $289,712 and $399,166, respectively. Medical formulas typically do not have a residual value at the end of their amortization period.      The Company evaluates each approved medical formula for impairment at the date of CFDA approval, when indications of impairment are present and at the date of each financial statement. The Companys evaluation is based on an estimated undiscounted net cash flow model, considering currently available market data for the related drug and the Companys estimated market share. If the carrying value of the medical formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over the discounted estimated future net cash flows. As a result of the evaluation, the Company has determined that each medical formula continues to provide benefits to the Company and no impairment was recognized during the nine months ended September 30, 2014 or 2013.   As of September 30, 2014 and December 31, 2013, intangible assets consisted solely of CFDA approved medical formulas as follows:   <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="80%" style='width:80%'> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:70%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> September 30,</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> December 31,</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:70%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2014</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2013</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:70%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Gross carrying amount</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 5,486,178</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 5,524,785</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:70%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Accumulated amortization</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (4,075,696</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (3,812,992</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:70%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Net carrying amount</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 1,410,482</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 1,711,793</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr></table></div>

NOTE 6 ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS   In order to expand the number of medicines manufactured and marketed by the Company, it has entered into contracts with independent laboratories for the purchase of medical formulas. Although CFDA approval had not been obtained for certain medical formulas as of the dates of the respective contracts, the objective of the contracts is for the Company to purchase CFDA-approved medical formulas once the CFDA approval process is completed. Some of the medical formulas currently in the CFDA approval process also come with patents. As of September 30, 2014, the Company had received the title to two unexpired patents that relate to medical formulas currently in the CFDA approval process.   Prior to entering into the contracts, the laboratories typically have completed all required researches and developments to determine the medical formula for and the method of production of the generic medicines. The application to the CFDA for production approval must be made by the facilities that will manufacture the related products. As a result, a contract typically provides that the Company purchases the medical formula from the laboratory and the laboratory is required to assist the Company in applying for and obtaining the production approval from the CFDA.   A typical CFDA approval process for the production of a generic medical product involves a number of steps that generally require three to five years to complete. If the medical formula is purchased at the point when the generic medical product receives the CFDAs approval for a clinical study, which is very typical for the Company, the clinical study that follows will usually take one and a half to three years to complete. After completing the clinical study, results are submitted to the CFDA and a production approval application would be filed. In most cases, it takes between eight to eighteen months from preparing and submitting the production approval application until obtaining CFDAs approval. Upon approving, the CFDA would issue a production certificate and the Company can start producing and promoting the generic medical product. Therefore, it is expected to take five years from the dates of the medical formula contracts until acquiring CFDAs approval. However, the actual time needed could be even longer due to the updated criteria in the drug registration process.   Under the terms of the contracts, the laboratories are required to assist the Company in obtaining production approval for the medical formulas from the CFDA. Management monitors the status of each medical formula on a regular basis in order to assess whether the laboratories are performing adequately under the contracts. If a medical product is not approved by the CFDA, as evidenced by their issuance of a denial letter, or if the laboratory breaches the contract, the laboratory is obliged under the contract to provide a refund of the full payment to the Company. alternatively, the Company can require the application of those payments to another medical formula with the same laboratory. As a result of the refund right, the Company is ultimately purchasing an approved medical product. Accordingly, payments made prior to the issuance of production approval by the CFDA are recorded as advances for purchases of intangible assets.      To date, no formula has failed to receive CFDA production approval nor has the Company been informed or become aware of any formula that may fail to receive such approval. However, there is no assurance that the medical products will receive production approval and if the Company does not receive such approval, it will enforce its contractual rights to receive the refund from the laboratory or have the payments applied to another medical formula with the same laboratory.   At September 30, 2014, the Company was obliged to pay laboratories and others approximately $5.19 million upon completion of various phases of contracts to provide CFDA production approval of medical formulas.

NOTE 7 RELATED PARTY TRANSACTIONS   Total advances owing to a board member were $1,354,567 as of September 30, 2014 and December 31, 2013 and are recorded as other payables related parties on the accompanying condensed consolidated balance sheets. The advances bear interest at a rate of 1.0% per year.  Total interest expense of $10,159 and $10,159 was recognized for the nine months ended September 30, 2014 and 2013, respectively.

NOTE 8 NOTES PAYABLE   On November 1, 2013 the Company entered into a revolving line of credit with a bank in the amount of RMB 30,000,000. Advances on the line of credit are due one year from the date of the advance and are collateralized by certain land use rights, buildings and accounts receivable and bear interest at an annual rate of 6.6% (based upon 110% of the PRC governments current short term rate of 6.00%). The Companys Chief Executive Officer and Chair of the board of directors personally guaranteed the line of credit. The Company is in the process of obtaining an extension of the line of credit with the bank, and anticipates this to be completed during the fourth quarter.   The outstanding balance due under the revolving line of credit was RMB 30,000,000 as of September 30, 2014 and December 31, 2013 ($4,875,353 as of September 30, 2014 and $4,909,662 as of December 31, 2013).  The Company has no additional amounts available to it under this line of credit.  This amount has been classified as short-term notes payable in the accompanying condensed consolidated balance sheets at September 30, 2014 and December 31, 2013.

NOTE 9 CONSTRUCTION LOAN FACILITY   The Company obtained a construction loan facility in the amount of RMB 80,000,000 (approximately $13.0 million at September 30, 2014) from a construction loan facility dated June 21, 2013. The loan facility is for an eight-year term, which commenced on the initial draw-down date of July 11, 2013, and is from the same bank that currently provides the line of credit as discussed in Note 8.  The proceeds of the loan were used for and are collateralized by the construction of the Companys new production facility and the included production line equipment and machinery. The loan currently bears interest at 7.205% based upon 110% of the PRC governments eight-year term rate effective on the actual draw-down date, and is subjected to annual adjustments based on 110% of the floating rate for the same type of loan on the anniversary from the draw-down date and its subsequent anniversary dates.  The loan requires interest only payments for the first two years. Beginning July 11, 2015, the balance of the principal will be due in annual installments over the next six years through July 11, 2021. At September 30, 2014, the Company had no additional amounts available to it under this facility.   Fair Value of Notes Payable and Construction Loan Facility Based on the borrowing rates currently available to the Company for bank loans with similar terms and maturities, the carrying amounts of notes payable and the construction loan facility outstanding as of September 30, 2014 and December 31, 2013 approximated their fair value because of either the immediate or short-term maturity of these financial instruments or because the underlying instruments bear interest rates that approximated current market rates.

NOTE 10 - INCOME TAXES   Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax laws or rates are recognized in operations in the period that includes the enactment date.      Undistributed earnings of Helpson, the Companys foreign subsidiary, since its acquisition, amounted to approximately $76.9 million at September 30, 2014. Those earnings, as well as the investment in Helpson of approximately $23.3 million, are considered to be indefinitely reinvested and, accordingly, no U.S. federal or state income taxes have been provided thereon. Upon distribution of those earnings in the form of dividends or otherwise, the Company would be subject to U.S. federal and state income taxes (net of an adjustment for foreign tax credits) and withholding taxes payable to the PRC. Determination of the amount of unrecognized deferred U.S. income tax liability is not practicable because of the complexities associated with its hypothetical calculation; however, unrecognized foreign tax credits may be available to reduce a portion of the U.S. tax liability.   Under current tax law in the PRC, the Company is and will be subject to the following enterprise income tax rates:    <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="40%" style='width:40%'> <tr> <td valign="top" width="13%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="top" width="3%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:3%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="top" width="15%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:15%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Enterprise Income </td></tr> <tr> <td valign="top" width="13%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Year</td> <td valign="top" width="3%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:3%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="top" width="15%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:15%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Tax Rate</td></tr> <tr> <td valign="top" width="13%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:13%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2014</td> <td valign="top" width="3%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:3%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="top" width="15%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:15%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 15%</td></tr> <tr> <td valign="top" width="13%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:13%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2015</td> <td valign="top" width="3%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:3%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="top" width="15%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:15%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 15%</td></tr> <tr> <td valign="top" width="13%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:13%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2016</td> <td valign="top" width="3%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:3%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="top" width="15%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:15%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 15%</td></tr> <tr> <td valign="top" width="13%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:13%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Thereafter</td> <td valign="top" width="3%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:3%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="top" width="15%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:15%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 25%</td></tr></table></div>   The provision for income taxes consisted of the following:   <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%'> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="6" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Three Months Ended September 30,</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="6" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Nine Months Ended September 30,</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2014</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2013</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2014</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2013</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:52%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Current</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:52%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Deferred</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 19,215</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (472,512</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 57,758</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (1,129,506</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:52%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Total income tax expense (benefit)</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 19,215</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (472,512</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 57,758</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (1,129,506</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td></tr></table> The Company has net operating loss carryforwards for PRC tax purposes of approximately $10.16 million at September 30, 2014, of which approximately $6.83 million and $3.33 is available to offset future taxable income through 2018 and 2019, respectively.   In assessing the realizability of deferred tax assets, Management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.  The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized.  Management considers projected future taxable income and tax planning strategies in making this assessment.  Based upon an assessment of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets are deductible or can be utilized, Management believes it is not likely the Company will realize all of the benefits of the deferred tax assets as of September 30, 2014 and December 31, 2013.  Therefore, the Company has provided for a valuation allowance against its deferred tax assets of $6,450,846 and $4,915,960 as of September 30, 2014 and December 31, 2013, respectively.   The Company has also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable.

NOTE 11 FAIR VALUE MEASUREMENTS   Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value, a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Observable inputs other than Level 1 including quoted prices for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can be corroborated by observable market data. Level 3 Unobservable inputs supported by little or no market activity for financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.     The Company uses fair value to measure the value of the bankers acceptance notes it holds.  The bankers acceptance notes are recorded at cost which approximates fair value.  The Company held the following assets recorded at fair value as of September 30, 2014 and December 31, 2013:    <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%'> <tr> <td valign="bottom" width="49%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:49%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="34%" colspan="10" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:34%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Fair Value Measurements at</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="49%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:49%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="34%" colspan="10" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:34%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Reporting Date Using</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="49%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:49%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Description</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> September 30, 2014</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="10%" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:10%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Level 1</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="10%" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:10%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Level 2</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="10%" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:10%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Level 3</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="49%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:49%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Banker's acceptance notes</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 116,047</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 116,047</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="49%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:49%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Total</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:12%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 116,047</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:9%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:9%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 116,047</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:9%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="49%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:49%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:12%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:9%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:9%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:9%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="49%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:49%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:12%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="34%" colspan="10" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:34%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Fair Value Measurements at</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="49%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:49%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:12%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="34%" colspan="10" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:34%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Reporting Date Using</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="49%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:49%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Description</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> December 31, 2013</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="10%" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:10%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Level 1</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="10%" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:10%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Level 2</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="10%" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:10%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Level 3</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="49%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:49%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Banker's acceptance notes</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 336,003</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 336,003</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="49%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:49%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Total</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:12%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 336,003</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:9%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:9%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 336,003</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:9%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr></table>

NOTE 12 - STOCKHOLDERS' EQUITY   Preferred and Common Stock The total number of authorized shares is 95,000,000 shares of common stock and 5,000,000 shares of preferred stock. The preferred stock may be issued in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely by the Companys Board of Directors.   Stock and Stock Options On November 12, 2010, the Companys Board of Directors adopted, and on December 22, 2010, its stockholders approved the Companys 2010 Incentive Plan (the Plan), which gave the Company the ability to grant stock options, restricted stock, stock appreciation rights and performance units to its employees, directors and consultants, or those who will become employees, directors and consultants of the Company and/or its subsidiaries. The Plan currently allows for equity awards of up to 4,000,000 shares of common stock. Through September 30, 2014, there were 175,000 shares of restricted stock granted and outstanding under the Plan.    There were no securities issued from the Plan during the nine months ended September 30, 2014 and at September 30, 2014 there was no unrecognized compensation expense related to securities granted under the Plan.

NOTE 13 CONTINGENCIES   Economic environment - Substantially all of the Company's operations are conducted in the PRC, and therefore the Company is subject to special considerations and significant risks not typically associated with companies operating in the United States of America. These risks include, among others, the political, economic and legal environments and fluctuations in the foreign currency exchange rate. The Company's results from operations may be adversely affected by changes in the political and social conditions in the PRC, and by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely affect the Companys operations.   In addition, all of the Company's revenue is denominated in the PRC's currency of Renminbi (RMB), which must be converted into other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval of the PRC government.

NOTE 14 CONCENTRATIONS   At September 30, 2014, one customer accounted for 16.6% of accounts receivable.  At December 31, 2013, two customers accounted for 14.5% and 11.2% of accounts receivable.   For the nine months ended September 30, 2014, one customer accounted for 16.7% of sales. For the nine months ended September 30, 2013, no customer accounted for more than 10% of sales.   For the nine months ended September 30, 2014 and 2013, purchases from one supplier accounted for 31.8% and 20.6% of raw material purchases, respectively.

NOTE 15 SUBSEQUENT EVENTS   In November 2014 the Company received the manufacturing certificate from the CFDA relating to the Companys new manufacturing facility. This certificate enables the Company to commence production in the new facility in accordance with the new Good Manufacturing Practice standards promulgated by the CFDA effective March 1, 2011.

Organization and Nature of Operations China Pharma Holdings, Inc., a Nevada corporation, owns 100% of Onny Investment Limited (Onny), a British Virgin Islands corporation, that in turn owns 100% of Hainan Helpson Medical & Biotechnology Co., Ltd (Helpson), a corporation organized under the laws of the People's Republic of China (the PRC). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the Company.   The Foreign Investment Industrial Catalogue (the Catalogue) jointly issued by the Chinas Ministry of Commerce and the National Development and Reform Commission (as the latest version is the year 2012 version, effective January 30, 2012) classified various industries/businesses into three different categories: (i) encouraged for foreign investment; (ii) restricted to foreign investment; and (iii) prohibited from foreign investment. For any industry/business not covered by any of these three categories, they will be deemed industries/businesses permitted for foreign investment. A typical foreign investment ownership restriction in the pharmaceutical industry is that a foreign investment enterprise (the FIE) shall not have the whole or majority of its equity interests owned by a foreign owner if the FIE establishes more than 30 branch stores and distributes a variety of brands in those franchise stores, which is not the case of the Companys business.   Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located throughout the PRC. The Company believes Helpsons business is not subject to any ownership restrictions prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson from Helpsons three former shareholders on May 25, 2005 by entry into an Equity Transfer Agreement with such three parties on May 25, 2005. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishing of Enterprises with Foreign Investment in the PRC on the same day and its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.   The Company has and continues to acquire well-accepted medical formulas to add to its diverse portfolio of Western and Chinese medicines.

Consolidation and Basis of Presentation The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and are expressed in United States dollars. The accompanying consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.   Helpsons functional currency is the Chinese Renminbi. Helpsons revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpsons financial statements are included in accumulated other comprehensive income, which is a component of stockholders equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is a party to the transaction are included in the results of operations.

Reclassification - The Company has made certain reclassifications to the condensed consolidated statement of operations and cash flows for the three and nine months ended September 30, 2013 to conform to the presentation for the three and nine months ended September 30, 2014. These reclassifications had no effect on the condensed consolidated balance sheets, results of operations or cash flows as of or for the three and nine months ended September 30, 2013.

Condensed Financial Statements The accompanying unaudited condensed consolidated financial statements were prepared pursuant to the rules and regulations of the United States Securities and Exchange Commission (the Commission). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Management of the Company (Management) believes the following disclosures are adequate to make the information presented not misleading. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2013 filed with the Commission on March 20, 2014.      These unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) that, in the opinion of Management, are necessary to present fairly the consolidated financial position and results of operations of the Company for the periods presented. Operating results for the nine months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014.

Accounting Estimates - The preparation of financial statements in conformity with U.S. GAAP requires Management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

Basic and Diluted Loss per Common Share - Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per share is calculated to give effect to any potentially issuable dilutive common shares. There were no potentially dilutive common shares outstanding for all periods presented.   The following table is a presentation of the numerators and denominators used in the calculation of basic and diluted (loss) earnings per share:   <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%'> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="6" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> For the Three Months</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="6" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> For the Nine Months</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="6" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Ended September 30,</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="6" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Ended September 30,</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2014</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2013</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2014</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2013</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:52%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Net loss</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (6,327,724</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (2,302,031</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (17,361,167</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (9,578,163</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:52%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Basic weighted-average common shares outstanding</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 43,579,557</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 43,579,557</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 43,579,557</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 43,579,557</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:52%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Effect of dilutive securities:</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:52%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Warrants</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:52%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Options</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:52%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Diluted weighted-average common shares outstanding</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 43,579,557</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 43,579,557</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 43,579,557</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 43,579,557</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:52%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Basic loss per share</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (0.15</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (0.05</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (0.40</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (0.22</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:52%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Diluted loss per share</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (0.15</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (0.05</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (0.40</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (0.22</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td></tr></table>

The following table is a presentation of the numerators and denominators used in the calculation of basic and diluted (loss) earnings per share:   <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%'> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="6" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> For the Three Months</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="6" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> For the Nine Months</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="6" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Ended September 30,</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="6" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Ended September 30,</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2014</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2013</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2014</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2013</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:52%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Net loss</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (6,327,724</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (2,302,031</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (17,361,167</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (9,578,163</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:52%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Basic weighted-average common shares outstanding</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 43,579,557</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 43,579,557</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 43,579,557</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 43,579,557</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:52%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Effect of dilutive securities:</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:52%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Warrants</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:52%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Options</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:52%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Diluted weighted-average common shares outstanding</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 43,579,557</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 43,579,557</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 43,579,557</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 43,579,557</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:52%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Basic loss per share</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (0.15</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (0.05</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (0.40</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (0.22</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:52%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Diluted loss per share</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (0.15</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (0.05</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (0.40</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (0.22</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td></tr></table>

Inventory consisted of the following:    <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="80%" style='width:80%'> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:70%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> September 30,</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> December 31,</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:70%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2014</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2013</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:70%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Raw materials</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 19,571,419</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 28,259,707</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:70%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Work in process</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 853,602</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:70%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Finished goods</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 4,113,606</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 3,590,937</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:70%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 23,685,025</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 32,704,246</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:70%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Obsolescence reserve</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (4,670,853</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (8,027,126</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:70%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Total Inventory</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 19,014,172</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 24,677,120</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr></table></div>

Property and equipment consisted of the following:     <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="85%" style='width:85%'> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:70%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> September 30,</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> December 31,</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:70%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2014</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2013</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:70%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Permit of land use</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 457,743</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 460,964</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:70%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Building</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 10,033,988</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2,494,623</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:70%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Plant, machinery and equipment</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 16,393,856</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 6,671,620</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:70%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Motor vehicle</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 150,611</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 151,670</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:70%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Office equipment</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 246,553</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 229,210</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:70%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Construction in progress</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 12,537,905</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 25,497,600</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:70%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Total</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 39,820,656</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 35,505,687</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:70%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Less: accumulated depreciation</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (5,951,165</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (5,264,350</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:70%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Property and Equipment, net</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 33,869,491</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 30,241,337</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr></table></div>

A reconciliation of total interest cost incurred to interest expense as recognized in the consolidated statement of operations is as follows:   <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%'> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="6" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> For the Three Months</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="6" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> For the Nine Months</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="6" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Ended September 30,</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="6" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Ended September 30,</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2014</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2013</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2014</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2013</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:52%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Total interest cost incurred</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 330,995</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 89,238</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 952,836</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 263,732</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:52%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Interest cost capitalized</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 5,751</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 457,782</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:52%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Interest expense</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 325,244</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 89,238</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 495,054</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 263,732</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr></table>   Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:   <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="50%" style='width:50%'> <tr> <td valign="top" width="33%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:33%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Asset</td> <td valign="top" width="2%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:2%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="top" width="13%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  Life - years</td></tr> <tr> <td valign="top" width="33%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:33%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Permit of land use</td> <td valign="top" width="2%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:2%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="top" width="13%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:13%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 40 - 70</td></tr> <tr> <td valign="top" width="33%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:33%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Building</td> <td valign="top" width="2%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:2%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="top" width="13%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:13%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 20 - 49</td></tr> <tr> <td valign="top" width="33%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:33%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Plant, machinery and equipment</td> <td valign="top" width="2%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:2%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="top" width="13%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:13%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 10</td></tr> <tr> <td valign="top" width="33%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:33%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Motor vehicle</td> <td valign="top" width="2%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:2%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="top" width="13%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:13%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 5 - 10</td></tr> <tr> <td valign="top" width="33%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:33%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Office equipment</td> <td valign="top" width="2%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:2%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="top" width="13%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:13%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 3-5</td></tr></table></div>   For the three months ended September 30, 2014 and 2013, depreciation expense was $321,020 and $210,182.  For the nine months ended September 30, 2014 and 2013, depreciation expense was $724,509 and $640,550. As of September 30, 2014 and December 31, 2013, intangible assets consisted solely of CFDA approved medical formulas as follows:   <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="80%" style='width:80%'> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:70%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> September 30,</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> December 31,</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:70%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2014</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2013</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:70%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Gross carrying amount</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 5,486,178</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 5,524,785</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:70%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Accumulated amortization</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (4,075,696</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (3,812,992</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td></tr> <tr> <td valign="bottom" width="70%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:70%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Net carrying amount</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 1,410,482</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 1,711,793</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr></table></div>   Under current tax law in the PRC, the Company is and will be subject to the following enterprise income tax rates:    <div align="center"> <table border="0" cellspacing="0" cellpadding="0" width="40%" style='width:40%'> <tr> <td valign="top" width="13%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="top" width="3%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:3%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="top" width="15%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:15%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Enterprise Income </td></tr> <tr> <td valign="top" width="13%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Year</td> <td valign="top" width="3%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:3%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="top" width="15%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:15%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Tax Rate</td></tr> <tr> <td valign="top" width="13%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:13%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2014</td> <td valign="top" width="3%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:3%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="top" width="15%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:15%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 15%</td></tr> <tr> <td valign="top" width="13%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:13%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2015</td> <td valign="top" width="3%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:3%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="top" width="15%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:15%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 15%</td></tr> <tr> <td valign="top" width="13%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:13%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2016</td> <td valign="top" width="3%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:3%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="top" width="15%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:15%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 15%</td></tr> <tr> <td valign="top" width="13%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:13%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Thereafter</td> <td valign="top" width="3%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:3%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="top" width="15%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:15%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 25%</td></tr></table></div> The provision for income taxes consisted of the following:   <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%'> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="6" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Three Months Ended September 30,</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="6" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Nine Months Ended September 30,</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2014</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2013</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2014</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 2013</td> <td valign="bottom" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:52%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Current</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:52%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Deferred</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 19,215</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (472,512</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 57,758</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (1,129,506</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:white;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td></tr> <tr> <td valign="bottom" width="52%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:52%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Total income tax expense (benefit)</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 19,215</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (472,512</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 57,758</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> (1,129,506</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> )</td></tr></table> .  The Company held the following assets recorded at fair value as of September 30, 2014 and December 31, 2013:    <table border="0" cellspacing="0" cellpadding="0" width="100%" style='width:100%'> <tr> <td valign="bottom" width="49%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:49%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="34%" colspan="10" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:34%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Fair Value Measurements at</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="49%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:49%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="34%" colspan="10" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:34%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Reporting Date Using</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="49%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:49%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Description</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> September 30, 2014</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="10%" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:10%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Level 1</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="10%" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:10%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Level 2</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="10%" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:10%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Level 3</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="49%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:49%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Banker's acceptance notes</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 116,047</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 116,047</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="49%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:49%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Total</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:12%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 116,047</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:9%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:9%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 116,047</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:9%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="49%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:49%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:12%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:9%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:9%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="9%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:9%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="49%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:49%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:12%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="34%" colspan="10" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:34%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Fair Value Measurements at</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="49%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:49%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>   </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="12%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:12%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="34%" colspan="10" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:34%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Reporting Date Using</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="49%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:49%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Description</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="13%" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:13%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> December 31, 2013</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="10%" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:10%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Level 1</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="10%" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:10%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Level 2</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="10%" colspan="2" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:10%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Level 3</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="49%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:49%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Banker's acceptance notes</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:12%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 336,003</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 336,003</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 1.5pt solid;border-left:#f0f0f0;padding-bottom:0cm;padding-left:0cm;width:9%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:1.5pt;padding-left:0cm;width:1%;padding-right:0cm;background:azure;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr> <tr> <td valign="bottom" width="49%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:49%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> Total</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="12%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:12%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 336,003</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:9%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:9%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> 336,003</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td> <td valign="bottom" width="1%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> $</td> <td valign="bottom" width="9%" style='border-bottom:black 2.25pt double;border-left:#f0f0f0;padding-bottom:0cm;background-color:transparent;padding-left:0cm;width:9%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'> -</td> <td valign="bottom" width="1%" style='border-bottom:#f0f0f0;border-left:#f0f0f0;padding-bottom:3pt;background-color:transparent;padding-left:0cm;width:1%;padding-right:0cm;border-top:#f0f0f0;border-right:#f0f0f0;padding-top:0cm'>  </td></tr></table> NOTE 2 LOSSES FROM NATURAL DISASTER   On July 18, 2014, the Companys manufacturing facilities and inventory sustained storm damage from a powerful tropical typhoon that hit Haikou on that date. The losses are comprised of $2,015,248 of inventory related costs and $260,345 of facilities damage costs.  The Company received minor insurance compensation as only the building of new plant was insured and the damage to it was minor.   The Company assessed whether any asset impairment had occurred as a result of the storm. Based on the assessment, no impairment was considered necessary. In addition, the Company assessed whether the damage caused by the tropical typhoon resulted in exposure to environmental remediation liability. Based on the assessment, the Company determined that no such exposure has occurred. 1.0000 1.0000 1.0000 43579557 43579557 43579557 43579557 0 0 43579557 43579557 43579557 43579557 -0.15 -0.06 -0.4 -0.22 -0.15 -0.06 -0.4 -0.22 19571419 28259707

853602

4113606 3590937 23685025 32704246 -4670853 -8027126 19014172 24677120 457743 460964 10033988 2494623 16393856 6671620 150611 151670 246553 229210 12537905 25497600 39820656 35505687 -5951165 -5264350 33869491 30241337 40 to 70 years 20 to 35 years 10 years 5 to 10 years 3 to 5 years 330995 89238 952836 263732 5751 457782 321020 210182 724509 640550 5486178 5524785 -4075696 -3812992 1410482 1711793 1354567 1354567 0.0100 0.0100 10159 10159 30000000 0.0660 4875353 4909662 80000000 0.0721 12983008 76.9 23.3 0.1500 0.1500 0.1500 0.2500 10.16

6450846

4915960

19215

-472512

57758

-1129506

19215 -472512 57758 -1129506 116047 336003 116047 336003 0 0 0 0 116047 336003 116047 336003 0 0 0 0 95000000 5000000 4000000 175000 0.1670 0 0.3180 0.2060 0.1000 0.1450 0.1120 0 0 2015248 260345 96382 131585 289712 399166 10-Q 2014-09-30 false CHINA PHARMA HOLDINGS, INC. 0001106644 --12-31 43579557 Smaller Reporting Company Yes No No 2014 Q3 0001106644 2014-01-01 2014-09-30 0001106644 2014-11-10 0001106644 2014-09-30 0001106644 2013-12-31 0001106644 2014-07-01 2014-09-30 0001106644 2013-07-01 2013-09-30 0001106644 2013-01-01 2013-09-30 0001106644 2014-07-18 0001106644 2013-11-01 0001106644 2013-06-21 shares iso4217:USD iso4217:USD shares pure EX-101.SCH 6 cphi-20140930.xsd 000340 - Statement - Reconciliation of Total Interest incurred cost (Details) link:presentationLink link:definitionLink link:calculationLink 000240 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:definitionLink link:calculationLink 000100 - Disclosure - INTANGIBLE ASSETS link:presentationLink link:definitionLink link:calculationLink 000390 - Statement - CONSTRUCTION LOAN FACILITY (Details) link:presentationLink link:definitionLink link:calculationLink 000130 - Disclosure - NOTES PAYABLE link:presentationLink link:definitionLink link:calculationLink 000030 - Statement - Balance Sheets Parentheticals link:presentationLink link:definitionLink link:calculationLink 000180 - Disclosure - CONTINGENCIES link:presentationLink link:definitionLink link:calculationLink 000360 - Statement - INTANGIBLE ASSETS SFDA Approved Medical Formulas (Details) link:presentationLink link:definitionLink link:calculationLink 000150 - Disclosure - INCOME TAXES link:presentationLink link:definitionLink link:calculationLink 000230 - Disclosure - INVENTORY(Tables) link:presentationLink link:definitionLink link:calculationLink 000110 - Disclosure - ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS. link:presentationLink link:definitionLink link:calculationLink 000450 - Statement - CONCENTRATIONS Accounts Receivable (Details) link:presentationLink link:definitionLink link:calculationLink 000270 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:definitionLink link:calculationLink 000190 - Disclosure - CONCENTRATIONS link:presentationLink link:definitionLink link:calculationLink 000040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED) link:presentationLink link:definitionLink link:calculationLink 000210 - Disclosure - Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 000050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) link:presentationLink link:definitionLink link:calculationLink 000330 - Statement - PROPERTY AND EQUIPMENT Assets Life (Details) link:presentationLink link:definitionLink link:calculationLink 000280 - Statement - BASIS OF PRESENTATION (Details) link:presentationLink link:definitionLink link:calculationLink 000260 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:definitionLink link:calculationLink 000080 - Disclosure - INVENTORY. link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:definitionLink link:calculationLink 000160 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:definitionLink link:calculationLink 000420 - Statement - FAIR VALUE MEASUREMENTS At Reporting Date Using (Details) link:presentationLink link:definitionLink link:calculationLink 000140 - Disclosure - CONSTRUCTION LOAN FACILITY. link:presentationLink link:definitionLink link:calculationLink 000380 - Statement - Revolving line of credit (Details) link:presentationLink link:definitionLink link:calculationLink 000200 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:definitionLink link:calculationLink 000070 - Disclosure - LOSSES FROM NATURAL DISASTER link:presentationLink link:definitionLink link:calculationLink 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 000090 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:definitionLink link:calculationLink 000060 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:definitionLink link:calculationLink 000310 - Statement - Inventory consisted of the following (Details) link:presentationLink link:definitionLink link:calculationLink 000170 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 000370 - Statement - RELATED PARTY TRANSACTIONS Owings (Details) link:presentationLink link:definitionLink link:calculationLink 000290 - Statement - BASIS OF PRESENTATION Basic and Diluted Earnings per Common Share (Details) link:presentationLink link:definitionLink link:calculationLink 000220 - Disclosure - BASIS OF PRESENTATION (Tables) link:presentationLink link:definitionLink link:calculationLink 000350 - Statement - ASSETS Depreciation (Details) link:presentationLink link:definitionLink link:calculationLink 000250 - Disclosure - INTANGIBLE ASSETS (Tables) link:presentationLink link:definitionLink link:calculationLink 000120 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:definitionLink link:calculationLink 000365 - Statement - Amortization expense (DETAILS) link:presentationLink link:definitionLink link:calculationLink 000320 - Statement - Property and equipment consisted of the following (Details) link:presentationLink link:definitionLink link:calculationLink 000440 - Statement - CONCENTRATIONS Sales And Purchases (Details) link:presentationLink link:definitionLink link:calculationLink 000430 - Statement - Preferred Common Stock And Warrants (Details) link:presentationLink link:definitionLink link:calculationLink 000300 - Statement - LOSSES FROM NATURAL DISASTER (DETAILS) link:presentationLink link:definitionLink link:calculationLink 000410 - Statement - INCOME TAXES Provision (Details) link:presentationLink link:definitionLink link:calculationLink 000400 - Statement - INCOME TAXES Undistributed Earnings And Income Tax Rates (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 cphi-20140930_cal.xml EX-101.DEF 8 cphi-20140930_def.xml EX-101.LAB 9 cphi-20140930_lab.xml Bankers acceptance notes Level 3 Bankers acceptance notes Level 3 Amount drawn under line of credit Amount drawn under line of credit Accumulated amortization Intangible assets SFDA Approved Medical Formulas Accumulated amortization Intangible assets SFDA Approved Medical Formulas Motor vehicle The amount of motor vehicle gross as on the date Building Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing. Property and equipment consists INCOME TAXES {1} INCOME TAXES LOSSES FROM NATURAL DISASTER: Trade accounts payable {1} Trade accounts payable Interest income Allowance for doubtful accounts ,Trade accounts receivables Advances to suppliers Carrying amount as of the balance sheet date of advances to suppliers. Current Fiscal Year End Date No of customers accounted for more than 10.0% of accounts receivable No of customers accounted for more than 10.0% of accounts receivable Enterprise Income Tax Rates for the year 2016 There after Enterprise Income Tax Rates for the year 2016 There after Amortization expense (DETAILS) INTANGIBLE ASSETS SFDA Approved Medical Formulas Construction in progress Gross amount, at the balance sheet date, of long-lived assets under construction that include construction costs to date on capital projects that have not been completed and assets being constructed that are not ready to be placed into service. Plant, machinery and equipment The amount of plant machinery and equipment gross as on the date. LOSSES FROM NATURAL DISASTER DETAILS Percentage of share owned by China Pharma Holdings Inc of Helpson Medical & Biotechnology Co., Ltd. PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1 Reclassification Cash paid for income taxes Cash Flows from Financing Activities: Allowance for doubtful accounts , Other receivables A valuation allowance for other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible Banker's acceptances Common shares authorized The maximum number of common shares permitted to be issued by an entity's charter and bylaws. Property and Equipment, net Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. Inventory obsolescence reserve {1} Inventory obsolescence reserve Allowance for doubtful other receivables deferred tax Inventory related costs Gross amount of an expenditure that is incurred in the current period but rather capitalized as a component of inventory Diluted loss per share The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Organization and operations Intangible Assets Medical Formulas Tabluar disclosure of Intangible Assets Medical Formulas STOCKHOLDERS' EQUITY Accounts payable for purchases of property and equipment Supplemental Cash Flow Information: Purchases of property and equipment and construction in process Purchases of property and equipment and construction in process Depreciation and amortization Research and development expenses Research and development expense during the period related to the costs of developing and achieving technological feasibility of a computer software product to be sold, leased, or otherwise marketed. Selling expenses Current Liabilities: Current Assets: Entity Registrant Name Number of common stock shares to purchase by warrants outstaning and exercisable Number of common stock shares to purchase by warrants outstaning and exercisable Bankers acceptance notes Level 2 Bankers acceptance notes Level 2 Bankers acceptance notes Bankers acceptance notes, Revolving line of credit with a bank RevolvingLineOfCreditWithABank1 Gross carrying amount Gross carrying amount RELATED PARTY TRANSACTIONS {1} RELATED PARTY TRANSACTIONS INTANGIBLE ASSETS {1} INTANGIBLE ASSETS Advances for purchases of equipment paid with banker's acceptances Advances for purchases of equipment paid with banker's acceptances Accounts receivable collected with banker's acceptances Accounts payable for purchases of property and equipment Other comprehensive income - foreign currency translation adjustment Income tax benefit (expense) Loss from operations Total operating expenses Total operating expenses Total Stockholders' Equity Total Stockholders' Equity Document Fiscal Year Focus Entity Well-known Seasoned Issuer Amendment Flag Percentage of one customer accounted for more than sales Percentage of one customer accounted for more than sales Loan interest rate per annum Loan interest rate per annum Construction loan facility details ConstructionLoanFacilityDetailsAbstract [Abstract] Reconcialition of Total interest details ReconcialitionOfTotalInterestDetailsAbstract [Abstract] Total Inventory Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer). BASIS OF PRESENTATION Basic and Diluted Earnings per Common Share Presentation of the numerators and denominators used in the calculation of basic and diluted earnings per share STOCKHOLDERS' EQUITY {1} STOCKHOLDERS' EQUITY ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS Net Cash Provided by Operating Activities Net Cash Provided by Operating Activities Inventory, less allowance for obsolescence of $4,670,853 and $8,027,126, respectively Cash and cash equivalents ASSETS Entity Filer Category Enterprise Income Tax Rates for the year 2015 EnterpriseIncomeTaxRatesForTheYear2015 INCOME TAXES Undistributed Earnings Adavances owing to board member Adavance owing to boardmember Assets Depreciation Total interest cost incurred TotalInterestCostIncurred Plant, machinery and equipment life Plant, machinery and equipment life in years Condensed Financial Statements Organization and Nature of Operations CONSTRUCTION LOAN FACILITY Cash paid for interest Effect of Exchange Rate Changes on Cash Common Stock, par value Construction loan facility TOTAL ASSETS TOTAL ASSETS Percentage of accounts receivable by two customer Percentage of accounts receivable by two customer Interest rate on advances from Member of BOD Interest rate on advances from Member of BOD Diluted weighted-average common shares outstanding DilutedWeightedAverageCommonSharesOutstanding2 Basic weighted-average common shares outstanding BasicWeightedAverageCommonSharesOutstanding1 FAIR VALUE MEASUREMENTS Cash and Cash Equivalents at Beginning of Period Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Net Cash Provided by Financing Activity Net Cash Provided by Financing Activity Inventory Changes in assets and liabilities: Gross profit Gross profit Common stock, $0.001 par value; 95,000,000 shares authorized; 43,579,557 shares and 43,579,557 shares outstanding, respectively Total Current Liabilities Total Current Liabilities Total Current Assets Total Current Assets Entity Common Stock, Shares Outstanding RELATED PARTY TRANSACTIONS Owings Interest cost capitalized InterestCostCapitalized1 Total Property and Equipment Total Property and Equipment Office equipment Gross amount, at the balance sheet date, of long-lived assets under construction that include construction costs to date on capital projects that have not been completed and assets being constructed that are not ready to be placed into service. Provision For Income Taxes Tabluar disclosure of Provision For Income Taxes. INVENTORY Cash Flows from Investing Activities: Preferred Stock, shares authorized Allowance for obsolescence, Inventories Allowance for obsolescence, Inventories Total Liabilities Total Liabilities LIABILITIES AND STOCKHOLDERS' EQUITY Intangible assets, net of accumulated amortization of $4,075,696 and $3,812,992, respectively Trade accounts receivable, less allowance for doubtful accounts of $27,912,179 and $13,301,622, respectively Document and Entity Information Percentage of no customer accounted for more than sales Percentage of no customer accounted for more than sales CONCENTRATIONS Sales And Purchases Total Total bankers acceptance notes Deferred tax provision. Enterprise Income Tax Rates for the year 2014 EnterpriseIncomeTaxRatesForTheYear2014 Outstanding balance due under revolving line of credit (RMB 30,000,000) Outstanding balance due under revolving line of credit (RMB 30,000,000) Work in process Losses comprised Losses comprised of natural disaster Accounting Estimates CONTINGENCIES {1} CONTINGENCIES CONTINGENCIES NOTES PAYABLES Advances to suppliers {1} Advances to suppliers Other receivables Net loss {1} Net loss Other receivables, less allowance for doubtful accounts of $70,004 and $43,064, respectively Document Fiscal Period Focus Percentage of purchases from two supplier of raw materials Percentage of purchases from two supplier of raw materials Total Level 2 Bankers acceptance notes Level 2 total Annual interest rate Annual interest rate Depreciation Expense property and equipment Depreciation Expense property and equipment Property and equipment consisted of the following: Assets Fair Value Tabular disclosure of assets vair value. Useful lives of the assets Tabular disclosure of useful lives of the assets. A reconciliation of total interest cost incurred to interest expense Tabular disclosure for reconciliation of total interest cost incurred to interest expense Consolidation and Basis of Presentation ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS. The entire disclosure of advances for purchases of intangible assets. Net (Decrease) Increase in Cash and Cash Equivalents Advances from customers {1} Advances from customers Trade accounts receivable Other income (expense): General and administrative expenses Common Stock, shares issued Preferred Stock, par value TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Additional paid-in capital Trade accounts payable Property and equipment, net of accumulated depreciation of $5,951,165 and $5,264,350, respectively Entity Public Float FAIR VALUE MEASUREMENTS At Reporting Date Using Net operating loss carryforwards for PRC tax purposes in millions Net operating loss carryforwards for PRC tax purposes in millions Office equipment life Office equipment life in years Permit of land use The amount of permit of land use as on the date. Finished goods Rawmaterials1 Current Taxes Tabluar disclosure of Provision For Income Taxes. Inventory consists BASIS OF PRESENTATION Advances for purchases of intangible assets {1} Advances for purchases of intangible assets Loss before income taxes Losses from natural disaster Losses from natural disaster Advances for purchases of intangible assets AdvancesForPurchasesOfIntangibleAssets Document Period End Date Document Type Total Level 1 Bankers acceptance notes total Level 1 Investment in Helpson, a foreign subsidiary for the company in millions Investment in Helpson, a foreign subsidiary for the company in millions Construction loan amount in total Construction loan amount available to draw by the company PROPERTY AND EQUIPMENT Assets Life Inventory consisted of the following: FAIR VALUE MEASUREMENTS (Tables) FAIR VALUE MEASUREMENTS {1} FAIR VALUE MEASUREMENTS INTANGIBLE ASSETS Advances for purchases of intangibles paid with banker's acceptances Advances for purchases of intangibles paid with banker's acceptances Proceeds from construction term loan Bad debt expense {1} Bad debt expense Amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected). Cost of revenue Preferred Stock, shares issued Retained earnings Non-current Liabilities: Entity Current Reporting Status Entity Central Index Key Net deferred tax asset, Undistributed earnings of Helpson in millions Undistributed earnings of Helpson in millions Net carrying amount Net carrying amount Permit of land use life Permit of land use life in years Basic loss per share The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. BASIS OF PRESENTATION (Tables) Basic and Diluted (Loss) Earnings per Common Share EX-101.PRE 10 cphi-20140930_pre.xml XML 11 R39.htm IDEA: XBRL DOCUMENT

Revolving line of credit (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Nov. 01, 2013
Revolving line of credit
Revolving line of credit with a bank			$ 30,000,000
Annual interest rate			6.60%
Outstanding balance due under revolving line of credit (RMB 30,000,000)	$ 4,875,353	$ 4,909,662

EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0`!@`(````(0!(8>].!`(``)T<```3``@"6T-O;G1E;G1?5'EP97-= M+GAM;""B!`(HH``"```````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M```````````````````````````````````````````````````````````` M``````````````````````````````````````#,F=UJVS`8AL\'NP>CTQ$K MDKRN&W%ZL)_#K;#N`E3K2VQB2T)2N^3N)SMM&25+"0WL/8E)+'WO$X&?`[^+ MJ^W0%_<48N=LS40Y9P79QIG.KFOVZ^;;[)(5,6EK=.\LU6Q'D5TMW[Y9W.P\ MQ2+OMK%F;4K^$^>Q:6G0L72>;+ZSLFFGO^Z[1*9/R>VN>I

$LJ\DK,5=SI@<^J+QK+/D/F0#:?RL7E'P`` M`/__`P!02P,$%``&``@````A`+55,"/U````3`(```L`"`)?]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7^ZBRBXL:NI3\(V(T M'4\4"_'L)MI<3_3_ MMCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X8<'%#U1?````__\# M`%!+`P04``8`"````"$`)NK?!#("``#0&P``&@`(`7AL+U]R96QS+W=O7 M3Q_N3!%3U375ON]":8XAFL?U^WF]*,SXU34[P&@&(3=H`0V M*,\VQ1Z:8C8-A&$GSI0W]NI_N/5/````__\#`%!+`P04``8`"````"$`_)MV M],P$``#Z#0``#P```'AL+W=O-`3+L288N0+;23]]5SAQ%^1T[LF6\?ZUN_JM=KGZ M_KHN!SNN:B&K:\O^,K(&O"KD0E3/U]8\F_WQS1K435XM\E)6_-IZX[7U_>;W MWZ[V4KT\2?DR`(&JOK963;.Y'`[K8L77>?U%;G@%3Y92K?,&ENIY6&\4SQ?U MBO-F70Z=T>A\N,Y%91T4+M6O:,CE4A3>=']1V,]F*$IY>N"/7&MX< M@TS48,&7^;9L,@CO0QWRY8P=YUS_4Z?B7O!]_9^17@Y>'T2UD'O]5TCMVW'E M@@/[]M#0K>#X:C8Z_W7+QO&H^?@3Y(=)O,PC[M)^#J@WO(R,,3HKY52.: M-Q94A^P+"4>HLQY`9+8U4)<"OJA@86O'L]"$-W#QG'ZB"TND,6WOD62QHF? M9H^,1![S_YP'R1TH(/,S`/*XX47?/(`PHQ_!)/09`?\SBBT[%(WZIL2[U[Q` MR''*DGDZO24Z`9`_+8IU,$>V@6/JARU_"=%A9"F)*)GJU'=\P1C9!HQ1G,'6 M"7DD$`G>&G-CG\*/9NF\W8V%,8G8C$R#,,AP_L\P-+8!7Q!-XSN?9>0OO^/P M.4J[;;`V(T'*[DDX]]F=3^@\!=RC;O8Q;;:!&\WBZ<_;./3\E+;GWO494V8; MF$'!9$'TPX^F0==IC)IML`9F4_`R;0L#!WN.&;,-R.A\0@%-,&6^YKMCBB&# MR[-W5Y&BD%NXZ*IGELA2%(+#5?/^!9WS.4;,,1`[6=DLRY]*7F,5%YV98T!V M+$[3$&/F&)B=KM$3^V/2G!.D]6KUA`*FSC&HPZR>,,;$'?H=ON`^0?:$#H;/ M,>`[?1@>;W+1:1Q.1\:`\;3,)*]%`>T1G:J#H89%C[#_N[>9AW1<##DL>CI! MM8,&*-4;*V!($37,'TPN&;1$MI0PEAQ[D(N)AT5/)U$P5"EH[+K'\[^W8J-G MH`]1K(.9=PU:/X&.U+5NUU@'4^\:\*84R28O8>YHN.)8!Q>! M:]![:"_,XS`?%N]BYJ'K@>G8K6#12X[1KAB=>821S4;)7<<97`BN<7N2M52- M^.<0$G^%*;;FS/,S$H3XX%3@U%V#913OI/E3M]QI:BX M3G&A.$RPD"PH"JR#478-E/4X=[J=:26D,\8HPZ(75^>:F%<+@%F)IZTFVL\5 MUL$HCPV4.SK`]4[H]X]#5)U2'V.48='SY[.;AS0LY1OL#T9Y;*"<*+[D"E++ MIG*]!D]H(XL71J#0'KIQ893'!LK=/LAH#FVD54FVJEAA?S#-8X/FGLY[KZLA MJ(*+'=;!-(];FH?M?0+O!S!N%_#BHC_TY-\>YO#CM>WF7P```/__`P!02P,$ M%``&``@````A`!CN8L(3!P``V!P``!@```!X;"]W;W)K547Y6GEL87OS?+3IMP6IY>5 M]\_?7^;:F]5-=MIFA_*4K[P?>>U]>OKYI\>WLOI:[_.\F8&%4[WR]DUS?E@N MZ\T^/V;UHCSG)_AE5U;'K(&OUTBY]I9/CZV#_BWRM]KY?U;OR[=?JF+[>W'*P=L0)Q.! MY[+\:M#?MN82W+P2R?`.*T%G!3X'*_=.!2;=ZH'/P#VVM(E6]/2C\NOT%T-QT2OX-$&%E?$!-+8S:Y7!C,,GQ+>B%,(H&B7A;$ MS97U?LY<9F]@,_O+N+&]`+9[.1R/NQX3VL=(,D:(D71,.$:0'$B_Z7(,#,GN MS%X3M\46@73L!09X]NN;1'*32*\12!Y,9+H\`Z\\\%T_=TT<&UM$MXDH91C* M0!!Y+J$9"V5$DC%Q"::UST.?#).Z"`]$Q`4;'(T$0D5-%VA@(I!,/[9(V`H, M?*D")W':TEF[A-2AD%IA%R0NP3AG4LD0(RE"E!8JTH.;D,#P'H$&)@))^L46 M`0?W02;$VA+6!3#W@,J[:2%U+0@%'N)#"2-QL*Y-CYZ!B3B)W1I;Y#)U/_)# M$M^U2W`N%`^)C<0E0@BP#FCP7()KIJ63OTB>:9B<+>#Z6FE@LKB0@6.+7(O= M32*Y2:37""0OND>>@4GT2&+%%K'14X&,%-&_=H&(@^.'1<%N:R[`620T)_%/ M$1$(*:-A[4'B&+15TX/7TD3>:)\V%E=>M[9PKOA0\G9IZ:Q8`G)3AL1&@@A8 M6Z)`$R3%B!2A%H.;L$2SQT_.3V8[`K0]$`%QQW0%J)F*:`@1(20?;P^(X))# M#(?5H_53BA`F=,"=.L<232H'2S3M`;39=I&`L62!"HVCW;]NA-*7X]JT@(@ M]:.>(+EE(^V`]VU@@:8[F"[0]A)((*FWF+G]QAQ6%.X[W527K8CAH592$$8D9I9YW\V=TIM(A7!(DV_,%VD[2Y0/$D^QLPRMBZUYB3>:_0[YWQ4D>[]@8)='I=LB@P$VME? ML#+3+$Q79EL+I&S(BV[%<=N/N8#=;;QY($3#H\]('B*"2/J2>"AE"('=48EA M24(:^5UM3DN3595,+^X8&[VY8&'@=/\V13&BE<_(+IM@(@A4R(;ULC628H1+ M'7W4AO.[^IR6)AK)V'''=!I#X<,S`&'6F($N(!@]+">884KX(J"&4@+YRE?A M1[L'A_2;GK(MC:4RGX0B[J!.*X.^FY33&A$!M*UL2+8V5@DBYE(I2;(F101C M'+)Z6!9PQIJ^8W)57N)HWI7VV/>$)/NCOED.X\[R+ZLFH?P MK`1O(G#$UIAA`6>*$4\DA-%<1XR3T*<8DO#:"QY/^\&PU+L:(&X;%[.,L99RO)LKB#KHBS5GI@+(X`(W'D]Y$X>V!D#S&.>?62 MK_/#H9YMRE=S&"3`[?W5_J#J,S@('6^WU97\#G"N=LY?\ MCZQZ*4[U[)#O8"A_H:#`*WLR9;\TY;D]4GDN&SA1:O_=PPEB#H<9_@+@75DV MER_FR*(_DWSZ'P``__\#`%!+`P04``8`"````"$`OB9!QY8"``!/!@``&0`` M`'AL+W=O>>OUL>A+Q7+6,:`<.@ M2MQJ/2Y\7U4MZZGRQ,@&>-,(V5,-2[GSU2@9K6U1W_EA$*1^3_F`'<-"OH5# M-`VOV*VH]CT;M".1K*,:]*N6C^K(UE=OH>NIO-^/5Y7H1Z#8\H[K)TN*45\M M/NT&(>FV`]^/)*;5D=LN+NA[7DFA1*,]H/.=T$O/A5_XP+1:UAPD6K%X8/D]6<^,`@;QF0&L!7BWD`_U>8G*/8OJN_L M`+Y*5+.&[CO]31P^,KYK-4P[`4/&UZ)^NF6J@D"!Q@NMC$IT(``^4<_-SH!` MZ*/]/O!:MR6.4B_)@H@`'&V9TG?<4&)4[946_2\'(D;41!(^DT2@_OE]Z(5Y M0I+TWRR^4V0-WE)-5TLI#@@V#?14(S5;D"R`V3B+()^7G8$:4W-CBFPIH!5, MXV$5)?G2?X`(JV?,^A(3SA&;%Q#%!/%!WR02K/^_2%,$9C`Z$WGBMT;6#A.? M8>))@45L7D/,-$*CAVR*YAJC-)CX77X.DUJ-5W&0)6F1SB&;&23*25@4 MIXTP4PF*SE6^GJ`!S]6%839OO788ER")21#GI\YNNC-$1DA6G*;@M+D[P1V9 MD>[8%RIW?%"H8PVD&'@94$AW([B%%J,]&ENAX23;QQ8N;@;G)O``W`BACPMS MYTQ_!:O?````__\#`%!+`P04``8`"````"$`-1(=:L$"``#]!@``&0```'AL M+W=O/SWN.?5C?/M45>F12<='$ MF#@SC%B3BHPW18Q_?+^_B3!2FC89K43#8OS,%+[=O'^W/@GYH$K&-`)"HV)< M:MVN7%>E):NI:-=I")*NHAOA5R5O5T^KT+;B:RH=C>Y.*N@7$@5=W8WF.!KGDJA1*X=P+DVT*GGI;MT@;199QP"K M1!G+Z;'2W\3I(^-%J:':`1@ROE;9<\)4"@D%C.,%AI2*"@*`7U1SI?5D3.*`OQSA!8<880S_&B@`3A MZQ371M093*BFF[44)P2'!O94+35'D*R`W#NS<0Q>_V45/!K(G:'$>($1N%!0 MGL>-'Y*U^P@Y3<^:[52S6%Y*=KW$9-!PDW[B#_>*NN\5IGQ@:?`%V1K[^GNE M^O"-V(3?[[NU$\`>_'A7H4X5T>Q2DDPE5Y#]5#&"7-CQ_\>.$<,1&T7OAU=; M;ZUF/M+,+\/?O:I(7E7L7U)<^(-`QN4RQ]"':_IRV5A-WY/?!)$P24@&0N\:+D@5P3H.R8*NX._7)(P'`C6HFTK]M;5 M3!9LQZI*H50<3&P>6;.2#.A=#]P%RQX<.U M^0T``/__`P!02P,$%``&``@````A`'*=\H-V`@``108``!D```!X;"]W;W)K M&ULE)5=;]HP%(;O)^T_6+YOG`!)`1&J0L56:96F M:1_7QG&(U3B.;//U[W=L`PO0L>XFB?%[7C_G'-M,'G:R1ANNC5!-CI,HQH@W M3!6B6>7XQ_?%W1`C8VE3T%HU/,=[;O##]..'R5;I5U-Q;A$X-";'E;7MF!## M*BZIB53+&Y@IE9;4PE"OB&DUIX4/DC7IQ7%&)!4-#@YC_1X/59:"\2?%UI(W M-IAH7E,+_*82K3FZ2?8>.TGUZ[J]8TJV8+$4M;![;XJ19./G5:,T7=:0]RX9 M4';T]H,K>RF85D:5-@([$D"O"(IW,Z`@M"=?V]%8:L<][,H MO8_[",H[BY(+P[_-G?'`(NGRW:^?$EUS#\W5G07.H79RD?_:5[SO<%<[CK?G` M%6Z"<%!:NN(O5*]$8U#-2^A8'-V#@0[W0!A8U?H#L506SJ__K."ZYG!:X@C$ MI5+V.'`WS>D/8/H;``#__P,`4$L#!!0`!@`(````(0`&]H?!IP(``$8'```9 M````>&PO=V]R:W-H965T4!W(CK?PI)2JH0:F:D5TIS@M7%%3DT$8IJ2AHL6>8:JN MX9!E*1C/)5LWO#6>1/&:&M"O*]'I'5O#KJ%KJ'I:=S=,-AU0+$4MS*LCQ:AA MT\=5*Q5=UN#[)1I2MN-VDS/Z1C`EM2Q-`'3$"SWW/"$3`DSS62'`@8T=*5YF M^"Z:Y@DF\YG+Y[?@&WUPCW0E-Y^5*+Z*ED/8T";;@*643Q;Z6-B_H)B<53^X M!GQ7J.`E7=?FA]Q\X6)5&>AV`H:LKVGQFG/-(%"@"09.!I,U"(`K:H1=&1`( M?7'C1A2FRG"EDLIIX;.9TIN$*P\$*X[:M=Q-`5B&T\,(;\=#UBR M-7>VR)4"6D-+G^=Q.IF19^@#VV(6YYC!,>+^#<0)27X.B4=A3T/`0V\$,CXT MV7QZ"3< MA<=<4O\N(O>(L6]PZ']]!$?RX3W7R[?@4_EQS^O#]YA+\M]%Y!Z1#IW^-$BW M#K9#_.EFG]F1&=C7AV;LEAC^\\38;0E;=&KJ9+TL/,;G.1R/DC@YL7U_A)B$ MDS3=:W3!P%%IW_-V,-Z%/PK])N_HBG^C:B5:C6I>@I,P&`&%\@>AGQC9N*PTX/`P"74IK=Q!ZU_1=P_A<``/__`P!02P,$%``&``@````A M`#F.)#;``@``_@8``!D```!X;"]W;W)K&ULE%5; M;YLP%'Z?M/]@^;U<0Y*BD*H)Z59IDZ9IEV?'F&`5,+*=IOWW.\:!0MC:[B7! MA^]\/M^YL;IYJDKTR*3BHDZP[W@8L9J*C->'!/_\<7>UQ$AI4F>D%#5+\#-3 M^&;]\!"ZR9V744+5A'EB(;5\"87LB(:CO+@JD8RDK5. M5>D&GC=W*\)K;!EB^1X.D>>S;"[7K7Y^<7920V>D2K$Z9/DV1=>,T@VE,D4 M8"_$@X'>9\8$SN[$^ZXMP#>),I:38ZF_B]-GQ@^%AFI'(,CHBK/GE"D*"04: M)X@,$Q4E!`"_J.*F,R`AY*G]/_%,%PD.YTZT\$(?X&C/E+[CAA(C>E1:5+\M MR#]369+@3`(>9Q(_<()EY$?SMUE<&U$K,"6:K%=2G!`T#=RI&F):T(^!N5-F MX^BU_DLJ:#0DMX8EP0N,0(6"\CRNPRA:N8^04WK&;*:8Q?48LNT@)H.&-^T, M+[S^V&77(4SY0%*O"[(UU/7W2G7A&[`)O[MW8PW`W>L)QO=NIXBE-X:D4\@% MR6Z*&)",Y(3_(\>`H<4&T8?1?!S0XST02##T0`._]Y461TB%@$!Z<8+^\:/ M84:F]A367VMW>P=8/PTYL*]$'GBM4,ERN,IS%C#CTBXP>]"B:9?`7FA8/.UC M`=\9!M/G.0#.A=#=P&ULE%5=;YLP%'V? MM/^`_%X^0R`HI&I"NE7:I&G:Q[,#)E@%C&RG:?_]KG$A?'1K]I+@R_'Q.?=> M7]:WSU5I/!$N**MCY)@V,DB=LHS6QQC]_'%_$R)#2%QGN&0UB=$+$>AV\_'# M^LSXHR@(D08PU")&A91-9%DB+4B%ATY0D+#U5I)::A),22]`O"MJ(CJU*KZ&K,'\\-36%!E5&CT<:\;QH03?S\X"IQUWNYC15S3E3+!G4GYGY\^$'@L)U?;!D/(592\)$2DD%&A,MY61 MLA($P*]14=49D!#\W/Z?:2:+&'E+TP]LSP&X<2!"WE-%B8ST)"2K?FN0HT3U M).XK">QX)7%\ M9=\A5/G`4N\+LC7T]7:E.OD*K.1WYVYU`+A[/^[XW-T<$=IC2#*'3$CV<\2` M9&3'^Q\["@PM-E#O^8NQN*W&+`:8"6+W+B)Y%['_%V+D#X1<7RX%CA$D[U(= M>])*6XT)=2]Z]FKECQ.P&P+"E>N%X_?)\/W*=T-O.0;LAP!WZ07>I;HC:W"K MKK>FP!-KSJ2OMAJCK?F!/[D1._T:U/79F50V&1(L_"`(+\K;:P>C5*EXFT)[ MTZ-23Y**\"/9D;(41LI.:@QZD/8^VD_H.U==L$E\ZT1P[>?Q!"9Z&[?Z#3!1 M&WPD7S$_TEH8),R6ZA MQD;_,=[\`0``__\#`%!+`P04``8`"````"$`!LI@+[$"``!#!P``&0```'AL M+W=O^Z]OBQOGD6#GIC27+8Y MCH,((]926?"VRO'O7_=72[@1KC2-1K"$&XM>E*,!%T\5*U4 M9-.`[^T0M.E=2R-`'0A2[0UYZOP^L0F%;+@H,#FW:D6)GC=;RX MG>-PM>SS\X>SO1X$UW+_5?%B^^\99!L*),MP$;*K84^%/85;`Y?[;[O"_!# MH8*59->8GW+_C?&J-E#M#`Q97XOBY8YI"@D%FF"2628J&P@`KDAPVQF0$/+< MW_>\,'6.DVF0S:(D!CC:,&WNN:7$B.ZTD>*O`\4'*D+0D:\N2XQE&X$)# M>9Y621HOPR?(*3U@;AT&KAYS0H00C0$PAB&]':2C\H6;)5MTFTHM^[%4&;B M`QG))!^1L6"HVB#X)#WQ.F6'20>8]&UE@%QNT()S#*Y\VI(T\;Q.V6&&RDGZ MCC;TV^7:%GRNG9UI.\Q8>^HQHXQ//Z)MP>?:,\_K?#O,6'ON,2-MZ,W+?5OP MN?:UYW7:#C/2SB*/&6G;O\#@C/V_H2WX3#L['12G[3!C[5,W.FTWS-Q9%TQ5 M[`MK&HVHW-E!%<,A]6_]#%U/^C'H/\`,ZTC%'HFJ>*M1PTK8&@4SJ+ER4]`M MC.SZ2;*1!J97_UC#SXK!>8P"`)=2FN/"SEG_^UO]`P``__\#`%!+`P04``8` M"````"$`STWA\E$#``#Z"0``&0```'AL+W=O8 M)MCINO2E#7[C,KY_J*GCDG1*R681H$HZW;612I8L]KIB:RY0W\LI5= MS31<=KM(M1UG9;^HKB(:"O2\8II\*_V MHE4O:G5QB5S-NON']JJ0=0L2&U$)_=R+AD%=S+[L&MFQ305U/Z&4%2_:_<69 M?"V*3BJYU1.0BZS1\YKS*(]`:3DO!51@8@\ZOEV$-VBV1BB,EO,^H-^"']3H MK\($SHA M69P@P(,-5_I.&,DP*!Z4EO4?"_45'47P()*`^^%W/,%3@@C]OTID'?4%WC+- MEO-.'@+H&MA3MKPQ*,FMNS*)^*=`*CN-QF233>?0($18# MLSIGL$NL7R'R(Q*!OZ-)*/W])LTB*"8,CB913H[Z?2$KRZ0C)G6)]5N$XQ$V M&GM\.T`#+T+0'GFC[LXKRTS[>%.296GB`FL'H'%.3]X=9U#>Y..>C_R\T9V#?G[;RRS&".)GDR)5ZRZS%" M:88HCH\5.N;H>\P9V#=WZF?;;Y89S)&8(G3L,IY20TWE99PZ`T5%]CKO\/>X,[+J#5O=RLXQU!_]OREIU.Q'3=`UN`5R0E"U(_/8S!-$W+2<1UZ\^+MXX69["<(`7D)#I!] MT,$SU@AKL1&I@8IRA)_`SM]+;#K64[_HUU.]&HH.);>,K&DPQN^\[. M;GNA9=L/L8W4,'/[CWMXQ^(PX>()P%LI]3LXOK4M_P(``/__`P!02P,$ M%``&``@````A`%LW(+SM`@``&`@``!D```!X;"]W;W)K&ULE)5=;YLP%(;O)^T_(.X+-M]$(56;JMND39JF?5P[8()5P,AVFO;? M[Q@G!$B7I3=)"(]?GG/\P?+VI:FM9RHDXVUF8P?9%FUS7K!VF]F_?C[>)+8E M%6D+4O.69O8KE?;MZN.'Y9Z+)UE1JBQ(:&5F5TIU"]>5>44;(AW>T1;NE%PT M1,&EV+JR$Y04_:"F=CV$(K>[AK;*A`A:$P7^LF*= M/*8U^35Q#1%/N^XFYTT'$1M6,_7:A]I6DR^^;%LNR*:&NE]P0/)C=G]Q%M^P M7'#)2^5`G&M$SVM.W=2%I-6R8%"!;KLE:)G9=WBQ3FQWM>S[\YO1O1S]MF3% M]Y\$*[ZRED*S89KT!&PX?]+HET+_!8/=L]&/_01\%U9!2[*KU0^^_TS9ME(P MVR$4I.M:%*\/5.;04(AQO%`GY;P&`?BT&J97!C2$O/3?>U:H*K/]R`ECY&/` MK0V5ZI'I2-O*=U+QYH^!\"'*A'B'$!_L#_<]QTM"'$;_3W&-45_@`U%DM11\ M;\&B@6?*CN@EB!>0K"OSH3]O5P8EZ3%W>E`_%&@)L_&\\OUPZ3Y#"_,#%-B_0:1#H@+?H,DE#Z6O"RG82C"MD9RT9#;%W!OF&#$!%-B?8F8N,&#KG?3 M<&9#]N"&D[F;89*^K3@-8QS@4UMZ_?48\1(O3&,4#_X3.RCQ>CL-S^U.N:9S MAKG4.4-$O7\2^A$ZS?M$#5;^]6H:GJLE0\E&S3#FP0'&\.19:]=CP@]3E/JG M\B9NT7O<-#QU\T>YQLTPQLWSHR1$WFS#K,>([\4H\(*3_\0N?H^=AJ=V&.-9 MYPQC[&Z"*$8P;U-D/4$2Y,78^X>=?N>-3I3+FU7#,[OTM%Y,[PQSW!`(]D,\ M0^#LUS$&@;;%8(>&`DSOS.%NSKZ.;.DW(K:LE59-2]B,R(EA<0ASM)L+Q;O^ MC-MP!4=R_[."-S"%`Q`Y`)>&UL ME)3;CILP$(;O*_4=+-\OYI3#1L!JHRCM2JU453U<.\:`%8R1[9S>OF.IX MCD_:T M'()D2^(PG!))18<]8:'O8:BJ$HRO%-M)WED/T;RE%NHWC>C-A2;9/3A)]7;7 M/S`E>T!L1"OL:8!B)-GBI>Z4IIL6?!^CE+(+>SC06&PF`&*ZG]CON# M5?TP[(VRL)O#8P.?(@Z;$`8@KI2REX/[%XT?M^(/````__\#`%!+`P04``8` M"````"$`YG*S.EP"``"JEV)D+&T*6JN& MY_C$#7Z:?_XT.RB]-17G%@%#8W)<6=MFA!A6<4E-I%K>P#^ETI):6.H-,:WF MM/!%LB;].!X3246#`T.F'^%092D87RJVD[RQ@43SFEKP;RK1F@N;9(_02:JW MN[;'E&R!8BUJ84^>%"/)LI=-HS1=U]#W,1E2=N'VBSMZ*9A61I4V`CH2C-[W M/"53`DSS62&@`Q<[TKS,\7.2+4:8S&<^GS^"'\S5.S*5.GS5HO@N&@YAPS:Y M#5@KM770E\+]!,7DKGKE-^"'1@4OZ:ZV/]7A&Q>;RL)NCZ`AUU=6G);<,`@4 M:**^M\%4#0;@CJ1PDP&!T*-_'D1AJQP/QM%H$@\2@*,U-W8E'"5&;&>LDG\# M*'&F.I+^F02>9Y($7C\N)L&([VM)+9W/M#H@F!60,BUUDY=DP.(:&D`L[S<$ M)ES-LRORI8`VL`G[^6`RFI$]),?.F,5[F'&'(2#?>0#=:P\?:SLP>,3H2GO2 M\7I_BX`97F&&'>)&&6@>5W;@'`/WE7+:\0;E@$E])FD.BU)U$_GEY?DR^]?E=P8P0&[W$C#OS&2!IWO,%(P(0,DOXT'<3Q M_YB"=#A@81!;NN&O5&]$8U#-2P@WCB;`H`N^_J_!\```#__P,`4$L#!!0`!@`(````(0`7#A=%^@(``(0) M```9````>&PO=V]R:W-H965TB$#7R\^?YCO& M[T5-B'3`H1,+5$O9SSQ/%#5IL7!93SJ(5(RW6,(CWWBBYP27.JEMO-#W4Z_% MM$/&8<8O\6!510MRRXIM2SII3#AIL`1^4=->'-S:XA*[%O/[;7]5L+8'BS5M MJ'S2ILAIB]FW3<@(?M1_=[24]0)%J9M,_"@`N;,F0MY198F<8BLD:_\94;"W M,B;AWB0"^GT\=,-I$B3IVRZ>(=(%WF*)EW/.=@Z<&EA3]%B=P6`&SJJR"/KS M?&50DLJY44DZ%=0"MN-A&4V#N?<`+2SVFM6Y)APK\F<4V5'B`=\1$DH?0KX. MI\10!'(&<-;2*Z.)!YKXN+(N,7]-,6*#A89LES50)2T0K#%@C,8$*Z.)=7LG MJ9OYPY]T+,X/XI/AJ:`1+M3\?ER59..>_'7#5D9C<,/(M:K)#^$W`>%"O!]0 M)=F`R;A%*Z-)#:'O!E8\-W'@/.[)J<11"]./$*HDF]#:Q)71O$QHXA<03CY" MJ))LPHG50Z-YF=#$+R!4D_'=KQV59!-.+4*C.1*&]BZ;^`6$V4<(59)->'JG MF8MB-.88!G`.K5.0'^)OGD.8>*,FOOY:U&J++?.M[NU%4_W22>/$G\8VWD@2 M9T&2I2<7V$TY`*[I;O3N"J<3-%S8-DO1XG:R9A^NF/ M-7S;(3!K?!?$%6/R\*#F]/'[T_(_````__\#`%!+`P04``8`"````"$`'KN( MR/D"``"H"```&0```'AL+W=OD.P_?KQ M><]Q;%9W+T5N/!,N*"M#Y)@V,D@9LX26AQ#]_O4P62!#2%PF.&AN M_?G3ZL3XD\@(D0802A&B3,IJ:5DBSDB!AU+2QT1UP61K-/NA+L`/;B0DQ<=<_F2GKX0>,@G5]L&0\K5,7B,B8D@H8$S7 M5Z28Y1``/(V"JIT!"<$O]>^))C(+D3J,UTXYFV@]_^ZXB>E>QNZ;H^8-`;B^7$H<(DM=6 MQPN\?O0;K5G4>W%0F.V5L4B/P;-E#_*RNZ;H>8*_T^V>E'CH:;#R1FMFM2=17^?.XO^H1==WSB.&[@V[-6TC,W^X@Y)1Z:&P2_ MT1I=L$OFNN.7S745E\QUQ]\PIV\`?4`6A!_(EN2Y,&)V5*>[!YEO>]N+Y]Y5 MY\:@?^,LX30;]T=P4=7]5CL!+HH*'\AWS`^T%$9.4EC*-N=0"ZZO&MV0K*J/ MZSV3<$74KQE\$1`X)VT3Q"ECLFFHT[#]QEC_`P``__\#`%!+`P04``8`"``` M`"$`"1L9.0H&``"3&```&````'AL+W=O1^2>2<-R$-)P&Z`%BJ*':YJB+,*B*)#T(6_?6>Y:W!U* MLM1<)%;R[>C?F=GYE\SMU_=F&[Q675^WNV5(%G$85+NR7=6[IV7X]U\/7Y(P MZ(=BMRJV[:Y:AC^J/OQZ]_-/MV]M]]QOJFH((,*N7X:;8=C?1%%?;JJFZ!?M MOMK!OZS;KBD&^-@]1?V^JXK5N*C91C2.9=04]2XT$6ZZ2V*TZW5=5O=M^=)4 MN\$$Z:IM,8#^?E/O^X]H37E)N*;HGE_V7\JVV4.(QWI;#S_&H&'0E#??GW9M M5SQN8=_OA!?E1^SQPRQ\4Y==V[?K80'A(B-TON[JF$'.NU!5ZV7 MX3=RDS,>1G>W8X+^J:NWWODYZ#?MVR]=O?JMWE60;:B3KL!CVSYK]/M*_Q4L MCF:K'\8*_-$%JVI=O&R'/]NW7ZOZ:3-`N07L2&_L9O7CONI+R"B$65"A(Y7M M%@3`[T%3Z]:`C!3OXY]O]6K8+$,F%T+%C``>/%;]\%#KD&%0OO1#V_QK(&)# MF2#4!F&@WOX[O31(9`2-^[LOAN+NMFO?`F@:^,I^7^@6)#<06&^,07J.;PQV MI-=\TXO&I4#W4(W7.YK<1J^0P-(BV1'$)_(C1'I`(I!WT`@;=S6>UZ9AV$,8 M'+2Q^!!VE)\9A#L(]XG\'.%)@^^Y7)J&ER'$GJ01_XLS@R1C3CF5:0T4:@KTXN02-19F4&, M2`%93,4A2>,N_-#&*$I3&/N432FBF?)X[O0A)G,*;`AO$=F`:$T[45#V3/1>A7"I%Z'3Z/9&I+_)\_C2, MQ*'NSPQBQ$DFTD2FJ$%S%TE8*B0C)\XN@?.`4WC!6-:KD$QT`K(Q,APX,V&( M%"R1.(F(43$1\=0N7A;)$?_XO-;C*B1TRH0IMF6,4`8J4YZB:9G[3$PY8/+H__*4<94_JOFT?U-DRUB9D@I"$));Y/@1]V4B1SE?9&J>(KP!C9W$ M,D8>3Y1@`O>@CZ1Q*AU3].7I47[Q>*%F\+OR!/8/R]CLP:4_$017V6?@X5^D MIRY?]"H'&6G_<9X:]GN M,V&.([X\Y"#ZV?/SZRJ=.XE`)CNG<2P0: M(9EE3(]Q)I))@95G@AP#/(GZ.>3R$SS2Z`2C_LHL\W%`1!K3>#H`1MUYQA=X ME8.PN8,([""6,0(5`0.!^S&ZH7I,DB2II&IJ$E\@\I#+7KJQN9=(5,/,,D8H M27D";T%0(^0>`XDFG"4G+ESL*B\9:;_4SDUN+&-F&2N0<"G@>03M(O,+O\0+@==L.'Q_T M:^O#?R?<_0<``/__`P!02P,$%``&``@````A`.ZF6'&1`P``:PP``!@```!X M;"]W;W)K$\DX93 M5DU=-/!=AU09RVFUGKI_?C_+8A)>8#5I,*1E:L*;&`QV;M\;HA.%>3RL(+?#_V2DPK5SN, MFTL\V&I%,W+/LFU)*J%-&E)@`?Q\0VM^<"NS2^Q*W#QMZYN,E358+&E!Q:LR M=9TR&S^N*];@90%QOZ`AS@[>ZN'$OJ19PSA;B0'8>1KT-.;42SUPFDUR"A'( MM#L-64W=.S1>H,CU9A.5H+^4[/C19X=OV.YK0_/OM"*0;5@GN0)+QIZD]#&7 M_X+)WLGL![4"/QLG)RN\+<0OMOM&Z'HC8+DCB$@&-LY?[PG/(*-@,P@41L8* M`(#?3DEE:4!&\(OZNZ.YV$S=,!Y$B1\BD#M+PL4#E9:NDVVY8.4_+4(2JC4) M]B8AT._'@T$PBE`4O^_B:2(5X#T6>#9IV,Z!JH%W\AK+&D1C<'X[(J"0VCLI M5E,`EL,R/,_B<.(]0^:RO61^*@E,Q>(-1=I*/,!JV2#BR]FD&/+J.AW;L+55 M^',M&1Y)+,6B3V&@P7N.T61!A%!6_>F3DZ8NO*-#C"Q$+1FIW`9)B@*4=,E1 M42R.)2@,?10'78H-2(CT>D@YR8*,+4@MB15DXON^G<7C\6'HQ]VX@0>E?SV> MG&3A)1:>EFB\89SXH\@JTL6Q8N0'"0JZ$`W$^".($U^X&9-*^X49`6[S!\DX-'HRZ)^$*Q6 MMZ,28.#_(ZVGY-F/T'``#__P,`4$L#!!0`!@`( M````(0"HO`5N$C@``-^P```4````>&POZY^\'F'=("/(Q!5`4=TFV6P;W_V+)S,@LDG(?V`T8W6)E9,07W[Y%Y'?_^?EVF'TLIK/! M>/2G)QMKZT^R8M0;]P>CZS\]^7!Q^/S5DVPVST?]?#@>%7]Z89[XYF?WIR,Y]/OGGQ8M:[*6[SV=IX4HQXWN9S_IQ>OYA-ID7> MG]T4Q?QV^&)S?7WWQ6T^&#W)>N/%:,ZZ&Z^VGF2+T>"OBV+/_;2]N?[DS7>S MP9OOYF_VQ[W%;3&:9\"1'8SF@_E==C1R"P#W=R_F;[Y[H:%N^.OL_7@TOYDQ MM%_TTZ?=8K*6;:VO9IOK&]OIPY/QQ[5L8\G#K]/1'I3SXGHPFT]S`#S);XMT MU-=[[XY..MG9N\[Y^T[V[O1X_^CD^^YJ=G2RMY:.C3N]N)LT)]I8?_Z7I6^< M%=/!6.CI9_OYO/%R!P3V#8F'P_PZG>7KJWPX:[SC][<'ZJ?Y$)3WB\_9GXN[ MQMOKZ^L;&^N[N]L-A.XMIE->SPX'LQY3_%3DTZ4@?OW\^<;F\ZV-=/H`QOCV M=CS*NO-Q[Y?5K'N33XM9=KJ8&WO"KTM>.QP,BVFV!TJNQ],FZ-W;?*@!Y\5D M/)TS3;8WOIWDH\;(`(7?4#F^.\_GBUFZ^M<_%8W?_!0_C(>+T3R?WH$5EFX, M^_IDG,[FW_RQ&`Z?_S(:?P(-13Y#(OO9T6RV**;I"Y&1JH@_1(Z:J[7)0?JZ M9Z[V"?ZRE:Z^=WJR?W#2/=C/^%?W]/AHOW/!'V\[QYV3O8.L^^[@X**;K7P8 MY8O^8%[TG_'O[G[V]%DZT7[10U@W3%B;JWA2=&:S8C[[)GUW+Y_=F,;HZ1_% M7Q>#C_FP&,T;&'B;CWXIIE_/LKS7*R8HNUZ3=!?3O%]H@+33+)L6O8+I+H?% M:C8L9KPZ'(X_Z;KY+:>\FGZ$46'2`@(VN!Q`HRXT] MTE?/IMBI*89$-D7,,9%R7,U&Q5SO0^G%[6*(UNAG_0+SU1OD=(ZS3K>+H*5;#S@]'N27@^%@/BB:PI/P^R2_$[.G,W5ZO>D" M#!6?L?E@/GWN.->_W'A:4F\ZOLU03?/Q;0NWU2?)GH-D1Y=)#J::BX;MF3YW M%.N-1QCH!?+%W\-Q/LJN\IZV?M>PP-T;\/]\7DQOL]%X#C,MV7J=/2NH3'%P M,AX][WE-51G65%=+84QG/!Z/KAV$_>*JP+[VLWG^.1MZ(['BY]<8*R]HO7>OUO8NAZG9>OE[=V7D9%I68 M-W^M`'"_\';Z&"JX!Y4TR0?]YX-1ULLG`U14BLSS8HYK*Z'(IR/\B2;;5U3+ MV%1[#X]C6MP@0NA_5!=_-T3-$;&-4BD`3O2/CSIOCXZ/+HX.NEGG9#_K7ISN M_5G.Y\%Y%QK_YIGG?.# MDXMW!Q='>YWCANKI/&`F5Q.]4S%Z*;`/3I4U[.;]4U3M%MZYMW$M"@:MM]0V MM)N5=.&J=4D5?L-,I"^7@FC\6#\$>7W8 M@V"W#F^'N77H?0"WN[+="SS:]W!Z-SL]S$[/#LX[%T?XNB9K>Z?OS\X/WN$! M'_UPH#CO]/T!XG/2^;!_A!^\U-O=>G3@NI7B];S`)5NT&'+_(!V_-R9^Q\^9 MNO?2QX'[[[*J5*2COI^.<7TGT_'58)X^.\6[PHDAG@K.0<.B=(EFJ@/2*;XO M1LR!$XWJSONW@Y%%V?*1XYSI*^?%#+7;!J03 M'K-#G(`K>2@CXCS!TQ_,\AD>0CK6J6BYE?6-I^.ZB\O9H'^W1-%K1;>>GPF_ M()W!:39G*+(5C^!G#02C2@H\TOF2E>)C/T&ZRHE<83-02P88J)<%SG>P6G)$ MFA[9D5DT#1$:LH4KY4(T$_3@Q3XB*"F=@Q3:!RU_ MU&_IFR&BL?TM\_W=]"&L96UD2@%*22O(9Z97 M[R'M63441C^W1+H&=2TN@@X,)??1D+T(_(<9@#.N#8B'`#\_O`UP` M%'W/QC7P+"13[)8N%*&KHK:Q6B,J.KBZ(N$B&WCPN6>LF)T3[F>!+=$X*B9"CAKT&\-F6`I+IG&0;6"Y6X?7YYQ2`E*IZ9O9).]1@L)DFSUY M\N9T>IV/0JY,C',B#\V2CEZUXCME__S[_\[G)BS?? M06\0CZMSR_SVR_20$I(;LI#X9W[>5,_6,VK<#_@H(ZG^O&% MK3!_LW>#RLO.2(7SVQIII;71WV'Z7WR#W:(U4/^/7]S`0R'WJ6LX)_Z%X[D=&"J$P4Z MOEYXIT9]=[$8T"9U)[!532@,26`U#:%UB;;\2K^GAN2*+6WN!B>7*KW@J*O]+ M6./KUBQK$]VIN$@U:S,\6,T*,_**&/\K'RU4$Y^"2063 M!OI=!%SI:W0`.`(D**)!3OYF6&;;3;F'52'P#E,P'&:7;+-`$\K3:T,'SB1Z M2(JH?:-K62>;WTU,BS0AEO(AS7PSF$14B+)23?#"Q)1EKUA8SC$`(,;B,1HL M;\$8J,Q68!\P%$K03;0*GRB3V,%@K4RYASP$_6(.?Y=FSKO%\&[\I M:T6)$G*P:FFDHE9;<\8W[\$3DI]@DH7ODH&A6,"IR6WU'0#FJLT6\(*; MWE?`TBD=TBP'`IDE7I\@4SZ!.!_9#`MZOI$BECE["ROD"PF"]P;.%*5:_7:4 M_==B5&34'!VTXHVP:> MD^.GF0#DH$F#+E1%V8WLP^QCVT0?ZS0%=IS`^=5X.!@+>S^B5PH\->U49A2/ MU\VC?R:`R65I]X_W<'^9L>_S8,RE/!4[);"$_>$Z]^0/\23DE@NCX,DY9.*- M*Y.:8?#N`!?3JS1L M`$P3Z.$9Z\/(#&M7ZQA*Z)!"^>7F7G]8ZZYEWW[<,REO(U1R.#38Z_KHP3(F`WO MGCM+576#,<(HYQE)49-)8AFS:Q[51+16Z7/+5!1%%=GH6D(:T\N@K-P&^N0^ M\V(Z^6HQ,L4#(6-.%L:S+7AV/B]&3'\Y6`OJQ%[T]0C;H,\Z`Z3LJK2A_#X1 M']%I1;_R)X9%1`I7#(+YS`YH=)TY>@I6Z90#0]888DM5LH[I:G[*^E1(,4*D MR>BJ"_^$.7T+65CA>V(K1DXQ<&49(>Q$G%JU&*V\H:U[_@A<'VN/8]:?0IAJ M$INQ9%XJ'H,"S-L)G6*P`"#C4?1^\98(A'NG!UXW2,7H'E1L-PXP$JG*1XU# MT+#C"F.P0,BZ.X#,`Q)JVI@@8LV:.%U4"H%5P\09@JYZL;*<4:.*`#U'"!=# M]#N3E2+2HA7?G!?!R<;PK5X.`XXV.%F6(J-9MT\A8S^96;RC]T93B0L3@ M8RS9N->7.'+JC+!6D28'2M`K6'`Z@M]^$^!;+3KV7DOOZ748+:A9-KF-LS\F M_=5JX!>AY7,9B[5JP4\$L:7Q)\D[6ZC;VJN+Z4*67FPV+:[5LX>D1_U909DKMSD(R907F/50G!91D054 M3['\>;/KIK=;MP5[H_?,HC7B!5-R?DCGA*G2P!>%5;%AHT(J.-6*.$2;1 MP@BOA(-:4#ZQ?&H>3PRTA`R\4L1:QJ"Z35DF=,E?%S*M4.(V_\6Y,%4$>0%F MBXI

>0L!-FA$7#HE>),N(KO-)?O:.A@LC!.W#$XE3-%*4 M,Y^$0!1?O$(M/?78(4O9&9$Z&F8D*S'O4A2$$K>$A,__'$7;4D].L5$;\GK- MMRWC]`U!@#FI?N+`:\SUWMH5-OV1@Q:AG[_YQZ_!=M1B$93:;Y,FLJ.J;JAG MN5(1 MGX9/1N!D-E/Z#41[GJ`%CE1QBG;;<->#AL19D-\F.*=Y5>]'"$J01E[<3IS5,<+G MKK0LQG0Q`>)/F]]"IAA@VKL=C,GU2E7),AK9D$3"Q4M?=$$/87[DP[;](HI> M\;4!Y0,O9T=CY-7'6L*EY4[TEQ8/U.!';BV1CXO*BY7.\$BP^W.>T*J=.8`@&FCTMCJ MKERFA6G--<2-K[[:_D8-;NEBV;^FH8@J--8$74&P](*4\;?]$+;"^T`<]8P$ M!;0I;3,FKRV!B^&R?ECXY)'&!6QXFWFI%C+WANL;RWQ#6N@C-\H:+AOE]$-V MHRDO+.!Z;W&6VT?I,80Q)PK%VH<<-".S=):GZ0\KNZM;'.=YN;F=/GF6_K"R MR7FGS=7UY@F_E8V7JUN[.E+SLO$27?PO7_%D*WWB>+[!M34NJ=(\?;]L`(K\ M,HOA00/%/^93,E#-PV//TVE/G25(?PY2\=OA363<."%=965];6.GY4HUE&4S:D(*8/PME,JB"K!UQH[F` MK`%:TR*CYE$W+'03G-K, M>IV#=D!4SJ9JF,4Z-*

(5_$W<:PL2R!/LAA]'$S'(P%H3I3J1`[Y(1L-0$MWI/4##OL%Q2)0S1K& M=3IJI2)A7$V)OX"^!C6.3GZ@F>OT_*?E3U(!-IG<,IF,;Z=CCJ($^;`2Z#RU MHBG]IAG8UO*"Z9S5:"E]=IY_(@QY]KCA%'9Q>0AW)+**<-SQB'M(E"YX9NT?(J7:S.31I"/>>GV1 M_GXFO;$*D7HJ`9$,J,&0CGX_1MW2R4/K0_/@Z>D5E68BB["!].4],AGQP*>C M.T7T9F>SD2!]^9B!WR@A%RLMU1/`Z>B5>!JXY8D_&)P^J5'A(&S"S@.G0Y?M MQ"DP&8*RT\*+EX@9-\]ON=/:KG-#WJ:W=8X`4B36Y^!S+;P0#$U$KU'*GW?4 M:4Y$"4$CKJOZ_[5E?3#PCU_WRPCR,7D6!:E9?@VQKGTX:VT+GRW+H$#N1)B\S^P!F9KD&287ZTKIL=Z##].&XO51"JT2PO"Z,0/.;A?%! MN\M$#VE$-7TN72!&%"=7F<1B%3H12#PU55Q'(-/XC+]1!@YVVCVB5:8;)'N# M)WL:$.Y#A80YQGN:*_1\SFDPO`W7HD`,:EL*R0/3-'*TAC@OED8QQL7&RQ=: MOI^.1J3P_./7X\%5@=)4*JZA[[?7>?*RX1QOZN?MU^E<(:YR'3GWU[BVC5%H M4=Q:K;-+H*KX^>D6'2CKK":F>KK);30;KS;-C0M+/4:0'K424=OJSOIKM]+N M]CH'IM=;O("+SLGW1V^/#Y;<)V`F:`?D'-$3?N](&*9^*P,\/)%%53$'/61\ MA`)JM,S$WJ4K;`(2JQXTR;_WN:S3E+0\]]$:?O3!:=,*B<&&:DBQ][A?L?* M&^@$>V4M^V+U)#"CWT7W_(B<\/C2JJF:O@J<`QK?3D#+K4VV9;`R'_EXUSG( MOV(^PYQWB7C9I>I"CLH%'U/'@>MJ9U9#M'V$8%' M7-W^&*=N4A$*#:K<-XDD\G]*A)/D4/.7)49:)/8J=B00:NC,E^LJH*/'-/)@ M.E=WCPFC,?H1R@^IGG.W"BG:5?G&)UJSG3NY`4('?LG1% M6320X!*6YABS'YMAI!YB>=-8-BMKN05\=R8(XHHK.$P4-7S!:0#*+S8Y^DOV M6.Q9P2HIT'1IU[>K&9S:T`Q?*-6>>LZ"!/UAEMLRMF8R$F$S[?*:A,VK38.9 M&V@V5G=>T8CX=//5Z]67=$X+D*=;KU^3<$GN9Z&"V&AD.PNI9KVHB!IG)8:J--*FB_M8]C(FB#7"5"(] MO[2Q-6O7.%M-,G!=*.)@.@5>]67$,6@GX269S`!I2;2[X-[K",LT>."EL&!K M#)Q$"CC@M&#L)Z)OH%\/5&+&*O.886,M]_I$>6I,[ MU\4K$;8N:>//X,GUI1&U![%<#;0(@'_=TDH$PBZN[I'UNM."CI*.?"DWJ\W* M#NUI\G)'5XOY`@S6]C(S_ZZ"8TLJ@92*+Q-D2[.2S_9KII`$_T#5$H^U!Y96 MPU,IPN%R49WP#***O#E2J?G;*.;;3!(-A8MY(153V M7DFG/TH=H(;D331L-CL%;[586@.=_U&-HNUUE7!3PRQ7DEHPS(A'R:54FJ\B M/OR>8.)>+\S=%!!IB/3#Z*F\4]&,$5=5/Z3CB+7]E4B-)_%VI/2)#HD^M/S^ M#[J=C!SFZ7EV]N%\[UU'&4VN=VCX-4U\/_[=!F3*;^Y:+J7SVV$/CFIMO09]U:.&NZP2` M-32@/8N)&A_PX%!#.LC&H0I9>&\APXE,\4_*,6I2Y8(@.OZKK(7#Y%JSYL@1 M"CIZ'YHR=*ZE4RD$$I"RC[^40GT)*D&N9/TL9T24%W)OQ>?2TD'\(/D@M:X M$XG!\^B1-B`ALG.-,!5Q84_H!M-G3-X#P4-R=G0E='5.U@/0F*G4\MX[:9^1 M?)?HPD1&D@G[IU!AZHZ9FTH@U73JF_(Y8?-(!G/Y5X3*G\9TF,!-=@3"3XL% MP0XZNZ)!OQ'HA@2=T9/KN%?<)I.#3G+MH)$P#O`:F_F#1N@G\STB9JVXYTOX MVI^[%@2^$,-7+@8Q%1T5O9G'9$?&"D&>;LE1$V2`UDH0XLD73L_8^Y(TYPC` M*!Q/<&Z:WY"141Q6F23ZV[<+/-Y+7$8U:GJ)K!0G#/UV3JLBQS5;[R=U#!`2 MY=A=.1`F`.%TEMQI9["4XO#>S9XO$P1N=]F/!DZL*QAS'XE1)I,J/YEAMS8* M/`]*O/CN;*[B@\CM%H+,QQ!&A&@G\.;%LD(;CESX(%<&46RP4GG\K%U>@FQ7 M9H:$>3S^%#;KGP/CQ_%0<02)M%@2QS1./-J,\!8'>89CASHLR(ZOI%\LKM%? M@3NC>Q56`B(=#9'B"7B/[N9$9RN=JRK$U;C,J14%PT&$';FT;_,\(U<9;CGR M2*);IWMG\T6?VQOCN3*\*6H]Y:&]*HVRW52,!QQQ\ZZ--ZYC`KU8A:=RZ M^"L(X*?00F@]>5;ON56J3>?I9F;P!#X^>C'_)-MC+1$"W_5&\(M/\!@'3JS) M2#"+;3U<80L/@8(#-!A6>+U!L[7LPT11PH29/C*K5]M*,KAMV&E;F+*RDLQC M.(05=%:0Z![Q!CE!6AC="P%N_KH=6]/?/?QENLPE*@Q-<*IB3NMK$QE$]`JS M1P&M&>.4W8-"HB_"D.&.VPFN%F2\H](*FSHLZ/0B;$P7E@*,HH_SXH)Y%">C M=,DC>08N8B7\]%RRF`@6QM'_JR*15(\V;*$1Z6:=SG1:&H3(4C?TR@?<'!?V M,\%M=#'B+AQH4?V5A]$?TH"EPJN0,O)O4%<)]D(2)6C!:I\:3#JP!A1M4'G@ MA4';&L"(Q=`>:IR>^N0KF(G.I*NBULJ>C1T2OTN#&4/YCF`4P2*B*V+(%%\> M?0:_6ZF]$6DTM^.*'PJK8[?@-'>L+SY1^DG=079`49H;]U/'&/&IH`RW*/#< MQ:\15#HQR2)Q3-4IR`!10C(R62"*\[PZQMV$7ZP$S!;B"6<<<`DI#0Z[J)LH MO[-RM6&CE541(HK.T)R!(THT[55:;M M16C-A:$\Y1P[P58E6QNOAPA$2DZZ7J$Q80W&$.L;,I\2B&`FC:\;T6M#="_& MEMJT1@"QJHRM0AMZD-6;#5J]"^P"D3;0U"RA5ZK$L_C$];LS"P,N@1?LYY\$ MO)P*LKYA/7.QU!.L1:M+6JT^B#O'X2J*CEE,..0Z^3:-Z*DE1%!`!@N&?;1M M01;!"T9@O_X8B9#PA?=JP)BJMVD+G7H@KM&QVB`\UOLI#C*^#!,(/YZ]HA4H MN5%(BD?Q(Z,8TSLZ?#%[I_%T9_Y@R*,\:)!R2`\8I;R8UI98LP]U\,GZEM7' MG;6-U['XN)!YAMZ*Y93;@][A(HD)G`)B^24@RW#$7*8\S"]MHQ`O!+)ZMFF: MH?.#8[M-G9M6:0ZX..^<=#M[=OEDB@HKS+RTU,+C7W)="5'8W,$/Z9WLIVL[/.3QU*#C-4M5_ MY!G`G<\,R2(J4!(UK)(+:K@J$5G-?O6)&8PY'Y,AH/1W0!EHN_3=ID'API=U(H,-'NVNY7V8K+]YNRX",97VG+ M`E`7&URKH&8=8!:M^7P/IPQUT`A@;R,_[G+7]E?/0,X%KWKE;>]0QRQTA1V= MJ]8D[3IC7""]=T/_7%C/22^+]TGG],P[Q&^;Z4IKG+7K!:[$ M)I@,#))WG=%@EM)BTM*%)+U.DF" M66,E"-PA=&&O(+..?S\GOWLAE%MCKDREV,Q/QH8M5^$'\G^Y_E4)[;$FHD%7 M?4KDXOR#F;KL^+1SDAUV]G3%>;-QSVJJ_J`EZ[O\5=:L*T M=N=&?1B,(/LDP;4V'%.JTCXA0829):Q12=MK9+)(.J5![)Q_>M[G]@G7.("T MNYYK;RN<:&OZD"ZT*US,#)@;6R:XO6DYTXO95E`S3 M0KHS-"@;?=_!W!-Z$UVIWC0,9J-I!+1<#8-^DJJ*M9[GLN>DT3T73XY6/#J3 MN'K_7.Q[K-"@1(#,B10K>*>.*4%YN;:YOO.5+Q<_QGPDU'.VH[P!+7I-ECJI MDRY2RE^>)#.@4-,.OE:.?);%ZZHIX]0_L2UFWPQ?\'6,UN04S9\RC@L0<+TI M=F^F\Z"1,^KPF$U0K*$[34`CCH:@B:^)LV>1`VSR>%XOXM`:V&.,$<"Z&DR5 M@Z:V816../9/"NFGBD2'11W*&Q(:J-;$-W%ESV9PW]%A/H1JDF_L* M3Y-C\9^E44Y&!S1D'@K.^'J9'=-Z"WW4_&PZW\W3\WBIW)98M/I+N*:?[ M3+@MV6,3:V/F;+DR5G54/4AP9##+5['W1*R.,+X0;UI4RBWR5N4DHO^8Q$7G M?QVT1W4;ZE*];U3+3>Y86-=&BR,>SIZ$[/4MO7>T\:C]5AJ^&)%ZEW7@@T-N M.]4R@/(X5(!4#_AL/4EH2^7#?+Q@"E=_N+H3][],:!C`"K@SPW(Q8##L='5. M="SQBG0IRXI6)'G)V3DC6E[>4OL4TI+]P`%X:67'H#Z:9-?2TA!N$A(R$F57 M=7F_4-B$:U9#KV.BO>5W7HNAQM*_LDZ)MIV_^4##).QC%T"6'P<25_I+H&JJ MWF([I!&;3M4FW&]+I3?;=5_RY>Y:F;-J]26%2SNH[;]8 MQ'3(OK_=4=RM,VC^$F*H%Z[_$SKK2VUNK6T%MY5)S.,B$.P;[5Q$IX81)(H: M#)RBFWDU,W#CHO%&-8U,E&.G\:\H[Q"V&^WG$EC/5.Z*?DLF6O#B74C3`-." M2\I<_2QBW:?H*."C#/"VR,70N^E9$U3?BA;6U%KH.DY8S;)1G[B(LT8:7WV# M+[VS)(:O02IWT[KOZZ"NJ!5.2,-=B-^D,-<[$%I2Y5(F7*ZA6=30H=NZ)'IN MOT&C2LB@C%V1N>_/?[GR%2OHB8_M^&LQD@!YGHYR8A"7J(R";S40M'I[26V7VZN[FPTSBVO<)Y\ MD]/CZ[OI&R[%7:%72.:N^,;-QM'U"X@>?"1E2TR2L00N[+$F5G."P"JE'[2' MT*L,G_B,6A5MZZ`8Q"8*!9AYI M)3`#PY%5=1^3-,,HQEPPK MV5[+9-NNWI=W>Y6H1=9U#S)JN1U`Z3=C3Q+@LH68+.FM:WE^J$7N\W+T%3\9 MN>7;V'(NRC!LR);%AX$B0UWDKC](Y*H=5!U'"=]I<0\@=MG)2SN8,8H.6"2+ M$+`HA%T5=BB\Y#3S.^J(5.L+G!!P5N/%RW"GM&-!,4WDP%+H?6W5.*G*?+'3 M^QYF_+)H)K!I:+81OU553W1SI&)TC[C.1W^6#MJ^U=ISG(1'/EP.M=3IV9GGIL[/6`JDCUIK6JHGBEX]>R'V8&$YV1"F,?_M)@2NM:S>?Z)I,HAB5B&`&"J M,TAB05MY1NZ%.OUB9)]#<7X3CQ$R:."_`^-35R$=Y.Z!%*YP6>T3N+:22LG2 MK@V5>=@Y.L]^Z!Q_.,C>'W2Z'\[=MP-3PV0%VXT-2T<_\A7+X+C3&::K\*W! M"(");^*EM:`2M\DT:6R!PRET%T$8(SDYQC^EMT)?A9%_.?47D.>E6T6F6O4= M9,6F?!8<*/[RB3$FL)8ZJR#/N2I#'U;PATNTDN`RDZ"EHKNF>9C9VHZD_+6T MW$_P'GKQ_!P3U8&5@[,HW%6"?9!:!E_9A3J3+7*MI`((,%!)6&UX0`W#ONI! M``+1W`4`3K/$7*(V2V7*74U[F],(0/70MN`S"GP>D2/`WJ)RQY)C*UJA&B,7 MH\98Q5T0K02)244X=4J:#C51'(QL7@@2=B045A(<2(>SL<;2`:46P$NQ2BUP MGOW8E++CK;\LR,Z8@"GB%NI!-9VJ#L5.&[LS?5+=?O(*N9A[S4_H;F;ABH0$ M#5ZF9<3#RG`(]US+J/RUMKZX(B296M=:35X`8+H#)'M5J'&4?,A&428%QUC? MFP%:BJ9C.ZH`#B@$5T9['B.`S\,&W347'YK4(_R;3`A#W"1\3%IM\X!`W.JG M,?C$/-IA>QJ)"[P)'2KRB^/N;O)P^19)F3!F9\#0CI7C3I4#8M:5KF_T0!A# M0T#G7!_O&9`_YV?8/<3TU1258*O:4P=`#"4K?!:EHGJM.%WHX5K1GQ?]:Q-! M9D2FU$.&_#9T8=4F&,-7EDB8W.'%FU;E)8NI:VNVN]RM_P][+1;FI`IA>6Y]1>7!@O*;Z:2E8568>Y8UOW8.-^$I:6.XV+U?3/4W M/HG.H$G$A8US:=/D1_25I5JLH5S=/"19[1"7Y7.L([!?2.A-H%$E[GW+UY*1 M5%).SAQG?7D6NFAHSQBZ5G1S\-$)^IX`8^U/Y"&>NHE'#-'%DBGO[9JDO[6> M,_:Q'[I6O#Z!AC$M;D0W^AH:W+]J][#]VU#\M-I19=]4H6'L$;LF8SCFPG3E M2.6VCLJ+8S?C+%8OK=SO[Y(-NNHKQ2I!_CIW7?7DVV#VSX@`XZ>3]()<`GEY@6;Q7%H71(XFJN]FUDKOS,O+WJNY*V_\5UOY?'2''C:M4,,2$?&<4,>PCQJSQ(]4\+(-?^"T)F8_'JW?0N MZJ&$1&*!=UW&P:G\"7INL`;[F&17,(TK1J!- MS1BR#-'T^9IE3^E5GZ'L>&6'FJHGU)J?`7#*.4MI6E56F*A\T$&6;SYXSFF+ MH9%3=6,?$&,!G$KFR^_@49N0?7$3Z*R@V97\\\Y)X=C, M-5+!;_C/A+L78'LQNLH_4K)6?K:"ENOAF,007E1O.HZ$I+'!FFR%6TM[D1"I M8=?8VM/&?)V2("T^SOS-$3N*=U.VRE#X>)(E@FH?Z?$2A)Q%1,&OX1-,V0H- MK]'@AP/(#I-.!*&)"^C]ZR+:I;NV:,J7_SR&]=T^IO6+T5G%._97A2A:EH9O MFK3*KU]6)O42#N'+6;F^O<[E6MU1DW%VN,Z[.A"A7+_27=V(0='O>PLZ76=/H5Y[@@Y&A=`[E,*&[%AC6%`Z7_N=I7;F$F4S;: M@%$7]*N%&=E\?,EQWHSM4E'3P[QG@/ M#D8?Q,,9[&B[JD^0B\J-#N5-`2S+?2$&13G%%53FJ"K<\3 M.K>D&M$XU6EIA4%%NARTGT1S]GP?,?%CO,'-FPM-'R:4?14#5[_N9XS*F.]U MQ]O[^`%3`7OF^A3LH.NH;]57YN>(GVZ0-`MF>]&1PK(9]KU]=L7U*6\TU$/' MR9?-'FS4RIG_5Z,X_*C/D*=,NX>GPX1D&H.IHJH&&N&M,RPAD9D]25\[CQ?" MN8)&^IQI_3&HPY8/0:6C*_L\<`F[9H9&8/5,;,)%X"O'7,+V+#L(+31X;C') MHHQ%NDKK-]ZSE0OCD08VJ[L/VOR_[4K]V/8CF"V]D@(;[S->!E\Q]SI=^M\@W;Q$9NDTX_#RK"&T#158^K+I MYL[T\7?HR1WZZ#J3P?)+V^XBSS.TR&W.06AK?)L)^1I[.J)**^'RK8C'RB<6 M_?^^!4)C8V"N_\AO)]]F;PPIN.Z:;6G>INLU6`E6RE0_=_>QI@SK_\A(IS/=]B`%P#BXZ1\?=9\O` MX9C%6OPNPQ=-[6=NO..^KHJ$4B[CS$_ZO%3((7MDMZLN'X;V])??P7;R'F(O MW,/(+A=;/DNCHZY\R6[*2R&[WP#@Y'PYF!=6=JA-?$`H-5%5*5W^F&+K\@O1 MEU\),4I[K5=8SLJN&+?,WESGBB+]?= M69QTEG!U??N[W,G,NUL[[>\J+\IE&O&8E_E,"D\-I^TSDH:WIO@4CMKE]^VO M[@B69>^G]^.W3[&E*9;L!DI+*8:KSS@^K42SW36&8YA^ M'2%]M>GA=!5<=*AMT*Q&>)+X)H_0&>G%V=G],Z80X<>WWIR)M4SO]?S"B0G! MY[1V&LU""OY!!=^Y]ZT&\&VCJZ$H+%*_R#B=8?GE%MFIOEO*IRT?,I$/3I&N MV>G39&L'5N(-&=7[,=+A46R4>53]SMJCU'UC(?A[=\<"4O'V='_INZXUK?IV M.O1\V0T,#R*`5,):MNX/[CYVVL>.=P%$^D[''3*->D`(2L><5HI9H06O M/,Z_]"B_TIJ5JR4:?M'R$]\/,PRGJM>R<*HZA7QV8]E\PQ-;^1&9 MZG0).X580YI=5Z)SJ+?I6.1Q08U61VQ'Y+#[Q+[U&P'2%ZKGQS(.3E0.+D4W MM(.5+:,B.XOP"#E[Q,PI,/7U8P2/K`1_'1SY#X(TG)!*N%"ZX"3X8TJY/%ME MZ5DY>_(C=7'3/=,>-,YL$!EZ'%SYO*H,NUVZG&[H2U[>^5=>;AQ\^)*5=U7Q MH,K6>I9$URF7];"R1YV]WW/^X1Z$:L)FJ_)JNOL:^Y01^H/:K?V]=/:0#Z`0 MI!2E"_\;@=Y^:"ZZ?UAP;RQOH*'>?*:++LL>4`=HZ^1Z6#-]X80I/*YURVH, MQ<15SD9MG5O+QH5VSW1>AX\EW64/3-9H.ZM.UGCXP&1;]T'6>$@ZTO>2[57Z MR&@8[V<_^D]"EB1)9W[$R^DK?A7+BT"$!7TM4]U8E(XKIWYPZ$F\M!9>+#O& M_'N$`*%^H6HOXCM54TTXCZT"$&C--C0M7-DV+G.5>.3.W;C6XEC7*.5_,9O,W_U\`````__\#`%!+`P04 M``8`"````"$`HQ`(I]X+``"<:0``#0```'AL+W-T>6QEOO7P)?^^K&&R\*I_K@?5_7W'`1+;WP<:K_ M_=Z^&.O:)G'"I>-'H3O57]V-_OW-;W]SO4E>???+D^LF&I`(-U/]*4G65[W> M9O'D!L[F?;1V0_AF%<6!D\#'^+&W6<>NL]S@H,#O&?W^92]PO%!/*5P%"Q$B M@1,_;]<7BRA8.XGWX/E>\LIHZ5JPN/KX&$:Q\^`#U)>!Y2QRVNQ#A7S@+>)H M$ZV2]T"N%ZU6WL*MHIST)CV@=',=;@,[2#;:(MJ&R50WBD-:^LW'Y52_U+54 MY'FT!!!_^.\V2K[[7?KR[H_OWO7_\^UW__J;N_SWC]]4O_OQ6[V7LR$TP0;[ M:;[O[R4+7Z>4>YD$-]>K*"2"#$!-J*VKYS#Z.;3Q.W`&$`]_=G.]^47[ZOAP M9(#P%I$?Q5H"5@;YV)'0"=ST%W/']QYB#W^V<@+/?TT/&WB`.4;VN\`#,^'! M7LKAO'P>$$TNTQAA<#*9>(3*%(!(#A[<+Y/S4XU,'*]A.Z]C],?Q8E+LETL: MKZI?5'1X#*_"5H1/_/@PU6T;U4H.=B-EDW@=^9V-V.3R;9*9MVB.I MDG&^6+4;,C1MF:IL86A_&-V>39WRF35)EZ7AV3CWSG\ MY,P%3:K%T#N:%'D*N<[)"V7;-CB)7-E8+[*!*N_Y?M'DF4-L@^#(S37TFXD; MAS9\T++W]Z]K:()":(W117OI[UI^_1@[KP.#M0)B`S:1[RT1Q>.C$Q"]FTWF\I'.)Q/91`T;_B03_3#$/\E$;?@WEZ;3 M+)`L62`+>EKBX52I_WXTF4S&@\OQ>#RQS(%E,24_9![MA4OWQ<79DS0U51$, M`<'$'$\N#0#2M\:,U5D1F`!@-!R.AX.)8<%_UA:='H%LG0YUU58E"!19E2!0 M9%76K?WS"UR1:HT!1DL!Y MCIOKI><\1J'CP]M>/B)_W3,2S@3!29^IGCQYBV=@QJTNI[I)69R*0Y'U+)Q- M6".K/[*&QF4Z89/$.G"7WC:H2E?PKO5+4"/JMEUPHL.P8)*Y0[G8U4,K9.83 M',%,S2PM.`!\(G<)P1$R9"P7?D5E)"/$9"0#!&4D(T1EA-"I"ZY;VHE+I8N,#W7(-G1-_?SPV``HW0@P4,R?):><.D_ M7?P7]EY>V@J;'4ED\1&5HD:W8.6#!<]**53FA>O[7[!6_G-5E&=8\;JY?EF1 MT_JPUP+/>^.N`7P+R\K9V[04IQ]`9TV#C,9!FK->^Z^?M\&#&]ML`P9CP8[B M\G7Y:<9ZB/+S!]][#`.7K=GI*9D?XBAQ%PG;(,+.6C3A,1OPP.X"83S'\+<: M^(.>SL(?UH1JC0AZ4D7 M^.^1TN;2[U%J)OD6'+U4,WS8`^`HEDTI5E6*(6:'2"M5`!_VJ,"&JBNGY`V: M5Y)(.A M*D52#*IR9&D*0U6*)!!494AJ"54IDF)0E2.)*52E2`(!-*(D0U)+J$J1%(.J M'%F:PE25(@D$51F26,(\<8KLT673=!&5K)_"UL#FI5`P4#[]W[75RZIU(770 M-&D"6OGP=/:4SAS!%FPN1:;2>+&4DZ^=:D]1[/T"DTR\:&H!BZENK.-%=HFW MH$=^CIWUO?L"4]'TE-#+ZB@!6S"5_&'96]>Z,)>NGR.P"%BZ11&MDK-)?>O" M_(YG\(OMK1[2"@(7=U1C0%UG&*2[@*00PETB[,$4?&V]SMI7>8L_6NXZ.42DZ*2!MW\%A,^EE-D8^%*F*WH3^Y M(J0SIZF"G#BX#YMS+(UR=Q0C>7^4!_E3",-C41U20FB0_#45[^6 ML*HOP>D)EU8;'H(2/:M:?%I0'H`'-[SP/J_A%3-I$H$-`CW!SM'D'*[%^QN] MG6I*&C+.TZ2%0FM@BOA9%8V(HPDG#ZI.J=D-7/X-93=9:"2JB_,SG[H9#?'E+8$6Q=G:QV'D=!.J*\$81\^H0O=AH/+GLVIJ.WA(4&2&X^2?CV%T3! M`'Y+6&3HBB6\+/E1Q]JO+)&4W>ANIX3-I<)*/"B'C1JN*AN.EHFP`EI(CS]M M-XFW>N67CSJL&4F`D$=K:W/SMI1`*_Y^+?`%7\@LN4Z.R!J-^*H%B0=XUO($ MNS=J'+NE/"D/QP;4;SSWD?C!77VUW0HE5=H1$!):%C#I2JNT M(UB!T@)WZTJKL*.%L5[J:RBH^\M:._*^BKL_17!16J4=>5\U!7V5TBKMR/LJ MBMP55VE'H$KT9<$776F5=N3SA"68)ZB,I1UYW0\%=;^;47F/-P0]/J52V@[> M$1UAZRZBHY1*:37>RTU!+T^IE/;B_=L2].^42FDIH$8?!.B,"`YZQL-CZ\.R+")^)XE<-=S07Y'BC#P7)_2F*"AWQ%`SX*`+HS_"<$7B$ MB09Z237$^S!V=5W(%+'`JP^.PN><_A-6P`2!%*G]UM$CN%__$A90@JYC/>XJ2@P:<( M=L>2W9[Q,]S1)%PG<)"H/8HX$PA+! M<1_!508%B9V,(DCC'TX<8K1PH;OCHPT2E==L0/>_?"EO=\/TGN"3>-B-<(KY M`"AJZ:ZQ-]5_O9J/)[9UM7(S[L_&%9;K#B\EP=GLQM.:SVUM[TC?Z\_^! MRO"Q15?PW)LC'@O$'E\$5VT,K*N-#P\/BC-A,_!?RF-3G7Q(X;.;60%LV,"7 M"]';%(]5NOD_````__\#`%!+`P04``8`"````"$`^V*E;90&``"G&P``$P`` M`'AL+W1H96UE+W1H96UE,2YX;6SL64]OVS84OP_8=R!T;VTGMAL'=8K8L9NM M31O$;H<>:9F66%.B0-))?1O:XX`!P[IAEP&[[3!L*]`"NW2?)EN'K0/Z%?9( M2K(8RTO2!AO6U8=$(G]\_]_C(W7UVH.(H4,B).5QVZM=KGJ(Q#X?TSAH>W>& M_4L;'I(*QV/,>$S:WIQ([]K6^^]=Q9LJ)!%!L#Z6F[CMA4HEFY6*]&$8R\L\ M(3',3;B(L()7$53&`A\!W8A5UJK59B7"-/90C",@>WLRH3Y!0TW2V\J(]QB\ MQDKJ`9^)@29-G!4&.Y[6-$+.99<)=(A9VP,^8WXT)`^4AQB6"B;:7M7\O,K6 MU0K>3! M`6#?!TVM+$6:]?Y&K9/1+(#LXS+M;K51K;OX`OWU)9E;G4ZGT4IEL40-R#[6 ME_`;U69]>\W!&Y#%-Y;P]?O/R\1?E>%G$__K#)[_\ M_'DY$#)H(=&++Y_\]NS)BZ\^_?V[QR7P;8%'1?B01D2B6^0('?`(=#.&<24G M(W&^%<,04V<%#H%V">F>"AW@K3EF9;@.<8UW5T#Q*`->G]UW9!V$8J9H"><; M8>0`]SAG'2Y*#7!#\RI8>#B+@W+F8E;$'6!\6,:[BV/'M;U9`E4S"TK']MV0 M.&+N,QPK')"8**3G^)20$NWN4>K8=8_Z@DL^4>@>11U,2TTRI",GD!:+=FD$ M?IF7Z0RN=FRS=Q=U."O3>H<],9&R;,UM`?H6G'X#0[TJ=?L>FT M1.[P:3?$45*&'=`X+&(_D%,(48SVN2J#[W$W0_0[^`''*]U]EQ+'W:<7@CLT M<$1:!(B>F8D27UXGW(G?P9Q-,#%5!DJZ4ZDC&O]=V684ZK;E\*YLM[UMV,3* MDF?W1+%>A?L/EN@=/(OW"63%\A;UKD*_J]#>6U^A5^7RQ=?E12F&*JT;$MMK MF\X[6MEX3RAC`S5GY*8TO;>$#6C\S210*:D`XD2+N&\:(9+:6L\]/[*GC8;^AQB*X?$:H^/[?"Z M'LZ.&SD9(U5@SK09HW5-X*S,UJ^D1$&WUV%6TT*=F5O-B&:*HL,M5UF;V)S+ MP>2Y:C"86Q,Z&P3]$%BY"<=^S1K..YB1L;:[]5'F%N.%BW21#/&8I#[2>B_[ MJ&:+T5';:S76&A[R<=+V)G!4ALZ%8J MNU'N_*J8E+\@58IA_#]31>\G<`6Q/M8>\.%V6&"D,Z7M<:%"#E4H":G?%]`X MF-H!T0)7O#`-005WU.:_((?ZO\TY2\.D-9PDU0$-D*"P'ZE0$+(/994FRE)")J(*X,K%BC\@A84-=`YMZ;_=0"*%NJDE:!@SN9/RY[VD&C0+= MY!3SS:ED^=YK<^"?[GQL,H-2;ATV#4UF_US$O#U8[*IVO5F>[;U%1?3$HLVJ M9UD!S`I;02M-^]<4X9Q;K:U82QJO-3+AP(O+&L-@WA`E<)&$]!_8_ZCPF?W@ MH3?4(3^`VHK@^X4F!F$#47W)-AY(%T@[.(+&R0[:8-*DK&G3UDE;+=NL+[C3 MS?F>,+:6["S^/J>Q\^;,9>?DXD4:.[6P8VL[MM+4X-F3*0I#D^P@8QQCOI05 M/V;QT7UP]`Y\-I@Q)4TPP:&PO=V]R:W-H965T$&%9P24V@:E[!3JZTI!:6>D5, MK3G-FB)9DDX8]HFDHL*>8:P_PJ'R7#`^5VPC>64]B>8EM:#?%*(V)S;)/D(G MJ5YOZB>F9`T42U$*>VA(,9)L_+JJE*;+$GSOHYBR$W>SN*&7@FEE5&X#H"-> MZ*WG$1D18)HDF0`'+G:D>9[BEV@\BS&9)$T^OP7?F8MG9`JU^Z)%]DU4',*& M-KD&+)5:.^AKYOZ"8G)3O6@:\%VCC.=T4]H?:O>5BU5AH=L],.1\C;/#G!L& M@0)-T.DY)J9*$`#?2`HW&1`(W3>_.Y'9(L7=?M`;A-T(X&C)C5T(1XD1VQBK MY!\/BHY4GJ1S).F"^N-^)^@,>U&O_W\6XA4U!N?4TDFBU0[!T,"9IJ9N!*,Q M,#MG77%%3"F@#W=A.XJB?D"U$R(Z8Z2VFTT;,[B!&9P@!?6>1 M8/UQD:X(S&!T(7)PYF^,3#TFOL2T$;-_(5H:X:#'-;JB%,,9%QJ';053C^G' M3,/VX7E=TK?>]9SY3CSG*O1)W?\_K\K?/#V=- M5_R-ZI6H#"IY#NF$P0"NBO9WSR^LJILA7"H+=Z9Y+.`5R6%"PP#`N5+VM'"W M^_S2G?P%``#__P,`4$L#!!0`!@`(````(0"^-6#$QP(``$('```9````>&PO M=V]R:W-H965T7YYP#QZOK)]&@1Z8TEVV. MXR#"B+54%KRMK@U0/NF;,('!H=8YK M8[IE&&I:,T%T(#O6PIM2*D$,#%45ZDXQ4O231!,F430-!>$M=@Y+]18/69:< MLEM)]X*UQIDHUA`#_+KFG3ZY"?H6.T'4P[Z[HE)T8+'C#3?/O2E&@B[OJU8J MLFL@[J*E3F^B9?; M*0[7JSX_/S@[Z+-[I&MY^*!X\8FW#)(-9;(%V$GY8*7WA7T$D\.+V7=]`;XH M5+"2[!OS51X^,E[5!JJ=04`VKF7Q?,LTA82"39!DUHG*!@#@%PEN=P8DA#SU M_P=>F#K'DVF0S:))#'*T8]K<<6N)$=UK(\5/)XJ/5LXD.9I,@/[X/@F2>19G MT[^[A(ZH#_"6&+)>*7E`L&E@3=T1NP7C)3B?(G,M1L+C4CQ?:DL*4`/,\(D9\S_C[K)Q0KMBBV"I9MXQZ` MMV=+AF3;2\4\\I(!"63H[216#)4^6SB-1TMOG"8]U_B5>_SM:XH!&YB#`DV3C--^[I&03R=1>?7N(I#N?<:L,*N_W=6.VG, MFGI_5VRG\:R3>#X4;$>"),H6@\O+![S3_^&UD\:\F?=WO$X#*7O)_U`!;LNT`7<]R1UHP5;$M:QJ-J-S;?I1`S?Q3WRIO$GLZ1L\WT$+[AA/Z%]#" M.E*QST15O-6H82581L$,RD@>;5W];PK6)P^J(`Q*64YC2P M9]M__=:_````__\#`%!+`P04``8`"````"$`:*I6!VL"```3:.0RSB.++-]O>]MB%BH&7(0Q(GYYYS[F)/GP^R1CNNC5!-CI,H MQH@W3!6B6>?XU\_ETP@C8VE3T%HU/,=';O#S[/.GZ5[IC:DXMP@8&I/CRMIV M0HAA%9?41*KE#?PIE9;4PE*OB6DUIX4/DC7IQ7%&)!4-#@P3_0B'*DO!^$*Q MK>2-#22:U]2"?U.)UIS9)'N$3E*]V;9/3,D6*%:B%O;H23&2;/*Z;I2FJQKR M/B0#RL[-"IX2;>U M_:'V7[E85Q:ZG4)"+J])<5QPPZ"@0!/U4L?$5`T&X(ZD<),!!:$'_]R+PE8Y M[F=1.HS["<#1BAN[%(X2([8U5LD_`925'3C' MP'VA/.QX@W+`9+XBXS3V5P=Y)PWN'I=VX&OI4<<;I`,F2-]5AH&[5'8-'_QW ME,\-=T'7#L97#@(F.!CX>%5:V?\Y6RL"W]:P6G,(=-$$<`+I6RYX4[ M0+IS??87``#__P,`4$L#!!0`!@`(````(0"R%CM_WP(``!X)```9````>&PO M=V]R:W-H965T$'!12E53= M*JW2-.UP[8`)5@$CVVG:?[_/=IH"82RY24+\^N7Y#OAC=?M:E>B%"LEX'6/? M\3"B=9%;$59CZ[`4EWCP/&?IOJ*ULB:"ED0!ORQ8(]_=JO02NXJ(YWUSD_*J`8LM*YEZ,Z885>GR<5=S M0;8EQ/WJ3TCZ[FTNSNPKE@HN>:X:$/*5W^LR#]:69/@:!("_7$]<(+Y MU)]&_W=Q+9$)\)XHLEX)?D#0-7!/V1#=@_X2G'5D(>1G.#((2>^YTYO,5E!+ M*,?+.EQ$*_<%4I@>-)>3:7&7+/!ZA4NL)OHW65LP1@;-?SF9%G?)PL5'O]AZ6LW$D'FG;)BU MS?!:)U/1-3Q:W.69>+U[)E8SS#.\UN&97<.CQ7T>OYN#Q&I&*M<6C%5.3[;6 ML3'>[5K<)^OWE-6,D+4%8V2+:\BTN$_V\139GK*:X1H.KW5J"'/IBE09=9^H M=R8E1Y$]&GHMI^>@CJF_:)GLA+,#H"$[^D3$CM42E32'D\AS9O"0"#O?[(7B MC3GHMUS!7#(_"W@/H3`%/`?$.>?J_4)/T-.;S?HO````__\#`%!+`P04``8` M"````"$`+O1>#<(#``"2#0``&````'AL+W=O)F(-"N/(?GKS^?/#\21 MBI4IRT7)0_+.)?FR^^73]B+J%WGB7#G@4,J0G)2J-JXKDQ,OF)R)BI?PY"#J M@BFXK(^NK&K.TN:E(G=]SUNZ!=$%!58[+,\4^^-*7&*9//U6(J:[7,8]QM=L.3JW5R, M[(LLJ844!S4#.U>#CL>\=MPLP1!V=D+\0+OOH5;GD01#8"#"+_ MO89Y]#&*VX49_KZ&?&ZF[7OMI/S`SKGZ(2Z_\>QX4A`I@#1@-C;I^Q.7"4P# MQ)KY`;HF(@<+^'2*#-<3I)&]:;HL5:>0S)>S8.7-*PGK2+2"OCL%-14Q%<% M3B`P=""0F^D@*$80G"\DB_2-85S?BCM6S#N%`0)9F`Z"8E@2@_':&=&*Q4"Q MZ.(V[/'/%`89F$PG0W%(8-3=3`1FW$@KAF1+4Q&/%3V[00:E,)T,Q2;9RHP; M:<60[,%4Q&/%#;+E/60H-LG69MQ(*X)F[2_HFMJK3#\?DM_@@B*:GC$4FUS4 M7F9:,@Q,[4]`L<5F)272$H.MKSU=`V/)#;;U/6PHMMAZ6[UQ M:(G!9M5)/);T)D854#C2AHG#LV8.]_YG4\6W+$JK$*/&.21#S)Y!9["5+/72 MG`>K=1#T=65RXAX\>8*IWK&'.PGMC7466\V0C]HE^X&F'X/)AWOU=#Z]LQM\ M=ME2K1GR^58%Q1]H;O'ACCV=3^_O0S[?*LV(CL\`WZJB^`/-+3X8YQU\J#;7 MGV^59T2UQLC?B&^LN<5WUW&!W9K-UQNWZV]\'OAV&;<^PS'T-N;ZN^O0@)9W MQ#>JW_&YX%LUA*TS^OR,3W>\NG\K>'WD,<]SZ23BC!TLA=+O[G8M>=LK=P^@ MN:W8D?_.ZF-62B?G!WC5FZT@@[5NC_6%$E73'>Z%@K:V^7F"_SX&PO=V]R:W-H965TV[WBVA=/RS-EC_R( ML;#`H>0K^RA$M7!=GAYQ@;A#*US"SIZR`@EX9`>75PRCK`XJ>[.77!:+S," M!#+M%L/[E7WO+Y*Y[:Z7=7[^$GSFG;\M?J3G+XQDWTF)(=E0)EF`':6/4OHM MDTL0[/:B'^H"_&16AO?HE(M?]/P5D\-10+4C`))=H M6=]#!49IUF$P6[I/D-/THMGT-=.Y+MDV$IE!Z1LW"Z^^ MOAZ2-`I9/D!JN2!;7:ZW*]4<7XKE\9OW;M0">+<\@?[>;5\Q\W1)W)<8)DE? MT3'1<$(=IRG3,)8,@G)V*,+`2/E&:6X[FEL=8SNJB$<5R9!"XX2#=,MV':<, M6MF0S+9:_B34*39*,ZE[\S:,IO,HFNJ2[;@D'IO[8:UOPC6%)L8$V-]VZ4YGTL8[^'9>P; M]C#7R".T]CTL-;6H2[W`[("W.,^YE=*3G$A"R':[V@Y+]X&\ZXSUC;^`&[B_ M'L-P5:^[;0`,-Q4ZX!^('4C)K1SOX56>,X4O!%/CD7H0M*I'C!T5,-;4?QYA MBL5PMWL.B/>4BN9!WN#M7+S^#P``__\#`%!+`P04``8`"````"$`*F`]GCX( M``".)@``&0```'AL+W=OG@O\BE60KBH(*"M3>W6NC)%*K8@G9['[[ZV&F&9@FQ-WS330_>YYF MYFF@';G_\N-X:'P/+TD4GQZ:6JO3;(2G;;R+3J\/S;^_SOZZ:S:2='/:;0[Q M*7QH_@R3YI?'/_^X?X\OWY)]&*8-4#@E#\U]FIZ-=CO9[L/C)FG%Y_`$G[S$ ME^,FA7\OK^WD?`DWNVS0\=#6.YU!^[B)3DVN8%RNT8A?7J)M:,;;MV-X2KG( M)3QL4CC^9!^=$U0[;J^1.VXNW][.?VWCXQDDGJ-#E/[,1)N-X]:8OY[BR^;Y M`//^H?4V6]3._B'RQVA[B9/X)6V!7)L?*)WSJ#UJ@]+C_2Z"&;!E;US"EX?F MDV8$VK#9?KS/%NB?*'Q/"N\;R3Y^MR[1SHE.(:PV^,0<>([C;RQTOF,(!K?) MZ%GF@'=I[,*7S=LA#>)W.XQ>]RG8W8<9L8D9NY]FF&QA14&FI?>9TC8^P`'` MW\8Q8J4!*[+YD;V^1[MT_]#L]EM:KS.`Z,9SF*2SB"DV&]NW)(V/__(832AQ M#5UHP*O0T'NM_K#3U7Y!I"=$X!5%KCX`.-1L$O`JQ@Y_.3^<$)D&O`J-;FNH M=4;=(:C63'XDQL%K/@[7KV:8AHO&WOSRA+6NR,K>_/:4M0&JP)O\X*^9-%2T M*!MXDX_\>-IM7G59$9N;=/-X?XG?&W!E@,)*SAMVG=$,#98>RY>O7%[0']4S M%#)3>6(R#TTX%JC5!$["[X]=O7/?_@XGSE;$C&F,5HZ88`0[2YBLJ8*I"F8J ML%1@JV"N@H4*EBIP5."J8*6"M0H\%?@J"`J@#?;D'D&!WL(C)L,\PM4=(Y"F MZ8HA&(%#3!5,53!3@:4"6P5S%2Q4L%2!HP)7!2L5K%7@JU)XV(@=+(SZR>8E(>DKM$R)20&2$6(38A(3XA`1%4G(-[OVW<(W)9*[A:H\%*5K4U=7K7QZ$PTQ" MIH3,"+$(L0F9$[(@9$F(0XA+R(J0-2$>(3XA09&43(+NI612=>^+O0*++GLA M"&]JV8U_0HA)R)20&2$6(38AGFO,%&!*<9(SZ:$S-1!%@=:]HTJZ_!L3G3H///+J3Y4[G#S M/`A/PP4A2T(<0EQ"5H2L"?$(\0D).,G6JV00S*O"H!;[2I/NH^VW<0S3AFM0 MQ1G3A3::-]=,I&P/)P5[5&"*,05[")FI@RP.BO9PHL-WJX(]_7(#,L^#*9>,% M8ML+TOD[Y4OQ!*/N\DNM*9!>'*CU%9.F&,4K1-,&G9X2,D-M/=>V$,ET-@K5 MIIN+J"[((KU);IUHAD.@^%:B?HBZCZ M"08HGV4LUQ1=ZI+"`\"3S$)IF2H3( M&^L:I64V#U%M-A^SU4XO*"8LEQ-4*RVGONP<\-Y4T3G`IB^V#NSJH]801W*. M$Q$DB4G(5)!"4B8_0@'Q<$N^7D?HM,^743)/L`4`S_KT_E`G==+MSOH=+KE;RXS>02X)A8B MF7%!X`'I*%TG+!;42UV>:8K;:178@H>:-;HKI,Z""J3>AB0MZG5TUO1;*M M45IF\Q#59O,Q6^WTV!,D>7/&RXD_$,)_2S^&E]=P$AX.26,;O[&'/>"B\'B? MX_Q)E*>L1A0^9D^HL-I1N6[`+Y`5O&O`KUR4/_6,)SA.^L&X9\`/+!6\;\"> M?@4?&+#E3#DTC09KO:H^Z<$G53G@?FFP.V+5F+XQK_P$[E2&6_D)W&0@3Y6: M.31@`[HBR]#PJ[AY9TRS6E$6W;XS8/^0ZI@C`[;<*+='!NR74>Z,#-CLHMP; M&;!3!;R=)X:G@ M7#@'7@,``.0*```9````>&PO=V]R:W-H965T`EO4JD*9N!1;5U=*"A.B09(TL M$;DE#OC7D-F7E>_?+=T7R$9\P#Q8#/PV&-H@7(BF"0G":(=T.CU'SPA&SY@N M#.7!&MIN_--N@JX;5!Y`32^[PT.`:XGP_7G#;R.PF+"%"1M$1RA`KA>*8/`, M\IK\#7-L05>XAH9IN[Y./!ZJ0VB2;2T4TO8>5."=5COKNKR<9P1W75E+6#=S MNUN@Z89*1NN(I[K\UM).G1^<:5`K&6H9-ZEQ9KXX:@2/-7E MMY:NDC-W`"MWO90:W?5U,`W%4+SNK22AFM";3Z!C+N>K/MAS8D='5U%PNLOH M?TV/&MUS9@?("44G!D;HC>LYC`S_?431X83P@S,S@H+J=AY'DH?HGAYK.J$' M+V^K0B/,]JK#_&DN/WZ[P%F[+#1\'X:=44=[MQ_;@<['DS><`S53UZL?3,\T M0V\XC$@<#@5ZG`H@NJNG-P-0SWSTKL)V,2B/-4WA+%`6?>)YK)Y8[W!=\^.(VUF:76=>EZMO#Q=KN.&[S!G:,BFWY=Z:VHM1.SE/@ M]":W4!UEMQ3[8&15[PL;:6"[J/]FL$UR^.IZ>*]3*K?P```/__ M`P!02P,$%``&``@````A`#SBC7.,`@``C@8``!D```!X;"]W;W)K&ULE%5=;]HP%'V?M/]@^;TQ"5`@(E1T5;=*FS1-^W@VSDUB M$<>1;4K[[W<=0Y06Q-B+$]\;G->Z@8R^@J5WJX\?EGMMMK8"<`09&IO1RKDV9C^C;+7LZO-;PMX.WHFM M]/ZSD?E7V0`6&[?);\!&ZZV'/N4^A(O9R>K';@.^&Y)#P7>U^Z'W7T"6EY2>DQ*QLTZK/P$5'[@"2W)@P>>!97P;36>C\14D+&34&7S@CJ^61N\) M-@U*VI;[%HQ3)#[O"*UX[-J#,SJC!'.UN`O/JV0\6[)G+)TX8.X#!L<>$_<( MAJ*],JI=K^S!7MG7UJ=R'P)#F>2\S/A_9#PXHSCVR9\:#)C)`#,YKXR0ZPUZ M,"JCK0O2`72%-#;54-KWZQB[_O+N^D5="GV10R3&E8.DYN?=WKZ5O"SEP6^E M0F32'<-AEV"SO7<2S_]IQ:]ZRQ\BP](EX\4[)^'\A^.AP)3P">K:$J%W_FPG MV/!]M+]VUHE/^7U\DJZ[7F7]![P.6E["-VY*V5A20X&4HVB&)3;A0@D3I]ON M4&ZTPWN@>ZWPW@?L^5&$X$)K=YR@,.O_)*N_````__\#`%!+`P04``8`"``` M`"$`AC3O2J@"``!0!P``&0```'AL+W=OS$0DC8HI$I7=9NT2=.T'\^.,6`58V0[3?O?[VRGC#39 M2E_`/CY_W]WY[EA=/\H6/7!MA.H*G$0Q1KQCJA1=7>"?/^XNKC`REG8E;57' M"_S$#;Y>OW^WVBM];QK.+0*&SA2XL;;/"3&LX9*:2/6\@R^5TI):V.J:F%YS M6OI#LB5I'"^(I*+#@2'74SA450G&;Q7;2=[90*)Y2RWX;QK1FV`P.3E]YR_@FT8EK^BNM=_5_A,7=6/AMN<0D(LK+Y]NN6&0 M4*")TKEC8JH%!^")I'"5`0FAC_Z]%Z5M8+6(TJMY,E\`'FVYL7?"<6+$=L8J M^?N`.G`%EO3``N\#RVP1S2_C6?(Z"0D>^0!OJ:7KE59[!$4#DJ:GK@23'(C/ M1P2A..S&@0M\B1'X:N`6'M9I%J_(`Z2.'3`W`0//`9,,"`*B@S*H35=V8*?L M(N4`Q]+!4OFVV]<'5!DXPA7$(H.(S%LK.K]6-DJ"Y/,+QOXL_```` M__\#`%!+`P04``8`"````"$`A>-_U+D"``!;!P``&0```'AL+W=OUZ,P;F\ROH9-,/^V[FUS)#BAVHA'VM29F1;9C>)81NUGU]?@M^ M,*-GS]3J\%F+XJMH.10;M@DW8*?4$T(?"PS!8GJR^J'?@._:*WC)]HW]H0Y? MN*AJ"[L]!T/H*RU>[[G)H:!`XT=S9,I5`PG`U9,".P,*PE[Z^T$4MLY(E/BK M^3Q>K)9`L^/&/@CD)%Z^-U;)/PX5'KD<2W1D@?N19;;PY\M@%H+H/TBHRZ@W M>,\LVZRU.GC0-"!I.H8M&*9`?-X16$'L%L$961(/&<&HC+7%5.Y<8"P3G9>9_8\,@C,"UR'Y*%X,O$[9 M8>(1)AX0$X,`N=X@@D$9;%V0=J`KI*$?QM+8KS/H^LN[BXOZ%(8BNT@(*T=) M+<^[74PE+TLA>"KE(G%_#,==`LWVWDD<)#YD=ED!UTT57&1G?>"8_OJ M0X'@J9*+G'I)IK2X*Q$>W M!U4$IW>(#C-T&V']W\?C=-O/5CI\@-G6L8I_8[H2K?$:7@)EX.,LTVXZNA>K MNG["[)2%H=8_UO`3XW"``]S"4BG[]@+"=/@M;OX"``#__P,`4$L#!!0`!@`( M````(0`/[FKQO@8``'$=```9````>&PO=V]R:W-H965T\;HKJLK'(>&*-\DM6[8O+<6/]\R7X MM+1&39M>]NFYNN0;ZWO>6)\??__MX:VJ7YI3GKX=4WFVGB_=X%M49EMHZ/ MEZI.G\^0]S?BIIF(W?V!PI=%5E=-=6C'$,YF#XIS7MDK&R(]/NP+R(#*/JKS MP\9Z(NO$F5CVXT,GT+]%_M8H_Q\UI^HMK(O]'\4E![5AGN@,/%?5"S6-]Q2! MLXV\@VX&_JI'^_R0OI[;OZNW*"^.IQ:F>P89T<36^^]>WF2@*(09.S,:*:O. M\`#P[Z@L:&F`(NFW[OI6[-L3_&\Y7I#):KJ`*,]YTP8%#6F-LM>FK9#I?#Q;3*8$QKSE..6.1]2<(:[9X5KN]+#?&T7";6!*I)%KB"--I#J(^(@$B(2(1(C$B"0JT42"3>XC M1*)A0"28"BD`7DK"PTD09;@O$7DNM]=PY(7*+ MV2'B(>(C$B`2(A(A$B.2J$1+%`X(+5%ZVDSAU'GG:4/#Z`IPHBX(AZR,V9=& M-8XC! MD5H+Q#5W`B*M9#%@Y&,48!1B%&$48Y1H2->'-F+JED#UF;]_GR2LH8-F0J2Y M%4C5QW%0(\X=^Y+R>D<1R\F2BAR MHH715:(MW"V5OE37'ZD$;_:D3+P35&5BB&[MLF(%6?<5X`JF.9&:\ M8O*%%1-XYB[G9&'\!@R$3?]4H4#]>)%`-\>+A14?;^:XBZ51GXFPZ<;39:9- MX2V9[RM&WEKV^6P)0W2S5%0VBFTGK-@+9_:^C3O.Y5+UA174CQ++2#(05NJ( M9&:T7:&PZD>,!.I'C`721YSK!9T(JQ^-J"D-[_8'E(:WWWS5BWJ^?POH(NJM M)T=&;1LENA-6?:UY'#FPFTJ)<6US*Y=TFP=QR<1=&F=T((+WM1`*U(\7W35> M;(RW(&2Q,A8J_69"ST=(&?8KICC[!L+>,9=Y? M:[&&G_,#?+F&7[\#?+6&'X`#G$S@B;H#U7@BC\S7].#$/G`JKNF9A^]X9`$^ M0\\%QP/X#-V!#U]/P_K"@PV,L84)&;2'Z1B:C2<7X@\EN(59ZB;)EIG#!Z]K M>LS_3.MC<6E&Y_P`!3/ICN::?3)C?[3\\'FN6OC4U9U#)_BTF<,'@PE=T8>J M:L4?H)(M/Y8^_@\``/__`P!02P,$%``&``@````A`$"S#7P.#@``Y$<``!@` M``!X;"]W;W)K=6;.[UXHLVZI8EDM2)C-OOPT"31Q^1I$SN8GBC]T-H!L`T4V)M[__ MM7]M_+D]GG:'M[NF=]-N-K9OF\/C[NWYKOF?/^+?!LW&Z;Q^>UR_'MZV=\V_ MMZ?F[_?__M?MM\/QR^EENSTWR,+;Z:[YZ\G0X M[M=G^O/XW#J]'[?KQU)I_]KRV^U>:[_>O36EA='Q&AN'IZ?=9AL>-E_WV[>S M-'+;WN\WQ<#H\G6_(7$MV%,<\;`U;9.G^]G%'(Q!N M;QRW3W?-3]ZHZ`3-UOUMZ:#_[K;?3L;_&Z>7P[?DN'N<[MZVY&V*DXC`Y\/A MBQ#-'@4BY19HQV4$EL?&X_9I_?7U7!R^I=O=\\N9PMVE$8F!C1[_#K>G#7F4 MS-SX76%IS<=O]L?>"3?^+P]G>.= ML-EL;+Z>SH?]_Z24IVQ)*[ZR0I_*2M"[Z?;;06GD@F*@%.E3-W^-8DW M2(U?:(D&4PZ4/KFEX55=["E%^E2*9.)"0WTE3Y_ M!OW+#0Z5'GUR@]>-S*/9)H,OIIV,Z^6FO&JZT'^XL>M&Y_$<$?_AQJX:G\>3 M1/R'&[T<;(^GAU@*K')E/SG>GA'PZ_K)D?>,T/^@GQQS3P>=UM^%!="2Z[?< M#L+U>7U_>SQ\:]`>2P$YO:_%CNV-A#7>".1,K;:&[^T,M"4(*Y^$F;LF#8#6 M_(FVLS_OO6%PV_J3MJ"-DGFHD;$EQBPA]AMA-G1!Y(+8!8D+4A=D+LA=,''! MU`4S%\Q=L'#!T@4K%Q0&:%%XJAC19/@5,1)F1(S8NP\,=-!\)R`LP2JA"R(7 MQ"Y(7)"Z('-![H*)"Z8NF+E@[H*%"Y8N6+F@,(`5$-I0?D5`A)F[)OU[8=$H M&9H:E5#'"5(E4D4)2`0D!I(`28%D0'(@$R!3(#,@,?`PF!1$!B(`F0 M%$@&)`<.N<^.I MA*K5`20"$@-)@*1`,B`YD`F0*9`9D#F0!9`ED!60PB16D.A4;07I\NH0TG8L M%#%6!Y`02`0D!I(`28%D0'(@$R!3(#,@5X42&P//^3^U)I MQXZ)0ITJBQDK0A_5-J203S-#W]P'SLT]TE*L&*.M!%&J%4WSSNZ8:2DVGUNV M;(^)W`_S\!M1PSF_[#9?'@XT$A*JV3P"RK=5%BZL./Z2R/27)-07[E^"J2H!U8J5CF$D0I6#9*0ID6H`MYY89VTLB(;ODI3\.[]_S$I4E M*S?)O([.\-SF@Z@ND0?$AYXQPYYSPV.I0:48,K(4NWU;,6(IZ>!.M]_O.(Z( M641W*F&DFTL976PN8RG57*\][#D1S5FD;,YVLLB@3"?73#G3F2KATOU^$`4W MX4PZU!O.='PR9BE97I;EGDJ1`Q,IJ4!$CXI*[780#`<#V[TQF]*S/&&DK:>, MM%1F6_<[PT[/=P*36VJVIT36\@%/J23'])1$(AB&IYSAC84CA3_U/`@9:5L1 M(QETKQ<,@T'7F<$Q"VF]A)&VGC+24ADC:;W7ZWL]OVV'(6>94LWVE$@=/N`I ME6GH]A]$11;GU-#NP9BE=-1#1CKJD4(\I[KMGN?9AF+42AAIVRDC;3MS;7N] M/KBI&@K-IO,!TDT36A*)':_;HQJ)&[4ZH2E$O/85DR/U.K]MU MUD;,AG0/$D;F=`+;&4LIV_[0]YQ.YBQ2,YO$4=MTDSQ>?/1FJ0[LNN\/H@+O M3C*Z&[K>4U)Z(H2LV*MN#)%"@5J.?C?H#]O.&2%F/3V!$D;:>LI(6\]LZWZW M,^SWW##GK%=:MR>:.#-?\N"5-U)U]#9=*%&'3H#5CN:WW;JR>-+@3D"%M*V( MI:0+:=_WVSWK?;[O8&SDTJ9Z&:22A.OY=<>-V)39VA M]:@?/(G$9FIXT%EY8Y;2TR1DI*=)Q(AFK&'+.0O$+&6VZ'6=O35A*=UBRDBW MF#&R6W3F?(0D01HAA1@BA%E"'*$4T031'-$,T1+1`M$:T0%1:R8R%2*S,6/UFI M\H4=9PTI9*\A-[=C11W*$%&$*$:4($H198AR1!-$4T0S1'-$"T1+1"M$A87L MN(DT M0+1$M$)46,B.A4COS%C\[!J2::(5)(ET>C06YRR1.1C52X7L:F_7.>1&6HH3 MW!A1@BA%E"'*%3+Z-4$TU8KZONIUG=/Q3$MQ5^>(%HB6B%:("H5D5^U(BLP6 M(_G!Q-J7^;$51XG,.$IB^"M4>E2%-IWC',$C+<7.B1$EB%)$&:)<(:-?$T13 MK7BAJS,MQ5V=(UH@6B):(2H4JHNCR'8ACO\H8Y+YLQ53B MDP6Q:FD]=W3.$RMDA"!!E&I%41BF*HV3(6=:@+V?HYD)HJE65):=K62F!=CR M',TL$"VU8GV?5UJ`+1>6&7NU_J@"<66.AB4(L03%)FN6I?VV4Q`8LY3.34-& MIF)-,JS,J\I+T!ZZ7RV(M2%V1,)(-YA).&.G6 MIHPNMC9C*=G:L.L/`F<+F[.(;F[!2#>W9'2QN15+R>;\7M`/G&);P2*8Y8MD M$?>)[@?W^]**??95R*YAN17>,4OIBE+(2%>4(C8O1]CM=]VR">OHG2AAI"VG MC+3EC!'=BJHLU^LYT, MM.T5HXM=+UBJ-&_M'4%M?>>?W"%*B\XLD*4>:QL9ND4$I4>%5E[IH4+BG*+C M`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`K]3H)TZD)%OW,@G;HKH=^C7M=YDQX&4M_**ZW*TR#_.ZH<.GP]G>KD*E>KIS0WT-ITM_7:R M+;X8]W0XG/D/&DBK>C_/_?\!``#__P,`4$L#!!0`!@`(````(0!"$<+G=@8` M`*X9```8````>&PO=V]R:W-H965T&ULK)E;;ZM&$,??*_4[ M(-Z/S6+C"[)=Q>:N5JJJT_:98&RC&&,!2<[Y]IV%7?8R/JYSE)>0_)B9W?W/ M+`R;U6_?RK/QEM=-45W6)AE9II%?LFI?7(YK\^^OP9>%:31M>MFGY^J2K\WO M>6/^MOGUE]5[5;\TISQO#8AP:=;FJ6VO[GC<9*>\3)M1=6Q;UFQK\G+8P_^94 M7!L>K

CONCENTRATIONS Accounts Receivable (Details)	Sep. 30, 2014	Dec. 31, 2013
CONCENTRATIONS Accounts Receivable
Percentage of accounts receivable by two customer	14.50%	11.20%
No of customers accounted for more than 10.0% of accounts receivable	0	0

XML 14 R33.htm IDEA: XBRL DOCUMENT v2.4.0.8

PROPERTY AND EQUIPMENT Assets Life (Details)
9 Months Ended

Sep. 30, 2014

PROPERTY AND EQUIPMENT Assets Life

Permit of land use life 40 to 70 years

Building life 20 to 35 years

Plant, machinery and equipment life 10 years

Motor vehicle life 5 to 10 years

Office equipment life 3 to 5 years

X

- Definition

Building life in years

+ References

No definition available.

+ Details

Name: fil_BuildingLife

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Motor vehicle in years

+ References

No definition available.

+ Details

Name: fil_MotorVehicleLife

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Office equipment life in years

+ References

No definition available.

+ Details

Name: fil_OfficeEquipmentLife

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Permit of land use life in years

+ References

No definition available.

+ Details

Name: fil_PermitOfLandUseLife

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Plant, machinery and equipment life in years

+ References

No definition available.

+ Details

Name: fil_PlantMachineryAndEquipmentLife1

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: fil_PROPERTYANDEQUIPMENTAssetsLifeAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 R25.htm IDEA: XBRL DOCUMENT v2.4.0.8

INTANGIBLE ASSETS (Tables)
9 Months Ended

Sep. 30, 2014

Intangible Assets (Tables)

Intangible Assets Medical Formulas
As of September 30, 2014 and December 31, 2013, intangible assets consisted solely of CFDA approved medical formulas as follows:

September 30,

December 31,

2014

2013

Gross carrying amount

$

5,486,178

$

5,524,785

Accumulated amortization

(4,075,696

)

(3,812,992

)

Net carrying amount

$

1,410,482

$

1,711,793

X

- Definition

Tabluar disclosure of Intangible Assets Medical Formulas

+ References

No definition available.

+ Details

Name: fil_IntangibleAssetsMedicalFormulasTablesTextBlock

Namespace Prefix: fil_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: fil_IntangibleAssetsTablesAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 17 R42.htm IDEA: XBRL DOCUMENT v2.4.0.8

INCOME TAXES Provision (Details) (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

INCOME TAXES Provision

Current tax provision. $ 0 $ 0

Deferred tax provision. 19,215 (472,512) 57,758 (1,129,506)

Total income tax expense $ 19,215 $ (472,512) $ 57,758 $ (1,129,506)

X

- Details

Name: fil_INCOMETAXESProvisionAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.

+ References

No definition available.

+ Details

Name: fil_TotalIncomeTaxExpense

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I.7)

-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6509736

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section I

-Subsection 7

+ Details

Name: us-gaap_CurrentIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I.7)

-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section I

-Subsection 7

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Deferred Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6510177

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name: us-gaap_DeferredFederalIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 18 R37.htm IDEA: XBRL DOCUMENT v2.4.0.8

Amortization expense (DETAILS) (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Amortization expense (DETAILS)

Amortization expense relating to intangible assets $ 96,382 $ 131,585 $ 289,712 $ 399,166

X

- Details

Name: fil_AmortizationExpenseDetailsAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives related to intangiable assets

+ References

No definition available.

+ Details

Name: fil_AmortizationExpenseRelatingToIntangibleAssets

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 19 R9.htm IDEA: XBRL DOCUMENT v2.4.0.8

PROPERTY AND EQUIPMENT
9 Months Ended

Sep. 30, 2014

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT
NOTE 4 - PROPERTY AND EQUIPMENT

Property and equipment consisted of the following:

September 30,

December 31,

2014

2013

Permit of land use

$

457,743

$

460,964

Building

10,033,988

2,494,623

Plant, machinery and equipment

16,393,856

6,671,620

Motor vehicle

150,611

151,670

Office equipment

246,553

229,210

Construction in progress

12,537,905

25,497,600

Total

39,820,656

35,505,687

Less: accumulated depreciation

(5,951,165

)

(5,264,350

)

Property and Equipment, net

$

33,869,491

$

30,241,337

Construction in progress consists primarily of the construction of a new production facility and the acquisition of related equipment and capitalized interest during the construction period. During the nine months ended September 30, 2014, an aggregate of approximately $17.16 million was reclassified from construction in progress to their respective property and equipment category as the assets were placed in service and depreciation commenced.

A reconciliation of total interest cost incurred to interest expense as recognized in the consolidated statement of operations is as follows:

For the Three Months

For the Nine Months

Ended September 30,

Ended September 30,

2014

2013

2014

2013

Total interest cost incurred

$

330,995

$

89,238

$

952,836

$

263,732

Interest cost capitalized

5,751

-

457,782

-

Interest expense

$

325,244

$

89,238

$

495,054

$

263,732

Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:

Asset

Life - years

Permit of land use

40 - 70

Building

20 - 49

Plant, machinery and equipment

10

Motor vehicle

5 - 10

Office equipment

3-5

For the three months ended September 30, 2014 and 2013, depreciation expense was $321,020 and $210,182. For the nine months ended September 30, 2014 and 2013, depreciation expense was $724,509 and $640,550.

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2921-110230

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13-14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 20 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\P9CEA9#9C,%\R-3DV7S0Q8C!?.39E.%\X.&(S M.3@T83`S8S4B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I7;W)K#I7;W)K#I%>&-E;%=O#I%>&-E;%=O#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DE.5D5.5$]263PO>#I. M86UE/@T*("`@(#QX.E=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D%$5D%.0T537T9/4E]055)#2$%315-?3T9?24Y4 M03PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/D-/3E-44E5#5$E/3E],3T%.7T9!0TE, M2519/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E M;%=O#I7 M;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E M;%=O#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DE.5D5.5$]2651A8FQE#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E!23U!%4E197T%.1%]%455)4$U%3E1? M5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O M#I%>&-E;%=O#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D9!25)?5D%,545?345! M4U5214U%3E137U1A8FQE#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D)!4TE37T]&7U!215-%3E1!5$E/3E]$971A:6QS/"]X.DYA M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=OF%T:6]N7V5X<&5N#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/E)%3$%4141?4$%25%E?5%)!3E-!0U1)3TY3 M7T]W:3PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E)E M=F]L=FEN9U]L:6YE7V]F7V-R961I=%]$971A:3PO>#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/D-/3E-44E5#5$E/3E],3T%.7T9!0TE, M25197T1E=#PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/DE.0T]-15]405A%4U]5;F1I#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/DE.0T]-15]405A%4U]0#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I. M86UE/D9!25)?5D%,545?345!4U5214U%3E137T%T7U)E<#PO>#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/E!R969E#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3D-%3E12051)3TY37U-A;&5S7T%N9%]0=7)C:#PO>#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-/3D-%3E12051)3TY3 M7T%C8V]U;G1S7U)E8V5I=CPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O6QE#I!8W1I=F53:&5E=#X-"B`@/'@Z M4')O=&5C=%-T#I0#I0#I0&UL/CPA6V5N9&EF72TM/@T*/"]H M96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E M;F5D('=I=&@@36EC'1087)T7S!F.6%D-F,P M7S(U.39?-#%B,%\Y-F4X7S@X8C,Y.#1A,#-C-0T*0V]N=&5N="U,;V-A=&EO M;CH@9FEL93HO+R]#.B\P9CEA9#9C,%\R-3DV7S0Q8C!?.39E.%\X.&(S.3@T M83`S8S4O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N M/CPO'0^)T-(24Y!(%!(05)-02!(3TQ$24Y'4RP@24Y#+CQS<&%N/CPO'0^)SQS M<&%N/CPO'0^)V9A;'-E/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO M'0^)SQS M<&%N/CPO3QS<&%N/CPO2!#=7)R96YT M(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)TYO/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^)SQS<&%N/CPO'0^)S(P,30\3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P M9CEA9#9C,%\R-3DV7S0Q8C!?.39E.%\X.&(S.3@T83`S8S4-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&8Y860V8S!?,C4Y-E\T,6(P7SDV93A? M.#AB,SDX-&$P,V,U+U=O'0O:'1M;#L@8VAA3PO=&0^#0H@("`@("`@(#QT9"!C;&%S2P@;&5S'0^)SQS<&%N/CPO M6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA'!E;G-E6%B;&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ M+#(Y,RPR-S,\6%B;&5S("T@2X\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO3PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^)SQS<&%N M/CPO3PO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPOF%T:6]N(&]F($EN=&%N9VEB;&4@87-S971S/"]T9#X-"B`@("`@("`@/'1D M(&-L87-S/3-$;G5M<#XD(#0L,#'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^)SQS<&%N/CPO M'0^)SQS<&%N/CPO'!E;G-E'0^)SQS<&%N/CPO M2!I;F-O;64\+W1D/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO'!E M;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S,38L-#(P*3QS M<&%N/CPO"!B M96YE9FET("AE>'!E;G-E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S2!T'0^)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0^)SQS<&%N/CPOF%T:6]N/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XQ+#`Q-"PR,C$\3PO=&0^#0H@("`@("`@(#QT9"!C M;&%S&5S('!A>6%B;&4\+W1D/@T*("`@ M("`@("`\=&0@8VQA'!E;G-E'0^)SQS<&%N/CPO2!&:6YA;F-I;F<@06-T:79I='D\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^)SQS<&%N/CPO7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA6QE/3-$)VUA2!#;RXL($QT9"`H)B,Q-#<[2&5L<'-O;B8C,30X.RDL(&$@ M8V]R<&]R871I;VX@;W)G86YI>F5D('5N9&5R('1H92!L87=S(&]F('1H92!0 M96]P;&4G6QE/3-$)VUA2!I2!O9B!# M;VUM97)C92!A;F0@=&AE($YA=&EO;F%L($1E=F5L;W!M96YT(&%N9"!2969O M2!I;G1E2!O9B!B6QE/3-$)VUA2`R-2P@,C`P-2X@5&AE('1R86YS86-T:6]N('=A2!T:&4@0V]M;65R8VEA;"!"=7)E874@;V8@2&%I;F%N(%!R;W9I;F-E(&]N M($IU;F4@,3(L(#(P,#4@86YD($AE;'!S;VX@2!&;W)E:6=N($]W;F5D($5N=&5R<')I6QE/3-$)VUA6QE/3-$)VUA2!A8V-E M<'1E9"!I;B!T:&4@56YI=&5D(%-T871E6EN9R!C;VYS;VQI9&%T960@ M9FEN86YC:6%L('-T871E;65N=',@:6YC;'5D92!T:&4@86-C;W5N=',@86YD M(&]P97)A=&EO;G,@;V8@=&AE($-O;7!A;GD@86YD(&ET6QE/3-$)VUA2!O=&AE M6QE M/3-$)VUA6QE/3-$)VUA2!I;F-L=61E9"!I;B!F:6YA;F-I86P@2`H)B,Q-#<[ M36%N86=E;65N="8C,30X.RD@8F5L:65V97,@=&AE(&9O;&QO=VEN9R!D:7-C M;&]S=7)E6QE/3-$)VUA6QE/3-$)VUA'!E;G-E6QE/3-$ M)VUA6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)W1E>'0M86QI M9VXZ8V5N=&5R.VUA6QE/3-$)W1E M>'0M86QI9VXZ8V5N=&5R.VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P M.V)O6QE/3-$)VUAG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F M,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M M(#!C;2`P<'0G/B9N8G-P.R`\+W`^/"]T9#X@/'1D('9A;&EG;CTS1&)O='1O M;2!S='EL93TS1&)OG5R93MB;W)D97(M=&]P M.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/CQB/B9N8G-P.SPO M8CX\+W`^/"]T9#X@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!S M='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#$N-7!T('-O;&ED.V)OG5R93MB;W)D M97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT M;W`Z,&-M)SX@/'`@86QI9VX],T1C96YT97(@6QE/3-$8F]R9&5R+6)O='1O M;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUAG5R93MB;W)D97(M=&]P.B-F,&8P M9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S M='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/CQB/B9N8G-P.SPO8CX\+W`^ M/"]T9#X@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1&)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT M.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ M,&-M(#!C;2`P<'0G/CQB/B9N8G-P.SPO8CX\+W`^/"]T9#X@/'1D('9A;&EG M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M M.F)L86-K(#$N-7!T('-O;&ED.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R M+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M)SX@/'`@86QI9VX],T1C M96YT97(@6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O M6QE/3-$)VUA6QE/3-$ M8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$8F]R9&5R+6)O='1O;3HC M9C!F,&8P.V)O6QE/3-$)VUA M6QE/3-$ M)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z M,&-M/B`\<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O M;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R M+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!A;&EG;CTS1')I M9VAT('-T>6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R M93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D M9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G M/B9N8G-P.SPO<#X\+W1D/B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M.24@6QE/3-$8F]R M9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P M9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S M='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\ M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)VUA6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O MG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P M9C`[<&%D9&EN9RUT;W`Z,&-M/B`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`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!A M;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R M93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D M9&EN9RUT;W`Z,&-M/B`\<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M M86QI9VXZ6QE/3-$8F]R M9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P M9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S M='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\ M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R M93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D M9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G M/B9N8G-P.SPO<#X\+W1D/B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$ M,24@6QE M/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC M9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I M9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!A;&EG;CTS1')I9VAT M('-T>6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$8F]R M9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O M6QE/3-$)VUA6QE/3-$ M8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE M/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O M;3HC9C!F,&8P.V)O6QE/3-$)VUAG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R M9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M)SX@/'`@86QI9VX] M,T1R:6=H="!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O M6QE/3-$)VUAG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F M,&8P9C`[<&%D9&EN9RUT;W`Z,&-M)SX@/'`@86QI9VX],T1R:6=H="!S='EL M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUAG5R93MB M;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN M9RUT;W`Z,&-M)SX@/'`@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6%L M:6=N.G)I9VAT.VUA6QE/3-$8F]R M9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F M,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M)SX@ M/'`@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA M6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE M/3-$)V)O6QE/3-$ M8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$ M)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA"TM/CQP('-T>6QE/3-$)VUA M6QE/3-$)VUA2!T:&4@8G5I;&1I M;F<@;V8@;F5W('!L86YT('=A6QE/3-$)VUA2!T:&4@ M=')O<&EC86P@='EP:&]O;B!R97-U;'1E9"!I;B!E>'!O2X@0F%S960@;VX@=&AE M(&%S3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P9CEA9#9C,%\R-3DV7S0Q8C!? M.39E.%\X.&(S.3@T83`S8S4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO,&8Y860V8S!?,C4Y-E\T,6(P7SDV93A?.#AB,SDX-&$P,V,U+U=O'0O:'1M;#L@ M8VAA'0^)SPA+2UE9W@M+3X\<"!S='EL M93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B9N8G-P.SPO<#X@/'`@6QE/3-$)VUA2!C;VYS:7-T960@;V8@=&AE(&9O;&QO=VEN9SHF;F)S<#L\+W`^ M(#QP('-T>6QE/3-$)VUA6QE/3-$ M=VED=&@Z.#`E/B`\='(^(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0W M,"4@6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O M6QE/3-$)W1E M>'0M86QI9VXZ8V5N=&5R.VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$8F]R9&5R+6)O='1O;3HC M9C!F,&8P.V)O6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA6QE/3-$ M)VUA6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUAG5R M93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D M9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G M/E)A=R!M871E6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[ M<&%D9&EN9RUT;W`Z,&-M/B`\<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E M>'0M86QI9VXZ6QE/3-$ M8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F M,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\ M<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B0\+W`^/"]T9#X@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1&)O6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P M.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F M,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M M(#!C;2`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\=&0@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,24@6QE/3-$)VUA6QE/3-$8F]R9&5R M+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$8F]R9&5R+6)O='1O M;3HC9C!F,&8P.V)O6QE/3-$8F]R9&5R M+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O M6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$ M8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D M97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT M;W`Z,&-M)SX@/'`@6QE M/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)W1E>'0M86QI9VXZ M6QE/3-$8F]R9&5R M+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE M/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$ M)VUA6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$)VUA6QE/3-$8F]R9&5R M+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)W1E>'0M86QI9VXZG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R M+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M M87)G:6XZ,&-M(#!C;2`P<'0G/BD\+W`^/"]T9#X@/'1D('9A;&EG;CTS1&)O M='1O;2!W:61T:#TS1#$E('-T>6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P M.V)O6QE/3-$)VUA6QE/3-$)W1E>'0M86QI9VXZG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[ M<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P M<'0G/BD\+W`^/"]T9#X\+W1R/B`\='(^(#QT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0W,"4@3PO8CX\+W`^/"]T9#X@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$8F]R9&5R+6)O='1O M;3HC9C!F,&8P.V)O6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$)V)O6QE/3-$)VUA6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)W1E M>'0M86QI9VXZ6QE/3-$ M)V)O6QE/3-$)VUA6QE/3-$)V)O6QE/3-$ M)W1E>'0M86QI9VXZ3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P9CEA9#9C,%\R-3DV7S0Q8C!?.39E M.%\X.&(S.3@T83`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`[8F]R9&5R+7)I9VAT M.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!A;&EG;CTS1')I9VAT('-T M>6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D M97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT M;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B0\+W`^ M/"]T9#X@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS M1&)O6QE/3-$8F]R9&5R+6)O='1O;3HC M9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I M9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G M:6XZ,&-M(#!C;2`P<'0G/B9N8G-P.SPO<#X\+W1D/CPO='(^(#QT6QE M/3-$)VUA6QE/3-$8F]R9&5R+6)O M='1O;3HC9C!F,&8P.V)O6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$8F]R9&5R+6)O M='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R M9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!A;&EG;CTS M1')I9VAT('-T>6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[ M<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P M<'0G/B9N8G-P.SPO<#X\+W1D/B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,3(E('-T>6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F M,&8P.V)O6QE/3-$)VUA6QE/3-$)W1E>'0M86QI9VXZG5R93MB;W)D97(M=&]P.B-F,&8P9C`[ M8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL M93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/D]F9FEC92!E<75I<&UE;G0\+W`^ M/"]T9#X@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$ M8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F M,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\ M<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F M,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT M.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ M,&-M(#!C;2`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\=&0@=F%L:6=N/3-$8F]T M=&]M('=I9'1H/3-$,3(E('-T>6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P M.V)O6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB M;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN M9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B9N M8G-P.SPO<#X\+W1D/CPO='(^(#QT6QE/3-$8F]R9&5R+6)O M='1O;3HC9C!F,&8P.V)O6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F M,&8P.V)O6QE/3-$ M8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F M,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\ M<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B9N8G-P.SPO<#X\+W1D M/B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)VUA6QE/3-$ M)W1E>'0M86QI9VXZ6QE/3-$)VUA6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$)V)O6QE/3-$)V)O6QE M/3-$)W1E>'0M86QI9VXZ6QE/3-$)V)O6QE/3-$)V)O6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O2!A;F0@17%U:7!M96YT+"!N970\+V(^/"]P/CPO M=&0^(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1&)O M6QE/3-$)VUA M2!A;F0@=&AE(&%C<75I2!A;F0@97%U:7!M96YT(&-A=&5G;W)Y(&%S('1H M92!A6QE/3-$)VUA6QE/3-$ M=VED=&@Z,3`P)3X@/'1R/B`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`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT M;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B9N8G-P M.SPO<#X\+W1D/B`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`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S M='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\ M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@G5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R M+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M)SX@/'`@6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O MG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P M9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C M;2`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,24@6QE/3-$)W1E M>'0M86QI9VXZ6QE/3-$8F]R M9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P M9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!A M;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$)V)O6QE M/3-$)VUAG5R93MB;W)D97(M=&]P.B-F,&8P M9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M)SX@/'`@ M86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R M.VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB M;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN M9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B9N M8G-P.R`\+W`^/"]T9#X@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#$S)2!S M='EL93TS1&)O6QE/3-$)W1E>'0M86QI9VXZ M8V5N=&5R.VUA6QE/3-$)VUA6QE/3-$8F]R M9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA6QE/3-$)VUA M2!A;F0@97%U:7!M M96YT/"]P/CPO=&0^(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0R)2!S='EL M93TS1&)O6QE/3-$8F]R9&5R+6)O='1O M;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O M6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA'!E;G-E('=A'!E;G-E('=A'0O:F%V87-C3X-"B`@("`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`[8F]R M9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS M1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\=&0@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUAF%T:6]N/"]P/CPO=&0^(#QT9"!V86QI9VX],T1B;W1T;VT@=VED M=&@],T0Q)2!S='EL93TS1&)O6QE/3-$)W1E M>'0M86QI9VXZ6QE/3-$ M)V)O6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$)V)O6QE/3-$)V)O6QE/3-$8F]R M9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$8F]R9&5R+6)O M='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R M9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!A;&EG;CTS M1')I9VAT('-T>6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$)V)O6QE/3-$)VUA M6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P M.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F M,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M M(#!C;2`P<'0G/B9N8G-P.SPO<#X\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\ M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SPA+2UE9W@M+3X\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C M;2`P<'0G/CQB/DY/5$4@-B`F(S$U,#L@041604Y#15,@1D]2(%!54D-(05-% M4R!/1B!)3E1!3D=)0DQ%($%34T544SPO8CX\+W`^(#QP('-T>6QE/3-$)VUA M2!A;F0@=&AE(&QA8F]R871O2!U M;F1E2!T:&5I M2!C86X@2!I2P@<&%Y;65N=',@;6%D92!P2!T:&4@0T9$02!A6QE/3-$)VUA2!B965N M(&EN9F]R;65D(&]R(&)E8V]M92!A=V%R92!O9B!A;GD@9F]R;75L82!T:&%T M(&UA>2!F86EL('1O(')E8V5I=F4@2!W87,@;V)L:6=E9"!T;R!P87D@;&%B M;W)A=&]R:65S(&%N9"!O=&AE2`D-2XQ.2!M:6QL M:6]N('5P;VX@8V]M<&QE=&EO;B!O9B!V87)I;W5S('!H87-E3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\P9CEA9#9C,%\R-3DV7S0Q8C!?.39E.%\X.&(S M.3@T83`S8S4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&8Y860V M8S!?,C4Y-E\T,6(P7SDV93A?.#AB,SDX-&$P,V,U+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R"TM/CQP('-T>6QE/3-$ M)VUA6QE/3-$)VUA'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'0^)SPA+2UE9W@M+3X\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G M/CQB/DY/5$4@."`F(S$U,#L@3D]415,@4$%904),13PO8CX\+W`^(#QP('-T M>6QE/3-$)VUAF5D(&)Y(&-E&5C=71I=F4@3V9F:6-E2!I6QE/3-$)VUA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5]. M97AT4&%R=%\P9CEA9#9C,%\R-3DV7S0Q8C!?.39E.%\X.&(S.3@T83`S8S4- M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&8Y860V8S!?,C4Y-E\T M,6(P7SDV93A?.#AB,SDX-&$P,V,U+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SPA+2UE9W@M+3X\<"!S='EL93TS1"=M87)G:6XZ M,&-M(#!C;2`P<'0G/CQB/DY/5$4@.2`F(S$U,#L@0T].4U1254-424].($Q/ M04X@1D%#24Q)5%D\+V(^/"]P/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C M;2`P<'0G/B9N8G-P.SPO<#X@/'`@2!O8G1A:6YE9"!A(&-O;G-T&EM871E;'D@)#$S+C`@;6EL;&EO;B!A="!397!T96UB97(@,S`L(#(P M,30I(&9R;VT@82!C;VYS=')U8W1I;VX@;&]A;B!F86-I;&ET>2!D871E9"!* M=6YE(#(Q+"`R,#$S+B!4:&4@;&]A;B!F86-I;&ET>2!I65A2`Q,2P@,C`Q,RP@86YD(&ES(&9R;VT@ M=&AE('-A;64@8F%N:R!T:&%T(&-U2!PF5D(&)Y('1H92!C;VYS=')U8W1I;VX@;V8@=&AE M($-O;7!A;GDF(S$T-CMS(&YE=R!P7!E(&]F(&QO86X@;VX@=&AE(&%N;FEV M97)S87)Y(&9R;VT@=&AE(&1R872!D871E2`Q,2P@,C`Q-2P@=&AE(&)A;&%N M8V4@;V8@=&AE('!R:6YC:7!A;"!W:6QL(&)E(&1U92!I;B!A;FYU86P@:6YS M=&%L;&UE;G1S(&]V97(@=&AE(&YE>'0@2`Q,2P@,C`R,2X@070@4V5P=&5M8F5R(#,P+"`R,#$T+"!T:&4@0V]M<&%N M>2!H860@;F\@861D:71I;VYA;"!A;6]U;G1S(&%V86EL86)L92!T;R!I="!U M;F1E6QE/3-$)VUA2!F;W(@8F%N:R!L;V%N M6EN9R!A;6]U;G1S(&]F(&YO=&5S('!A>6%B;&4@86YD('1H92!C;VYS=')U M8W1I;VX@;&]A;B!F86-I;&ET>2!O=71S=&%N9&EN9R!A&EM871E M9"!T:&5I2!O9B!T:&5S92!F:6YA;F-I M86P@:6YS=')U;65N=',@;W(@8F5C875S92!T:&4@=6YD97)L>6EN9R!I;G-T M'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA6QE/3-$)VUA"!R871E'!E8W1E9"!T;R!A<'!L>2!T;R!T87AA8FQE(&EN8V]M92!I;B!T:&4@>65A M'!E8W1E M9"!T;R!B92!R96-O=F5R960@;W(@6QE/3-$)VUA28C,30V.W,@9F]R96EG;B!S=6)S:61I87)Y+"!S:6YC92!I=',@86-Q M=6ES:71I;VXL(&%M;W5N=&5D('1O(&%P<')O>&EM871E;'D@)#2`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`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT M;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B9N8G-P M.SPO<#X\+W1D/B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)VUA M6QE/3-$ M8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F M,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\ M<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B9N8G-P.SPO<#X\+W1D M/B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O M='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R M9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS M1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\=&0@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F M,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT M.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ M,&-M(#!C;2`P<'0G/B9N8G-P.SPO<#X\+W1D/CPO='(^(#QT6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O M6QE/3-$)VUA6QE/3-$ M)W1E>'0M86QI9VXZ6QE M/3-$)V)O6QE/3-$ M8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F M,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M M(#!C;2`P<'0G/CQB/E1O=&%L(&EN8V]M92!T87@@97AP96YS92`H8F5N969I M="D\+V(^/"]P/CPO=&0^(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q M)2!S='EL93TS1&)O6QE/3-$)V)O M6QE M/3-$)VUA6QE/3-$)V)O6QE/3-$)V)O M6QE M/3-$)VUA6QE/3-$)V)O6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O MG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P M9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C M;2`P<'0G/BD\+W`^/"]T9#X\+W1R/CPO=&%B;&4^(#QP('-T>6QE/3-$)VUA M69O&EM871E;'D@)#$P+C$V(&UI;&QI;VX@870@4V5P=&5M8F5R(#,P M+"`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`S8S4O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO M6QE/3-$)VUA2`H86X@97AI="!P&EM M:7IE('1H92!U2!O8G-E2!L:71T;&4@;W(@;F\@;6%R:V5T(&%C=&EV:71Y(&9O6QE/3-$)VUA2!U6QE/3-$=VED=&@Z M,3`P)3X@/'1R/B`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`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M)SX@ M/'`@6QE/3-$)W1E>'0M86QI9VXZG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R M9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS M1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\=&0@=F%L M:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@G5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT M.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M)SX@/'`@G5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I M9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M)SX@/'`@86QI9VX],T1R:6=H M="!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O M;3HC9C!F,&8P.V)O6QE/3-$ M)VUAG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R M+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!A;&EG;CTS1')I M9VAT('-T>6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P M.V)O6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$)V)O6QE/3-$)VUA6QE/3-$)V)O6QE/3-$)W1E M>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$ M)W1E>'0M86QI9VXZ6QE M/3-$)V)O6QE/3-$)VUA6QE/3-$ M)VUA6QE/3-$)V)O M6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA M6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P M.V)O6QE/3-$)VUA6QE M/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)W1E>'0M M86QI9VXZ6QE/3-$8F]R M9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O M6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$ M)VUA6QE/3-$8F]R9&5R M+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O M;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O M6QE/3-$ M8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE M/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$)W1E>'0M M86QI9VXZ8V5N=&5R.VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$8F]R M9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$)V)O6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F M,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I M9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G M:6XZ,&-M(#!C;2`P<'0G/D)A;FME6QE/3-$ M8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)V)O6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F M,&8P.V)O6QE/3-$)VUA6QE M/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUAG5R93MB;W)D97(M=&]P M.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M M/B`\<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I M9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G M:6XZ,&-M(#!C;2`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\=&0@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,24@G5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P M9C`[<&%D9&EN9RUT;W`Z,&-M)SX@/'`@G5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F M,&8P9C`[<&%D9&EN9RUT;W`Z,&-M)SX@/'`@86QI9VX],T1R:6=H="!S='EL M93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA6QE/3-$)VUA6QE/3-$)V)O6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)W1E M>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$ M)W1E>'0M86QI9VXZ6QE M/3-$)V)O6QE/3-$)VUA6QE/3-$ M)VUA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SPA+2UE9W@M+3X\ M<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/CQB/DY/5$4@,3(@+2!3 M5$]#2TA/3$1%4E,G($5154E463PO8CX\+W`^(#QP('-T>6QE/3-$)VUA2!B>2!T:&4@0V]M<&%N>28C,30V.W,@0F]A6QE/3-$)VUA65E65E2!A;F0O;W(@:71S('-U8G-I M9&EA6QE/3-$)VUA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS<&%N/CPO'0^)SPA+2UE9W@M+3X\<"!S='EL93TS M1"=M87)G:6XZ,&-M(#!C;2`P<'0G/CQB/DY/5$4@,3,@)B,Q-3`[($-/3E1) M3D=%3D-)15,\+V(^/"]P/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P M<'0G/B9N8G-P.SPO<#X@/'`@2!A9F9E8W1E9"!B>2!C:&%N M9V5S(&EN('1H92!P;VQI=&EC86P@86YD('-O8VEA;"!C;VYD:71I;VYS(&EN M('1H92!04D,L(&%N9"!B>2!C:&%N9V5S(&EN(&=O=F5R;FUE;G1A;"!P;VQI M8VEE2!C;VYV97)S:6]N M(&%N9"!R96UI='1A;F-E(&%B&%T:6]N+"!A;6]N9R!O=&AE2!O9B!296YM:6YB M:2`H4DU"*2P@=VAI8V@@;75S="!B92!C;VYV97)T960@:6YT;R!O=&AE3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%\P9CEA9#9C,%\R-3DV7S0Q8C!?.39E.%\X.&(S.3@T83`S8S4-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&8Y860V8S!?,C4Y-E\T,6(P7SDV M93A?.#AB,SDX-&$P,V,U+U=O'0O:'1M;#L@8VAA"TM/CQP('-T>6QE/3-$)VUA6QE/3-$)VUA2X\+W`^ M(#QP('-T>6QE/3-$)VUA7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SPA+2UE9W@M+3X\<"!S='EL93TS1"=M87)G M:6XZ,&-M(#!C;2`P<'0G/CQB/DY/5$4@,34@)B,Q-3`[(%-50E-%455%3E0@ M159%3E13/"]B/CPO<#X@/'`@6QE/3-$)VUA2!R96-E:79E9"!T:&4@;6%N M=69A8W1U2X@5&AI2!I;B!A M8V-O3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\P9CEA9#9C,%\R-3DV7S0Q8C!?.39E.%\X.&(S M.3@T83`S8S4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&8Y860V M8S!?,C4Y-E\T,6(P7SDV93A?.#AB,SDX-&$P,V,U+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R"TM/CQP('-T>6QE/3-$)VUAF%T:6]N(&%N9"!.871U2!);G9E2`S,"P@,C`Q,BD@8VQA2!A;GD@;V8@=&AE2!W:6QL M(&)E(&1E96UE9"!I;F1U2!I2!O9B!I=',@97%U:71Y(&EN=&5R97-T M2!A(&9O6QE/3-$)VUA2!T;R!H;W-P:71A;',@ M86YD('!R:79A=&4@2!B96QI979E2!H87,@86YD(&-O;G1I;G5E'0^)SPA+2UE M9W@M+3X\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/CQB/CQI/D-O M;G-O;&ED871I;VX@86YD($)A2!A8V-E<'1E9"!I;B!T:&4@56YI M=&5D(%-T871E6EN9R!C;VYS;VQI9&%T960@9FEN86YC:6%L('-T871E M;65N=',@:6YC;'5D92!T:&4@86-C;W5N=',@86YD(&]P97)A=&EO;G,@;V8@ M=&AE($-O;7!A;GD@86YD(&ET6QE/3-$)VUA2!O=&AE"TM/CQP('-T>6QE M/3-$)VUA2!H87,@ M;6%D92!C97)T86EN(')E8VQA"TM/CQP('-T>6QE/3-$)VUA2!I;F-L=61E M9"!I;B!F:6YA;F-I86P@2`H)B,Q-#<[36%N86=E;65N="8C M,30X.RD@8F5L:65V97,@=&AE(&9O;&QO=VEN9R!D:7-C;&]S=7)E6QE/3-$)VUA'0^)SPA+2UE9W@M+3X\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C M;2`P<'0G/CQB/CQI/D%C8V]U;G1I;F<@17-T:6UA=&5S(#PO:3X\+V(^/&(^ M+2`\+V(^5&AE('!R97!A'!E;G-E6QE/3-$)VUA6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P M.V)O6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O M6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA6QE/3-$8F]R9&5R M+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUAG5R93MB;W)D97(M=&]P.B-F,&8P9C`[ M8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL M93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B9N8G-P.R`\+W`^/"]T9#X@/'1D M('9A;&EG;CTS1&)O='1O;2!S='EL93TS1&)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[ M<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P M<'0G/CQB/B9N8G-P.SPO8CX\+W`^/"]T9#X@/'1D('9A;&EG;CTS1&)O='1O M;2!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#$N M-7!T('-O;&ED.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F M,&8P9C`[<&%D9&EN9RUT;W`Z,&-M)SX@/'`@86QI9VX],T1C96YT97(@6QE M/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O M;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUAG5R93MB M;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN M9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/CQB M/B9N8G-P.SPO8CX\+W`^/"]T9#X@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL M93TS1&)OG5R93MB;W)D97(M=&]P.B-F,&8P M9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S M='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/CQB/B9N8G-P.SPO8CX\+W`^ M/"]T9#X@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!S='EL93TS M1"=B;W)D97(M8F]T=&]M.F)L86-K(#$N-7!T('-O;&ED.V)OG5R93MB;W)D97(M=&]P M.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M M)SX@/'`@86QI9VX],T1C96YT97(@6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F M,&8P.V)O6QE/3-$)VUA6QE/3-$)W1E>'0M M86QI9VXZ6QE/3-$)V)O M6QE/3-$ M)V)O6QE/3-$)W1E>'0M86QI M9VXZ6QE/3-$8F]R9&5R+6)O M='1O;3HC9C!F,&8P.V)O6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$ M8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O MG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P M9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$ M)W1E>'0M86QI9VXZ6QE M/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P M.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M M/B`\<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC M9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I M9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G M:6XZ,&-M(#!C;2`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\=&0@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$.24@6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB M;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN M9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B9N M8G-P.SPO<#X\+W1D/B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@ M6QE/3-$ M)VUA6QE/3-$8F]R9&5R+6)O M='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R M9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`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`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN M9RUT;W`Z,&-M/B`\<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M86QI M9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC M9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I M9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!A;&EG;CTS1')I9VAT M('-T>6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB M;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN M9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B9N M8G-P.SPO<#X\+W1D/B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@ M6QE/3-$8F]R9&5R+6)O='1O;3HC M9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I M9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G M:6XZ,&-M(#!C;2`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\=&0@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)VUA6QE/3-$)VUA6QE/3-$ M8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F M,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\ M<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$)VUA M6QE/3-$8F]R9&5R+6)O='1O M;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O M='1O;3HC9C!F,&8P.V)O6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$)VUA6QE M/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z M,&-M)SX@/'`@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6%L:6=N.G)I M9VAT.VUA6QE/3-$8F]R9&5R+6)O M='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[ M8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M)SX@/'`@86QI M9VX],T1R:6=H="!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P M.V)O6QE/3-$)VUAG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT M.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M)SX@/'`@86QI9VX],T1R:6=H="!S M='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUAG5R M93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D M9&EN9RUT;W`Z,&-M)SX@/'`@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT M+6%L:6=N.G)I9VAT.VUA6QE/3-$)V)O6QE/3-$)V)O6QE/3-$ M)V)O6QE/3-$)V)O6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA6QE/3-$)VUA6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$ M)W1E>'0M86QI9VXZ8V5N=&5R.VUA6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA6QE/3-$8F]R9&5R+6)O='1O M;3HC9C!F,&8P.V)O6QE M/3-$)VUAG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R M+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M M87)G:6XZ,&-M(#!C;2`P<'0G/B9N8G-P.R`\+W`^/"]T9#X@/'1D('9A;&EG M;CTS1&)O='1O;2!S='EL93TS1&)OG5R93MB M;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN M9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/CQB M/B9N8G-P.SPO8CX\+W`^/"]T9#X@/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS M<&%N/3-$,B!S='EL93TS1"=B;W)D97(M8F]T=&]M.F)L86-K(#$N-7!T('-O M;&ED.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[ M<&%D9&EN9RUT;W`Z,&-M)SX@/'`@86QI9VX],T1C96YT97(@6QE/3-$8F]R M9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$ M)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F M,&8P.V)O6QE/3-$)VUA6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUAG5R93MB;W)D97(M M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z M,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/CQB/B9N8G-P M.SPO8CX\+W`^/"]T9#X@/'1D('9A;&EG;CTS1&)O='1O;2!S='EL93TS1&)O MG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R M9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS M1"=M87)G:6XZ,&-M(#!C;2`P<'0G/CQB/B9N8G-P.SPO8CX\+W`^/"]T9#X@ M/'1D('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!S='EL93TS1"=B;W)D M97(M8F]T=&]M.F)L86-K(#$N-7!T('-O;&ED.V)OG5R93MB;W)D97(M=&]P.B-F,&8P M9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M)SX@/'`@ M86QI9VX],T1C96YT97(@6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O M6QE/3-$)VUA6QE/3-$)W1E>'0M86QI9VXZ M6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC M9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$8F]R9&5R M+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R M93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D M9&EN9RUT;W`Z,&-M/B`\<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M M86QI9VXZ6QE/3-$8F]R M9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P M9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!A M;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P M.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F M,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M M(#!C;2`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\=&0@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$.24@6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z M,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B9N8G-P.SPO M<#X\+W1D/B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)VUA6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC M9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I M9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`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`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z M,&-M/B`\<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P M.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F M,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!A;&EG;CTS1')I9VAT('-T>6QE M/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z M,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B9N8G-P.SPO M<#X\+W1D/B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24@6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P M.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F M,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M M(#!C;2`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\=&0@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,24@6QE/3-$)VUA6QE/3-$8F]R9&5R M+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[ M8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!A;&EG M;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F M,&8P.V)O6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC M9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$)VUA6QE/3-$8F]R M9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F M,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M)SX@ M/'`@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA M6QE/3-$8F]R9&5R+6)O='1O;3HC M9C!F,&8P.V)O6QE/3-$)VUAG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R M+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M)SX@/'`@86QI9VX],T1R M:6=H="!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT.VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUAG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P M9C`[<&%D9&EN9RUT;W`Z,&-M)SX@/'`@86QI9VX],T1R:6=H="!S='EL93TS M1"=T97AT+6%L:6=N.G)I9VAT.VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUAG5R93MB;W)D M97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT M;W`Z,&-M)SX@/'`@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6%L:6=N M.G)I9VAT.VUA6QE M/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)V)O6QE/3-$)V)O6QE/3-$ M)V)O6QE/3-$)V)O7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`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`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT M;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/D9I;FES M:&5D(&=O;V1S/"]P/CPO=&0^(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0Q)2!S='EL93TS1&)OG5R M93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D M9&EN9RUT;W`Z,&-M/B`\<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M M86QI9VXZ6QE/3-$)V)O M6QE/3-$)V)OG5R93MB;W)D97(M M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z M,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B9N8G-P.SPO M<#X\+W1D/B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@G5R93MB;W)D97(M=&]P.B-F,&8P M9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M)SX@/'`@ M6QE/3-$ M8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F M,&8P.V)O6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P M.V)O6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R M+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M)SX@/'`@6QE/3-$8F]R9&5R+6)O='1O;3HC M9C!F,&8P.V)O6QE/3-$)VUA MG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[ M<&%D9&EN9RUT;W`Z,&-M)SX@/'`@6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O M6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O'1087)T7S!F.6%D-F,P7S(U.39?-#%B,%\Y-F4X M7S@X8C,Y.#1A,#-C-0T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\P M9CEA9#9C,%\R-3DV7S0Q8C!?.39E.%\X.&(S.3@T83`S8S4O5V]R:W-H965T M'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA2!A;F0@97%U:7!M96YT(&-O;G-I6QE/3-$)VUA6QE M/3-$=VED=&@Z.#4E/B`\='(^(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@] M,T0W,"4@6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P M.V)O6QE/3-$ M)W1E>'0M86QI9VXZ8V5N=&5R.VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$8F]R9&5R+6)O='1O M;3HC9C!F,&8P.V)O6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA6QE M/3-$)VUA6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA MG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[ M<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P M<'0G/E!E6QE/3-$)VUA6QE/3-$ M8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$ M8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$ M)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA2!A;F0@97%U:7!M96YT/"]P/CPO=&0^(#QT9"!V M86QI9VX],T1B;W1T;VT@=VED=&@],T0Q)2!S='EL93TS1&)O6QE/3-$ M8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F M,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\ M<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B9N8G-P.SPO<#X\+W1D M/B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)VUA6QE/3-$ M)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z M,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B9N8G-P.SPO M<#X\+W1D/CPO='(^(#QT6QE/3-$)VUA6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O M6QE/3-$ M)W1E>'0M86QI9VXZ6QE M/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$ M8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O M='1O;3HC9C!F,&8P.V)O6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z M,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B9N8G-P.SPO M<#X\+W1D/B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)VUA6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$)VUA6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$)V)O6QE/3-$)V)O6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P M.V)O6QE/3-$)VUA6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)W1E>'0M86QI M9VXZ6QE/3-$8F]R9&5R M+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[ M8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!A;&EG M;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O MG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P M9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C M;2`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I M9'1H/3-$,3(E('-T>6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F M,&8P.V)O6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$)VUAG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R M9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M)SX@/'`@6QE/3-$8F]R9&5R+6)O='1O;3HC M9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I M9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G M:6XZ,&-M(#!C;2`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\=&0@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,24@G5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P M9C`[<&%D9&EN9RUT;W`Z,&-M)SX@/'`@6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R M93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D M9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G M/B9N8G-P.SPO<#X\+W1D/CPO='(^/"]T86)L93X\+V1I=CX\"TM/CQP('-T>6QE/3-$)VUA6QE/3-$=VED=&@Z,3`P)3X@ M/'1R/B`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`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S M='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B9N8G-P.SPO<#X\+W1D/B`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`[8F]R9&5R+7)I M9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G M:6XZ,&-M(#!C;2`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\=&0@=F%L:6=N/3-$ M8F]T=&]M('=I9'1H/3-$,24@G5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P M9C`[<&%D9&EN9RUT;W`Z,&-M)SX@/'`@6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D M97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT M;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B9N8G-P M.SPO<#X\+W1D/B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@G5R93MB;W)D97(M=&]P.B-F M,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M)SX@ M/'`@6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC M9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I M9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!A;&EG;CTS1')I9VAT M('-T>6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$)V)O6QE/3-$)VUA6QE/3-$)VUA"TM/CQP('-T>6QE/3-$)VUA6QE/3-$)VUA6QE/3-$=VED=&@Z-3`E/B`\='(^(#QT9"!V86QI9VX],T1T M;W`@=VED=&@],T0S,R4@6QE/3-$)VUAG5R93MB;W)D97(M=&]P.B-F M,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\ M<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/E!L86YT+"!M86-H:6YE M6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA6QE/3-$8F]R M9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R M9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS M1"=M87)G:6XZ,&-M(#!C;2`P<'0G/D]F9FEC92!E<75I<&UE;G0\+W`^/"]T M9#X@/'1D('9A;&EG;CTS1'1O<"!W:61T:#TS1#(E('-T>6QE/3-$8F]R9&5R M+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[ M8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL M93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B9N8G-P.R`\+W`^/"]T9#X@/'1D M('9A;&EG;CTS1'1O<"!W:61T:#TS1#$S)2!S='EL93TS1&)O6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^)SQS<&%N/CPO'0^)SPA+2UE M9W@M+3X\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/D%S(&]F(%-E M<'1E;6)E6QE/3-$ M8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O M6QE/3-$ M)VUA6QE/3-$)V)O6QE M/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6EN9R!A;6]U;G0\+W`^/"]T9#X@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T M:#TS1#$E('-T>6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R M93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D M9&EN9RUT;W`Z,&-M/B`\<"!A;&EG;CTS1')I9VAT('-T>6QE/3-$)W1E>'0M M86QI9VXZ6QE/3-$8F]R M9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P M9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S M='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B0\+W`^/"]T9#X@/'1D('9A M;&EG;CTS1&)O='1O;2!W:61T:#TS1#$R)2!S='EL93TS1&)O6QE/3-$)VUAG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R M9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!A;&EG;CTS M1')I9VAT('-T>6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O MG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P M9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C M;2`P<'0G/B9N8G-P.SPO<#X\+W1D/CPO='(^(#QT6QE/3-$ M8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC M9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$)W1E>'0M86QI9VXZG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT M.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ M,&-M(#!C;2`P<'0G/DYE="!C87)R>6EN9R!A;6]U;G0\+W`^/"]T9#X@/'1D M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$E('-T>6QE/3-$8F]R9&5R+6)O M='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R M9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!A;&EG;CTS M1')I9VAT('-T>6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$)V)O6QE/3-$)VUA M6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P M.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F M,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M M(#!C;2`P<'0G/B9N8G-P.SPO<#X\+W1D/B`\=&0@=F%L:6=N/3-$8F]T=&]M M('=I9'1H/3-$,24@G5R M93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D M9&EN9RUT;W`Z,&-M)SX@/'`@6QE/3-$)VUA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/"$M+65G M>"TM/CQP('-T>6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O M;3HC9C!F,&8P.V)O"!2871E/"]B/CPO<#X\+W1D/CPO='(^(#QT6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA6QE/3-$)VUA6QE/3-$ M8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)W1E>'0M86QI M9VXZ8V5N=&5R.VUA6QE/3-$ M8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)W1E>'0M86QI M9VXZ8V5N=&5R.VUA6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O M='1O;3HC9C!F,&8P.V)O'0^)SPA+2UE9W@M+3X\<"!S='EL93TS1"=M87)G:6XZ,&-M M(#!C;2`P<'0G/E1H92!P6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ8V5N=&5R.VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$)VUA6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[ M<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P M<'0G/B9N8G-P.SPO<#X\+W1D/B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H M/3-$,24@6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D M97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT M;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B9N8G-P M.SPO<#X\+W1D/B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)VUA M6QE/3-$ M8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F M,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\ M<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B9N8G-P.SPO<#X\+W1D M/B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,24@6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O M='1O;3HC9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R M9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS M1"=M87)G:6XZ,&-M(#!C;2`P<'0G/B9N8G-P.SPO<#X\+W1D/CPO='(^(#QT M6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O;3HC M9C!F,&8P.V)O6QE/3-$)VUA M6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$)V)O6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R M+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M M87)G:6XZ,&-M(#!C;2`P<'0G/CQB/E1O=&%L(&EN8V]M92!T87@@97AP96YS M92`H8F5N969I="D\+V(^/"]P/CPO=&0^(#QT9"!V86QI9VX],T1B;W1T;VT@ M=VED=&@],T0Q)2!S='EL93TS1&)O6QE/3-$)V)O6QE/3-$)VUA6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)VUA6QE/3-$)V)O6QE/3-$8F]R9&5R+6)O='1O;3HC M9C!F,&8P.V)OG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I M9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G M:6XZ,&-M(#!C;2`P<'0G/BD\+W`^/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P9CEA9#9C,%\R M-3DV7S0Q8C!?.39E.%\X.&(S.3@T83`S8S4-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO,&8Y860V8S!?,C4Y-E\T,6(P7SDV93A?.#AB,SDX-&$P M,V,U+U=O'0O:'1M;#L@8VAA"TM/CQP('-T>6QE/3-$)VUA6QE/3-$=VED=&@Z,3`P)3X@/'1R/B`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`[8F]R9&5R+7)I9VAT.B-F M,&8P9C`[<&%D9&EN9RUT;W`Z,&-M)SX@/'`@6QE/3-$)W1E>'0M86QI9VXZG5R93MB;W)D97(M M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z M,&-M)SX@/'`@G5R93MB;W)D M97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT M;W`Z,&-M)SX@/'`@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6%L:6=N M.G)I9VAT.VUA6QE/3-$8F]R9&5R+6)O='1O;3HC M9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$)W1E>'0M86QI M9VXZ6QE/3-$)V)O6QE/3-$)V)O M6QE/3-$)W1E>'0M86QI9VXZ MG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R M+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!S='EL93TS1"=M M87)G:6XZ,&-M(#!C;2`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`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT M;W`Z,&-M/B`\<"!S='EL93TS1"=M87)G:6XZ,&-M(#!C;2`P<'0G/D)A;FME M6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P M.V)O6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)VUA6QE/3-$8F]R9&5R+6)O='1O;3HC9C!F M,&8P.V)O6QE/3-$)VUAG5R93MB;W)D97(M=&]P.B-F,&8P9C`[8F]R9&5R+7)I9VAT M.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M/B`\<"!A;&EG;CTS1')I9VAT('-T M>6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$)V)O6QE/3-$)V)O6QE M/3-$)W1E>'0M86QI9VXZG5R93MB;W)D97(M=&]P.B-F M,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M)SX@ M/'`@G5R93MB;W)D97(M=&]P M.B-F,&8P9C`[8F]R9&5R+7)I9VAT.B-F,&8P9C`[<&%D9&EN9RUT;W`Z,&-M M)SX@/'`@86QI9VX],T1R:6=H="!S='EL93TS1"=T97AT+6%L:6=N.G)I9VAT M.VUA6QE/3-$)VUA M6QE/3-$)V)O6QE/3-$8F]R M9&5R+6)O='1O;3HC9C!F,&8P.V)O6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$8F]R9&5R+6)O='1O M;3HC9C!F,&8P.V)O6QE/3-$)W1E>'0M86QI9VXZ6QE/3-$)V)O6QE/3-$)VUA6QE/3-$)VUA7!E.B!T97AT+VAT;6P[(&-H M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U% M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O M:'1M;#L@8VAA2!);G9E2!#;RXL($QT9"X\+W1D/@T*("`@("`@ M("`\=&0@8VQA2!/;FYY(&EN($AE;'!S;VX\+W1D/@T*("`@("`@("`\=&0@8VQA M'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P9CEA9#9C M,%\R-3DV7S0Q8C!?.39E.%\X.&(S.3@T83`S8S4-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO,&8Y860V8S!?,C4Y-E\T,6(P7SDV93A?.#AB,SDX M-&$P,V,U+U=O'0O:'1M;#L@8VAA3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\P9CEA9#9C,%\R-3DV7S0Q8C!?.39E.%\X.&(S.3@T83`S M8S4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&8Y860V8S!?,C4Y M-E\T,6(P7SDV93A?.#AB,SDX-&$P,V,U+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^ M)SQS<&%N/CPO'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA65A2!A;F0@97%U:7!M M96YT(&QI9F4\+W1D/@T*("`@("`@("`\=&0@8VQA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P M9CEA9#9C,%\R-3DV7S0Q8C!?.39E.%\X.&(S.3@T83`S8S4-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&8Y860V8S!?,C4Y-E\T,6(P7SDV93A? M.#AB,SDX-&$P,V,U+U=O'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'0^)SQS<&%N/CPO'!E M;G-E('!R;W!E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'!E;G-E("A$151!24Q3*2`H M55-$("0I/&)R/CPO'0^)SQS<&%N/CPO'!E;G-E(')E;&%T:6YG('1O M(&EN=&%N9VEB;&4@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M;G5M<#XD(#DV+#,X,CQS<&%N/CPO7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO'0^)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA"!2871E M2!I;B!M:6QL:6]N"!2871E'0^)SQS<&%N/CPO65A"!2871E'0^)SQS<&%N/CPO'0^ M)SQS<&%N/CPO"!A'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA'0^)SQS<&%N/CPO"!P'0^)SQS<&%N/CPO"!E M>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Y+#(Q M-3QS<&%N/CPO7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^ M)SQS<&%N/CPO3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\P9CEA9#9C,%\R-3DV7S0Q8C!?.39E.%\X.&(S.3@T83`S M8S4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&8Y860V8S!?,C4Y M-E\T,6(P7SDV93A?.#AB,SDX-&$P,V,U+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%RF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`P,"PP,#`\ M3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\P M9CEA9#9C,%\R-3DV7S0Q8C!?.39E.%\X.&(S.3@T83`S8S4-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,&8Y860V8S!?,C4Y-E\T,6(P7SDV93A? M.#AB,SDX-&$P,V,U+U=O'0O:'1M;#L@8VAA'0^ M)SQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\ M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^)SQS<&%N/CPO'10 M87)T7S!F.6%D-F,P7S(U.39?-#%B,%\Y-F4X7S@X8C,Y.#1A,#-C-0T*0V]N M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\P9CEA9#9C,%\R-3DV7S0Q8C!? M.39E.%\X.&(S.3@T83`S8S4O5V]R:W-H965T'1087)T7S!F.6%D-F,P7S(U.39?-#%B,%\Y 4-F4X7S@X8C,Y.#1A,#-C-2TM#0H` ` end XML 21 R43.htm IDEA: XBRL DOCUMENT v2.4.0.8

FAIR VALUE MEASUREMENTS At Reporting Date Using (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

FAIR VALUE MEASUREMENTS At Reporting Date Using

Bankers acceptance notes $ 116,047 $ 336,003

Total 116,047 336,003

Bankers acceptance notes Level 1 0 0

Total Level 1 0 0

Bankers acceptance notes Level 2 116,047 336,003

Total Level 2 116,047 336,003

Bankers acceptance notes Level 3 0 0

Total Level 3 $ 0 $ 0

X

- Definition

Bankers acceptance notes,

+ References

No definition available.

+ Details

Name: fil_BankersAcceptanceNotes

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Bankers acceptance notes Level 1

+ References

No definition available.

+ Details

Name: fil_BankersAcceptanceNotesLevel1

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Bankers acceptance notes Level 2

+ References

No definition available.

+ Details

Name: fil_BankersAcceptanceNotesLevel2

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Bankers acceptance notes Level 3

+ References

No definition available.

+ Details

Name: fil_BankersAcceptanceNotesLevel3

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: fil_FAIRVALUEMEASUREMENTSAtReportingDateUsingAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Total bankers acceptance notes

+ References

No definition available.

+ Details

Name: fil_Total1

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Bankers acceptance notes total Level 1

+ References

No definition available.

+ Details

Name: fil_TotalLevel1

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Bankers acceptance notes Level 2 total

+ References

No definition available.

+ Details

Name: fil_TotalLevel2

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Bankers acceptance notes Level 3 total

+ References

No definition available.

+ Details

Name: fil_TotalLevel3

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 22 R29.htm IDEA: XBRL DOCUMENT v2.4.0.8

BASIS OF PRESENTATION Basic and Diluted Earnings per Common Share (Details) (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

BASIS OF PRESENTATION Basic and Diluted Earnings per Common Share

Basic weighted-average common shares outstanding 43,579,557 43,579,557 43,579,557 43,579,557

Warrants $ 0

Options $ 0

Diluted weighted-average common shares outstanding 43,579,557 43,579,557 43,579,557 43,579,557

Basic loss per share $ (0.15) $ (0.06) $ (0.4) $ (0.22)

Diluted loss per share $ (0.15) $ (0.06) $ (0.4) $ (0.22)

X

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: fil_BasicLossEarningsPerShare

Namespace Prefix: fil_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

BasicWeightedAverageCommonSharesOutstanding1

+ References

No definition available.

+ Details

Name: fil_Basicweightedaveragecommonsharesoutstanding1

Namespace Prefix: fil_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: fil_BASISOFPRESENTATIONBasicAndDilutedEarningsPerCommonShareDetailsAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: fil_DilutedLossEarningsPerShare

Namespace Prefix: fil_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

DilutedWeightedAverageCommonSharesOutstanding2

+ References

No definition available.

+ Details

Name: fil_Dilutedweightedaveragecommonsharesoutstanding2

Namespace Prefix: fil_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of options.

+ References

No definition available.

+ Details

Name: fil_Options

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of warrants.

+ References

No definition available.

+ Details

Name: fil_Warrants

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 23 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8

BASIS OF PRESENTATION (Details)

Sep. 30, 2014

Organization and operations

Percentage of share owned by China Pharma Holdings Inc of Onny Investment Limited 100.00%

Percentage of share owned by China Pharma Holdings Inc of Helpson Medical & Biotechnology Co., Ltd. 100.00%

Percetage of acquired by Onny in Helpson 100.00%

X

- Details

Name: fil_OrganizationAndOperationsAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1

+ References

No definition available.

+ Details

Name: fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfHelpsonMedicalAmpBiotechnologyCoLtd1

Namespace Prefix: fil_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Percentage of share owned by China Pharma Holdings Inc of Onny Investment Limited

+ References

No definition available.

+ Details

Name: fil_PercentageOfShareOwnedByChinaPharmaHoldingsIncOfOnnyInvestmentLimited

Namespace Prefix: fil_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Percetage of acquired by Onny in Helpson

+ References

No definition available.

+ Details

Name: fil_PercetageOfAcquiredByOnnyInHelpson

Namespace Prefix: fil_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

XML 24 R44.htm IDEA: XBRL DOCUMENT v2.4.0.8

Preferred Common Stock And Warrants (Details)

Sep. 30, 2014

Preferred Common Stock And Warrants

Common shares authorized 95,000,000

Preferred shares authorized 5,000,000

Number of common stock shares to purchase by warrants outstaning and exercisable 4,000,000

Shares of restricted stock granted and outstanding under the Plan 175,000

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

No definition available.

+ Details

Name: fil_CommonSharesAuthorized

Namespace Prefix: fil_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of common stock shares to purchase by warrants outstaning and exercisable

+ References

No definition available.

+ Details

Name: fil_NumberOfCommonStockSharesToPurchaseByWarrantsOutstaningAndExercisable

Namespace Prefix: fil_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

No definition available.

+ Details

Name: fil_PreferredSharesAuthorized

Namespace Prefix: fil_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Shares of restricted stock granted and outstanding under the Plan

+ References

No definition available.

+ Details

Name: fil_SharesOfRestrictedStockGrantedAndOutstandingUnderThePlan

Namespace Prefix: fil_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: fil_STOCKHOLDERSEQUITYPreferredCommonStockAndWarrantsAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 25 R30.htm IDEA: XBRL DOCUMENT v2.4.0.8

LOSSES FROM NATURAL DISASTER (DETAILS) (USD $)

Jul. 18, 2014

LOSSES FROM NATURAL DISASTER DETAILS

Losses comprised $ 2,015,248

Inventory related costs $ 260,345

X

- Definition

Gross amount of an expenditure that is incurred in the current period but rather capitalized as a component of inventory

+ References

No definition available.

+ Details

Name: fil_InventoryRelatedCosts

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Losses comprised of natural disaster

+ References

No definition available.

+ Details

Name: fil_LossesComprised

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: fil_LossesFromNaturalDisasterDetailsAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 26 R31.htm IDEA: XBRL DOCUMENT v2.4.0.8

Inventory consisted of the following (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Inventory consisted of the following:

Raw materials $ 19,571,419 $ 28,259,707

Work in process 853,602

Finished goods 4,113,606 3,590,937

Inventory Gross 23,685,025 32,704,246

Inventory obsolescence reserve (4,670,853) (8,027,126)

Total Inventory $ 19,014,172 $ 24,677,120

X

- Definition

Rawmaterials1

+ References

No definition available.

+ Details

Name: fil_Finishedgoods1

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: fil_InventoryConsistedOfTheFollowingAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

InventoryGross1

+ References

No definition available.

+ Details

Name: fil_InventoryGross1

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Allowance for doubtful other receivables deferred tax

+ References

No definition available.

+ Details

Name: fil_InventoryObsolescenceReserve1

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Rawmaterials1

+ References

No definition available.

+ Details

Name: fil_Rawmaterials1

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amount (lower of cost or market) as of the balance sheet date of inventories less all valuation and other allowances. Excludes noncurrent inventory balances (expected to remain on hand past one year or one operating cycle, if longer).

+ References

No definition available.

+ Details

Name: fil_TotalInventoryNet

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_InventoryWorkInProcess

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 27 R8.htm IDEA: XBRL DOCUMENT v2.4.0.8

INVENTORY.
9 Months Ended

Sep. 30, 2014

INVENTORY

INVENTORY

NOTE 3 – INVENTORY

Inventory consisted of the following:

September 30,

December 31,

2014

2013

Raw materials

$

19,571,419

$

28,259,707

Work in process

-

853,602

Finished goods

4,113,606

3,590,937

23,685,025

32,704,246

Obsolescence reserve

(4,670,853

)

(8,027,126

)

Total Inventory

$

19,014,172

$

24,677,120

X

- Details

Name: us-gaap_InventoryDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 6

-Subparagraph a, b, c

-Article 5

+ Details

Name: us-gaap_InventoryDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R32.htm IDEA: XBRL DOCUMENT v2.4.0.8

Property and equipment consisted of the following (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Property and equipment consisted of the following:

Permit of land use $ 457,743 $ 460,964

Building 10,033,988 2,494,623

Plant, machinery and equipment 16,393,856 6,671,620

Motor vehicle 150,611 151,670

Office equipment 246,553 229,210

Construction in progress 12,537,905 25,497,600

Total Property and Equipment 39,820,656 35,505,687

Less: accumulated depreciation details (5,951,165) (5,264,350)

Property and Equipment, net $ 33,869,491 $ 30,241,337

X

- Definition

Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.

+ References

No definition available.

+ Details

Name: fil_Building

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Gross amount, at the balance sheet date, of long-lived assets under construction that include construction costs to date on capital projects that have not been completed and assets being constructed that are not ready to be placed into service.

+ References

No definition available.

+ Details

Name: fil_ConstructionInProgress1

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.

+ References

No definition available.

+ Details

Name: fil_LessAccumulatedDepreciationDetails

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The amount of motor vehicle gross as on the date

+ References

No definition available.

+ Details

Name: fil_MotorVehicleGross

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Gross amount, at the balance sheet date, of long-lived assets under construction that include construction costs to date on capital projects that have not been completed and assets being constructed that are not ready to be placed into service.

+ References

No definition available.

+ Details

Name: fil_OfficeEquipment1

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The amount of permit of land use as on the date.

+ References

No definition available.

+ Details

Name: fil_PermitOfLandUse

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The amount of plant machinery and equipment gross as on the date.

+ References

No definition available.

+ Details

Name: fil_PlantMachineryAndEquipmentGross

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: fil_PropertyAndEquipmentConsistedOfTheFollowingAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tangible assets that are held by an entity for use in the production or supply of goods and services, for rental to others, or for administrative purposes and that are expected to provide economic benefit for more than one year; net of accumulated depreciation. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.

+ References

No definition available.

+ Details

Name: fil_PropertyAndEquipmentNet

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Total Property and Equipment

+ References

No definition available.

+ Details

Name: fil_TotalPropertyAndEquipment

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 29 R40.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONSTRUCTION LOAN FACILITY (Details) (USD $)

Jun. 21, 2013

Construction loan facility details

Construction loan amount in total $ 80,000,000

Loan interest rate per annum 7.21%

Amount drawn under line of credit $ 12,983,008

X

- Definition

Amount drawn under line of credit

+ References

No definition available.

+ Details

Name: fil_AmountDrawnUnderLineOfCredit

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Construction loan amount available to draw by the company

+ References

No definition available.

+ Details

Name: fil_ConstructionLoanAmountAvailableToDrawByTheCompany

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: fil_ConstructionLoanFacilityDetailsAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Loan interest rate per annum

+ References

No definition available.

+ Details

Name: fil_LoanInterestRatePerAnnum

Namespace Prefix: fil_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

XML 30 R2.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Current Assets:

Cash and cash equivalents $ 4,269,037 $ 5,993,139

Banker's acceptances 116,047 336,003

Trade accounts receivable, less allowance for doubtful accounts of $27,912,179 and $13,301,622, respectively 30,642,878 45,147,602

Other receivables, less allowance for doubtful accounts of $70,004 and $43,064, respectively 516,095 175,739

Advances to suppliers 9,040,464 7,626,716

Inventory, less allowance for obsolescence of $4,670,853 and $8,027,126, respectively 19,014,172 24,677,120

Total Current Assets 63,598,693 83,956,319

Advances for purchases of intangible assets 41,653,862 41,701,505

Property and equipment, net of accumulated depreciation of $5,951,165 and $5,264,350, respectively 33,869,491 30,241,337

Intangible assets, net of accumulated amortization of $4,075,696 and $3,812,992, respectively 1,410,482 1,711,793

TOTAL ASSETS 140,532,528 157,610,954

Current Liabilities:

Trade accounts payable 3,131,988 1,877,437

Accrued expenses 214,740 323,651

Other payables 1,293,273 1,312,361

Advances from customers 1,773,478 2,228,238

Other payables - related parties 1,354,567 1,354,567

Current portion of construction loan facility. 1,625,118

Short-term notes payable 4,875,353 4,909,662

Total Current Liabilities 14,268,517 12,005,916

Non-current Liabilities:

Construction loan facility 11,375,825 12,484,183

Long-term deferred tax liability 232,866 176,414

Total Liabilities 25,877,208 24,666,513

Stockholders' Equity:

Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding 0

Common stock, $0.001 par value; 95,000,000 shares authorized; 43,579,557 shares and 43,579,557 shares outstanding, respectively 43,580 43,580

Additional paid-in capital 23,590,204 23,590,204

Retained earnings 71,535,109 88,896,276

Accumulated other comprehensive income 19,486,427 20,414,381

Total Stockholders' Equity 114,655,320 132,944,441

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 140,532,528 $ 157,610,954

X

- Definition

AdvancesForPurchasesOfIntangibleAssets

+ References

No definition available.

+ Details

Name: fil_AdvancesForPurchasesOfIntangibleAssets

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date of advances to suppliers.

+ References

No definition available.

+ Details

Name: fil_AdvancesToSuppliers

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, which are not elsewhere specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableOtherCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableTradeCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The current portion of prepayments received from customers for goods or services to be provided in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CustomerAdvancesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of deferred tax liability attributable to taxable temporary differences, net of deferred tax asset attributable to deductible temporary differences and carryforwards net of valuation allowances expected to be realized or consumed after one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31958-109318

+ Details

Name: us-gaap_DeferredTaxLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Subparagraph 1

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IntangibleAssetsNetExcludingGoodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.6(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 35

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6386567&loc=d3e3927-108312

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_LiabilitiesNoncurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

This element represents the current portion of a long-term real estate loan to finance building costs. The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project (generally one to seven years), usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee. The effective yield on these loans tends to be high, and the lender has a security interest in the real property.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

+ Details

Name: us-gaap_LongTermConstructionLoanCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

This element represents the current and noncurrent portions of a long-term real estate loan with an initial maturity beyond one year or beyond the normal operating cycle, if longer, to finance building costs. The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project (generally one to seven years), usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee. The effective yield on these loans tends to be high, and the lender has a security interest in the real property.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20,22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongtermConstructionLoanCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20

-Article 5

+ Details

Name: us-gaap_NotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The carrying amount of other receivables, net, due within one year of the balance sheet date (or one operating cycle, if longer) from third parties or arising from transactions not separately disclosed.

+ References

No definition available.

+ Details

Name: us-gaap_OtherReceivablesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of accumulated other comprehensive Income or Loss at the balance sheet date before fresh-start adjustments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-Section 55

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=34712771&loc=d3e56426-112766

+ Details

Name: us-gaap_PreconfirmationAccumulatedOtherComprehensiveIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 R45.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONCENTRATIONS Sales And Purchases (Details)
9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

CONCENTRATIONS Sales And Purchases

Percentage of no customer accounted for more than sales 16.70% 0.00%

Percentage of purchases from two supplier of raw materials 31.80% 20.60%

Percentage of one customer accounted for more than sales 10.00%

X

- Details

Name: fil_CONCENTRATIONSSalesAndPurchasesAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Percentage of no customer accounted for more than sales

+ References

No definition available.

+ Details

Name: fil_PercentageOfNoCustomerAccountedForMoreThanSales

Namespace Prefix: fil_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Percentage of one customer accounted for more than sales

+ References

No definition available.

+ Details

Name: fil_PercentageOfOneCustomerAccountedForMoreThanSales

Namespace Prefix: fil_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Percentage of purchases from two supplier of raw materials

+ References

No definition available.

+ Details

Name: fil_PercentageOfPurchasesFromTwoSupplierOfRawMaterials

Namespace Prefix: fil_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

XML 32 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8

BASIS OF PRESENTATION
9 Months Ended

Sep. 30, 2014

BASIS OF PRESENTATION:

BASIS OF PRESENTATION

NOTE 1 - BASIS OF PRESENTATION

Organization and Nature of Operations – China Pharma Holdings, Inc., a Nevada corporation, owns 100% of Onny Investment Limited (“Onny”), a British Virgin Islands corporation, that in turn owns 100% of Hainan Helpson Medical & Biotechnology Co., Ltd (“Helpson”), a corporation organized under the laws of the People's Republic of China (the “PRC”). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the “Company”.

The Foreign Investment Industrial Catalogue (the “Catalogue”) jointly issued by the China’s Ministry of Commerce and the National Development and Reform Commission (as the latest version is the year 2012 version, effective January 30, 2012) classified various industries/businesses into three different categories: (i) encouraged for foreign investment; (ii) restricted to foreign investment; and (iii) prohibited from foreign investment. For any industry/business not covered by any of these three categories, they will be deemed industries/businesses permitted for foreign investment. A typical foreign investment ownership restriction in the pharmaceutical industry is that a foreign investment enterprise (the “FIE”) shall not have the whole or majority of its equity interests owned by a foreign owner if the FIE establishes more than 30 branch stores and distributes a variety of brands in those franchise stores, which is not the case of the Company’s business.

Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located throughout the PRC. The Company believes Helpson’s business is not subject to any ownership restrictions prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson from Helpson’s three former shareholders on May 25, 2005 by entry into an Equity Transfer Agreement with such three parties on May 25, 2005. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishing of Enterprises with Foreign Investment in the PRC on the same day and its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.

The Company has and continues to acquire well-accepted medical formulas to add to its diverse portfolio of Western and Chinese medicines.

Consolidation and Basis of Presentation – The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and are expressed in United States dollars. The accompanying consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

Helpson’s functional currency is the Chinese Renminbi. Helpson’s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson’s financial statements are included in accumulated other comprehensive income, which is a component of stockholders’ equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is a party to the transaction are included in the results of operations.

Reclassification - The Company has made certain reclassifications to the condensed consolidated statement of operations and cash flows for the three and nine months ended September 30, 2013 to conform to the presentation for the three and nine months ended September 30, 2014. These reclassifications had no effect on the condensed consolidated balance sheets, results of operations or cash flows as of or for the three and nine months ended September 30, 2013.

Condensed Financial Statements – The accompanying unaudited condensed consolidated financial statements were prepared pursuant to the rules and regulations of the United States Securities and Exchange Commission (the “Commission”). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Management of the Company (“Management”) believes the following disclosures are adequate to make the information presented not misleading. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2013 filed with the Commission on March 20, 2014.



These unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) that, in the opinion of Management, are necessary to present fairly the consolidated financial position and results of operations of the Company for the periods presented. Operating results for the nine months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014.

Accounting Estimates - The preparation of financial statements in conformity with U.S. GAAP requires Management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

Basic and Diluted Loss per Common Share - Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per share is calculated to give effect to any potentially issuable dilutive common shares. There were no potentially dilutive common shares outstanding for all periods presented.

The following table is a presentation of the numerators and denominators used in the calculation of basic and diluted (loss) earnings per share:

For the Three Months

For the Nine Months

Ended September 30,

Ended September 30,

2014

2013

2014

2013

Net loss

$

(6,327,724

)

$

(2,302,031

)

$

(17,361,167

)

$

(9,578,163

)

Basic weighted-average common shares outstanding

43,579,557

43,579,557

43,579,557

43,579,557

Effect of dilutive securities:

Warrants

-

-

-

-

Options

-

-

-

-

Diluted weighted-average common shares outstanding

43,579,557

43,579,557

43,579,557

43,579,557

Basic loss per share

$

(0.15

)

$

(0.05

)

$

(0.40

)

$

(0.22

)

Diluted loss per share

$

(0.15

)

$

(0.05

)

$

(0.40

)

$

(0.22

)

X

- Details

Name: fil_BasisOfPresentationAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.

+ References

No definition available.

+ Details

Name: us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R35.htm IDEA: XBRL DOCUMENT v2.4.0.8

ASSETS Depreciation (Details) (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Assets Depreciation

Depreciation Expense property and equipment $ 321,020 $ 210,182 $ 724,509 $ 640,550

X

- Details

Name: fil_AssetsDepreciationAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Depreciation Expense property and equipment

+ References

No definition available.

+ Details

Name: fil_DepreciationExpensePropertyAndEquipment

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 34 R22.htm IDEA: XBRL DOCUMENT v2.4.0.8

BASIS OF PRESENTATION (Tables)
9 Months Ended

Sep. 30, 2014

BASIS OF PRESENTATION (Tables)

Presentation of the numerators and denominators used in the calculation of basic and diluted earnings per share
The following table is a presentation of the numerators and denominators used in the calculation of basic and diluted (loss) earnings per share:

For the Three Months

For the Nine Months

Ended September 30,

Ended September 30,

2014

2013

2014

2013

Net loss

$

(6,327,724

)

$

(2,302,031

)

$

(17,361,167

)

$

(9,578,163

)

Basic weighted-average common shares outstanding

43,579,557

43,579,557

43,579,557

43,579,557

Effect of dilutive securities:

Warrants

-

-

-

-

Options

-

-

-

-

Diluted weighted-average common shares outstanding

43,579,557

43,579,557

43,579,557

43,579,557

Basic loss per share

$

(0.15

)

$

(0.05

)

$

(0.40

)

$

(0.22

)

Diluted loss per share

$

(0.15

)

$

(0.05

)

$

(0.40

)

$

(0.22

)

X

- Details

Name: fil_BasisOfPresentationTablesAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 R36.htm IDEA: XBRL DOCUMENT v2.4.0.8

INTANGIBLE ASSETS SFDA Approved Medical Formulas (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

INTANGIBLE ASSETS SFDA Approved Medical Formulas

Gross carrying amount $ 5,486,178 $ 5,524,785

Accumulated amortization Intangible assets SFDA Approved Medical Formulas (4,075,696) (3,812,992)

Net carrying amount $ 1,410,482 $ 1,711,793

X

- Definition

Accumulated amortization Intangible assets SFDA Approved Medical Formulas

+ References

No definition available.

+ Details

Name: fil_AccumulatedAmortizationIntangibleAssetsSFDAApprovedMedicalFormulas

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Gross carrying amount

+ References

No definition available.

+ Details

Name: fil_GrossCarryingAmount

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: fil_IntangibleAssetsSfdaApprovedMedicalFormulasAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Net carrying amount

+ References

No definition available.

+ Details

Name: fil_NetCarryingAmount

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 36 R24.htm IDEA: XBRL DOCUMENT v2.4.0.8

PROPERTY AND EQUIPMENT (Tables)
9 Months Ended

Sep. 30, 2014

PROPERTY AND EQUIPMENT (Tables)

Property and equipment consists
Property and equipment consisted of the following:

September 30,

December 31,

2014

2013

Permit of land use

$

457,743

$

460,964

Building

10,033,988

2,494,623

Plant, machinery and equipment

16,393,856

6,671,620

Motor vehicle

150,611

151,670

Office equipment

246,553

229,210

Construction in progress

12,537,905

25,497,600

Total

39,820,656

35,505,687

Less: accumulated depreciation

(5,951,165

)

(5,264,350

)

Property and Equipment, net

$

33,869,491

$

30,241,337

A reconciliation of total interest cost incurred to interest expense

A reconciliation of total interest cost incurred to interest expense as recognized in the consolidated statement of operations is as follows:

For the Three Months

For the Nine Months

Ended September 30,

Ended September 30,

2014

2013

2014

2013

Total interest cost incurred

$

330,995

$

89,238

$

952,836

$

263,732

Interest cost capitalized

5,751

-

457,782

-

Interest expense

$

325,244

$

89,238

$

495,054

$

263,732

Useful lives of the assets
Depreciation is computed on a straight-line basis over the estimated useful lives of the assets as follows:

Asset

Life - years

Permit of land use

40 - 70

Building

20 - 49

Plant, machinery and equipment

10

Motor vehicle

5 - 10

Office equipment

3-5

For the three months ended September 30, 2014 and 2013, depreciation expense was $321,020 and $210,182. For the nine months ended September 30, 2014 and 2013, depreciation expense was $724,509 and $640,550.

X

- Definition

Tabular disclosure for reconciliation of total interest cost incurred to interest expense

+ References

No definition available.

+ Details

Name: fil_AReconciliationOfTotalInterestCostIncurredToInterestExpenseTextBlock

Namespace Prefix: fil_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: fil_PropertyAndEquipmentTablesAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of useful lives of the assets.

+ References

No definition available.

+ Details

Name: fil_UsefulLivesOfTheAssetsTableTextBlock

Namespace Prefix: fil_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 38 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8

LOSSES FROM NATURAL DISASTER
9 Months Ended

Sep. 30, 2014

LOSSES FROM NATURAL DISASTER:

LOSSES FROM NATURAL DISASTER
NOTE 2 – LOSSES FROM NATURAL DISASTER

On July 18, 2014, the Company’s manufacturing facilities and inventory sustained storm damage from a powerful tropical typhoon that hit Haikou on that date. The losses are comprised of $2,015,248 of inventory related costs and $260,345 of facilities damage costs. The Company received minor insurance compensation as only the building of new plant was insured and the damage to it was minor.

The Company assessed whether any asset impairment had occurred as a result of the storm. Based on the assessment, no impairment was considered necessary. In addition, the Company assessed whether the damage caused by the tropical typhoon resulted in exposure to environmental remediation liability. Based on the assessment, the Company determined that no such exposure has occurred.

X

- Definition

LOSSES FROM NATURAL DISASTER

+ References

No definition available.

+ Details

Name: fil_idr_DisclosureINVENTORY

Namespace Prefix: fil_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: fil_LossesFromNaturalDisasterAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 39 R3.htm IDEA: XBRL DOCUMENT v2.4.0.8

Balance Sheets Parentheticals (USD $)

Sep. 30, 2014

Dec. 31, 2013

BALANCE SHEETS PARENTHETICALS

Allowance for doubtful accounts ,Trade accounts receivables $ 27,912,179 $ 13,301,622

Allowance for doubtful accounts , Other receivables 70,004 43,064

Allowance for obsolescence, Inventories 4,670,853 8,027,126

Accumulated depreciation of Property and equipment 5,951,165 5,264,350

accumulated amortization of Intangible assets $ 4,075,696 $ 3,812,992

Preferred Stock, par value $ 0.001 $ 0.001

Preferred Stock, shares authorized 5,000,000 5,000,000

Preferred Stock, shares issued 0

Preferred Stock, shares outstanding 0

Common Stock, par value $ 0.001 $ 0.001

Common Stock, shares authorized 95,000,000 95,000,000

Common Stock, shares issued 43,579,557 43,579,557

Common Stock, shares outstanding 43,579,557 43,579,557

X

- Definition

A valuation allowance for other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible

+ References

No definition available.

+ Details

Name: fil_AllowanceForDoubtfulAccountsOnOtherReceivables

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Allowance for obsolescence, Inventories

+ References

No definition available.

+ Details

Name: fil_AllowanceForObsolescenceInventories

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 14

-Article 5

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=35738203&loc=d3e5074-111524

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Face amount per share of no-par value preferred stock nonredeemable or redeemable solely at the option of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockNoParValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StockTransactionsParentheticalDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 40 R17.htm IDEA: XBRL DOCUMENT v2.4.0.8

STOCKHOLDERS' EQUITY
9 Months Ended

Sep. 30, 2014

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY
NOTE 12 - STOCKHOLDERS' EQUITY

Preferred and Common Stock – The total number of authorized shares is 95,000,000 shares of common stock and 5,000,000 shares of preferred stock. The preferred stock may be issued in series with such designations, preferences, stated values, rights, qualifications or limitations as determined solely by the Company’s Board of Directors.

Stock and Stock Options – On November 12, 2010, the Company’s Board of Directors adopted, and on December 22, 2010, its stockholders approved the Company’s 2010 Incentive Plan (the “Plan”), which gave the Company the ability to grant stock options, restricted stock, stock appreciation rights and performance units to its employees, directors and consultants, or those who will become employees, directors and consultants of the Company and/or its subsidiaries. The Plan currently allows for equity awards of up to 4,000,000 shares of common stock. Through September 30, 2014, there were 175,000 shares of restricted stock granted and outstanding under the Plan.

There were no securities issued from the Plan during the nine months ended September 30, 2014 and at September 30, 2014 there was no unrecognized compensation expense related to securities granted under the Plan.

X

- Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R1.htm IDEA: XBRL DOCUMENT v2.4.0.8

Document and Entity Information
9 Months Ended

Sep. 30, 2014

Nov. 10, 2014

Document and Entity Information

Entity Registrant Name CHINA PHARMA HOLDINGS, INC.

Document Type 10-Q

Document Period End Date Sep. 30, 2014

Amendment Flag false

Entity Central Index Key 0001106644

Current Fiscal Year End Date --12-31

Entity Common Stock, Shares Outstanding 43,579,557

Entity Filer Category Smaller Reporting Company

Entity Current Reporting Status Yes

Entity Voluntary Filers No

Entity Well-known Seasoned Issuer No

Document Fiscal Year Focus 2014

Document Fiscal Period Focus Q3

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

+ References

No definition available.

+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.

+ References

No definition available.

+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Details

Name: fil_DocumentAndEntityInformationAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 42 R18.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONTINGENCIES
9 Months Ended

Sep. 30, 2014

CONTINGENCIES

CONTINGENCIES
NOTE 13 – CONTINGENCIES

Economic environment - Substantially all of the Company's operations are conducted in the PRC, and therefore the Company is subject to special considerations and significant risks not typically associated with companies operating in the United States of America. These risks include, among others, the political, economic and legal environments and fluctuations in the foreign currency exchange rate. The Company's results from operations may be adversely affected by changes in the political and social conditions in the PRC, and by changes in governmental policies with respect to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among other things. The unfavorable changes in global macroeconomic factors may also adversely affect the Company’s operations.

In addition, all of the Company's revenue is denominated in the PRC's currency of Renminbi (RMB), which must be converted into other currencies before remittance out of the PRC. Both the conversion of RMB into foreign currencies and the remittance of foreign currencies abroad require approval of the PRC government.

X

- Details

Name: fil_CommitmentAndContingenciesAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14453-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14394-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14472-108349

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6851643&loc=d3e12021-110248

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14557-108349

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6851643&loc=d3e12053-110248

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14615-108349

+ Details

Name: us-gaap_LossContingencyDisclosures

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED) (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Revenues:

Revenue $ 5,566,543 $ 8,116,599 $ 18,802,602 $ 24,392,311

Cost of revenue 4,057,480 5,863,587 12,215,756 17,837,989

Inventory obsolescence 15,747 3,735,820

Gross profit 1,509,063 2,237,265 6,586,846 2,818,502

Operating expenses:

Selling expenses 745,976 921,851 2,193,823 2,435,592

General and administrative expenses 422,729 372,568 1,229,488 1,536,831

Research and development expenses 181,796 352,599 2,528,230 1,384,263

Bad debt expense 3,940,144 3,277,780 15,280,588 7,910,583

Losses from natural disaster 2,275,593 2,275,593

Total operating expenses 7,566,238 4,924,798 23,507,722 13,267,269

Subsidy income 65,086 65,086

Loss from operations (5,992,089) (2,687,533) (16,855,790) (10,448,767)

Other income (expense):

Interest income 8,824 2,228 47,435 4,830

Interest expense (325,244) (89,238) (495,054) (263,732)

Net other expense (316,420) (87,010) (447,619) (258,902)

Loss before income taxes (6,308,509) (2,774,543) (17,303,409) (10,707,669)

Income tax benefit (expense) (19,215) 472,512 (57,758) 1,129,506

Net loss (6,327,724) (2,302,031) (17,361,167) (9,578,163)

Other comprehensive income - foreign currency translation adjustment 33,366 880,315 (927,954) 3,918,978

Comprehensive (loss) income $ (6,294,358) $ (1,421,716) $ (18,289,121) $ (5,659,185)

Loss per share:

Basic $ (0.15) $ (0.05) $ (0.40) $ (0.22)

Diluted $ (0.15) $ (0.05) $ (0.40) $ (0.22)

X

- Definition

Losses from natural disaster

+ References

No definition available.

+ Details

Name: fil_LossesFromNaturalDisaster

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Research and development expense during the period related to the costs of developing and achieving technological feasibility of a computer software product to be sold, leased, or otherwise marketed.

+ References

No definition available.

+ Details

Name: fil_ResearchAndDevelopmentExpenses

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Subsidy income

+ References

No definition available.

+ Details

Name: fil_SubsidyIncome

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate cost of goods produced and sold and services rendered during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

+ Details

Name: us-gaap_CostOfRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1,2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 940

-SubTopic 20

-Section 25

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35710027&loc=d3e41242-110953

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 10

-Article 5

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of the cost of borrowed funds accounted for as interest expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 9

-Article 9

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 330

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4542-108314

+ Details

Name: us-gaap_InventoryWriteDown

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(b))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-Subparagraph (b,c)

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669619-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

This element represents a sum total of expenses not separately reflected on the income statement for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 7

-Article 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.7)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4,6)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OtherIncomeAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591552-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=35736750&loc=SL4591551-111686

+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.5)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 5

-Article 5

+ Details

Name: us-gaap_ProvisionForDoubtfulAccounts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Expenses recognized in the period that are directly related to the selling and distribution of products or services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_SellingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 44 R12.htm IDEA: XBRL DOCUMENT v2.4.0.8

RELATED PARTY TRANSACTIONS
9 Months Ended

Sep. 30, 2014

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS
NOTE 7 – RELATED PARTY TRANSACTIONS

Total advances owing to a board member were $1,354,567 as of September 30, 2014 and December 31, 2013 and are recorded as “other payables – related parties” on the accompanying condensed consolidated balance sheets. The advances bear interest at a rate of 1.0% per year. Total interest expense of $10,159 and $10,159 was recognized for the nine months ended September 30, 2014 and 2013, respectively.

X

- Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R11.htm IDEA: XBRL DOCUMENT v2.4.0.8

ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.
9 Months Ended

Sep. 30, 2014

ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS

ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS.
NOTE 6 – ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS

In order to expand the number of medicines manufactured and marketed by the Company, it has entered into contracts with independent laboratories for the purchase of medical formulas. Although CFDA approval had not been obtained for certain medical formulas as of the dates of the respective contracts, the objective of the contracts is for the Company to purchase CFDA-approved medical formulas once the CFDA approval process is completed. Some of the medical formulas currently in the CFDA approval process also come with patents. As of September 30, 2014, the Company had received the title to two unexpired patents that relate to medical formulas currently in the CFDA approval process.

Prior to entering into the contracts, the laboratories typically have completed all required researches and developments to determine the medical formula for and the method of production of the generic medicines. The application to the CFDA for production approval must be made by the facilities that will manufacture the related products. As a result, a contract typically provides that the Company purchases the medical formula from the laboratory and the laboratory is required to assist the Company in applying for and obtaining the production approval from the CFDA.

A typical CFDA approval process for the production of a generic medical product involves a number of steps that generally require three to five years to complete. If the medical formula is purchased at the point when the generic medical product receives the CFDA’s approval for a clinical study, which is very typical for the Company, the clinical study that follows will usually take one and a half to three years to complete. After completing the clinical study, results are submitted to the CFDA and a production approval application would be filed. In most cases, it takes between eight to eighteen months from preparing and submitting the production approval application until obtaining CFDA’s approval. Upon approving, the CFDA would issue a production certificate and the Company can start producing and promoting the generic medical product. Therefore, it is expected to take five years from the dates of the medical formula contracts until acquiring CFDA’s approval. However, the actual time needed could be even longer due to the updated criteria in the drug registration process.

Under the terms of the contracts, the laboratories are required to assist the Company in obtaining production approval for the medical formulas from the CFDA. Management monitors the status of each medical formula on a regular basis in order to assess whether the laboratories are performing adequately under the contracts. If a medical product is not approved by the CFDA, as evidenced by their issuance of a denial letter, or if the laboratory breaches the contract, the laboratory is obliged under the contract to provide a refund of the full payment to the Company. alternatively, the Company can require the application of those payments to another medical formula with the same laboratory. As a result of the refund right, the Company is ultimately purchasing an approved medical product. Accordingly, payments made prior to the issuance of production approval by the CFDA are recorded as advances for purchases of intangible assets.



To date, no formula has failed to receive CFDA production approval nor has the Company been informed or become aware of any formula that may fail to receive such approval. However, there is no assurance that the medical products will receive production approval and if the Company does not receive such approval, it will enforce its contractual rights to receive the refund from the laboratory or have the payments applied to another medical formula with the same laboratory.

At September 30, 2014, the Company was obliged to pay laboratories and others approximately $5.19 million upon completion of various phases of contracts to provide CFDA production approval of medical formulas.

X

- Details

Name: fil_AdvancesForPurchasesOfIntangibleAssetsAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure of advances for purchases of intangible assets.

+ References

No definition available.

+ Details

Name: fil_AdvancesForPurchasesOfIntangibleAssetsTextBlock

Namespace Prefix: fil_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8

INVENTORY(Tables)
9 Months Ended

Sep. 30, 2014

INVENTORY (Tables)

Inventory consists
Inventory consisted of the following:

September 30,

December 31,

2014

2013

Raw materials

$

19,571,419

$

28,259,707

Work in process

-

853,602

Finished goods

4,113,606

3,590,937

23,685,025

32,704,246

Obsolescence reserve

(4,670,853

)

(8,027,126

)

Total Inventory

$

19,014,172

$

24,677,120

X

- Details

Name: fil_InventoryTablesAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 2

-Paragraph 6

-Subparagraph a,b,c

-Article 5

+ Details

Name: us-gaap_ScheduleOfInventoryCurrentTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R19.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONCENTRATIONS
9 Months Ended

Sep. 30, 2014

CONCENTRATIONS

CONCENTRATIONS
NOTE 14 – CONCENTRATIONS

At September 30, 2014, one customer accounted for 16.6% of accounts receivable. At December 31, 2013, two customers accounted for 14.5% and 11.2% of accounts receivable.

For the nine months ended September 30, 2014, one customer accounted for 16.7% of sales. For the nine months ended September 30, 2013, no customer accounted for more than 10% of sales.

For the nine months ended September 30, 2014 and 2013, purchases from one supplier accounted for 31.8% and 20.6% of raw material purchases, respectively.

X

- Definition

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6327-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13531-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6442-108592

+ Details

Name: us-gaap_ConcentrationRiskDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_RisksAndUncertaintiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 48 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8

INCOME TAXES
9 Months Ended

Sep. 30, 2014

INCOME TAXES

INCOME TAXES
NOTE 10 - INCOME TAXES

Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax laws or rates are recognized in operations in the period that includes the enactment date.



Undistributed earnings of Helpson, the Company’s foreign subsidiary, since its acquisition, amounted to approximately $76.9 million at September 30, 2014. Those earnings, as well as the investment in Helpson of approximately $23.3 million, are considered to be indefinitely reinvested and, accordingly, no U.S. federal or state income taxes have been provided thereon. Upon distribution of those earnings in the form of dividends or otherwise, the Company would be subject to U.S. federal and state income taxes (net of an adjustment for foreign tax credits) and withholding taxes payable to the PRC. Determination of the amount of unrecognized deferred U.S. income tax liability is not practicable because of the complexities associated with its hypothetical calculation; however, unrecognized foreign tax credits may be available to reduce a portion of the U.S. tax liability.

Under current tax law in the PRC, the Company is and will be subject to the following enterprise income tax rates:

Enterprise Income

Year

Tax Rate

2014

15%

2015

15%

2016

15%

Thereafter

25%

The provision for income taxes consisted of the following:

Three Months Ended September 30,

Nine Months Ended September 30,

2014

2013

2014

2013

Current

$

-

$

-

$

-

$

-

Deferred

19,215

(472,512

)

57,758

(1,129,506

)

Total income tax expense (benefit)

$

19,215

$

(472,512

)

$

57,758

$

(1,129,506

)

The Company has net operating loss carryforwards for PRC tax purposes of approximately $10.16 million at September 30, 2014, of which approximately $6.83 million and $3.33 is available to offset future taxable income through 2018 and 2019, respectively.

In assessing the realizability of deferred tax assets, Management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those differences become deductible or tax loss carry forwards are utilized. Management considers projected future taxable income and tax planning strategies in making this assessment. Based upon an assessment of the level of historical taxable income and projections for future taxable income over the periods on which the deferred tax assets are deductible or can be utilized, Management believes it is not likely the Company will realize all of the benefits of the deferred tax assets as of September 30, 2014 and December 31, 2013. Therefore, the Company has provided for a valuation allowance against its deferred tax assets of $6,450,846 and $4,915,960 as of September 30, 2014 and December 31, 2013, respectively.

The Company has also incurred various other taxes, comprised primarily of business taxes, value-added taxes, urban construction taxes, education surcharges and others. Any unpaid amounts are reflected on the balance sheets as accrued taxes payable.

X

- Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R13.htm IDEA: XBRL DOCUMENT v2.4.0.8

NOTES PAYABLE
9 Months Ended

Sep. 30, 2014

NOTES PAYABLES

NOTES PAYABLES
NOTE 8 – NOTES PAYABLE

On November 1, 2013 the Company entered into a revolving line of credit with a bank in the amount of RMB 30,000,000. Advances on the line of credit are due one year from the date of the advance and are collateralized by certain land use rights, buildings and accounts receivable and bear interest at an annual rate of 6.6% (based upon 110% of the PRC government’s current short term rate of 6.00%). The Company’s Chief Executive Officer and Chair of the board of directors personally guaranteed the line of credit. The Company is in the process of obtaining an extension of the line of credit with the bank, and anticipates this to be completed during the fourth quarter.

The outstanding balance due under the revolving line of credit was RMB 30,000,000 as of September 30, 2014 and December 31, 2013 ($4,875,353 as of September 30, 2014 and $4,909,662 as of December 31, 2013). The Company has no additional amounts available to it under this line of credit. This amount has been classified as short-term notes payable in the accompanying condensed consolidated balance sheets at September 30, 2014 and December 31, 2013.

X

- Details

Name: fil_NotesPayable1Abstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19,20,22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 50 R14.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONSTRUCTION LOAN FACILITY.
9 Months Ended

Sep. 30, 2014

CONSTRUCTION LOAN FACILITY

CONSTRUCTION LOAN FACILITY
NOTE 9 – CONSTRUCTION LOAN FACILITY

The Company obtained a construction loan facility in the amount of RMB 80,000,000 (approximately $13.0 million at September 30, 2014) from a construction loan facility dated June 21, 2013. The loan facility is for an eight-year term, which commenced on the initial draw-down date of July 11, 2013, and is from the same bank that currently provides the line of credit as discussed in Note 8. The proceeds of the loan were used for and are collateralized by the construction of the Company’s new production facility and the included production line equipment and machinery. The loan currently bears interest at 7.205% based upon 110% of the PRC government’s eight-year term rate effective on the actual draw-down date, and is subjected to annual adjustments based on 110% of the floating rate for the same type of loan on the anniversary from the draw-down date and its subsequent anniversary dates. The loan requires interest only payments for the first two years. Beginning July 11, 2015, the balance of the principal will be due in annual installments over the next six years through July 11, 2021. At September 30, 2014, the Company had no additional amounts available to it under this facility.

Fair Value of Notes Payable and Construction Loan Facility – Based on the borrowing rates currently available to the Company for bank loans with similar terms and maturities, the carrying amounts of notes payable and the construction loan facility outstanding as of September 30, 2014 and December 31, 2013 approximated their fair value because of either the immediate or short-term maturity of these financial instruments or because the underlying instruments bear interest rates that approximated current market rates.

X

- Details

Name: fil_DebtAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for long-term debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 22

-Article 5

+ Details

Name: us-gaap_LongTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 51 R16.htm IDEA: XBRL DOCUMENT v2.4.0.8

FAIR VALUE MEASUREMENTS
9 Months Ended

Sep. 30, 2014

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS
NOTE 11 – FAIR VALUE MEASUREMENTS

Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. To measure fair value, a hierarchy has been established which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs. This hierarchy uses three levels of inputs to measure the fair value of assets and liabilities as follows: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs other than Level 1 including quoted prices for similar assets or liabilities, quoted prices in less active markets, or other observable inputs that can be corroborated by observable market data. Level 3 – Unobservable inputs supported by little or no market activity for financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.

The Company uses fair value to measure the value of the banker’s acceptance notes it holds. The banker’s acceptance notes are recorded at cost which approximates fair value. The Company held the following assets recorded at fair value as of September 30, 2014 and December 31, 2013:

Fair Value Measurements at

Reporting Date Using

Description

September 30, 2014

Level 1

Level 2

Level 3

Banker's acceptance notes

$

116,047

$

-

$

116,047

$

-

Total

$

116,047

$

-

$

116,047

$

-

Fair Value Measurements at

Reporting Date Using

Description

December 31, 2013

Level 1

Level 2

Level 3

Banker's acceptance notes

$

336,003

$

-

$

336,003

$

-

Total

$

336,003

$

-

$

336,003

$

-

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19279-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementInputsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

ZIP 52 0001010549-14-000619-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001010549-14-000619-xbrl.zip M4$L#!!0````(`,*`;D7"YW;;JH,```8C"@`1`!P`8W!H:2TR,#$T,#DS,"YX M;6Q55`D``[MN9E2[;F94=7@+``$$)0X```0Y`0``Y%UK<^,VEOV\6[7_@5-; M&R=5+9O@F]WI3/F9>*IC>VUGLOMI"R(ABPE%:@C2;LVOGWM!4@(EBB]1W:EL MJKIBF^`]!Q?W!1`@O__KYT6HO+*$!W'T\82.8[H3 MLB!EI0S%.M5T79E,L/WG:1(J M`!#Q]U$<1=GBX\D\39?OS\[>WMY.\>IIG+R<^6EREJZ6[`P:3:`52P+O)+^O M_@9-5?6S(.(IC3Q6M'R?\@0#]8WR'+ MM\[RBV53GVVUX\P[?8E?S^!"C>19$%:H>_,@HLLY319T'H>H77[JQ0MQI^KJ MZII1&$2_5^Y\TP4EXKKNF;BZ[F^:[-6.>P97RX8=]%[1^?L=#E7%X^4IY6O% M@Y48&K&;ABIOL>XD#^JZ"$W)V?_\_.G)F[,%G6R/+XH,NM@#6-Z_?8\DWW,A MZ9'-%*&Y]]C9CR<\6"Q#%"O^-D_8[..)MYP'DW(P3C]S_T0Y$W(*XWE_2?E< M\9D7+&@(5GE[=W.B>'&4LL_I(PJX)L9_ZR=*%@7Y[[\\79W\8&B6J^KV]V>R ME)YB=X2:KJL3W6T1>OV/+'BE(8M2?IY>TB19@L6C/,@'N>>%V?0YI%Y#-I/0W;'TLLL2>#&WOK05\15NGH;O0)ZG*R`2G_74<\Y9RH=:BZ6;KF.YD@]7Y`U%VL%Q=->T=.(VX.:070Y.W=FL:TJ MN'[]V0LSK.M^C&/_+0C#_KYN$-5P*J[>CC(RK9KX2H@M.VQO4@-]""HQ4]=, MS=GVX=["=T6;MD4@:QG-HHML^D!7F$F>$^JSP14#@6#DU!0,-<+'(;';:<>V M#=G8>U!(,N9_"N@T"(,T8(.COP8%BZ%6&-1+'@-_=PPTW3+)`'192Z*\&-I_ MHKFZ9NM[AT`6/@Z)70HZ`360_A0N,Y[&,$DL4\=@'=BV;LBE\Q[!AX/OFI^F M.9K>$_HJ8\_Q(PMIROP'FAQB_D0W#=.2/'"_[%$HC$;@4QR]/+-D<1G###O) MO#2(HT\QC08KPM),0J2!:`&HD+F+4U9:ZU`"AF.;NBDY8HW0PT!W(5W5M2RM M.^0(\988FN681!KPEF!W<(R%.81JNC@SZHH((Y_N'WFHP>[BR!O:?Z+;IJ.9 M54/K"GBO!!-*)TUU:HUZ&$K=#-R"ZD1OQWA(BGX_I;'W^Y!E-%6>\.P(JR;> M>+&(HZY(=9%6-QT);UO>`6`'09W[?H!>1<,'&OBWT25=!BGM/V73=--5-56> M2-1+/AQ]).Q'EM(@8OXU32)\"`'U7[;(1`4`#A5X0?\@81-(IC"?VA!I!QF5 MT^[RC^.XEF9;@QF!7P#$+$@6%!4JM1!T7DIY@/F..Z MAF,96F4%8@CPT;GO&I\*L5AWR*C,A;/BTS&6<%QZ25<#4KYAF:8N+V7N2CT( MM*:JUEP#_B.=(:70#KE\C%[OKI6T88Q(J,OZ2B\ZYV$8O^&,["9.KN)LFLZR M$^>,=B6F-7N@HS)>T0GF*QM^&N^VC[>4G_Z*^JF(/Z M(QV%8$U5H%KCT;N?\ABN>0Q^+1^1#"DI#LN`%@'")'IM'%C>IU`=G7=DW3 M;B!1XTR#"!P1OK,C#U9"!W<>(:8<0.210=V:-=?$_UM;7YJ691JZO("42QH@ M7M\5[V#QZKHCB+^"N3]1R?^5NXBW'_I#>5_9(W@`D)X#Z75`FJ&[FDY("]!E MS-/[67&I]Z`8JFD;U35>2=Q0H)KA,1U+-QU[5*"6@=(T8D*Q/#)DTY`1V]%M MUW&[0*ZW`_Z:0#E\%;\U%M:U.H7NR7N(=R56`'],8LYA'C-K7ONM-1-BJJYJ M2;XK"1L&4M,=3=-M39Z`'@C2;!X66*1C6".B-3JS0QQ3#AK[T)Y8&$+(O?Z\ M9!'O[\^V8;KR(GU5W&"DFM%R->@1&1FI><@TXNJ.IH^.V1*%35.>OC9@_L@B MEM`0EP[\!9K`_/65#1U,0]-L30HF+?+'XU(SW.":IN5\<2ZM(=XUG*_! MJC$+F+KEZ*0?*UPJ?&2O`1X(K%EM[VT=N@OJ,@QY M<6&_])%HU)F(9MNVHWY!&BTA!>Q$->68\@4(-1F+[1+@H_?@@U:%#X(9OTGB MQ1U-,P@^5P&G/&5);SN!'`0)L##6O6(/`VYQW>X,2AW=+QF&V'6:[N\>,'&P M*CM;=T0>`ECC"(:K&3!W.`I@BWYU4[5M^:GHJ-#-D5"SH.9WVZ!QY)^R*0_\ M5;[1H?=X6J;J%+FP(JB_^+9I10/.3B>[;1:I[=`$,JNF.G6JV[,7I#=JC95. M-`LW^NI'0VW6[H18CFG:KGI$_"9[G1#5,!Q;WO#=AH^S".HQG5R7Z=V!&P:Z?F\D:8HV$W#[YAPUSLB[!H,@'#T=7>)/(_#IT'3G`C MDE$9_(K`X6!U'NZXE;PW$E:+7QNNJ9KC][#%FZ$(MW6M&ZK8S#*XG)CHQ#+D M+705<4.!:H?/AAZ/BM,V=(9MD>WCXH[)9_J9\>O/,#N/$S^(:+*Z3=E"['^'.Y-8+/P,CM\32U<= M4][3>T1V?PPMU!80MFU4'@/]R;705M#8NJH;_X^LHK7`LE7;LKZ:/N#^(I)< ML(@->58R(:Y&S&W^.W(/QZZ;1-J:2;2C8[?8M&G;IO,%2#3.+(D&)875CT7^ M/&;8=,S"E2RMNIY6"!N$41L[=553==**T70\X`9<)7@I#KYYJ^>$1IQZQ99' M\5N8GS;P?\ORRO:.I?MP0! M5[,KQQ7^I#IHBD&Z2QQ7/IC_E74PV)$GEN;B6*1CC#D* MK[;RSM$BM8O]V#+66*#:F]]DV%]1L)(0F,\RQG1[,5R4,Q^^EW/V278V$'[#-0 MH7:1ZX(N<"/S:YP_J[I;J:PZ\T//O*#^%9L>_EQ@LQMC5^H@L$X[+?9@;321 M'\(9?>%D:]VD!6<\3LT+\#(IFN:J[N5!>;6O%&)MCLS+9-JJ_!/)A?GT/D;>HS M-)4TLJL]23X6MT;S-TS-5-41N3TD;$D#O_2BPGD@D`HY[2_?;$NJAN4XS4/= MA<'1.]&H='P7N-FH]!'ZT/%\?[.^;'2JF[0Z``W-L'F MY_.&8ZFV?A2*'=\'U[8X#1>[J'#?&^,.I]?HPII3/==U,+OMU[(>LMT#Y@5& M8VS>!AN56Y/>8%1-=S`S_*P!Y7.QO=IG_L7J%XY%[GI_W[F7!J\'&IYFNI8A M[Q_K#GH4KHV1T'(=\:*?`[G>1C[,"_:^\^.!)4'L;X_5`0:J&<96\!F`?^P> M-->EU.^]U1NT2.WF2;5]F@B*H<*!A(%MI[C/EB MXP^^K?<`!>+GEN2SX#NB#P%N4@;$>]M5.R/OT=1-$$'&&LF8MG71'?,H5'MI M;R#7Z]F,>>G][/JS-X?@R1YIRNXCE`2>O?71JT.\%-?*I">-O']PC$6ZLX^WJ497>='&-L_ZF\_2"O001/F^[G^42 M#EAW+K]^UPMO;(:-FE0UUU:=L1E>1_[AVEM_D+`CTGBL&C6&YRG<%HUML]H4 MG/G^6'SG]7#%N(:NF96%J(W4@7"-\Q4(#L3N!+?>*(S76KYRU?9Z"%M3W9W= MRK+PS?/OZL)1]4MA9;4Y3B5NN;I=C'UOU&/Q;3X':MF&-A9AZ<6]<1A"2F/^ MKT$ZOZ#1[RQY@E9LF1ZX#$)/W,I!&5VU M&NX+<-RM)WPM<"/S:WF5CVJ4'R+LS:_^.X%K6\:8,3IATS0-XC9]I[`#?DL/ M-HL2_!A]L(EI&!T_M=A`H)('+C(>1(SS*\:])%B6^QERUX`RXB$.`P\F$L]` M\2*,O=^;C/B';\+TPU\F$_;R>3+YYB7]@+\O%9ZN0O;Q&[J,^8<%3:!`>:]Z M"T7\6Z;YW\O64_$#72P_1%.^%'\ZFY87SY;XDS)0ZMW]\[5"E(ER:K?`H6`>Z>^[;`->P/V*3\S?GP'8J]2&`.RN?* MWP/LL'++0^#/JS#IG*8*7(0^157,GRA.9Y6?6+CDT/6?F1]X-,Q[BO^4BR!. MF3>/XC!^62F7,73E4UKA5-R[14O"5^)J0+@UF+%@ MB<>$RK'U'U+0^Q9&&.U8E]=6:N!+% MP#(&5>0#@XUR/^*LZ,VF#^CZ;*6(3\=.<7V!+>"N>G5`G(-XD^[MZ*ERKJ2K MI8@/NU'"*99BK\+ M`V0Y.#;U>:Z0&+HT$[=BY_*[WP'G`&0%^0@CM(=K0D6,W(I%Z'WEV'W5J%1F MC@7XX8QZF#5S1G!=\)1U$<_R;T`%H>\L&`PE_'\: MQ-Z<+:K7P1A`;`"!":-VS,47LG(XN/0*9@_&E](@Q`W?4$=1X8[S),Y>YG&6 M*Q6RQZGRO-$H^$480(3BRE8BDU5:HLZ;5A+>.LZ> MYHF>YL]^_'4JQD8;@<$F*8L844,N=W:,I0#!<1]\\54>!3,Y72F:B3%1-=&Z MP9F251[RP'2++P.)PUX0^)3SEP1#`SC=&U2ST$TPQ%S\,O^RZ+;(7(7IYNB8 M\@:#1I M42YA/@Z!'8<5!9T+M#P:*=>EB^);JN'B]3IX\+Q/-:FS"$Y@$4@"?^04W\A$ M5^NZ86T`4)"(/;\,'P:(]7]Q_=>;^VOEVU]!\6"4)<2]""D;!A"A4J@G^;JK M&BFT^+7KB=('YC3W(B\_\PXZ0SO)+52XY(2*J0UT:U&4B&AW64CSEK[(>J@0 M/\`D#783)^D,IC4Q#L:O#-^;EE?66$1@JA)R\,>OJH3=J<`E>##P]C=S`3QY M)&K5!_!KL)O\2MT,0)H@H'9!9[E^T5IF^7,CT!P:@W`VGN>K*6,1Q@QP-9&< MQ7V)C]/(W'3I>J*(80Z$+'&GZ4O^KL\00TDQ-H5!_Q*)VD)\@T`0/U]@"*9R MU?[+Z=.I\N/Y^8.<2+&W6!RSSQC">"ZQ*LT'2Z<)/]WMH+=6')80=;T%ZF'F MYPF:EJ\K1,QX,\>JIKNU'[X)#YODR5HNYJ$J@83!P>U$9!!>#;;FE<&=AOEZ M@*A*-^%*5CW$_P70+13HR>/_1TBM<7RWK))+OWID$?1F&IS6 MI8RD>.\X:H.5K\?!$4^+8[]"!^#*M8.NT#R%@N:P(@8)^=,[)<&(C%%8U'IB ME1_&)=^;BU"AM%=M"ZT0615%UW;`T#KR'\%!\/P'.D&!\"-D$HY%7BA>U9@G MRE(V-JS38)UA(J?".$L'++\.I,2XS5?QY%.JV#9>,*EBHZ)!'(E">(85W?H3 M>1OPHO8L>0O%Y,3!DKF($>L.E%8*N2:6C)-NACWG)0I1U$Z=9:QUF&*RSQ+V8^LG/1Y@E]M;-Y=]YK4+8%MI\4% M;O+UH/*`0<-RI`+$2RU"U/#1F_QJ&%S;6%5]>:ZE?*[,POB-KUTG+[GP8@3. M#%.-*)US]`%T10SQBRF,>3'5U1$;T,1DNJ"QE#/4(*F&B.R+N`ME*8,@\*[>BM!U)2WD7I_//0>HXP]FDY=KQ=RL0\[3)N3T+1^R MB&:^B,E[-%X;V-Y@DKLI+999PC-,D86U)%E89,:$O61A-0-7,\`3@ZA2!'!H M7^[;J"SB["R>%5>JBW6%)P7";C=%%LRNQ`2Q1PRPLM8W<@!J;:33:73 MNLR1\OU&@6!G<;'F(>M&3']JE7,*DZ`(4E_ITG*I(A57FT;_8N]JF]O&K?7G M=J;_`9W=Z28SD$N*HEZ<[/#@P$J&KDPH#$`.12>7O,L6^XV!%$P+PX#O38$T[-R_/-KT9?D M$!:M_!L)E:M^NAY-"6$B'C_H3.:K&/E2[UD499#,9].S:T5YI[7,MCK_.]<` ML_B7-_ESF`OF+=XN!'`,,_U@DI"( ML;:],KU>YLW=NRCV2C\JS09)@"XT0X>\`>I^`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`[5QYN[M3WD,"O$NUU49= M3/)ZK$0F"$D+$&B!0T0^/)$)0M("!%I`XP($1"8(20L0:`&-"]`NNU0W4[G= M=7NIZH8[WYL%[]H,_-U$IOL'_K+8'_E,FBYM3=L?F/9>L:R6WCRY62O,+2\Q M$=<.>WT2?0CXGTKE[VL`<[1_,$?-YO*K/G>Z`S[H]DA"7L[AUP0BZ3#I,.GP M]CK+NZ3#I,.MT6%[P)V^S>W^@#2$A+A9Y"4A)B%NC1"/ MN#L8@@X[)"&[TF&$B_`;"/W-)?C#V#YRMP8/'!,\>JP?'9U?(,B[L^HULC]L M(N@UG8NKO3NL!\MO=8+("=QSH!.$CM#%-QDY;@*W%$M2X&,A,"DP*7"C"=Q2 M+$F!CX7`I,"DP(TF<$NQ)`4^%@*3`I,"(R-PRU;D#V/LN"CB88P73G;5/%K" M:9LX?!A\V]FAM0!+-!T:(M*MZV%$L2WF,A,`DO"6\3>=M2+$EXCX7`)+PDO$WD;4NQ).$]%@*3 M\)+PXN`MPI7TYCA/7UY+_SA+91SA6TI'Y&.H\3W<<;@IVW=?1_[*D/=ZB"2D M!1,.1&B2(!\?F4F029";SN'6HDF"?'QD)D$F06XZAUN+)@GR\9&9!)D$&1^' M6[=4?QB#R+EVY"*")KM9?Q&WD9O\VMX]HK0"-KY[1$YJQ&[/$&G)L4])YP- MMW:_LDYLE_3CI?1='TF<("0)/GP%D`3CYC-(L$423!+<(,J2!),$MTR">Q;I M!TEP3_L;OOVKKTC-]:UO\L[#+%;V^4AYW/K MUMX/0]]6S3J04Y8DF"2X91+? M1<&9[P,>*13N4QQ*7PIU!;QX&\;^UY_^],<__%@^_3ZZ%5$:)_?G4OEAK`"] M^8W,CR/-IL]B_+95OV?^#/R+%^^$EGY<^=CKCYO=,I2_BR(FV+"MQ] MK3]75Q\__]LD?CVO@&>]YN4YG6.L`552:5-" M/&;I1+!Q'(;Q'=32:1V(/)9$(&^7I,.'[(@D_[QHZYJ=+&\FQ7U6T:A]$89J MYOF0SS57BD:T-/W?![N=CVU!^[TOZG^U>XK@Z@:YE]Q"+/S4/ M`AL-V*1%.]!-!WZ^Z(SZP\#GA;!QS]^""$]'DXC!GK/\5)U^9C-@LB7VA6C6]0.XDH)U]',H0 M?8WM[)!3&%]XR2-G;CNQ).D]&@*3]#Z1PD/7X7T+WT&'MO$7X21C8S`%I#:, M=S*2:B("=A/'`;Y9!J+X%(WO["C6S4ZZO=IA;?A"6X_;MNX"^R0FV-C<5C1) MFH^0S"3-6]/:X>[(XB,'GPD$D9BT=W[2/",(YNW]:";4C>_]F@@ZVCZ/5N&, MM1]F($.76UU\?O>.G,+MQ)(T^&@(3!K\U-E&EP^L'N_V\*T$M8W"""<;332& M?+Q6<2B4+R)?L$0HD=SB"[V`:*K<^%Z/UMUHW6T?K@][O#^P^-!U2$W:Z(06 M$8@DR8W@,$GRH25YR*WN@-M=?),31&I2FU-:++.2#>Y^L9I`PN)L_U6<>B&; M.W@UX.+TIH`FGF%+.D.*AUIO+U@KG@U?I+-'W+)[W![@V[&,1D9:8"A!@R5) M+SU?_9F>7Y^SB M__[Q_M.'B\NK=7.)&H#>,HD2-.9%`1,E8AL#61PPMW@C8+@;(F"X%`%C9PJ# M/JD"!AM:!L$- MW^*C?H]H>WS'L5\RMSC,UJVWF0QU0FUB*_*=A^WLV5#N/&QL%X>SZ4*Y0-+;K0TYAN\^=D<.'+CZW(D=.X79B21I\-`0F M#7XBA?N\/[!A^H'O^'3;&-RRZ<=AIG@?XC1.V*V82#]LU?8IY*L4[>SI4"Y3 M-+:G0TYAV[5XW[:)O[CXVTXL28"/AL`DP$\68%M[]B;^TD0#OYWCXW@L?4&6 M#>KJ4()^[%T=<@IW>WWN(@Q@<>3\;2>6),!'0V`2X*<*<'?$NW:KYAHH^8MP MKO&R6'J'F=']'$?IKB\-QKPOH5OIH)( M3=H[5VF*782-'H^R9V#%Z:<-S6R[\?UA$T%'VPO2$IU.UQGQ8=?B?3K]@8W" M[<22-/AH"$P:_%0-=KEKN;P_'!"%CV_VT41+R2]"J5/F^7XVS4)/![H+Q"P1 MOO2T[00=BQ'-HAO?_]&:'*W)[8'6KUP^4@.=7Q.(),DDR23)+Y3D M;K_''9?,)#N39(3SDPT!U%%91]981I;"<\\#FG,6B12QO>0%$>N1+W0-[79)OP,\F[YTY_!A?\1[(WPGVM'(2`O,)VBP)$EN")E) MD@\FR1;O]FSN./BL*6ADI'YK2O[1`_K-OP7R]I%ZKBM0Y9K#U,/)3*13]OW!%ZJ(+!0TZ2Z`:'[X69C4R#DX6`)PO;HQD)-@TCM*) M8B(*(+DO8I86D>4MSG2$80ZO9-X-%/4&LF)*,8,2_`Y%3044]7M[<&+WV52& MH7[=G:<@UW[H*27'$E(<)_%T.4=5[-)89T0F$R:";A^*_3%Q51L47(?WG<3 M:P?&*H=**0&@WT'QV0RDS8#!E$ANM1\`_6S5T`19F$(R<-=)#5RH(8DS#5,< MZ?KWRNI.]?:\197Z,?PC(S]+$B@<0#6_(GZ?B4AI#$PJ-U'!A7GUZS4HPQR5 MPA^#'Z2O<34O4TPJ_?`X#L/X3IW6#X1IWRQ7G*(I6T4K]D6H8_#ZP,(U5PH] M6KFR)+36VE6+0ASUQ64->^K"2&U6\.WBS*[1\H-)-WMF/WB\T)7K1S4&KEX. M4=UO*\2[Z.7+VG@7)T8*KR:)$.R#Z>%>7"^MJX%#DIS`),7`J!B7>DA,@M&4 M>/4UF@0;!S*.45M#P4.@PL_>-(`%[%WJ\<7#Y0@<>DQ$SA)/D@^B.\TH*,! M'1[P=J[(75+DERBRMB61!.,B.,%)>H%8+QPB."Z"$YRD%XCU@L87R`A.<))> M(-8+&E\T8DFHNO?+W9NG&'>_>YN?"OO5ABV"SR3Q$;B$:?Q9B":"OL_S#Z-] M03AJ-F\=Q^*C$3Y'&8TC+0D`J2Y*T$EU\?%V..)=9TB<)=%M('D)=!+=)O)V MY';YT"%?U:2Z360O@4ZJVT3>=OL.'SA=(FT#O%/7O)B^T;/>-Y?3#^-:[_W2 M0GK%L0(Z`B/R6]CXSHZ\H.ZB_ZL;U6_UA,A)[?*!B\_5&R(9:<'\`Q&:),K' M1V82Y6U)W2$)0<;AUJ))@GQ\9"9!WI;4/7?`!T-\ZT6(A(1D&36#29;1DYED MF<;)^#B,<`E_@]=II/OAWZ^XQ$7'6S2.O%O2\5$\@%I[O#KA;+CIVNFZO-OK MD8*@&KNU%$M2XX:0F=3X,'Q&NF<>C8"0&",F+XDQB7&;Q+@WQX`)Y^Z@K MIP5G=QHEYJ$7Z^%&W9 M"+;3F$/WZ)]$,I4FUFFH(\!FVQB$]R4K6RG'H0'=LY34`^4C&K&/`7Y-HM&S M0"@&5NM5XC`;<]YF,M0)M48;#KV_J4W:L+N=>35I0U=K0V_4>FTXT`@"!@XI M9U//G\!D.EF)0M\:Q:#1Q!&-)FP:2.R&SQ_B-$[8K9A(/VS/3(-&$T"Q]0<,'DH@F#Q^U3FJU[_WX MUTQU;CQO=OHIB6_-_.DL"BY*S3N7R@]C!1R_@IIX&\;^UY_^],<__%@^ M^#Y*O>A&`G6,&4BMN9_Y``9\^2S&?_OAW.Y9MF7_!_Z,'.N'GW1F_MSIB)O? M.YV2?,$8W+Y\>J"Z<[P_>75V>7?W[_]Y8*=??ERQ;(@$4QY/\Z]722$9J5O,BY(5B^OZ50IJ<0WJ) M@!]$_HG=Z7^BV`"CP?(!#"7'4B.1Q%/F!;=>Y`O%TO@!:/4VDBV3."LK[&%5 M0HF\:9RDVD-=7@J-8N"E(L=L#I3>`&"PU%L$BIT`,H'J`E660>:%X3V3`7`' M`#&&]S6[!,:",QB^^A.6`/,`J/R%(M*(I1.9I`(^&VO66CE[G^IL>"D+A0?< M3.#?.(*7W3,HJ3),3B=PV6/^1+]`D^G;&Q8>@.+'60B%]/TL*5.(($^0T63* M@DSHW.8O4.7U0$PU8\:%W@;`>64X9!('T%3!O@K*ZN&K3]AR9Z%3V%*[B]I< MUNY$A/"#;DRQCO2STNR-LH_ZW!EV+?P,OV888H>30&*7BXS4*:B)H!. M2[D']9=Q<-"6LXZ%ST[LJJ)/0F,`E(0Z]:`]>(^T4,,H"8_(1/=\)6:F?0)H M2TU4MRUH/KI%^@9`P_#JP]#82X'7%;J2F,G(&*0W@JX_A%+![_JY$U;)>"G5 M_3>J+$.Q@>C:4\7NH:C:X"`W"AI4I+]$0GO$5/"6,+X#3@<",@T],=!"&*TW M4:>B%)CCW7HR-#H"B'Z%YR"7WKQ]&3Y#@KJ=E5*]-H?S?!2IJ`F`<,+>YRW? M]Y+D7K\W)^1Z/8!&Y`L1J!4E&6=IIKN#:I$4UX6O(`ZC#J6Q@;XBOHERC2V* MH%-5?<+.5-[&LC`MDUW4T'+O.(%6&@BM9T;/C6B:ZE\M MNQXFR2C+^S1-,Z@I=BTB,9:IRE5[D:I1J[A:?JTLE;('V_7H#*#2HG;8OM/4 MT2.2>R[\XE>;%_K[4%X-P96N.!6'H)@K#7=MM]SFS7/##9OGAMMLGGMT$^I@ M[1OVOG,+LM'4K5M[VM_[7&37;_[=-[#E1*_&@*SK%Y2V#=.ZCQIHW*:YLK:6 MI+S>"J.VL;>V05"3##5:AJI#1VH:6)K&%@;*?8T^GQ/,F\:?N\:VH?S>E_33 M`8XGU9M>2$`L_M0\"&PT8),6[5R+'&H>>)H'PJ'HACU)CXPU#[V_Z^^)ML#, MK2O>5!M3T'%[TUZO9CN60.R=!@WH^W2.8N]MOZ>]WPV?.PBVUAOVN3W`YS"P M<<0E$2#E10DZ*2]&YKK<[?;X8+A^BS@1%U>\B)VL=C]WDG&8-+X_HZ")NVD"ZP=UOT>3:V=UJ]ZW!JXO#_JDYJ\G,ZO"422 M9))DDN072;+#AW:7CT;X_.4B4I.723+"FG] MR$=\O=U>K7@V?&'.YCW;XCV$L;71J$@+3")HL"1%;@B929$/I\@#&_X?.:0B M^S.5Y!_7>29:^*YY@@L:X[)F+,/3L\)MR+LX^90E_L130GTM-^SL_)]GES]??&'O/GYFG_[Q^>?_.?L"WSZ^P^O=AAFZZ$/JXO=9Z20@ MRLRAF]*MC?',,?6B;.SY^E!][K(F=Q8`7TJ/-OD!=\YD:H[.FUV5<%E&VA,( M5$<"3RMH3>E$NU\0,WVB71__]X"R7AHG4OLZ*0[^SXHZ7N=:YX2=A>DDSFXF M*]Y7)E[NSN9:.TB9^V'12?HB,1YNUITA+[P`!,;/1/%EX;MCD?/<.4!\_6MQ MH71*,"^97&2_/.RO_0&4)=%Y[3Q^FCT&=N?/+I4)_A@7"$7PF5`C?L*^Q-/' M/#&HBG^(PN_*^A2]4.EZ@81,ETA8>Y9_U3E"H)T6"'DK?YZ8Z8,Z.?B4R#AO*9K9>KG`4'N)!#E( M2Y1>.'HQ'E[FM0@5$`(BOV4&)^UQQ`.FB-PC3B!N11@;1U[&@\3<#\5:YQNY M?Z:@N`9MPSB+J7AR*JAR(R+(N+]HU;G7$D`Y++RAS+U5:/17/%?-*V.:*=W( M0`&TGXN\]8,TR%"FIL"ZJN\DE*ZB&4L>28I$E]UQ<.;-<:R`5OC3*)*M4K!L M66H])J6;IGEEW,\QJOQD_(X4=0!EU[ZJU/)KI"EY:-:'2J!S<9&%FXZU+K/* MUVLD#^N;HP3S$1V82^X27;QELN3WZ^N`QVT<:L]07J6?4*F8%55DGC-55P!; MN&D"=,=:-XWG*N,=JF@)MS6WCR-J?9ZOV/W#KS%8R5;1#ZFIELE/EV,Z,=Q,[ M:SLS[WS:@DC(XH0B-;S8\?SZMQL@*5*B9$G6!:3ZU)F-+)%`H_'@Z48#:%@B MF4]L/Z7)MZ#R!\Q#GBIOBMKE0"^^*MN?Y"21(R`.9=*OB'T%PO9DLBH&3.`. MY%!#S91HY'0`XSW].\79M*!RW,C\9&'<'SE1)%$\X4]16QD^\V/^4:3R@@$- MCA9:%_`*1IC6SL+!)>PYBA_"$]$CFE:.OJ4@0OR`WR0Y:@3HQP$?,T&/6'LB MUZ*ADA5UWK'T99V7`@_JDS;(U3AAB]JQ\A>@$.`.LB4^G0X*F M>IC+*8B2%U+QX:^1GTD_!VV"1642/*$M@`[F%+/2WL"^ST&_D$!N7H*UG%\A M=<(L'$R+=?*+_PAV(Y#*0-Z%\B)GA%F0.&8/LM*.AJ<\S?6]>P!9DJL-7XG' MMN!G*W#0PK$L<1MFD`KX_20WH0KV^(MG)PF@T#:&,PY9B2W&D?(\W4_@-R\9 M8JG?5:1\[1/SV+W(#8;#PP$))!MARK`XS'*)3?>[N%D0=`V?@^1.02?GI6.Z M)"!M($!,MUC>PC$/L#2!81M:"WT*%!1GZLHT))B7S3)\*-SHS%=-'7QHEHX> M,T>#[%G9+YCA$(8;SL^DZ8!?,3D:4%>$:,3L;(-IP]L/L/D)0Z<2Z=-/B82* M,#&72=*FY,^GVT*=#>(L2YXVB(%]Q^Q)Z+^8@NL8/"^0RV,R-Y\^0P03NU7T MC431/KCR2;F"LQFH"GMBNA^%4RWZFXWR32I-09;(+B;M17E``?"K%82[[;RK">Z_ED[&"Y:(W#22)/X29F MOAAFTYO.[E6C[(2^8&T=4[BE/8V3W0%#TXEJ33R/^M0<#EJ,8.B0,FYYJ) M2S6%GL1S20LMM=B`U61$9ZED?2Y9HU08819%L1P;";4[,N>;&,=HI@3TPWQK MRQ`N1FM"[:N.RVUC=,6$V*?1LW-P3!R8LB-2(4"B:`N0#E$) MB8_P+:61[]O'9D\;07$GPL]J=35E#3W``Z<#T9JG(WIB3N2(]VY&"^+VDR4 M\^[-&A&]0O+J&SF1_`P.V],='FYE0H"])K'NYB.!-QB9?[S!4\%PXYFB`9Z4@;W,=4Q8Z(4(8B82Q8Y"3#JWEL_!-= M*.&MEV98ELK+WD[S!\.[WV.:^7:2^3WY/)7><[!>MOE"-N'\4%IC2!2&TCGO ME^6*W]FP.1(NA+G1K\/H",)2 M7`J.S`F_"NL'=@>&%_.^IM,JN=L(G[GY]!X[W3#$?SG0G68C5+XR52@.+IR_ M860!X3J5G#R];%P6D@U'RW<1*P$8H[^D$Y_&Q]/;6Q-SK&O]Y,I&:4QPV,6> M3.L.-EID/\7O9T<3)CCVA%U/Y.@<=_ZIO9;ICX7!,4T89HF`GV_.M'M,Y^N) MVUIR<]LD+`R#V(>YN<@M/BG1,/[Y0TY73F,C..= M#9D3I%)(YH,_;'#^+3%?`QK`Y.D8P;F/&8RJB"?A[F)'%+(_:TZ6\3R-L<&# MDTDEIG[^%@%EY"*S96`1,@%<=*E[+W(L9RQ"!M'0$7:XGP\GY_(&#_PX@`)@ MYA>`RO;J?:->_#B"2:^'.,I8&5$[F='-'S5`GL7!L:H->OU]2S_IML&$-1>_ M"L_UC)[>Z322YV;*^J'<&DREC$8GVP;9'01.,L;#7*INS"X?96V'CIR"4GD= MF-)?T@76(>8+N9L5X"LQ0H[$"`'/%U/I2\.:DGEC<\9>&=W-U^$FZ9]O#Z]TCZN.L#NR1K,4_E=N9D,I1>3TT+H!^-;%I0VOL_))=X+*I58NG?,:"Z MD<)#\..4<&&RG"+#R$=/Z>T1:00>\#J28:;$^`%]1AA7L@/V>&3[CUYFY?X= M@_AFEEY`-1U,I<"!-5C M!OR4T;&QPG^.P\3MFV]_DZC61*-^87:=-V<>?\Q/N3)UIA%MQ[/U%CZG4+)$1/8]'1HM&I M!)X'\@0A"YYR3E01:$*<2,@3@C:E*B>OB7#^7'R(RI+(8DZUOH=`"$[R$.]K2=.@IL&\:33`1@`3\&5$9>^-+9.YI(Y@#-P M:62-V24*'O"M%CK?TM6H82!V6.2J:YC'VA)1";D+8T4;F,)XOY'"U#;@!P<_ M?$#W\-?DW@M1KI-9@7Y60_&=*V%]/R?65WB9^9']$7'P(6EN>9$3D_0^1;;T M3X-`3M0#X066W0,R==D$XDGP'J(OV7L3.L#PR7!,KM]A$?B..--.5C6+QR$$ MI15]BI1L%EB!O-.W:MA@8I7L9'UA@!TAK_WHTH&1\ASE[:'$52IU@Z;N:\.(\!W[ML_)NFF(F]K.KC]=:'>G_^]"D6C6.1_P0$["1=@\ M8M_2>T408:[#^NGF%+2_(\Y"L8TM%BLIW&/2N,!;LDOSJ[=B[X=DHL9>*S`,#'?B"L@0-&+N!B\HZ5YLOLRY#8@P@<(%YY%(F5=S04TCCB MH+?39BUHCUAORUWD!4^Z[%'@6;8EC;\EX2=<2X19;7+U43I-%7=(220G_D-R MDP^J1O@,:-SJLXSS!2]&8KRCG:W<]Q;[&@C%G"I,95-++P^($>LRX@I:N)?)[<$^EZR;2-3?F%5 M->N&!)6X9%8E8'_+$S&`L+]J`W3A<*"5"4*$*N.H.2"OP$_Q9;8:H-)72:-%8TI MM$*!W2*I:4YX,H4:=-G,LKOL:^E`YU`ED8E;O*3M@&X&ASO,XTHR[]O-DEZQ MB'U?3]5:<#U5:Y7KJ79V3;1Z>8JW>C?`G)OAE5!KW;1JMI50*XA1T:S:%Q,6 ME=,47[0:'L$0RG1E^J\W\%O>Z:[B*$JP%"[A7MEN>H._+L;\.]48*@- M9>4L1_LNSO=NJ'.R&V*4(IZ5N$6=D[TJND.KL4B%D(NZJCM];"]3V>;H8X4T MRHK3Q[[S[=6)/I1'[B'0A_(<#O2Q0MY9Q>F#O`_R/FI%'\ISN#@[S/"\=VU( MA'R0`_)!&L^3B/Q8E@QJBP&;S6RX%2O88J<^+@H7UH[%.KI8*$^W'*;+@F\W MO^"WQ;4\TUBPF"=^7'HUKY`W;8/)FE<+,58T=$O*F]Z&N;E+J!,CEVL2Z(?+]'-Y+4_@JA]>%RGP.L=L[O%=) MJ[;VVJ82ZM^+@[:$H=NT5I\S>8J#VNSIC57RN1P>C]1@IJ&0-HF5#P_,Q,JK M@OIUJ]O0VV:#F.3E4/Z!E$AT3'1,=+P^J-M=O=L^(1Y1#,BUU2:Q\N&!F5AY M92?9U,U&3V\;*^23/#PN>9F;K&"\OOF":/V>UD3<-!60'XF+%+.KC_":.R_D MVNL^]_C`B60GO.2XQO8PO4#OM%R]AG5L'#>0R&T_[KM\R_:QUDO7FU=GQ9>Q M%8WI*T,@-9BL**-+(N.*@)G(F$+Y:E)(=0/YRJB06+@B&"86I@B^B@1"+K'" MX"4R)C*N$QDK'+A7AD0V%K:7']/;1%8L'>_T./-'8^8]:4,6:AZ/-'_,`Q:! M[)KKAZ%FL2!X&OC!(POL4%S[\?GF3`2WQW$`Y?`0+_Q@XW'@?W-&+.+ND_:] M:1R;'6WDN"[>%<*B8AIK#1.=Z?C:X]"QAM,O=XY/FI-W/5O[OGG<;&I.J+$' MYKCBZH_(A]<'(8@[B"/H%Q1(_)`&WX?0:?=#K.E$E`$?>KH6\'#,KE=+264P".%W?+F?2L?MXUS3LT$HMB-1/^E[9!UE+8"A;3YF'LV-B,> MPX,HPCWW!.[D>^6]:L=!JB\`J>,#(!TO`5$T!"QJMC.`"KEG`2S[7+[$[1BZ M'(N!1J,<$UQK&;`9U!9'SOQ6EJH>1M!&?N]P M(?F(?97M06P+.&#YI=6_9R'4(K3%O-S#:0^Z'#"-?T!9D1\X%G/+A$D$!BW+ ML5PNMO\`<,IKV9]HN1PLJ+ZBHBT0LS_1:0&[?>XZ(&^80!9!EB%V0D@"@`GR M\F!-UM+"1>!EXM=9UA%*..=6\JTIOFW.@W7`04=<+TB%-"FN0<+L_*A"AH8L MELAE>.41`_1I[)XY7@C-B$2`4&Z[SMZJVWH)ZV.9+F6WC/;>J]CK"B]0K0V M;4^8&_H(JE@T_X$!FF)HFZ`K<6V4#H-I-`X/`&H+`@#74G:@Y/-9.0;[8&S/' MUM@(K'N"8.AO5P[GA)3ZS!6]&0YY@BIF64&^_O3WOWWW+GWP`W."7[%YGSC#IW"(7'KC M.`I+WL3VHC-VPP?_>G5NM@S3,/\'__2:QJN?4(Q_'!WQ^V]'1ZEOL,8R]M7U MW85FFIH`Q/^9;>-'[[R[S+&XM(2/?NS:TJY9'$9-,I`EKT;(7@(:X&2( M#(8P>F&4NTYJG5_#D_P;<)?3(N9>6,69@Q+$J!&X"U=$$/)H- M-N98N_/3+[5!IB$=6C)TP-+"N)!CM(\%\Q!=2`=P;B=,'_`_8R<0XT:#,E$^ MT,>(@9^&?(Q5QF!P8:CZ_9`'#XG]0-B*H39RO)DG8V_F61`3K=]$I!@]RDC< MJ21LFJ#"I-QHTB)QP]RDW]$%39@?ZDY5BF:6A#11-/22#KHJ0B+FI)WD*_B."FWD2_W>D8I">NA2Y;*`7AQ8YPF:'\6 MQ,!*0]">RX+R*O6I%T!N%\FR*+R.;\EJ9_M(#(3$2%M^$/@PC6%89/\I_W2" M.$`42]O9S+?SRVR7`NF.TZ&SG%8C;@T]Y\\8OP:$/'(7.[<@`E]YD$"HU?E1V%1P M=82A!5=0NH5#W[7#N=.-)?2M MTJL?V074JR8]WX6ZRR^MKK2^"<>DUQUM]-[@C0B%*^M;Y91A&BIT`4BWQ3[8 MYD4)(D`@0BQ:+L8"/F*D\'[\:H^4[:>)VK!+N,X5%N04;ENW50"S@F[A"Q1. MCB%AF31;+^=P1[=H5=U-O.%B=X1WKYWC5H8O&&A6V$&L^G@A%W%O#`4?8OQP MSD,K<,:X'"'T'6>:)\A7T$2L[UONU$)LU\?P((643'=6,CAHT0BH[0DC91$XA?G.)#*4;U^9N%A\HJ) MC:N-8&)C8N.ZL#%YQ0>Y#[=9Z5VXXI(@Y8"[KDZWNOI4$^.W5FI8Y3I#S8#] M[G1;'L]7%>FJ3E24Y)D:3%F4U"OQMT*=H>149F>JW:KK=P`3&R7YA7B[(G@F MWB;>/@3>)J^;V'OO>B7V5J@SB+VK@W/RN@]\86%=F*NQL*!R!KA*<[/"#@CI M=94E@UTHMEK+!`3M*D";]$IZK9!>U7#*JC7W(&!7`-BD5])KE?1*1$Q$7$M@ MDUY)KU72*Q$Q$7%%@$UA^:WIF\+RZC(TZ97"\F3["-JD5Q439-+%B+*==#%B MY4=*Y;SORM]ZH[#_7?6LKV1.*Z#7S7K@+X`L^>#[[X/ZP9LT6PD_G.Z@I#LH MU1LOY(WOC:%1LNDVIIF^ MJ/AM3'17975'""F;Z*AF=$1W559WA)"RB8YJ1D&CV% MF(-X6&GL$@\3#]>%A\DK)C:N-H*)C8F-Z\+&Y!4?Y'Y=NJMR\\!5,BMZ38P? MW;JPO8`]W559K8F*DCQ3@RF+DGHE_E:H,Y2Q='9R3U[VGA07YD0$8\:]W;^+PZ)ZQ\5M,I2@R M*>82*5YZXS@*SYW0W=]]I]?KC^>7]SUB_]^N;S[76A@ZK#$!M3]DD0B#G[X M'/`!#P)N:\RSM3-_-/(]32A75.)D$O=E=2C#_YEMXT?M;LBU"):$VJ]-KA,!OZ7?@E/6K*F$&L259<]-,Z$$\\=BSJG MOM1&[$GK^RRPL3GG3L"MR`_"8[4P<)MU@OQT+?+*A,\!X-K3KOP' MF2W#;(AL&8:^O!(T9OMC4+XN:@8L9*DW&EEA3A3*7DY&NL;&XP#JM.=5@Z]I MEQX>'7,>N/;999[V&I]-'^K^B-^E?YW\^(.N/0X=`,D]@^=SI8K/K.^X0"V` M<^T>2#E*(.>/$RP!3J/`L:(4C'H*:!"36X[`2P(JT`O<+8C:!N^`EP".,KY""R#_AV70`^#"2^U.NH_'S[ MX.X*9H5O&W`LE./DW_,Q!R:Y@ MPJ@@8ZKI:7%K:I&^P)TXX\<"W#QX`2^AVZ35D;7V:M'VN3+6QCMR`@.C&HQM*>8 M0=8,0P_8*K5X`"6HTX[%*`0;*Z!P@CET+-PJ9;H@*$9R(A#)A$I"_` MJ3A0T*H+[C@=@3-@,4%JB')1O.-9;FQS$!Z&U[WFH_RAM%QC'_@>Z]4UGBH9 M973Y/0B?4[<4?>""1N*D+8D,J`AH4<*>UA,,,6O(`-\:R,HEO4YI&N`.)!U* M+LBI/7%MF/T``J*3P08#+KH`O`U9:%9M)KG4J9]JVW8*TF6=5BSA'HQJ(!H& M;V%15N9"@7#CI!-=]BC;'?#[V$T=*H32D>,-Y!-)&TIN'WS(E@"38"*0< M60"X4_(<*^L'/DN\@$#T&WX:<;!TTL!$[)LHN=!?T!CH]\1:Q=Z`/?@!SB\* MC7+]/C1GQ*S`SWISP*1U1-TR-_1GM#O/M9CTRU[=MTM0H"T[55\P>`/^P+T8 MW6+P5;'E'BL.W?3!K(>@G!ONP8-]1WM]\^E]YAF-XC!"&,HNE*4`&&0W)*\C M6OJ2`W)="\8Y%0]J/`8G$/"$?^70@-5^>B^+G!HZ3H(%?"-?ZJ#T00$C>`YL M#T@A'47FYNK/@;S4@LVW1063!8^@>RFQ<`.$LM=)9VO*>)U=7-W=G-Y=7E\I M8KU.R[P3<&7!N;$`6."]!GBJW8^%HX$>IMDY[OQ3S";EUPAFBSL/.+SS3EWV M":J82=L'=/[H9S6$TU6TCMO_%-@RS>/&_,KVJ+2N M@2^F,KGXU62/*HSYB,]M";ZYHG30%9X_3[B1]!K`\S6-*2&KH'@!(=G&<1R` MZ0EY:L7AY3`>CUUGILU-\_CDG\F;"=(#]@@&*0)?!VEZ8RKI/FU7* MA/:6X;-BZ`W\1V!9>.?B`3VA/;!>.\]ZMU_>WU[\]PL0GW;Q*_RO(L1WF0N/ MI#.RS#F6))/$,4;,B]$MD7,_"VRLC#WQR>3P[,/YJ9RCB>FA/\])\?CC5''P M2<0PT%,"9R!?.O>0Y<)BU,,7TW8,CVE@0='C1RN=^`U8?%H@?H?`#FQAE86O MF#[SL^_;VJ>"')\#^.C`@V*Z+H('4/XH=N]9XM!F[>3"#\/XS2<&0T&3E&YN M:P#,Q7,!]5<,&L*O!]<3]WP'<,^F?-?!/ M@<_,M,]#%HR8]@O,U=&%UC%>=@R^I';%'YC-H%G!V`\2E]M_A&)-0Y+SM0<( MN037+8S$E/,C!D6A\UY/HFOX2"&ZQK3W&$P(A]JO#C98NPQ=D#\L5@,F(!(@ MBP.O6.H(%/R M[I18N?HU7VJW$.D0DYW4>^3^V.6IRWS#QW$?IDCXJU3I=(@1W>NLLF-M@=Y% M7T['X,1\.PMSPY#$"38.-SE6)Q5-,<#)CWNUG#@5^Y!XYCF47'IVC!$\Z+4S M!O-+_S[F&:ZGJA7?36ES\M)$I]H?OB,BDTD4+:4/5'2>#S\YG@-UB]D-+F[P M`&>P<#Z8R$M_GB#,YF1>`'*1X"\3E2/03*8#:63%T=^^\29 MX/A&^H.>X[!_`PWBI#CQ&1H_:);+H-2!(Q8>`L>/<;8J=<3#-_TX!,\C#,4< M5C!]P+EF.P.Q:A%I2-WW/C[Z5GOM_``L#LY%P.X3[R*=&CE9!_P(C\%SN3!J M;JJ5?PR;#H_"L\#,0Z`F5E:B2%`W#AQHUQ1F/UQ>Y-$:#G&FCGH9ILL,CT/? MY1C1'[$_0!.1T)%8"I`!=@?+AHI"(;=49":#:(KF2'*"NC1X$&PYL"RH:>)3 M-PVM'X!U'F+@/$AFTS8."*.C=A(HPD6&@7@5&R??3N,!3A*@ MPWD\N*DS`8C)Z$O[;J^LE%J.B5N4AIA8\)6#?F&VCT%"&15#'8"VI^"0>$)B MZ>^10U?"OWW'MX9\5/P=P`#%.JYPI$"+8P>X*UG["6!6&2&O1\QQ<4X*/H:, MN!E/'LL M#3VS1"C%SDPQ/C0IT)D89<$1)<+)P8Y<"E6(!9UT'0\M.7O2&FWD1*.-Z,8Y MR).D/("N7$+0[G`K!!"?=GH?<+$](+>N*XL?LT"L54P5*54HME(P.=)Q+21; M/YPLUZ)-0-OT'H#!XIS+\1F>=$3`R=/^'<-\3BYR@K38G6G;"Y[\62:"UQ'1.PG4H!'X,V0A8DCUE?D,&`'!(Q$H.?W!L MC(EA5!Q^_^W#]87V^C=0/(`RK>):4,I$@A_$0G@<9DUMF(D6]^U/I&-@R+(% M39@"Q5RLG"8(%4/R2*9&Y!@ZME,3`-,+)I^T[72IU79$O%?#*X,&ONOXV!F_ M@<9Y(#UK="+05(ER\&-IM'!V/C`=)13GM\5/GS&@_K33>7+F8!4$$>U[ST)' M>+:?@04PXB]^*5T^*N[VP-F>Z`TQK\0Q(@:.V$,AUT2$=>MS[B'#X`XFNVR6 MF(1#L!1`'Q0RQEFHH&&YX)/VY#.K.GD?_\OQ[;'V\^GIY[S9%:NC@`_^#0DO ME"462[-A7+`@64G)C&QVT5V`\%&,QR-I MVHO+[Z=@7O)+8L(1L%)3P%S48Q(7GY!;7O4<]ZIDX7XKW_\J&.*\@1C$GI7X MX-DZ1.)3IZ,P79,X+C,PZ2H':B-9R9:3)Z$:EV6+%:6=CBOGHN^`$,!_+B[4 M"A7P!`2?^ZCMP8XLS6EA19+(IE..">G7X,LDO+TAI^!KLC-QOY M819(3,O&!\LT6`9,E"D!9SH`8Z1"%#!9M@$\@34&A>$4!9[U1SSGWS'Q@.\) MMWE0V((SJ3SQ5%.YA6*DX(#D4'!$UH`4I5-K42RW_)2LZK%D%;4$&9D.([$G M1X0,4%;T`)[2H%C>XD_K0:I=KK5"8:4K>H7`Z%P*+W#]9^B^X+/HQ!N>3N[D MWK%3^X]8VO+H4%&8]@@N M0N/(M(N4FN&UV!72RK-PJ`VR/4>B7X6SAS\NL^8@XYB>F,8G8HSSUFZM4EO9 M-H*9I@Z9C:L<')U$VYE(VD2FE?V;V&.Q+8S&G&XL95ZQSROS?<9Q$,9H MPQ,(!K'+9S90I+16-%&WDTU8^/Q%:D_R,:F96&#R2S'VF`Q/1PR&B1>(Z<,Q M%I#MM_+P9W2_\HQ9VLA%OEWFA^4K`"2$:;YK8Z@+9INI@_9'8NPFBRC/%Y0&,44:>+D%"R?%4(R\+Q5IZ@,2I&D<_2P2>,DT-.1K\D'`!RY:!`S_L8Q40^VUV`<7"J_.]USAV\@!B,8% M'![\(??"#\+=T=-N]<>.EVR>F4!?%VCVH-/"$`/.`(<$N=J`.8'[M`A9T%@G MXX8Y%JDX_(K^<3@9) M")JZ9V[\]/;_#J3UN%G4SY%K"%,B5G72I'P/OF;9*`5J$6P&)%RSP M<&D1G+I;C+;N,^Z$42894S]WW!B5A_OK4!?9*2,4<7FTR@+=M)#T<($H!#"3?2,*]CQS/8G#[*)WR3XXNY(^847;\-+V]"WXLGN5<-I?C1LZRKGZ&6*4CK-JD%\6G9<\&'Z[J9H-&91OO M5E)F\7:\3EU5O,V;\-+MJWS`9!U2!?PCNID^B#Z(/POE"="CAT MR^A1G3MH%'#B*J&PK3-O8WO,NT\%;Y-M<=%8)7H]5""3"HD+%."")@%Y_T`F M%1(7*,`%Y!;'3U;J-%%/)R#/]` M2B0>)AXF'EZ=AQMZTVCH1M,D"B$>KA9VB8>)AVO#PV97;W9,W>QTB4.(B*L% M7B)B(N+:$'%/;W=/@(?5NZM;(0IY&0\K&(1?`.AG0_#[6?N0:0UF$A/,/=:O M')Q?0,C;6]6KI#VLHM(W="YNX^9P,[I\S@@J#N!6$XP@&,*V>I.1PP9P375) M#'PH`"8&)@:N-(!KJDMBX$,!,#$P,7"E`5Q371(#'PJ`B8&)@14#<,TB\OM9 M[+A(+O$83)+LAMEM#&_KA.']Z+>>!JT&NE3&H"F^MDP`5A3`I$O2I8JZ)&(E M8JTT@$F7I$L5=4G$2L1::0"3+DF7*NJ2B)6(53$`URRVOHN@574SBD.X"/"K5*XK:DNB7@/!*M(FYKJDLBWD,!,!$O$:\:N%4PDEZ=Y.G%6/KU.')\3[U0ND(YABIO MX0XC3=FN;1WE*U/?.H.*@53GNF$)<<^L1%<1`3,RL/9F)F8N;:@+FVVB1F/CPP$S,3,]<&S+75 M)C'SX8&9F)F866$P*QCU;U9D>_[D<7FQJNN'H3;F@0SQ*X?=!6JE)>\UK&#C MN(&$;?MQW^5;MH,'<)WX)M59\=7NU\:QV2;^>"E\RV\2)Q42!>^_`XB"U<8S M4+!!%$P47"'($@43!=>,@EL&\0=1<'4@2Q1,%%PS"FXTB#^V0\$UB[SO=[=] M?6/OBB_6U=_D[0?8M35YBN.Y=K'W_<"W5K,.Q2%+%$P47#,*KE?LG2A8,142 M!5<$PT3!%'M7D#^(@M6#+%$P47#-*+A>L7>5*#@7>Y!MC=++2.?=FS@\ MNF=L_/:"!1ZT(?S,@UL,2W_V7<=ZN@,4O'=]Z^M/?__;=^_29V^M(;=CEU\/ MIM\2F\M//3L)==^AJ%D9FN5["*L;/OC7JW.S99B&^3_XI]/*+..2VYGCB.8NY5NQFK_;%QGGQ1A+(?XV1_!\TGBAA$M-_ M.]'P!CI)CB'1)@F_9+08R6"QN.N&8V:!#"6_)."<^J4PZ@RC;-PE(P5_+`)Z MV<6?C0SBXL`\LGS7#]Y&`?.@Q0'T[.P(+QG8.Q['DT[4UB3%PU4=/-TO&0C] M3(6K*Q,:#BU.?^K45<7Y]EM0-P\6FW7YS'*]\<$/!"7>#0/.M4_`X\/PQ?U2 MNQ[8)\A)F<08*C+&E>,182AZ+G:#QXRKJ]&]NF@559X"E+MV'@)5E+U-\KWP M;)B>WO)QQ$=]F)0V#5T-\B6\DSJ)/H@^".\+U:F`0[>,'O<=+U?*B:N$PK;. MO(WM,>\^%;Q-MFT89DLE>CU4(),*B0L4X((F`7G_0"85$A;1"$'E&IV`:`5334K M+WE[Y%@XMX_8`P_8/=*X,A6^?54;I M&SH7MW%SN!E=5CS9B\)7GAXV@&NJ2V+@0P$P,3`Q<*4!7%-=$@,?"H")@8F! M*PW@FNJ2&/A0`$P,3`RL&(!K%I'?SV+'Q6#`K0CSR(KLL_]31H-="E,@9-\;5E`K"B`"9=DBY5U"41*Q%KI0%,NB1=JJA+(E8B MUDH#F'1)NE11ET2L1*R*`;AFL>U=KA]HO;R>?V-!P+Q(O:0ORJS&$$U4=PFL MHG9.<0`?$6Z5PFU-=4G$>R@`)N(EXJTB;FNJ2R+>0P$P$2\1;Q5Q6U-=$O$> M"H")>(EXU<"M@I'TZB1/+\;2K\>1XWOJA=(5RC%4>0MW&&G*=FWK*%^9XE9/ M(0JIP81#(6T2(1\>F(F0B9"KCN'::I,(^?#`3(1,A%QU#-=6FT3(AP=F(F0B M9/4P7+M0_7X61,XQD0NWJYQF_4785GS)K^[F43`3,Q,SUP;,M=4F,?/A@9F8F9BY-F"NK3:)F0\/S,3,Q,P*@UG! MJ'^S(MOS)X_+BU5=/PRU,0]DB%\Y["Y0*RUYKV$%&\<-)&S;C_LNW[(=/(#K MQ#>ISHJO=K\VCLTV\<=+X5M^DSBID"AX_QU`%*PVGH&"#:)@HN`*098HF"BX M9A3<,H@_B(*K`UFB8*+@FE%PHT'\L1T*KEGD?;^[[>L;>U=\L:[^)F\_P*ZM MR5,\'OK6:=2@.6:)@HN":47"]8N]$P8JID"BX(A@F"J;8NX+\012L M'F2)@HF":T;!]8J]JT3!N=B[_,@`;_C7NS=Q>'3/V/CMK37D=NSRZ\$%"SP0 M)?S,@UN,+HO=WJ>>G<2>[_#=.^C:]ZYO??WI[W_[[MUL&9?>`_HG%/`?1T?\_MO142KP\NW/*L8Z M0B?$8+D_T*(AUP:^Z_J/T+*W9=RY@6,&H@C;>2@,#@O$X8'\/$$SJD.30$B> M,Q+86MQUPS&S0,Z27Q*83/V2Q_^)438`)&3QMR*PUEF$Z9;6L/80*PZ;(\MW M_>!M%#`/M(#0F3?^0(RR`;CC\3;!@:8<>:VKV7)FV[5BX>E^R4CK9PI^H:J; MJ:Y!+Z"0](6&$CW0W&87S*.G><9;/K-<;]WR<<1'?1YH34/?;(?1V-C9V"!5 M$PU5FH;.N96PD$DLI,S0V,06H`U[G_*$,_F?VT#W^KJM*+YW1?UK)U`X+"/0 M,,R6PN1/PX.4K8RRB8NVSD5-&A[J#`\%7=$%:SMS?,U]+S;*[_V6T6E[W*]U]SLL91%.MSML92-(]?LZ>VNJ;?,'B%7J;1]-=4E M4:_"`";JW25R&R=ZH]W3NX9Z:28KA]P=))E4:'*QGU/$O_G!5\WQM''@6SRL MU?1"\6/P];1Q2EY"5UECISB$U;M`\<"16T]=$O4>#(")>I>$\$F[J7<,];;R MUPV_"DXR%EX7H.@:Q@?'<\(AM[5[W[?5FV4H=`-#Y8T=W>:R%;.W<;56/-#6 MTDT336"'R$0U--=5FT3-!PAFHN:58=W4VSU#[S756P)1B$SJ.S^IWB*(RMO[ ME9E05][Z55'IRMH\BL*)U7Z8@9RT=:.A7F:Y`X=P/75)''PP`"8.7G:VT="[ M1DMOM-2+!-4-P@I.-JJX&'+=#WV7AQ;W+*X%/.3!@WJ7"R@T5:Z\U:.X&\7= M=I'[IAMG2SJ]Z.965HI`8+)40F9XVH.I-%;'W6R7:"VZ5:-.M$EL;M6IN^SN@1($KJIK2N4_3 MTR:R9]*M$G48&Z1JHJ%*TQ#=*J'BT%!PE85NE:!4U96C?LKD3K=*U']XD+*) MB^K$172KA$+#0T%7=,$ZD:*'$#[S8.1$&)AW,6@?A^H=07C!8J;BVP(57L)7 M1NFJK2!O2(<5W]#::G?U;DN]`P:5@RU1`/&NDDHGWE41N:V.H?!1$L$UFVCL:1$##SOHVHA90\?CP=3Y@SIA M6/'P1#U-GY(1BLJ:/L4A;';T9J^IG[352]5QX!"NIRZ)@P\&P,3!2T*XHW>Z M)DP_U#N27#<$UVSZL9\IWB<_\@/M@0\=RZW5]BG%HQ3UM'1*ABDJ:^D4A[#9 M-O2.:1)^U<)O/75)!'PP`"8"7IJ`3?IK3U5J^K=PSU9BH*L4E] MYRI561?1>O-OKA-J53-/FS*S[ MNB0./A@`$P+./*JZ4?.1A^%9CEA6/8I?A17K--RR1;HV0%YR<++B57:G6D9&6D<#UW=C&XKGD\4GB]Y`6WP"L>Z-B/ M86P<-Y#";3_NNWS+IK'>*>FWH,^JA^Z:^DFGI[=ZZIUH5X9&:K!\HHPNB9(K M`F:BY+U1LJ$W6J;>;*JWFJ(,C6Q^-45^9`"_["_;><#/[][$X=$]8^.WJ3LN MLM>>>G;FD=]!_[YW?>OK3W__VW?O!H[[]O2&6[YG.:Y<4;@>B$U.EWAW)0^C M,S^,+CTK#@)NW_GIMQ??QMP+>5:8!B4@@HE?AE>EE1M:=:4&@BWD@882,U)VD/R`__XR3MA!\GOW#95(V% MHI1[S_D+GG`\+1IR;+8(5XAUF3""?U#'6#ZJ7U06:DZ(+P]\U_4?P[=KMV*N M(@04-`G.9"P9R5"RN(O7M5H`T))?$NA._5(8DT;I!#<91_AC$>[+SJ$WMF"Z MVI6D)<-^;Z-<6Y,R#U=U::AA@W<<%V\S[M15Q?GV;_KFX@]^(*CP;AAPKGT" M.S`,7]POM>N!?8*$<;N,;[NNL<&5X\JIV0UO+:**D\!%EY[ M?5D596^3CR\\&V:OMWP,L]<^#[2FH:O!QX1W4B?1!]$'X9T<.G+HU%'>UAFY M08S\$D9N&&:+*%@M@),ZB2\4YHLF`5PM@),ZB2\4Y@OR+Q0#.*F3^$)AOB#_ MHA(AH?S>K_;.DHJT=[L-=EFUWRW8(K@FB`\@>TCEM\U74>F[W"K?VY4*>]7& M;;-IZ+V>>CD5*@=:(@!B72653JRK'FY/>GJC>4*8)=*M('A)Z42Z5<1MK]W0 M3YJ4UIA8MXKH):43ZU81MXU.4^\V&P3:"B0RWG`P?6$2MF?#Z?O)PG99"*1; M;.Q$H+J_%(RE*Y3BKO+&CA)F;L/^;5JKSUE"Q4'=UKMM];*"*40C-9A_**1- M(N7#`S.1\JJ@/B(*40S#M=4F$?+A@9D(>550M]I=O7NB7KQ((2(A6E8:P43+ MRH.9:)G\9/4PK&`(?T&"8D7WPU].I<15#K?*Y'RNB>&CU/$;M7B;5&?%EZZ; MC;;>:+6(093RW6JJ2V+CBH"9V'@_>%9TS[PR!$)DK#!XB8R)C.M$QJU>6S?: MY!H3&U<1O<3&Q,9U8F-5]]@KPR";#]#+C^GU=ANHYMV;35USE]V9]R7D@]C] MZ#SP$`H:\M,PY%%XAT+OXDZ\$4--H'.,5=/`G@U("AGUXY.(% M*WT6PA/^`Y>7KD"KG)&XKBX6;=!<;(2X$6^(E]QA.[9[79WM/,S--C495MN[ MTZZ]X$J[]BHWVL&0*"F^V=SB"NAJF:MDFT"@,D+8`N-N*&^8&$S+,VYY-VP^ M>=4ZNB]?R-L;]6HOU:JI&KC-JH%[TAD?G0'7CK0GSH+PI8O6ZU/1BH-@-8[9 MM]/QF0.BP75AAOVO06K3MRPO,%[W7AC'(FS@@;\(D1V([>/[D1WZ@/?"A8[GUF6F0-W%`WD0; MG(D#X(?]V+OKP<"Q.+D/1!%5=A^:1^4YS>1GMDH?9] MLV'J!DS:\-GO&Z:AFR>-XYSPV:>T:@]7\391<[?1TMM&3];<:1EZNVT<3R^3 M+K.RF2V#7GH1\^X=^$T^]HG;CL5YB0?14K&#.TR/LY\,-0LU@0 M/$%Q&AN!+"LLCNYPDK42>"MSR%'AD]+**'V7!W7-G2WLF[M=V=_"Q1^MDXYN M=M5+7E,YX!()$/,JJ71B7A61V];;C9;>/2G?"T3`52MW\5:BW>M.,O:SH?C4 MLF+.P?MW2C6Y; M[_34NP)=(399%LX_D!*)DHF2B9)?1,E-_<1LZ+V>>KG;%&*3EU&R@C.3!7GQ M%%W\N.*1\DL?RF0;K(GUHWREFS5[&]5GQ0-SIMXR#;VEX#V/RK!(#99$E-$E M,7)%P$R,O#]&[IKP7Z])++*[I1+Y-!]FLB$[45:Q+YI+GO4'$^<1?]\L'QW7U?I<"^/^ M']R"UWSQE#P>C1,;H;QQX(00 MMT*]_;1[R`>BAEKKIE6SK81:08R*[OZ^F+"H-`VR2S:R/7E]@J&M^TMUWN^< M!<]T%S%4!1AJMW"O+%>!UZK=@'^G`D-M:/=8Y5-W92<9E2*>E;A%G1FHBN[0 M:BQ2(>2BKNI.'\HG!P7Z6&&[K^+TL>]](76B#^61>PCTH3R'`WVLL#]2!S_8Q^HA#%)MG,J`J9)SRWT\GV4YN7`V6R'<0@KE+2[KF<:"=3WQX](+ M>X6E_KTE8:EH%)>4M[V\3L4,3AU5XN(5C8:+^P,^R2S^%[-9_%_<6P3^C8*? MU$E9;*&W*Q7VJHW;(X)KC1/=**-+XEN%`4Q\2WQ;(;C2T">^ M55+IQ+?JX9;XEOBVBK@EI1/?5A&WQ+<[3-.H2H!\84[^9T/D^SG'=\X'/`BX MK1Q>%;K@H/)6C:Y+V8:AV[16GS-YBH/:[.F-55*['!Z/U&"FH9`VB94/#\S$ MRJN"^G6KV]#;IGH7>2C$),M"F>X4)#HF.B8Z?LF-YUV]VSXA'E$,R+75)K'R MX8&96'EE)]G4S49/;QMT]?;6W&0%X_4+;JY2=$,[/BU3`?D1<_.W(/%O8^Z% M7'O=YQX?.)'LA)<)C!4.W"M# M(AL+V\N/Z<4B\C*1I:X*R2X6.0U#'H4?F!/\RMQ8/G:QBQM%CG/$EWW":T;. M_-&8>4_:D+MV\2X1C0EAM8!;J'5;8Y$V`,D13#&'7_'VD4+.;`VSJFG,L[5S M;B7?FN+;YMNY]XLFU`GI-5]8WF(*R<%U@JYPR3$.%+@#IMM@'V\Q,B04;ENW50"S@F[A"Q1. MCB%AF31;+^=P1VG+J^XFWO"Q'T08UCMG$=>^A/!180>QZN.%7,2],11\B/'# M.0^MP!E'CN\)?<>9Y@GR%301Z_N6.[40V_4QMVDA9I=R:+!4=K"0LG>H;*,: MS&14E9D^\@?N:B:-D,J.$%(VT5'-Z*A!(Z2R(X243714,SIZ^>V$-$*4NKMP M*_&]U4)X^]Z0^YYY7V&DB+]#C5D6'T?,L[CF^1$/%86Y$EN>:W)N8G=9CZI[ M:L)<(B7,QK6YV^0PF\_J8'9TH]4E!CF`-7?:F+\ULK%HUQGJ!FPWYUNR^/YJB)=U8F*DCQ3@RF+DGHE_E:H,Y2< MRNQ,M5MU_0Y@8J,DOQ!O5P3/Q-O$VX?`V^1U$WOO7:_$W@IU!K%W=7!.7O>! M+RRL"W,U%A94S@!7:6Y6V`$AO:ZR9+`+Q59KF8"@705HDUY)KQ72JQI.6;7F M'@3L"@";]$IZK9)>B8B)B&L);-(KZ;5*>B4B)B*N"+`I++\U?5-87EV&)KU2 M6)YL'T&;]*IB@DRZ&%&VDRY&K/Q(J9SW7?E;;Q3VOZN>]97,:07TNED/_`60 M)1]\_WU0/WB39BOAA],=E'0'I7KCA;SQO3&42W=0JNW_;-F6T&656S8EY]Q* M[JHTQ5V5=/U)9?TN4C;=QC33%Q6_C8GNJJSN""%E$QW5C([HKLKJCA!2-M%1 MS>B()FL*C1!EXX"KA?KVG6F<[JI4)[A'MT`HFL2)[JI<'+C2H"9;N79!Y;52Z.G$',0#RN-7>)AXN&Z\#!YQ<3&U48PL3&Q<5W8 MF+SB@]RO2W=5;AZX2F9%KXGQHUL7MA>PI[LJJS5149)G:C!E45*OQ-\*=8:2 M4QFZ-:AB&/0DRF*'(IAG?P\\4==.=[U[>^_O3WOWWW#A]S[.!_ MYTYHN3YF6KR\^O7BZN[ZYG?-\CWL^QL^^->K<[-EF(;Y/_BGUS1>_835_>/H MB-]_.SI*JU_CJ,/5]=V%UM!$,__/;!L_:A^O;V\O;K4/-]>?M*O3NR\WIQ^U M\\O;T]N[BQO1QJGC$!M0Z(I%7'O:OV/W23-/1/J"EJY%0ZZ=^:,Q\YZ2EK0Z M/X;:B'GQ@%E1'``4-/CDN$[D\%!CGJTYW@.`SP^>M#`.(^9XW`8)_&"DV6S$ M[KDV"/R1QK2Q_\B#0>QJ4>"/'8O!AZ?QT/<]J)5%VM")M%^8\]6/M?0KFT7\ M6+L#F:!#0ZPNX-"7HW'@A%")/]"^;^B&V=8;K1/\:R))P%UXUX:'PTA*^7VC M8^C-5AN?RS4@$5$\=YQ3:?;I;J(1*-7BS@,4.W(\/X#J`&7B>`7*Q+V088H5 MC870`-`JZK(?.RX.'ZS5XX_:V&5>I#W"(^)E*`IEPR<302)?<^0#HH[C?<(C MWW2&^D>E/PXYB!MHZ9>1YL`33H!I3;4A@UZQK#@0+0/%@\K"V(VP^=A(`8MC M[3T3W>>)[V3)^+JN>7Z^--0"C-S0`5:"YSW0?ABRX.E8NP0M`RVAN@N8G14S MIUJ+Q?A+7_;,#`BEI!SQK/%O8\$@V!W<>W`"WT.)X&G,WVH[LJ-=A_411T\+ M6I07SN81#T9B?`AX0VO#V!I.:ALB=!+UY7I>4N`<;LNX[S,/\!`[J$`1-&*.E'9^1@XVUN.2/F MAO]Z=7GUX56!."_,UG^;K[38<^3?GT&,5S^9QP;\GQ1Q(R*LW:!?N#L.?>\3 M]`_TZ^EH_-[Q(VX-/;"3]T]G_L?(-G?;OF4D*C97EGUJ_1D[`98L-924LP'A M%Y:?B0)H=JQ'CGX`M]D##^`MH+@1C$5L=>C'$1"]APU=J-'?IX02.@M?_=1J MMKN]=KLK!5NEMBV(V%1=Q"F'17%9FU+6YO9D_8T%8'7!K*_0K5]NSU_]E`R$ M]/VLP&N1&FWM\I+7L^+.'3>&YBS7K,;+Q\]J]6U%S&7&T-[%7'$<*2#O2F-I M37G%$/P([O4%"SRT7&`G1`6K`/-+:*>OO?KIR#@VV[GQ75;X2ZMO+JS>Z&RU M^KE`FI:CM64QYN!C6HQ&8UDY$@QM"PX+BG^Y",M!8HLBK`J+K8JR(C26D>6& M/8Y@4ATX4.=*CK0PEF:OW35;9D_65RAKG1IFRF^<--J]KM&=5WX<'MTS-GY[ MF<8(?O.#KY?>Y\#'6>6*E9VTFQT#5+>XT*Q='QS/"8?PW5M4P3JDL` M7"QKK2IF*FBV>X"3[L(*LB;^'`!(5F]$H]DY:1N-A`FF2ENOEMEV-+I&J]'J M+%G'=3_T71["E,[B-SSDP0-?O5U'K4[7`#Q,U5E6]B8DF*W_Q&ATS<9TFQ?6 M+S8=9X]>\6B-T6S`8.XF[#%3WKHUS:(&M`NM,YZKYS,&5J+KP4=P;[Z$"[FQ M?(BUN]U6,YLHY\M:KX[9&CI&K]-:7,/[-%JX#YY./?OBS]@98R!'C+?5V]!I]IHG[03(SY2^&2EF M9.ATNF8G1=NR(GSR`8V_\J%CN7S-IK>-CFG*6F=*6[>>DEI,H*KG:KD>#!R+ M9TU=@^A;G79*A].%K5G+;!V-7L,TGJGC#.8]41!;.#L7-OD>YD#K>"Z-=K/; M,Q++-:?4E]4ZV\!VJ]?MI*&[Y^H4O`A?CWD0%8"Z75&HOGFU'&YM1K&?Z_7GD_6S932R[H*&2$J9=1IB\\3`Z\\/HTDL6%%>) M0$@8&[U>N^`ZSI;ZTGI+XL(GO4;S9*O5S@\U8/V]=N.DV=FR`/,"#,)Z=9K= M9F-9`=(?<0W>8F,'GG?^XHO7ZDK[N]UMF^DTJ+S(%]6Y6.DX@SAI+%E]GL0O MON'6`;ZJ$2U'/'A%J?NZ9!V;E:ED-(!(9JJ8/ZC5;;Z.U1N$7#J-,R MVNTU>U,X]6D_7Q5.4$ M?@DBYR\FO>*(>?=.W^5RI]CMA_/3T_$X\!^XG2R_?_`#?'$-Q[!E=-N=7D*H M+Q=@9VV9;4GSQ&ST>HV-MP1>J.;79 M`V[LNGZ$W^[\]SX+[)&\ZF?EAC7;K78G<6OGE_OBJE]<<6JT;@`0U]ZI+9X/ M/P3^Z)-X\'KPWE]C?Y!Q#`QG%.WBPBHV*=`VQ)%0F3R_1K#.;/>*$DR7^<)* M7U3E#7_PW0`,7#4G^LV)AJ>877JAAW1I-DVH:G9J)_\O69I97/YD M('A>//$>#H/G,\\0#2-5A,I@V2WD4Q4YI4[&05" M1)3+$]K-*W4-?8#Y/X&.2'RZ185G$L`O#FC-Z>,"<;HXG.UMO/0^.:[[W/:I M`I>"7?NO=NX'SJVPX(G^&+2E2\1M-$\SJWO MK5MO)OP%=KC8PPYS87_$[]@W[/M0OO<[9P%NQE_'U)KM%.K+U;&:2.T=B-1> M3:3.#D3JK"@2?`SXZ2!:S5E,A6NL*-RDMKR3?`TS0X:7''],IU(#/W@$IP_? M_AQ84!94./9#'KYD8)B@S$[F3*]5:6%SQCD?<(P-P9-R\O$QV6+O\'"=0'8' M9OY?KY M^:KE74FXM)I>0/$_6RKRVTL4HHL3 MT%B&T!,1(]_Z*I^]\V$2:`T9.%E/Z5&$)J("S&>??&-!Y838D1N'3E;>3DW M(D76)OGJ]>"&8[#*BJ#Y6.+/^#:WX:5<5%0$U&!RCKMUUFF&V6UGK5BWWM*C MU%?^61Q&X!,%,+XP_@=.L!]\\@-^-V3>+7,7NR1S';\LNI)M,EVQUNU(.\== M3*3=G*`IG,3ZT=VC?QN/QZZ#V+MACY_2LR@OTFS3/"D1>+F*MR;S8OT>-XS. M9F6^]OA6$7%LEA[W7Z;:4GF3I\,;D3L$Z>3]$[0X+6RM^&6K72+A,Q5M7KA2 MT;*S&NN(=N4#4R=?AF5JAKXI*VT-)2;F88WM*RU-6JF@;XI4$>LRFV4XW3^U9OL5QH<9)KVNJH/'9Y[@3 M8O&6=+-U9/2.FD:QV$()6?FG\).-/W]PV?W"<@>@2"Z+++R4%77A14X$P_,> MUW+!-;UBH\62GOUR>76J??[E].;3J?;+]FT6OGBITK(RD]6)3XXH<5<7&Y;1OE'1V;CJ&G* M\N>5,-V$Z%MI56L)4-;_Z+EA$7)M'61:7 M?^7GBY]Z?>%N4G)6B./5L"_/[=.RX4(#Y_]\ZQ\<\!3`*T MT!KR$?_7JV$4C=^^>?/X^'@<3?N_3-U!2L+OWO>]/^]"CI;G&42%]V[ZUL M+M'*YOJMG'(T56CNL]3W@N:F,[G]4T?WR#Q99_"E6XGW3Q^RG]9J@=C\N?<6 M&)VCQM(M0"]6B)]ZL>+Q$;A%<H.U)V_"Y*_!X`A;Y4A%+U/-=4M/4BZ*P<^[Y(\`L``00E#@``!#D!``#=7-USVC@0?VYG^C_XT@>>'$-H>TTFN8X# M3LL,!0;(]=XZPEZ"ID:BD@WD_OJ3'9P8D/S!-47."\'RKK2__:U6G^3RTWKN M&TM@'%-R56N/[\_-1NW37V]>7_YAFD8/:,M'+.2& M:>`;[(,Q"G$`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`C$MC$#$'$@@P"M8R5?1E*QNIG*6F)BP] MH&J%C`E[,S-R(J,O#SM8Y(Y_IXGCNQA-L(\###G>EP@>*U9$JQX-((FQ;))DDM5@1XI13LL'36C9Z?UC MAKP<>K(TJD%3)F8Y77]J0E<*8/Z:XI@3H$`]"1#+Z!XE;NYLJ'`5&D6=:DY4 MW!UZ+S_:,`5AJ#=&ZQ3J7#ISU32G,!_V`4L2#7$67P_K,F-/62PZTBB@[H_H M#`48C[;J@OO\+"E7TXBH3%P*]G3/(X6)>B'4R*3*I(Q+:Q=N5SS_EO/5T5A\ M?G5ZXU'_IC]PAO:X(][:/2'T=3!TO@B%SM].IR<>G=N>?=ON"*5?>OQZF`6: MG,X>9OQQ>N5G1CD?,#K%JH$\+7&DU#&$)9!0.?]]?'WL-"%Q9CHC/,'0.U.W M*`_ZTXVUJFWF+1G-';\#J$`6-H]Z4"[L%'7??V,"<9NNB/)8?$]0O0VX$ M4N(*A+98BR^S-E-*5'"\JQ@N@,=O1,^+-A542/;ECIT=RI.SXZ@" M;G\!3'CJ\%B457"TL%OAVR.V<=H_;@OKAR^BNAJ&K,9)&X/>(7\ MHW<<[X/8/:8OS/">XDNC=]\S>M]3IU5-]@K[1.]K#VU8,'!Q["/QW8?8]<2SYY0%^-^X7,EK`=6JDUO$ M.WK?H-A/^E>`O5#ZN]2GK$T3LE4DR<%7CDYYYJ0HUS1YM]3*J1:;2J+ M>4>QW*]K2W&\&UL550)``.[;F94 MNVYF5'5X"P`!!"4.```$.0$``,V\&5"93M3F'*=H3M M%,\:.VL[M+W:$;;2:.I(64D)89]^)4-H`G9P(L7.#1!'_L^?[\@ZDA!\_#0? MYYT98AQ3GB^8GW:_7?IR.T!A: MF'`!2?IX(\?GO+CNTQ0*];%>#]FI;*%>68MFEKIDG;RS3D^.YCQ;,CK$^4J8 M=(0)G(P@&\,1S15-?I32L=0\^?WX[/1XZ58EOB&5%[<\(V=)]8ROV\>$@Q9RFB.(C3L//XXB+R7\3`1W0R/NX]M MNC#/#SJ%V7-Q/T$7!QR/)SE:7!LQ-*STL3"N$O)>I>(WI=;5]C221E@ZO466 MO(J(ZM`&/9:IZWM^TK(R-(337!AT_%+;J%\ZAM@DX!?2!MP60M88C6\1,VEU M17?)Y\+D+6CT[G8RPM1`O M;-?67OI$LNM@@M557[Y<"8KF`I$,98NPRO\N/[%QSG88.&X0NX[\(0Y]SP&) MZUP"'P2V&U^Y;A(/")QFLD!FV^+>)$3CU+ATQF?80$ M3F'.MX6]3K)QN#7-[+`GQXG\>NT&21SVPKX;@<23[X)`-KKN1^Z5O,&[<;U` MOG0'`1@XGKS):$??SL%^/`?:WAO*K`WBJYX??HEWG\*24/N7J_4F#15HS-.< M\BE#ER#V9%#9(6(9ON@C6U?FM:+-E^2Z=DPC]<,X=N->%%X'(!E$P'>\&,2) M&^F#K99N$6\M4Z8A>\&-S&48?=.'^E.J18BE)DQ#ZT>J$"3?9!%P_QYX?37B MZ/,K56T1Y6M^S'?%!`2?O4O?!?)!2&(3/?*98JL=L]J+:9+`N2FF[KTPZ@\B M^PK(<27LF>=;,TZ+U#=W:#H7D>NKF4D?R"#)- M.`@3-^Z#;T#F4Y_JBEJ+)*M\F*:GIL])-"C2Y(<@Z`';\[W$P'R@4KE%JG4\ MF:]K:FF8@*^ND9+V4ZS5:E9JPS2Z'O"B&^`/Y)H.Q(/H86FG#[%,%G-[`]$T_YJER[XV6YD1T` MM&6G?]Q=,T)P6:]=A!5.C#_4@TO5U64P]\;,0/E"LHT7XPNH-*53(F3; M/LUQBA%??#>P:*K6;G.A5,M5`[NF";S-36"NEMZO'=27IG:VQ6<*[7/!?=CN MVSW&LNTP4T37:._9!F`3W75U<\99Q;Q1V'W*RK6$SB:O\G;`C1SG/WWJ)]ZINX^@W<62&K4=F MB`C*[FU*..8RN>$P&:$>S7-Z)^_3[/QUY1LGO84Q,\#[C$X0$_?J4.>_4SQ1 M!SQWPWZ+2(VG0<^CH8R4S/`!YTAP'P]U1_]ZXLUSW]26&=012BE)<8Z+,\PR MOU3`W",",<2%1](I8RBS*1>:U#>.TW@"=!R:R<7#:T*L%&Z=; MRXJA`OIL_1KW'``F$T9G*+M&F3KBW*-L/,TAUZVEFT=JOJQJ>334L<>4"?Q? MD79W/D&$(\V)XAK%YKMV+2^&ANN*@RRAJL>ZW;F>>/,#\Z:V3%7&&00%TJ]Z6\9KH?;I.S6>([G`FF&N/[E;)]DFZ75FS,`L MW>T%(D(358CENE2F5D;%MJ.@Z0_Y6'V!C$$B M=(>:FNHM;))LZLM8#5TZM!/#'*DQK#]EZ0AR[8&]IGH;%75#7[N@_7@4A4U?,N\UQO[6/P/D:?_PR*O_`]02P,$%`````@`PH!N109_3*@A M1```00,#`!4`'`!C<&AI+3(P,30P.3,P7VQA8BYX;6Q55`D``[MN9E2[;F94 M=7@+``$$)0X```0Y`0``W%WK<^,VDO^E3S9,2(\'W[TZ?WWVBK#`X:X7/'[WRI/\Y)MOOGIW^^ M_;>3$W+'^*5/Q5J2$^)=>SXCD[47LH0&^?KUF[=OR]X--[^,^,2D84 MIT!^]_DB#%?O3T^?GIY>/\^$_YJ+Q],W9V=O3Y.&G__^=Y]]IAN_?Y;>7H>G MMTGS\].?/]Q.G`5;TA,OD"$-G+BC]-Y+_?M;[M`0AE7/DI2V@/\[29J=P*]. MSM^GF6Z`O&& M6CGH$NOE_-V[=Z?ZK]G6BIP;ILVSU+\ZC?Z8:^U5B)/J6LWO9]\*[K,'-B>: MY_MPNV+??2Z]Y_6P@V+R;G"W$*_4\#]DA#YH)RWX%RS[\&Y?XA_O4M MG3'_U-TA$G^A#NNY!B@CB8Q+6M'D!:R&6ZZ9FS. M!8-#1[J.NVPEF.-%Z[B"Z2SF3F0HUDZX5L*2!?-=HGH2M5"YZI?>AI&U9,0+ M''^M&U-7;7`4A0%1AWA8S4"8@4(L$2S@FXAZR#744\*#'8&!XAO""4CM!9<> MR!5R^',(EQV"+*GD@=AF?C/W.1>Z(_.9$PI8.0>$!BY9^>OE3/WE=9_,*3^G M>\>E0D2;&$_V;G%.Y4R+M98GCY2N])WG*?-#F?Q&F]G)V7E\C?J'^->_W@N^ M8B+\J%1J'L[49Y$Z17=7]7U06R%CD3!@OQU/)@KFUP_C#^1N./WX,+PE M5S>3X60Z>GC?%_`TTD;V"]YPACI=5`6CDEVQZ-^;0)U+82=&*K7[(+]3J5[_&IG2MSH?4 M_X51,0K<*Z7=W/Q7-FUM!28"8$PAIDTBX@2H$T6>7/7H9<)$!PE2S&>A_6)X MQ\?SR[4,U09"^[N`'3)7+<C7'ZC2[ MY-NQCO:&/H+CP4IX&,2*,-N M*S#&H'<\2<24**Y$L]40AJW)%CXKP)IHWH0"+RONU@TZ8;U##85"^HCN?+%8Q(9\<36:#F]N M)U_V"6#F^LAY53::I?8@.O#/FKNTQ#^K`E5MJ*!@AA`;]X0Y'=Y]?W-Q.R+# MR60TG?R&W/X0*LM"$SW5[;%ZR8/(E4;[%=X+_JA0(L\+\%C6$H6Y&O:HHVB& M-/$"<#O2Q&WM$RR(7K<=^#[R[],W,P-"PY)[F0'LXWT>/)[X'EA,[#T;N<4[ M636HK7\8^TNQ_;\X7(;Z4B>ZZ%&_H"LO5&:GU/9/YL#?H.^";G2,"9DQ!IT@ MV$H[\@8IVQF#ZZ24.'AA04\JHHZ"47<+C&:,K'SJJ+][`5PF,;'Q'-:KJZ2: M*8^GV\<=?CN,H<84]?Y3%#XJU] MGV#55#=&_C-'VN7?,S7'RMP?V7@^6:C/V_@I8.[%]A+2!]SK]`$_Q.D#U!EV M//^!^2O)@W@_-URN+CP>,F<1<)\_;B_Y;>@6;;N.P@:W^!]QX*@O1BH7++`2 M)",<1".S+='"D4@ZDH@'ERS0-I8P/6K\B2Y7?R5[8I)+_GI`E*B5R_!O28UU MWZMCR->GM>:8^M_[[AW=@+OT\O>XB')'/#!''4>E-_>B3"U#]Y_KR!?FBDE' M>*L85EGHMR9C(0*@G>"8]2C/J"_@Q^KD,!P`,YLO$!S`Y#WUW#M6[EMWT-!> M(,`!<]0=!Y4+LE+T].M`Y%1'0F#2-["5C[_4@[Y$^]T!1K$&!:O#_,9S8 MEVRHOXX>].B>`GA^L,1=,[B4I0$9!:$7;LF3%ZH-*N%!_.+\1?S\''"U8?4) M1``JRG#3NW5\-B!/"\]9L(TBZTE]&CUS M-VDW67O/C`@[ZN[3!JL4W+\I@"@`R6&8^('^J!!3%LM3TPG]R3(3"I\`[$]T MQ>5?LVFS>K==,E-%_O/39((P3X;+)0_T458.U^&""^]?S"U\,2QLB'PPK&*. M>R\$RM&]D<)&2MO>>R%6>N%N)?:D M7$)F9;GS[UR\^[6I_[;W/U.$3<`\?1\-D7C<.S M955+W&UL-7MK"0U2X@,2,'OO;WCI:ZTBEU0JW9/HA"19X.NM49221&]UDD0E MD--$1-$.6["H1\Y=J942/UK+@>X*7N)J:Z0,2^^OI$Y=`G^@[M(+/-CPZZPG MJ[50%L8B$H5;I%5T@"!,V0!?>HZRU(#-O3#GQ)MLSOX*4Q([\Q;F9'E-1L\4 MWNIE^OJO=.0.TD0MLO2E-]:Y8B*>X%VPA@5H1U_KG,_#)Z6P7BU&-3C>NP\V604PSF<;19"+[7@F ME>#284KP!P9(947O2]7MD0YE!J+@PDEC!H1G."@[U"QLA61;'4IU,HS*\?1N M++7GS^)#=\'AD\V9$+!(T.<^6;61IO8=^8R-R8*%/S"]TE^"ZU:59>^ULV/1 M1:SM6+*(*$<.:=8AWU;N)IYZ^D,.JX\?PU5!-1\ MC*C:7*B]S3T3>O-?8"-5K5&68B`&QEYB\L0'V"GT1,<[6^9B2?AF'G&PA8U? ML+Z`87V91KS$U@'#9&J3FKAV[(ZV(7<^P5Y[K?:2A*]#*'.A,PJZ:TCOIXD( MM@+_?_5_$;E>;1\-%)XU(&/4MC>CL7BD01PMH7:JX^BZEP=5_G/U?5`F92P2 MQK"R3**33\JF3X`QUD46-@WGQUX`3"Z&8:IW?66)^5H0L!KV8B8L,@M.>OXQITKAJ+H/ MV91G"HGW:J(65#(YGA==316Y"C2F@:WJT$YDE,-`/K^?SER=\-41'(7I?ON" M-93B;@KJ`W/-7+FVEO]+K74$S4@IAA M15+/+)+AUCM7K(;:R:^936;Q91RHZ1:DDU,^=)3!"%::2[L$IPT(X)VF&PN+ M>FVL7USC9Z&#N%['4ECOD09>4-^RV_&_B'=Y8QT>^)4WA?J+6/15YIE5_>RS M^'2=33=18LM&7=%6W$1`U)5DM@:(C@?/,.@;.ILH)8_+YM/6?KL.;T=J6`M% M_@I*'W*-]SA]2=&C3TT'U$;<3!A/'W?%(\M%8NQBQ-Y2ZBY"Z(67O MJ..+[N0)+"YU$Z5F4!^%N+?.U@GVY2P\MM%]D_`P?94R9U1Z,\\'CQ9XBMHY M4B2N$XEG2^P#)KGO#H@/.;%=[;.B7VB?(`O5DHI/D."A5[?E9I.7/<0TL8H. M3RS,5S0?8S'*#B;[C?#GCT*FJ&-&1-'(1E_D3%$XXH.C0X6>NX/$K4>UY7I, MQFE':\ZM%1W04*D7!N5O&[]]9[CT[CA:KX$\C$SGH\.D\/KFV0Q-Q6WQ2=ZK M1+"!H8A![^!3.>Z#1.SUNC]62NHHY.>!/6H?U2"\H\NB=-2%S5"IJ*L88W`1 MQS#M"!.@W!=XU(T\FWRZ7N>(Q-,Z1F`\C_WCP8LB7DMKFT#!(O#N(P]#.*G$T!KAZQ^*`)_I3+%#B MPY+L]-E.)FNYJKM64&WBZ@X5U7D2:YO*WLMH;=_2$/5V=7`=)-:.H^KN>,CD M+9RWWA2L$I7-<75Y#03!1Q%FXP M75QCE-D&OC'DCP'V8\+\N/#N`MB#_B/:',OVKIHWW(?KQ%LO8.J3(ICKA3]Y MX6((?(M"A^IZ("^;C<3!W3;'+(@B%3D4:RXZ]P&A9*88V;MPMC:<^AOG2E9] MPKZA5O:O//`K<6*]U="<9Q-_=4A-NI.AM(JKT)I'G5]"84T->'+<1%?19& MM\/IZ(K<#Q^FOY#IP_!N,KRW09.>%O(6&HN'"HDX*`)BO9ZVU7%4AW'G!],WRVJ@C,/LC`U!AR\2 MN^]RG#I]07)(V/=%IZ+)[E1454JV.2TK!6=;#P'EPIZ4:CUP7=\Y%.K32(D[#MRJ*/.?!:2_Y_%*#36(%%`3HMT=[=3E?GOKSDRY5@"Q9(;Q/7 M=H0P=K7>,.\QB+P?G.Q>?1BX^O_\7$+Q.Q:.YU/Z7+(Y/A(S]'[ZN$I`1;Y' M>4>RHB7Y&$[`N$"T.&&)LR7A3AQ"4WGZ8ES=:#N_-^X"9)3OH03H!0WQD2"ES/%0 MS]).1;C>)%0EQ*-7$0YE(#I&.YF%_%Q_EK3SK4_X51<:U^ MDU_7JUJB',UKV*/B7F/2)*)-@#C1U/N"$@,%9%W.C2;@N*$(/S'?_T?`GX() MHY('S+V!-/6B`"W5[2T$)]2(8B%*`3BX:DS"6IG<)@*C]V7QVJ!4DR<"0S%HY`D@0?CN;YJ2>RWWJ8:=4=& MH#07%!>.DN4'FYCH%BI=KBW;V+'&5Q^?8LZWI];61G7[02QM0=S>[F(><>F- MX@IUAVU0%E3*$G_!?&-2`:4S66N_+?O1*U#@XBD)=E><2G6CK2ZCUHGX+ M:;]FU-<1BW+!F+)]V*IE*K]X3!*U>9=0V#=;YC>MU986_)50_$W7?),DX$%2 M-KDA6&:&FT9215KW^1&H>LKU(71M*6&?W_%#0-U3P@E!>//5?*]42=F6,VY MD'&J2J@\&D2_6,M,S3+J.VL_[3I+K'RQ^&DY'>H_4V2K*]HNHC MJN'NQ_:B^]#=!ZB`W=$)OH[.9EGP,&A!`?PV:"XM! MKN(6%4U)^$'BN907V3&S^6DXSA`K7=VLC/,EOA7-=97_6+0%;Y=!&*7W=85- M+(1;V+VM2^D-TNNJ3$WPO3+GZC#QQS\/OO[+V>";K][J$\4?OQFR`\S-^J-*NDWX;9?NVG>;;ZNZQ5QO#ZG$6Y_-^B43>UY[/Q"4- MV:-:;G+S5=;*@J=L(5L+_K&:+DD(]P4,->,^](2MT'?[T^<(W@Q7PI,LC?@# M%Q@X=4P7#'RW59>O"DZ=AAU1I\UFPB&1$G,B<5"GXD4TL[2*O'ZX`H:V7@SM M#Z_N&=&,8U\LI+F.LN?G-@!%5"R_NQQ_&$V'/X\F'P,739LA"`#W*#I&`?T6B%00-?4299\KQ!1._@]1!A. M`=K_+/)QN^0RO(E\D=P"0)2WM>&/5BX"WB\M==;4CEU>3-^RDQIN`'5K7BF3 M/J&[5A,%KEUU<$($IT%%X@]0D#-@8ILM37SKS5E1[ORZ'KC0,S-Q4!XDP&)` ME@F37*%J7_&Q%E1F;S2U,63UHP(W&#A*]FH+;*BBO3"Q)@#L$J:!RZDY'"O MO8!J%^F)FBT6%0*O<4PQZXN_Y&XB(C+<)F)$4DYDQZHO^&NEEH.[\N93U^$C M.0W7`J(ITRQ/98_AAPWQC]ZES#'0&HM'&L2URO4B%[&!-[@=H[XAK%P5!P^[ M-1/1_DM_Q69E150/_HSZAA4:[L:3$TM?8%`UZH)L]"5Z M[@X.H_F<.>%X/GIV%DK+#&ZIQP'H6&VJX)_1[OFZ!"Z-2*#AU$9@U..,Y@>? MEH2C?IDAE_IG"2%&P+5O^&NCICP^VT]LESONM';H/15CH3=>[H_47[/$C;UT MOUW?T$NVU@\W%X[B@("/@.U.`H=5->[R(4&VCC<8C>X@>,N#1[60+_.1 MZ$DQ],"]2P,72[#8B`0:E&T$/D[BA;X!M(UF\DAM/Y==.UB5@#'^HR6'*BN7 MT^/I\-;`S_[X$E:GW304\^6\OLHP6S3E=I*='=9WN-A.GWB2UZGH;KE!;VLI MS@S%1-TY[V7XH@454&9;$C[Q-/'7,=*:61QGLXQFR/&^9"HS0YV593%KA&&$ M#U`FA]0X2.-WU(@^Z*?Q\?R"%SU6FO7#>?\T$0WGKI]-#:9K>R0%LR#/?<0- MT'@QOK)E7=8'5V=7M@;9N:-3$T7M>3DU1RCBAC2*=7YBWN-"_4LW3"@K=O3I M0T>#*S"$,J3_5][5-3=N*]F_@H?[,%/EI#R93+)S\R3;J?NJF M'I=K-O$^N#3QAMBK1G$S&,'CW2'<>D'"[]^.]`2ZE*W.5]#W#28*82;?[>1N M07Z?W#]-R9?IY/%I,?TRG;EWTC:<36TY"LV4K*X,VZRAI;\S<:\K\GDS"-(0Q6 MM)]NXR3[#NYV+\B6KY-+9(DQ73AR34\P/V()NX;!G/ M@#L#XO!%P0S!I\A%KPLT,($1Y'HQ50,@5LP.":01\E;9S][(7K!?@1&"YRC8 M!&N/_8OUXD_>3NZ6#"+A`B(KNO8.*6W\KD:B7>587*MRE_E@L#?](&768?9[ M3N+#/J?.2EGWLB`ZL)-!64S.*0[%WJ"O40P/6WW.SH.21Z,-YT&1-7`J'I0. M9:WSH)2R"GX0JX6]3M/!_BPH_7KI$`=*AZ4,.5"TP!VU$"W[!J3TAHH_[Z*[ M(PFN8CIVOV.C**U>)2NT*:X!SJCGDFJTIJ-Q3EB5O#_7WCY@:X7F+-:C@1,` M3J(#]-8G3E*W3ZB+< MU2?0D).(PV"*-\>VWM">S;W"0#4[-P.FNIX#Z9+^-J&LA,%9@@KYK8@"L*W' M;(8+U@1;B`U,16S@/RZ_O[S\<`P1_(5\_G1Q>7D)_Q47R-XA8R?=X"_J_T)^ M_'CQZ>?/%Y\^_5S^EBVF[9]6;B3=9CM3F;@CX%`RN"-&%QZ_6]?=,83M!_&1 M@DKA^%SCO$%2D6%S9<6I;E!>N:?^9PEG5-J@%;2H`<_8H8G=4*\_8RE0\60` M%\W;CUL\+:SU6I\OC%$#Y@YXG):ZKO+-:/DG&\-I^)(%8CL3I5`),H+GKIZ" M("21N9DK^CS,=R:&:1/AF0\7ILA<"-D-#UZ2O2T3+TH]'D6>ASN]:BB]^KR- M+#'76TT,T!;3^\ER>D,>)HOE5[)<3&:/$YX0^DB$,%<@-M`V]1)K`\<0'T`* MU"]K<6<`1P!9@(WR42MAHBH%K$2&)I3-C2W<5)2 M^]*TLU:?^7NX?+8^JJ$RV0I!A$FJ4%;;N<`[25>T7R#6\L%+>"B3B'_D@7?* MCCHU'WI9JY:FUA^49R@>/D+OC<9NU."$-Q@8T=*J(.0/ET?')MV'\FB<6EN(J1;6TO:P4(T'OB\>SQ+'H5B2JT_8C-RP=]5X^E`-R\[LOT=LAFKE5P+B+*B= M1'Z[/+5FMVS\NDV\&RF*F0SW=Y,KX)Z]FSZ2R>R&_&WJD_PSGJ-RV MM?K4;`\O$MO8?OW7./9?@S!4(-7H51M"1#3+DR(/NP-W M+L,-=I(5--JB?NWESY\N?OK\DZA?^_'BWS[\?/PL,?_AX\?'RP\5//S@.8A/;MN+4GRW`@BJ$8CW(YPBLM8MTJHES!45^3U$A^>@^6'6[(64F"ER.9^NS<]B5. MZ'+K18]>*+USZ-N"-8[('NJB[K5JO(G1D1^Q6.BH8+YG'V\@-/`BDH+H4[!% M6NYQ/\9(*ST_)V]D#^NIN"-[XQM!SS*?74]GR\6$1U3RIMEZ\,"0LO52I5ND MSYLX:I9^ZJ$<'S51A,LB3!@II;F$N)Z&J?%:#!DX9#B>+$HI_P4^T,Y*1!)O MR6KXG-7@(W&Q!:0X[-@-"R/#!M\31W'F%C+K?6^%QIV-N.PF]Z?<4A^(@,K` MA^FW/13QNJ(152IJW%%Z&J;D5MJLPO$"[E)U5_2#UTLRM^BX*4U37P$Z4 MC+>P/:5LF9VF6;"#?99B06L\A%[(Y$)1$7;B_A*^JF6[K@"BN]?-U:O+UF,6 M'4P9-KE!@4VYPMNM@$C'"Q8*"NJ40=['+N]FOTYGUQ!P\S\?_M=J[)D5U=GJ MEM)[$_U=P[R^_^WZAF9`0K@BXMTNR'*/Y%&4.CG#\"6<`$8*6M8=P4K_;I? M\S#T')3AF)G![?>#]P91$!\Z8")_#H6,3M$8,,SF2[;@/4R^3J[NW4)#9Y>K M`#`P]SDY:]!J6,(G/E\;;UX"IYKA7*H M*UU>YN08'?DWP*?*#`8TUIV#-&H"L?!XP/97`;'Z,S;2?MLB4?L)FI$0J$LL MK]F#%>U2[&$5%,;#;'/N:,/'.UY`HUFOC-4UL4?(^,_@S?E1 MA(O_^/'B\J<$VPMMW!3U&1JC2G1H.A)U0\#+H$,HZ+U_CQWSO/=\LO-OQK`*_3KQ7J!LGI)\B+-Q^O_M%AMOJ M_SF#P_O94!4?/@3QR`#>>\J^B;+"Y]7?XD-YZV(LI*Y#>Z2S.O<(.NKK'@OU2:8+3CY+D&_=$*U(7QDH$$PE472`"$[!'0O19Q(P2A["\9`HA:)NU'BK M]6*[7$_1.-Q\L]7+TC-%^EJHEC0[!*8IWM=7V=1RE M09I1?[Y9;NEM#&=]8&93>_^&M(+E9!VJ-NJ\($4>9__EDF&;#-'WFT*X,T1^ M2*,UV$UQ@XW8HW`?R:T7)+QV&&=4G7;1`VM>P.U=C)1![6,$Q32((%R&M4V, M-=4-"(`/88L`..?.?H&.\7)YSJ1%F5NGMN'I`;/AZ']*Z>80W@M2I@I^C)L.EQ4/;3J7G2QUC5V=(?D(@O MQH)"+X)0[*B8/#@Y5RN^W$5KN+/WEW'QTWS;U?E=L=$L[NMCL6.H;Q1XARJ* M<+SRJZ'R$,MK`P6Y-A`!4OZ&"H6L?=9&MLF`V0WNLM,:;/2OI46CU[ZIUJ?8 MF(6.HS0.`Y]K_L#^MGY3K29&KU@H@*Q7"!5?6VV?GXZN/'8@$,4>:%K,$5=P MV\YP>J9PNX;]$P=5&?G9O?)[/KZ2.Y MG2_(P]/B^K?)(_O7_);^TW0Y*IT:N\XT):U#P0&XB-^"[QT"U'Z[`^X+F''73:0 MJ?#[-^/R5-^&/DW@OQ4#%,:&S[TK&GQ/"A&0ELMK9<#7A/^EHHTK4,;8K/5A M&3S*YPP3+HG4\MFH@+#!BR<($U8I9R54Y-43S"FU@JAH$A5'L?LH5!M$CT/=D(T"1NM=?KWRWAFW73]#2..3#8=G/*3]2B/@BF,: M3?Q=$`6@#42$Y_HIH*9["XTU0[4P8,M%B/*Q-2'%Q9YS'UU#JS21UVNTQKR7 MV^WBJ%+PZRY-#\I:;JJG+=S&=:J!NXB#IANEVP+>O&O0TEBA?>]F,!KGJ@XX MBQ\\X?M58$GYN.6*@&U%R]WV+L&)IT5NJO_J<;#G8)0"EAI7SMY M`2@KF__YOC6?AL#.W4M[35V8H`^7X`=^U>^.`%_EUT M[>T#-GJ*::9Z&E_ZIUL-W#U5T30!UH'O@HBL1>NN84MCA%9Y'I/!&+^<5,[& MPB\RS*I)R=ZP5DRJ0QV+]S1[(<4Y1.F-H"KZI!V4,;>8(M#V@8U`5HVVG5$5 MM#I?L;#5U"MD/[Q:6F//KR8&0+;YIXO/GSYN:AF]7!8A<'Z-HR])AKESZ#RS)4B,7C+RXZ)5@EOUA6` M=/:YFDZNL?/P&)3;R=WB]\G]T_3+=/+XM&!_S):/DVQ!]U#=,GJ^8?/P*>W. M"^G?!BH.9;#*&!"!4,*EDJI8,LE(*9B`9,)%NP(PE+VJ81C(,490$])LSA9" M#X1P\DPO2=XV**'Q;6H7I.K`"$9NUP)6T%58QA!%UUU4F.,SB&)-&B- M9M+*O$`4*MEL@C4M-SCWP4:6E"Y["E=:1"T6Y6ODS5;R!D/6L+4*(#B=M:4] M9+K#%(!"0T[AO\,0M5(<.M"@"'AV03;?W+.3R%/+H2E[`DN=(Q.'Y,5A3<*Y M*H33U,%>B@9"69,866\'AWA.9M/J`O%2P@Z+D$SELSV)4^&P"K,T^&G4F$%L M\\$[NZ7^10^N`2`N5= MKFWT.X`P'']EO3.JSV15/XM"I58%E$->W"$2WKPM?%K1V"![+3RT'4(*Z0QY3:<<1YUSI/?KZ!OAOHIB M9E(IH>#;<&;;.=0:S9O=8>,V'BRO#FD0T32]H>DZ"?:P;D"$5UF"B&?#!529 MF#:\'310!ZN.0>S5Y/&.YZ0]+*:/T]F2%P1W#;2#+=-$+W)4QPRZ]^F&;68R M"AP$?C-CK%=JUK"V+(3E([I@)_M%FV]H/R/FQ'TV3)+1=MRU&8XR7#N'`0WX M4=-K&R$@LA+WNXRNDMGS,+L M369MIM]S036@7`].)]%&,L^IS8%96T`QLN(:%!D9F>[4=*84H%.;49(Y-`ZL ML/5A0;V9*%!ZD]PIKFT4"NH$?;>5GMD@[#GQH;2]9L!R3XKZT@ MH2K("@"@01='O=I1V6"W36JCU(7,U5C]K:52%U:B]XZHP=1S2$]E_B.8%TR0CZ$`N4:7!`/=H>@!$E++?B&$6(OUD*14\02 MCF4.W1P'+`#`Y9LEA#:-X'WO1A`$9W;5'S%[ M$1=FV4LY5/1E+HEGB)>R2%X-XEX3-#QZZ&(ON]0B&@>,&F[3)T(J>I>W,7X5 MO9GKHZ#56!K7:]?T-4YSK]%_^!`AM44=D"_4@[`Y^.J(P#(5GYKI6[C@6W.U M3I$/]TZ(>N\2JGJ8I!8)VW>HQO-XRU2[B_:'++TIPSAUX5G]VD![I0>I?`J$ M6HY7.5F_.N-4%)US9=:AC-/TBB.`.B+=81S[K^SD.HE:P3)'+34\F_W:P%,A M#E$9M1UI65*D!770C!Z5>_B1W.*6[*'J:?\I'9QS9EN8-L^'G;C.3,J M\]":4I_'T\`-D(K5O_V<#8XAN6C4C4K>:,YP7[WI8YNI';_N0"WPFRN=75_L! M*!.N^8UXGNRX%[$NA>'9FI<\4Y]XSU[`IE[!M<&FX05_+=YLV":(O&Z#]98$ M*7D6[-'A&]RX\^*7<%/#?=GPG?'CPRJ#`IDE#5WA1,NY.4"=A/J'-=!Y'$L) M,&E!M`X//OQ8.,6/O[P`6<=+_VSK9<3;[Y/X6P`)NRFT'R2?0YW4FRO:MP$<0AOS?[YU*CY0#HOK5ZIK;8Q)VI]E\LZ`O-%)2 M*]>?L4#.+1&)DG$O@_IY$@V>4,WP3I0W>WC%EA;NQ7!`"DG<"TX5HY\FT*$ M*W@R-46;U]5D4$Z,(B8^@;K;/OWV+]H,@5,_9P,W(S3\KO$I\J%(6+`Z9,==VGR3AP9WAM\;OXJZG^RK(`91-5GE M;ASN$')QIPB>/T4'=;>'UCHZ]OU97V-5;]:&X17%D\UY>R'2C=]12N90^QDL ML[5<)':=7>>MYK>M%DFHA^MKPB[=0^\S\$7+^]X@@N["AS6N7`7#L^PIFYRY MMAB>V[RY5CF>D5KK@*K0WDF6YPY3=)#FVF1YOO+28`VT$\42SF3QBTRIHU3U M+-)GJE$!YSYEC0LR_#U-Q`6T/7^D!<7[\4&#XZXH\PR=>G]T&@IG)722>NNM MZ"F\LA:U5%.XHF;@)H<(9L$ M5=S$8?N=!X:18O2TP?'Z=]`3R4@EU(22L4$Z&19O;(XF;GH,T7@W$TT<43):M\"?X]+"T$C-2XM> M@S=F-`/K<)2)V)=%D/YIGI-A]*J%V`=S!5$A$?/9-5L!%WP)M)YX8;L7G2%; M]:ZX-G_ZF*(=\]$7-J\R\\FC>MK"[7*G&JC;COER^D@>)E\G5_=3ZU/$ M@N*=LZ*NO6NS0M/[]A6X`7P<*`MK/B%Z-7&ZLK$GFCJ*_'G+4^A4O>J<5_*N MN3:_AIC&N,JME9EH?#+M=R8]V6GTY.=09V)O#`V@.7F>^\S)[\O3+2^6XU/_ MZNTI!:YTP7H$E^A0CYK[4!4K=(\&T.MS?V6Q;AP01T`*W"V7ZBR7J=''AX`R3BO<&-E6)*FKUK M@Z3?7$543JMH5G#LD[UHV#50]K*&A#6_[XA9X!>:KU+6N92=G==TP3Y)R8O, M)=3YN!T>H0Y%['`'Q14!)!$2;'(YVNC%_\L,9A/C21F2M&`\W[4]O\PVO*P7 MSUJ_HJ^I@+Z8=P4P1KW5W;!++#[F5SV'[Q])D-&;^#52?L);#UKX7JN$VU]D M78.,NN_M3W&WY<=TPH"[JY)W-CEDVS@)_E*F$7:]8<'EHE4'EWPJG'NU+$*O M%.$:H`RLT793&([.B"1LZOIHE<2SR0XB1OXJ-B8RY`UH"$_'-EAY#$Z]8],0 MM%.V#1NQHQJ.%M@;;K(6HQERP$IQ(A5VG(),I2W-@C6OOI1? MTJJB>H:W@R]:/%1UW*WK_61V/26/OTVG2W"-+::SY6_3Y=WUY-XY!]E@"[4J M&N-&]US<`IQ44.D[:S]IF4V@)MX.C4`J-@#_N/S^\O(#.\XF@KKD%_+IXO+R M$OYK;PY^(5%<)QZ`*,A*`*1KL.VP8C?B=5R:O*LSX5`%0_CX:A M5A4;]XTY*Y!S7W%MYYL8,AP(1(&*6FQ17DD[792<11W.2>-7<>4H>BIH,6:L M$$:.TEP!U!#+U.HO#!J[X3";0B78?1*DQ_*Q"Z"\$N57OE(O8:_\)`&9X8LH MB/53#ID;GDLB0A1AL@@75N8*0!X,`8&VKKGM=T]WX6TD\9-+GZZ%8/?@[W0;K4)6?V7H$!6.50`Q\>9OD131J-2D3HZT. MK76M70&*-]TSG&^ZRFK]&$"UWO0TB[X']8.?]%H=PP9:R;>M\,X^@^F51 M+_,^V`59RU=IKUTLKX*]KB&9&')%`')Y2C?H`L4;N39$J$,*?>#0!\^"2J12 MP357RB*'P[@6,F!]&,]29Z")L&?M!K&$[;F&6%#R7(EJFH0VI=[@)=Q28*S4 M"7)]7,RJ-S=(#6@]AVE$QN0@_3-E:CVQ7B=`KPLWX!IO;_<[>)YD$Y7L74*[ M@JY>W6]1(YL/R:AQ^N*ZSKA$6M<;-F+R=>J@[M9FU_,O4[*<_(=[N;(&79>$ MW9L-Q1DB1,US9#M?L1J(V7H MZPDS5P,_^<]C\Z7Y)-L^U9.HO9Y&/`;(]_/'Q^DCN5W,OY#99/FTF-R3F[O' MR>-RNK!U)K.@ONZ4-;0;8V]2-::H[DR-D&0AGZHHFF=>I=+X53MY5H8*VDD' M*%*4QBHT>8I>ZIUT-GM[MN0K0XM)$[%Z(??L>>US4="MFN&KV:X/:.A4>>X& MRJ..C)`'?AO&KWGUR5)<)17<&?8%O*D,<\*-!_I\"8W:Z#$V4N2O((> M]1$3K@]IQE1(BKC$[NP6U=/X1.MN-5"8+#E$>'GY7)`SAU)#"[02JTU&XK3% MYWZ/PT.4>)S"M'(!`,H/E>V3$33KL!$V_=V[;E.NX^Y MPG!DEGZGO&CY%8WH1EFW5_.2A?7&1"G4S4)>]A)JSNWA?)VRCX$S477][-!> M?,Q'!W''S!VOW._Z4!BP(V2F\W'<7;*!(K8\S*24X`I43"U0NRDU'HOA\*CR M+.0`7-"07ULMXR8_@P0O_=Y'`6B0JJ@]3Y6D(T_I)4DNDF1QA3[-@+7#B:X: MA3$_/R?TF6VU*P'-;#?.5BOH=L0P#M>]A3W66R]Y!D:39R^(TNQ8X3"(JJ6' MF+6\D..2\A^OXY0W+.Q&XA?*LP^#A`"/YHZ??1*Z8VV"4#@+Q#NHU<2V^ZD8 M`^I7AL!SCSEE\#A6EP#$]$)P1!\"'M:IR(2J_1K'`BT1A"(@R=NSFOPT5$G= M5*LIZV3BDZSG-5)J)1`LN,1_3=AY_D.7YSM_PHZ#NR[.CA^;MVG=2=U?4V-? MM&C:)0@J>BWU)\OP@,Q@$<'OD_5_'X($''LBQ#TO8RO!IL%+^-P3(Z70B25% MMH27RX%4"9X-P5:J7);5?!%KO3)*!D'V[BPY'D86:B5P]$`CBA:@MA/19F9H M7L!2!!@H@R0**/;]0H23R1AF=FBDV1N/"N+(*=A>V,:!UZP+:%K\V0$8@Y=P MATMCI9">G5P**9HG[XJ_.04>3PWHTX5#,(>GZX>I__^!`EB4XA6M5Y6S8KVG9'QK2ZX,B^,3="BB#0#TYC! M&/P"Y<%+LK)]=N)KL9 M6J,=_]%GG!PHZZ?!G?Z]TQ7P.WTFKVNH,S:%<3T[VSM(B+9E[<,?(./%"V%5 MG633R)]O'OB%LV0+:?(6CBK27"UTM#54O.9_J4@B7D:8+#C7"FFV#NB6.Z:M M5U.Z'=;<1;I^`PZS+7392\DK#4/XTZ<[^(E/]W$:L,Z7V1,I4/AN@LB+UH$7 M$O!*!-E!L/T`KT-X\*'Z#0^L^C.(_%13,(4_!%Y^^DV3K+OV!N["[(-GK?A&PD#9CRHE59P).32 M@(YBQ?0A"?7\@#W()ND+FTC\@)G%Y,\H?HUR9PP7O2X0P`1&0-R-[43`0C!`\1\$F6+.I25@O_N3M,)L^4^ZJX53)9$77WB&EC=\% M!:%<`L2"WY/IM[R/I1["(U1!(@P&>],/4F8=9K_G)#[L^:/L1ZQ[[(C`N99% MB+Q#+OV><*]QFO9=7QRH"5XU>/5U%.(F"F+63!P\6A>!2#DC/<<[F M/J8QK@ZG'+SQ,-D5QSFCV7RS]+XI,>*AJ3?11$?<]KP;WO0M;\>X,8WW-W MI[,ZZ,`^G6-^];%+;2(\JM>?\K"!UPJ%NEE$=O._,OL&AH476Y_@SM,/>IR M("((;^/D)CZLLLTA+'CWU0N$^A4;2X96(50PD`>'LY6S\#'IOV1Y,1R1D:MD M;>.062^%Q)/)6"6CP*0^6]$(E`@JM5R3NZW^(_T)E_/,S`_<[7$?>U$W?G1OH;%DJ):-3)D]!`R+HI+KBC2VG_8BLO'6<.I_<^:ZK:>! MFLCK-7##_0VBZ.I\LV#;N"189WE)M5^!,IOZD\B?'PO&/47,(Q`DQ MN"F49P+;`=R"QZOK\22"0KJHU4>>A7Q^#5>IN4<.H`*_?PTIAV098G':UH42QTQ5Z+".69P@5G&_@*V?Z.3^356^B]NE4& M0CM,=6IN(Z@C/JW+^?6_?IO?WTP7$/1UM_Q:BJQ4/6?SOZA0T1$C.KPMW,<5 MVP4[\UK((EP88=*(2=F4T3\96%O5OAEVQGLX>)?7!S$_-N?J$>Z%<0KC$$%7,*D$Q'(4+[Q7R M99/`"Z4)<_7?HY`H%86*Q?1>2=FB+2P.UE*'QEK#+H%.VN,J[#HP@/AV'U9I MX+\)EZ?L>US[/>X;*Q.%.I6*!BWZV5%J:L^-QNJ._D67=;GVE5:C8%1&NGP? M"UN"_+!Y/%$J'6#=;]G@F#-1R\X&DA7J MNAO*3J'K@$]R]O>09L.0UNQIM6-_ED7WK?*L&,,V;83E>/]C7T-#!5#`-O\'L( M'Z)?K.[`D!;F\MY<`[.I39H@[3=:(X+O0)=Q)^LY_#6\2C3^0EY<[?!]G$'$ZJB*FSAET\.N\)GF MFS-)CR`S3-/(81_E3F$;KE9.XW>\@AT(Q7A M&Z`O M_MF@)I1[JF>1;'L:%5`I8%5.=S$U6:_H M9O'5FBQU#!=VM6>'#7YH"4FN""DUX6>*4A>7BT?;LF6K)I15E(SOC>]7GTSW MEC5?_`DKE-VTKR_=5`_CT>V3A64:[]HO&37 M<^Y+KNU_"T!F8S%^974M>7?C,6N5UBT[<7B;SN%$U5E5[?5SHZ*2`6<:[M[Y M"O[X8:`0ZHQ?R7_\.T2YF]BC=3S0CE"UE_?L;^QGQ8_8_ZV\E+*?_!]02P,$ M%`````@`PH!N1=]$S=YM'P``\N(!`!4`'`!C<&AI+3(P,30P.3,P7W!R92YX M;6Q55`D``[MN9E2[;F94=7@+``$$)0X```0Y`0``Y5U;D]LVEGZ>J9K_T)M] M\%/[$H\S<6JR4VQ=;%74DE92V^.G%)N$6AQ3A`*2?O7[[Z@I$'O2#Z.'75T$,KW_^ M^O_O4_?_OK/__K^OIJ`F`O=%$:7UU?!<,@!%>+-$C`OHVKGU[_^/[] MU?4U*1\&T?=?R/_NW1AWN^+OWOS[]OQPEN#C7L=1''B1MZN8AS\$F<_ M'T//38A:XD]>,4N0?UWOBUV3'UV_^_'Z_;O7S[%?$'05A*7/>.L@%JJ3QFJB<5-GA\N[CQX]OLM\62^/F_.10O-CZ MAS?Y+RNE`XXX!ZPQOW_)"48P!'.PNB)_WLU'M7!X0RJ]"7ST>Q]ZZ09$R?Y/ M)_('41(D+Z-H!7%UPN0/5YEROR0O6_#K#W&PV89@_[,U`JM??_"VZ^!ZWSCA MZ+^EVWYSU&B+0(R+93\?XQ^4/@N>$Q#YP-]_F&C0ILY$K)U<(?2*HKP*20^' MZ%41@E>G$.#.^3OO$\Y]G"#72_;MA.X]"']])5WM35T1BUTQ!M[K!_CXQ@=! MAA#Y2R;^]=MW.SO[;_RCW_//S\%#0+X:)1-W`RH",XL5!2QRZZ"RL"[R]DWB MOV;$OF):PJ[$FZV+<'O7F/70W]=>(;BI`>!>",C1X2J-L31P2RJZX:LKB'R` M\A'[(OCO%5GB9BFXEWYM&=YEU>@X_WAIG&<`!1#KX/?=A`=XN9RER%>4I5/P M_E(4.%@DGX@U#-T'"O3EWUL&>44Y.M1_OQ34N=@]+`YRPQ&>5I]_`R_,8;U: MSC+H&G@_WQA,\FM>`ZV$"6X3RPPCFG,-A!Z<2OI8*E.Y^7C97GY`L,4@XCR3L,F MI%K.2B9.E&4LT]Y>EH.O(`Q_B^!3M`!N#"/@C^(X!8C)!:N\E9PPE6=P<_$U M]-'Q&.*?T"R$5=(R/I@*,YBX^"H[%RQ??LIQ42QK-1LEI1E\7&S)G>LP2^_# MP!N&T*W&(NEE+,.?HB0#]\/Z^Y]O3I0;XQ^H#K[WII/^8+(8]/%?%M/QJ.\L M!_T;9^Q,>H/%Y\%@N;B+W-0/DF/8NVX,OLXG-(3BZXAWCD&LW/@^ZVMI?/W@ MNMO<*D"8Q/N?5,UC]^/?G3@&2*=ZV$DO(,_TN#1#;$"L9/T7(1>\#CSQ0W3 M:@A-LI)-E/!T;VDCY8QAR?,@7JS%<^`!+/5]""8@V2G*&IUX56PABJ]W2YLM MS6F:)FN`CK+&0I(X%6RAB*>SPBT:^MD`QW\D1SKB)5RDVVT8G`9M6*5,AY>I M74M[+LT[_2AZQ#I`](*99W3S4A'3D:?KU=+VBB)/5<9#M0;XBF;L[9(KK,4* MX&+^.->;*64F8@(3-\Q*JAY^AA#-4N2MW1C$T]4(XQH]!'@PS#7AC$B"BD8P M)AJ=1,H;YTS-$-P"E+S,0C>/@F!/<$LB(NP!C%O%6);D%#;.BZIV(2SEX-D+ M4Q($^02A_Q2$(7.BD:AJ/%]R`+1T_N7<&8D[%9F//7_4^G#964<-+^/`O0_" M(`E`C(T_.Y5`0HK8FR0#0?(B"'-)5S>>6WD@C//V"J++!2R,EXBUP=R,1M:#7-8JQ&WH:IN(E$HQ96B:K;1*,;!/,L\RBD>1*TCI*0=>XULW618.WAO;KC^G&FP?NA>8T1DMN]C MF=2\TY6TDII9JL<+557C9JW"[5SN6==J,:NH.%72N"G(\?T@EV;F!OXHZKG; M('%96_NLTE:QPE39N%%K#A(WB(`_<%%$+I\XGI=NTBR`AKV=P`M8,XY$1:LH MDP'"N$`O'H@]&*V"_;6NH\SY]@'<8-S7((J#1S"*/+@!8QBS',&&C5G%GZHM[1G:Q1A-4794V#I/7^0>-SRLHYMC1<$O!B3L.!H'S"5RH]C-PF]EJ?I![(4P3C$\ M,BOM6NWHE>!P1:TV3)A7FC!<\MSKH:9PTL"19QI5+V55:&S0@,T<-L%+X6I93.#T/L8PQ![`_]Q?.SH-S,K6ZA)53&2, M6S"7UH48=B_(0,=_#T&&?N0[&Y+SZL_LY\P[&>SC;&J:M[EWJ,?:N)7[,(B" M!(SQ,M.O7@,I:%W4CM%A&C34A:[1!#_C%O'E./H$8B#D]PT*Q;M`*!L+X\Z` ME47-,W\Z:;+&4]:?P)G?U5(('=^9)7N)''\F?'\3+$*21//BR8FYV^7/HD9 M\9A=5F>6T\42__]V,%DNIL/I;#!WEB/\6V>""]W.YH//N,+HRV`TP?\RN40B*E[`&&A6C[_LU?% MP(.,<3)=[01DCM_%,A;@75'*N%.+A[1P7U&0@#Y\8@5@*04M@)^FGG%[+9\0 MC.,9@BOF*<1B"0M0+RG4VBD6#0E1MP"YY)F7P?,61+%P_F*7MX!$CK+&[3`L M0!@>)64=:2D7TDR!L"^53@=6]#-N[OX$(JQ.2'8J_4T09>^E)L$CX#,BJF43 M14($6C^",<<`8>766(0^MN\09IO">]DIIR\$%6Q`7T9OX^9[/#,^!N2-=LKA M'68\GU/%!J+D=&\]PS8YY@[B(99_XB8IRL(J;IR*!H9=QV_4$1X54F6DD;6.!J M:MP.?'::-I>0G+:37/KQ*]FP_A.H;=QY)1+KB1/B^^52CR(\T^&?<`):U.*Z M+4BJNU6#7'3%C5LG[D7CKPNKI2QDI**F<7'?3">1JU4J8QT)%14[E#?E.%T2 MW[X'(SR'IG@:WI?L,XL$SQ@GK'$0N>ADE8).EGL$UL4IA M-@,+!LOVOFA=QVH5?N..\!^TV$%S`R+`WJE@E;:49(K:QJV<\XT6;L:#0P'K M:"@J9YS'R4NF,,0#0/"P2WWGO13.]6#-LW^%.?+^?]+<>9N`9+K"'8XW&ZO_ MF'4]HBW0S8L#!)4I*7U-DI:UQ@H2IG/PC3A'F`FU7:8F(."@M"#:8<\>TYB\_# M\?3KHOVSO)1/F7AHER*FIN3_("%/BF=;M5CWFY>[F%P_/D3K'>Q1/>:)B_@3 M4H.&=+UW`!+A;DNYC.:AHCE'I;\:>`*6`U=C3%%87FC;`[G)QZT4-1;6L9EP:FM9//QU.PQ?S M$)'C<^B19G;3YIE253/#]3LSGUD:.,:%*"A*\_,:UJC8,3Y;36#8%ILS!+9NX.^G M^=WLCMWI3!ON<_(-&^L8ZW(`=LA9/H6`G2Y3KD['>H1$CDR])R,8\U#QH?#: MTW2IMTB9.ZW>L1I_#8X8]7GINORZI!+]*U M1*K$NW4:]W%/Q:X^?2[-Z$G%CO%Y"HRZ4Q;:AVSY<,/9VUQV]XLZ0+%S+UIW M"H>A=G[K0L%V**^A3D3BF@!HX&SA@Q4[&_<,H`#Z5?MB3B!-VC*S+TB807EN M:01C6SO3>@YLNR_DZ&F\A([W1QH@4/?UA!H-=*+3U`&,'2B4[2D?\YX2@0>2 M>[8X]1@^_9P][72CM]0!K$.7PAAJ#X,(N^P*W!1>0V;V&S5N"A=`XRZK8^D] M`/SL9MH8NA'G3E"EG)D<2G3?RG6AJOK&[0/*:WJV@7:#U#J`G3_]&S.@#U8K MX"73U>#96V,G&2MQ='Y^PY-&M#,[VJ>OWA#>_Z("H,H41'X99[HY( ME<>(P\!`/`5Y\VS<5L?X/0/4UL,]=-F.!QMB!93+M?;_@G1)8`4AHPME03DJ M>>,L1HOI<#8?+`:39?8V7]-\)_Q&-60VX0ND*D=`'&2^5J%;TYC:5B09*VXGFJ` MD<#-OKB=CZ>+Q6`QG$]O)\[R;NZ,^Z.%LU@.YN=;.[MIK3;/%JOE)ULX]B^N MHVCR+T,QFGS!P]YT_HTB$JND1NN41G8_(S.U-.6DUH'DFD^:N< MM:R!47?&EQ%>V4X^C6[&`P=[OLN%"A^CTJ)F5Z,BC1X3_`2A_Q2$Y$75ZBTA M:1^D7AOZCC$P)!,[)^*:FD>61BQ6CCZ(T>G.X.+TOSB3'EY/3^>SNWGOLX/7 MUM.A^B%'\CM:!R))&2\3QL]['R?F4+.!"^T^Y%]E#21-6M`8L&C&D>Q^P@E4 MID4UYH,QR1D^<[#3OYP[DX73(Q%V!:,!LV6M]L^42L\\/0_:C3@O8G2.2X*WH>M0#JC@D5>\XK@&]G+8,W?J/Q:*E@WX/9LE8C9DJEQJ!)C^'8<>G7FLQW#*.')4`;(HO( M>.EE-9HN#=^BQ3*4ZXZ]CB:]Z>U@Z?Q[H"1L>&Q,<\3P*(CF&R@UMB?9-71? MHZD3`>14T;X]*>2$>IVFXU/VT!G-OSCCN\'MP%GFFNSP4W1D7\(IY.9I\&DQZ(Q5KCG)S MNF,!!5$4)0*!FTV0/0Q/JYHV@KL-*>;@LORJ)IGRR(O\>XW]U%'D")&T02*33Y M=72E@H!8FBA!&8%$0GDG0*JJ[BT^&9Y*V1ND\.C.2+&XNR%>,S:HP13 M%O6N#JK2J'$)%NE]#/Y(L2Z#QRSUU:Y+O:-X`NRRVO)@E042>OO,\AJG?R$# MY7163(V[8\JG5R+W?RHX&FJUU. M(\A,!4TIJ/.,GS0+I13!%&6-2Y.&'8X8Z^)G`F9:O4@X7NPJUK'$!\"XW&DS M%$"4I[B<`R]TXSA8!5X.L?^?-,Y6I(6[ZLR+0#6;L8[7^D"9EW@9X@DKBL$^ M58D;+C#H8"/C-,G5M8Y524B,>Y;U+L83P2!.@@V6EC7I50I91TY5284IDA5M MD;B()'$F:;@7V-$#KH"BAX:^"G(1E\*CV;B.PYD=\/PC0A#_J2]YU%X8:&K9F5THC. M9BDHT10UTZX@'=*0J!H3J@V:D61%J?T?\FX(K9Y54KNM'P3KI8@81TWC%E37 M:,T";N@V+$+#-*.E)0I19;^@Y\"!>=H=!!M9TM20ODNU?@NC!.!E%'AF`_"7<_W3PO"4K=NYU M;Q7-6L.H.B!;3_N-5_2K-"2O(F/W7T?GS;32U:SB2PX(0011>U8@=0XR MM5VC,@0I=II]A2#P\@21@IJZPR^RQ_@&^*K+):K4Z`YM'@ MF)JV[I1F#R;%N'ELWG40EZMG`_J2"`C<13-N':H:[WB-FW<#4>D82+MO)AX- M96JI6D9FD_+A@]E7!MP%(K^"1ANM@?5A[2?0W@QGA+(#U0>)&X2-;9/3H@:# MY$BCII-/T8,;!7_F'3'RCZ?`.#8HKJ-JS@2(G#-W'\!TE>WY3)\B\N1@C^`W MR_#[O,,/3RC3U32*7O+';(`&TYX?5M*O1GJ59.\R]:I!LWTNJ*>=G M$&YC&.U63LYF>Q/`!'CK"(;PX:4'QXE/.VW>RF>ZW!_D<&X]TI>)G4OM>'^D M`2(RYWUU)R&+;'XEZZ@38&!&B(\R>54V[0M[^N2F(HRROJA^!J_U63.F^5HB M*SIN`\Z MM_[J[4Y*.7OZD4)"S0:ZQU5=!%M_US93BN10J!Y99,TEU++=(XJ#B\)#^%PS MDV2%5[I[O'"Q,>.4/?.IS/Y@Z8S&C6_D"]O5L!@0RJ3&(IAO6(K=>>FJBHPW M_Q[NT%L4Q-2(7K6$B6^#"JSP1,G6/>?#:=Q=OGYRH(OFYM'+60@Q0V$S=AR/ M9Z.QVQ)@;?SL#-<0AB%\PO7.C(K(-J]AP),537&O9WQ-YI:!J*HB`YV[3^22 M(@K<,*8%(LJ_-^$R@"2F>X.L*&AJM MAQN&013$:^`_0.A3>WVE@&7XTE1L/=3M[O)L!-_`FC3_6D9"RFB M*&K&DIYVO:$=U[?!ES1XP0VD;.\^7GW?N$DKZDX%;()DNAJ[D7\7T^)YU1*& MW>JI:=(G^K8>*;A)@ZSOT@+8^U_9C>E1P_8/L9"[D;?6_>7I:A5XX"`QS44^*6(WRJ<: MM[[3121,4)J]N)JMVQ\P:M0U'ZNDW9`S]1>XO8K6%#0-6&L+:EF[T>=@0,?_ M'^KP'V.>'<]+R>U)+'`?8/B\_.KZSF.F[1R)*]G-B`PJ=&I^5GK[[40/^J*; M5=)N$ICZTY'_>.FU."7G2WX!:!RLSCV/*]>XCA6WE&"*#(#[+=ZZ6JYB.TMI M\@GQF0R:[00UC(UL8E;E(BNWS M7E9B%U9UFZ+0]B[AHV3<4[:FSN<*A%@?+D[(PF!&LI1J\L'%L.\XVRV"C\"O MY)X[][!Q_2_I.'=<7\IV,B(N5K[+^'"-[(TRK2BR_VS#L.)$'W;WI4T2YS=J-Y/LZ9>R MBV(8LBR_>:ECRTG*J:_3PY7FX3!8UH/&#']W/A@[RT%_YLR7WY9S9[)P>N3* M]&)*=FK/=7'E&M<1II,23%5L+IL_9RY>\2R1&\5N=NSF%FSN`*^^^A&'LA:7\(;Z")_DWV/9L_LPEJ#1+4Q/U@Q1_N+Q>;F6/IIY/B9)-DE MWIWHJQM("Y#*U;.3$$E,6G M@>FJA[`/??YF$Z=-+1M+''E435243W"G)EYY5=>[:1_Y&B1KY\:-OE,O?`MJ M:+5!"80/][Y%FKNKAA<5R?I>M,,939S)T>J/Q:/GM MS!E*U*R&24HDDOK+&V/H1D.7'+A(7L1A$MF:+=PR(9_+_2?G$7\K>\\#]I'[ M=/.R7`.2TAT;!K,D.[C2*)4^MS'Y&C.#/,`"+3Q89V.X)5U#XF MV%JW/B_FI!.FHVQT+P[J]#@BN[A]P/.U-V,>*SSTA64,L"+!?3&?HA/YAR>+ M2.T;),WE%51;$+T>?> M7DTF#L^22L-RD92'^9LFA]<2G"%$('B(%NE]'/B!BU[P#X[S,9>ULYJSD,GS MX&M]GAV0Z3U+GUD>D'*)O@$7D2H4'B4K6LB8+"2MWQ.1$N1#4VX^=):;#Q>X M:R(ER$]-N?FIL]S\=(%T#G*"X+\BX*P2ZCYF[28ZRU<1IM;304Q`LGO-*7H8 M[\\-KB!Z:P*4PPH29];'^7XQ#+N[\% MY]Z3)7,`XM/L![*U+.-4&@Q!$HK+1P(.#Q:K6^R?-*EW/7\BCO(E^^$+OJ_=AJJ,-6[T'2"20@QL$W)&80(3ZLE` M1D&--MP8]^.+973=6X]39R,*[038[A&#P"*K3A M])O;0:YI.4%GIAD4DI[(Y1;W&;4^3BT'IP]DDY#O?A;FT$N:=EZ MV)1#Z?MZ7?N]U:CS<6@]F>Z1=!KJQ=_:#'))2S,"D+/]RSB[!UP3Z'UW(G__ MX/?9;Z%(M:[E_1,IR=3T[L5RVOOM\W3<'\P7)%/=\IO@\YR56?.VE)W%/;ST M&SMILH:(9'ZB'KBE%M1HP&?S<#QG2\>@]97:05X)_-EENT`!!XGV\V2D^77) M@L2Y%$LX2Y&W=F-P\[)78'?M@DP+D3]X!L@+8G(8F[;QJJ3=+K"K".'65YNY M4-/5')#=22_!W9'(^HG(!7PL3N'2378<>;D&)(LN;6!OVE07^&Z.HV#Q>[F; M23WL#NYIR0CF2+/@_\QWG4ER9KJ\MI[!/T' M,%U-8"^-$[@!"*^MR-4$X`\ANH4(+-=NE(E"F[MKMJ#SGD8]5@H)\>MAU+YO M59#H(#[)CK!\@HMTNPT#,B/-W:?;_2/2`N(D&[&;.UFDVL_/7Q!J&H%SK4ZJ M";NIDT/)C'WELKH[<>,Y\$#P2'P]I3,LNWGM4RQ;M#;FV-.O24^RG*HM&/SI MUVY>\&"T[]X"6Q?5-L;,Q7S0[%P(3NM3ZP3BI=SN`L``00E#@`` M!#D!``#M/=MRV[B2SV>K]A^P>5C//LBR[$G.))O,*5J7B6IE42O2F9.G*9J$ M+-10I(87.3Y?OPWP3H`@)7M&R!;S$$MD=Z,;C0:Z&PWHXS^^[5QTP$%(?._3 MQ>CRZ@)AS_8=XCU^NB"A/_CII[?O!Z.+?_S\[__V\3\&`[3$_MBU@CA$`T1F MQ,7(B$F$,QKHW>7US0T:#"A\:&_QSD+0A!=^\'S/BW>?+K91M/\P'#X]/5U^ M>PC<2S]X'#I1,(R>]W@(0`.`P@&Q+Q*\"L+3#0._OKH:#?]YMS`8_13P0QP. M'BUKGR-LK/"!@:UPN+=L?"1VJHYV753T$&3O]Q;-T/Z^L$*\06RHB@@#W&$ M9WZPF^"-%;O0Q;'W1VRY9$.P4^Y](B%)O#"R/!M(8A?OL!=5"!;D8*C][:/E M>7YD13`$Z5?XOM\3;^.S+W_[2+G[D+&XQAO$%/:!ROGI34AV>Q>_29]M`[SY M],;>;\D@Z[/?]@&^!)XSD,!W`:V1;_IZ""@AL,PX6A0-9R2LP.:H<`,*B/A[ M'$0$AWG_OAF^CD@.WAPK$J`0CZ@JD&L]'"L0H&!715ELRSU6%D"Q8_=/'FZ4 MA@DR(/KA?CVOT&N;>1(^B1/\ML:V[]G$)8Q=?6."Y;IS+$@,]'7%S2;2=HB3ZOF3X+ M*O`E(X2`$LI)H1\28KW>6O4V7YK:\I?Y[6*J&<;4-$3:XF`D.AI=<3HJT%&" MWVM%K)6QOC3,]?W8G.O+A:XM9]IXOIB;7[E)L@U0-B>^K\^)96*(4D,9N7[^ MZVY'2]V<&BOMJP;#7&1#E?AHA2WUX18$[>62R,)8XMQ%*ZL`"3? MXH@`:R6[D0%)=')U4[>9E!!***$JJ5Y%;<8"4XXY7_XR78[G4^&*4P60F'+!SAQTZCFDL#FR&W.IS`JYL07I7-R[.7T"T M!90U@=(V4-9(OTP=X^Z-];NIJ?U3;'?EUS*K>RMP\B@F8JB]&MK5\`7"%'W] MM3E$JH/(XB+>9\BQ^TBHJTZTR1=M.9X:,WV]NE^//VO&U-!G7>*CCI@R@QIQ M&LR((J"*XSF:50&+IM2_\X9 M)*6$&"E4IM7GFHYQ^TN&T.#WER%D,^9[D>-?0N[5T3@G3J9+8SJA>1]],9]H MYG1BF/`_&\[ZC"94T_EO"4!WJ_7T,R#,OTP3'^]^J=U/YH!4F39?BZ8L#.?2 M^7F[J-PP*EJFRV71-DL25UK/W-8?<@9Z,VYWE)(%#&!7ODML@L/LK]`Y:H:6 MS;\"AR@GA#(*Z(?L4Z^V4\U]K!F?9PO]5^,4NQ8@RPQ8Y!JU&S!M!+%6>CMM M5[AH:TT+0QR%"[+A/=YNX++\#9<<;=B32Z@B2K;W=UO3V9HQ!_N"E-@9*X]7R!9H*,$O]=*FU86NF%,C=E:OUMJYOU:6TSFAF:8T[5(/AY[FU\0*?,E736!5JFM"1M MG&*7/UJ>@Q)2J$2KU]HI=?U=*_JEFN+W[\1YPUY%;2H2Y`%%&A*!R13$AV'" M1&&OGX8*2^\`POK!\]CW0A)&T/;&W.*9[[K^DRCVZHH@\P!'7"UE1A39&57J M!D9;C#89X=X;/,(;-/7Q_WS6%Y/IFKIL#1&6`$H66_&>1IG`?UI[/_QOE-#I M-=0064T7-*6WTF#],-?:TM!87&KH=(#S)MU:(;'!"YP0-X:Y:VH%'B6PPL'8W^U\SP"Z_*;F2PG)PC?N_)1X^XRU MQ[S.M$64-8GV.$!)HXBUV@^,%_DZS5MNS<`R!5]W\WOZ/;@6I26UR1,,4MO) M>6O.3IM!9%,O5T62GA(IT^EMZO0CP+(];"&DS)I$)T7JQWMZ2^JJJB:_1:2L M1EB9*\I/?LU^3:^NAHEO1[>R_L68F'[;8R_$DZFIS1H)IJY))K4)YI>O&/F.QI9W8-TT_`E6F4VR3-Z#/?$6BP([QL[UM4JEX^!,2((J"*ID>^N#6CF8=PE"K39$:W5V2;(ALWY+AULA52 M-K=>U94GV\#K5\WV.P/R"E98I`XD%(5T,B"9H?&9ZW*]:TZJMZTCM'3O.>`R M)%]P(@69?CE;K.BWTDZ1*:.S:M(4@K80:^S_ MXPCX."Q=9@E?*C==?B0[6AN'DKM6%[[-WDANU:3?!MG5F@/Z:#"Z'MR,+K^% MS@7RA)>*-MS+.3R6@?K=HK3Y][3YT;M.S7-WD[Z``]];OI2)TF6U1S-2NF*6 M,O"VJ6GAG;25UG@CLLLAY@DK#LZ--%%,08.I.X+DT=9=_9[9L7[-;9#W0Z\1[G,-]0,P-68D`F M44P9^27PXWT&2`#D`B6?(?(BOF,R,DX<,*XOZ,1XL2'N;[*J%"UE+='PIXMN ML%7Q9.*`JPG37O#\`H$2JXZR5P_)'58@*'X@42&EYASH\]#TC7B_=PD.PDPH MX2LE9$CJ&DM"T."8OIKYP<2/'Z)-[&87+^B>#@%T4%R_4,AW))92HS-3#O"> MQY3Z9@[+GO=(@(WD_%U]G!Z+U47;R47@'R+\+;IU(3HZ@YAFUO9Q#LS.<))!@HK8)T!%9J:,TL$GRQ MW!C?88ONW%*>&@99)]"S:RPQ[YQ7QN"4=^M:H#J)`3(`+S9`O$9DD@\Y2C*R M'K&^T6Q8*R%"N7W6/0\BP<_8W8=4V'2\=8!4:K"]L+Z.B]Q?&HH6W=(2 MBV;[0IFXQ7G-&MT<#G*WZ1 MB6[)Y;Z8X(U2]M"ZL5F/QCK#J[F0I[^=E08P:9EA)ES#2U45EL=D$B4)8)02 M9XU=,`IG9<'*88(+&`(K`'"'=P\X2`X)U:4["D6)68W;B7$LEGEGS)K^K6\% MSHZQ7Z3FFR&4TA]_K*^EPJRNS1<0Z*[;D(9&X6M.^:60*]3B:.L'Y%_8R81J M>GM.CO-N;6):`G!.OI@*:7(SC>-<=G+XQ&57!=O+>]W'(2@+[QGQ59L&[?8012__8Y$ M6>`#=D=R@3(8)<5B'G)5BLHC)9F6]/-U!UU<*RI6T?'7O"Y495K2SS<=='&C MJ%A%Q]_PNN"8/G=55.//#W"54!T@E1)-#Q[!84O._H%7HP,T^\Q)U@%0B8%6 M2XBE&8JT,JB4?16\4)9_4::X(H<80`EYZH:_P"&=J&)::0$>IN#E"!X M`;'NFMO3*T)>L3>$FR[Z)JV)F7MWP$NY4J$[_/ED*CHX+^[18.+`Y-$S@#AQ M"`Q]>&!N\=C?[2VJDKJ<+Z.AU+K;]H.;\H2>#/Y\*E[Z,`.FZ;A0E(\;75W1 M2J\Z[T4]_ZGX2OHA8RO<@@=!_U`OXF"YM-Y0BV[Q(_&HB>J;%2.;Z[@[PGQOXB9J#Y7@NQYZS(A'PBUV M'GW?*3BO/U62]3SSQDKK1F6OM/)8R<4YS1TF-6IC/P07VHYI(4`MN2@"4&HA M!K_/]VP8XNR&"GU3X;NAT/XX'#7TQX^^A%T;5&-;>P(2T+J-TC!L>J^D,0DS M)[^2:*O1G:%B2FL#4VILTOOPH"%6JK;P+6]FV03&W'/#L.P,?D:':TJ'U3X@ M(:[>?9.$V5^Q%="K*S*)ND*K+M#;HP1ZJ[Y`[XX2Z-UW(!!\#+"VB8IZRN/Q M%)L\=CL2I7>GP-1`=V2Q)]JQ[0)Y_G.,Z:+K)ELKM46W[&"8?O8TW7_A3SN^ M"JTCAC0+_UX_$EN`@U@ZTL=:J81=8H"S,IY&2S+6I2!J>%/U\`F',!W8-`.?J\A] MV7^;>ZO`?X2)IP@,&U\K(4O=(:\[H\F1*^T`GB@[_^]/`NOI]KG86VGR8CL@ M*MD!>1RO/X2^BT-P:VQ,IX#@@/E@7PRD2&:4WR.!_G_*:Z5%"<]6%%4JQ?/, M]"SP=\!A=B.;OEE;3W=9^DLD8E=,)4=G^8JV\MC+!B01W^;6"*KDLGQK.71/ MI79BK_Y4*:]=<.55AUNQ%*VL;/LIOL;KRUKAE1+SB)\RZ'(/V)'"_]7"5J^$ MH&?:&VZ+2%Z=E=G,6RUS67UV5O;*ESB46>2?GU?EC3=G4.:*_Z%Y>0@`N5GI8>W-;U'UT!%;2 M`\MX3^*;@ONZ;/Q[I8:F<$>%WS"3`IUQN-$(LSR*8`VC]V_L\@K\QO=*#JID ML-`(V6,%Q>7^SOUY*'"6'F!%3X[3![6,GS'^AI\FQ0X\9%<4C3%W@$]*5-K\+X61\ M52)PW<,G'=;NAJ=&8%JWTZ2^^#G96,I567VH!N>UD)H:5K+"+JT(<-P)":VP MM&LF`5!#(,&1%Y:I2F_^KA8KRD[ZG("H1@_4BSJY5-T88DY,IQ):&9&/:RCOH/8W^9+DU]_343H?'U]Z&1AD*][O!*!)E"%Y!NOM+:**'7]>I+I8::Z`>OQ8.L"Z22ZXZ`<:80=JMAXUFCXY"HX!^'R<^J MP`Q0````(`,*`;D7"YW;;JH,```8C"@`1`!@```````$```"D M@0````!C<&AI+3(P,30P.3,P+GAM;%54!0`#NVYF5'5X"P`!!"4.```$.0$` M`%!+`0(>`Q0````(`,*`;D72-"BB7@8``$U(```5`!@```````$```"D@?6# M``!C<&AI+3(P,30P.3,P7V-A;"YX;6Q55`4``[MN9E1U>`L``00E#@``!#D! M``!02P$"'@,4````"`#"@&Y%".=\KUL&``#V10``%0`8```````!````I(&B MB@``8W!H:2TR,#$T,#DS,%]D968N>&UL550%``.[;F94=7@+``$$)0X```0Y M`0``4$L!`AX#%`````@`PH!N109_3*@A1```00,#`!4`&````````0```*2! M3)$``&-P:&DM,C`Q-#`Y,S!?;&%B+GAM;%54!0`#NVYF5'5X"P`!!"4.```$ M.0$``%!+`0(>`Q0````(`,*`;D7?1,W>;1\``/+B`0`5`!@```````$```"D M@;S5``!C<&AI+3(P,30P.3,P7W!R92YX;6Q55`4``[MN9E1U>`L``00E#@`` M!#D!``!02P$"'@,4````"`#"@&Y%TSP#A:$2``#>Q0``$0`8```````!```` MI(%X]0``8W!H:2TR,#$T,#DS,"YX`L``00E#@``!#D! 8``!02P4&``````8`!@`:`@``9`@!```` ` end XML 53 R34.htm IDEA: XBRL DOCUMENT v2.4.0.8

Reconciliation of Total Interest incurred cost (Details) (USD $)
3 Months Ended 9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Reconcialition of Total interest details

Total interest cost incurred $ 330,995 $ 89,238 $ 952,836 $ 263,732

Interest cost capitalized $ 5,751 $ 457,782

X

- Definition

InterestCostCapitalized1

+ References

No definition available.

+ Details

Name: fil_Interestcostcapitalized1

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: fil_ReconcialitionOfTotalInterestDetailsAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

TotalInterestCostIncurred

+ References

No definition available.

+ Details

Name: fil_TotalInterestCostIncurred

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 54 R21.htm IDEA: XBRL DOCUMENT v2.4.0.8

Accounting Policies (Policies)
9 Months Ended

Sep. 30, 2014

Accounting Policies (Policies)

Organization and Nature of Operations
Organization and Nature of Operations – China Pharma Holdings, Inc., a Nevada corporation, owns 100% of Onny Investment Limited (“Onny”), a British Virgin Islands corporation, that in turn owns 100% of Hainan Helpson Medical & Biotechnology Co., Ltd (“Helpson”), a corporation organized under the laws of the People's Republic of China (the “PRC”). China Pharma Holdings, Inc. and its subsidiaries are referred to herein as the “Company”.

The Foreign Investment Industrial Catalogue (the “Catalogue”) jointly issued by the China’s Ministry of Commerce and the National Development and Reform Commission (as the latest version is the year 2012 version, effective January 30, 2012) classified various industries/businesses into three different categories: (i) encouraged for foreign investment; (ii) restricted to foreign investment; and (iii) prohibited from foreign investment. For any industry/business not covered by any of these three categories, they will be deemed industries/businesses permitted for foreign investment. A typical foreign investment ownership restriction in the pharmaceutical industry is that a foreign investment enterprise (the “FIE”) shall not have the whole or majority of its equity interests owned by a foreign owner if the FIE establishes more than 30 branch stores and distributes a variety of brands in those franchise stores, which is not the case of the Company’s business.

Helpson manufactures and markets generic and branded pharmaceutical products as well as biochemical products primarily to hospitals and private retailers located throughout the PRC. The Company believes Helpson’s business is not subject to any ownership restrictions prescribed under the Catalogue. Onny acquired 100% of the ownership in Helpson from Helpson’s three former shareholders on May 25, 2005 by entry into an Equity Transfer Agreement with such three parties on May 25, 2005. The transaction was approved by the Commercial Bureau of Hainan Province on June 12, 2005 and Helpson received the Certificate of Approval for Establishing of Enterprises with Foreign Investment in the PRC on the same day and its business license evidencing its WFOE (Wholly Foreign Owned Enterprise) status on June 21, 2005.

The Company has and continues to acquire well-accepted medical formulas to add to its diverse portfolio of Western and Chinese medicines.

Consolidation and Basis of Presentation
Consolidation and Basis of Presentation – The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and are expressed in United States dollars. The accompanying consolidated financial statements include the accounts and operations of the Company and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.

Helpson’s functional currency is the Chinese Renminbi. Helpson’s revenue and expenses are translated into United States dollars at the average exchange rate for the period. Assets and liabilities are translated at the exchange rate as of the end of the reporting period. Gains or losses from translating Helpson’s financial statements are included in accumulated other comprehensive income, which is a component of stockholders’ equity. Gains and losses arising from transactions denominated in a currency other than the functional currency of the entity that is a party to the transaction are included in the results of operations.

Reclassification
Reclassification - The Company has made certain reclassifications to the condensed consolidated statement of operations and cash flows for the three and nine months ended September 30, 2013 to conform to the presentation for the three and nine months ended September 30, 2014. These reclassifications had no effect on the condensed consolidated balance sheets, results of operations or cash flows as of or for the three and nine months ended September 30, 2013.

Condensed Financial Statements
Condensed Financial Statements – The accompanying unaudited condensed consolidated financial statements were prepared pursuant to the rules and regulations of the United States Securities and Exchange Commission (the “Commission”). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Management of the Company (“Management”) believes the following disclosures are adequate to make the information presented not misleading. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2013 filed with the Commission on March 20, 2014.



These unaudited condensed consolidated financial statements reflect all adjustments (consisting only of normal recurring adjustments) that, in the opinion of Management, are necessary to present fairly the consolidated financial position and results of operations of the Company for the periods presented. Operating results for the nine months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014.

Accounting Estimates
Accounting Estimates - The preparation of financial statements in conformity with U.S. GAAP requires Management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

Basic and Diluted (Loss) Earnings per Common Share
Basic and Diluted Loss per Common Share - Basic loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted loss per share is calculated to give effect to any potentially issuable dilutive common shares. There were no potentially dilutive common shares outstanding for all periods presented.

The following table is a presentation of the numerators and denominators used in the calculation of basic and diluted (loss) earnings per share:

For the Three Months

For the Nine Months

Ended September 30,

Ended September 30,

2014

2013

2014

2013

Net loss

$

(6,327,724

)

$

(2,302,031

)

$

(17,361,167

)

$

(9,578,163

)

Basic weighted-average common shares outstanding

43,579,557

43,579,557

43,579,557

43,579,557

Effect of dilutive securities:

Warrants

-

-

-

-

Options

-

-

-

-

Diluted weighted-average common shares outstanding

43,579,557

43,579,557

43,579,557

43,579,557

Basic loss per share

$

(0.15

)

$

(0.05

)

$

(0.40

)

$

(0.22

)

Diluted loss per share

$

(0.15

)

$

(0.05

)

$

(0.40

)

$

(0.22

)

X

- Details

Name: fil_AccountingPoliciesPoliciesAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for condensed financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 10

-Paragraph f

-Article 3

+ Details

Name: us-gaap_CondensedFinancialStatementsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.3A-02)

-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph k

-Article 1

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02, 03

-Article 3A

+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257

+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6003-108592

+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6143-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6132-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6061-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 55 R26.htm IDEA: XBRL DOCUMENT v2.4.0.8

INCOME TAXES (Tables)
9 Months Ended

Sep. 30, 2014

INCOME TAXES (Tables)

Current Taxes
Under current tax law in the PRC, the Company is and will be subject to the following enterprise income tax rates:

Enterprise Income

Year

Tax Rate

2014

15%

2015

15%

2016

15%

Thereafter

25%

Provision For Income Taxes
The provision for income taxes consisted of the following:

Three Months Ended September 30,

Nine Months Ended September 30,

2014

2013

2014

2013

Current

$

-

$

-

$

-

$

-

Deferred

19,215

(472,512

)

57,758

(1,129,506

)

Total income tax expense (benefit)

$

19,215

$

(472,512

)

$

57,758

$

(1,129,506

)

X

- Details

Name: fil_IncomeTaxesTablesAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabluar disclosure of Provision For Income Taxes.

+ References

No definition available.

+ Details

Name: fil_IncomeTaxesTableTextBlock

Namespace Prefix: fil_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabluar disclosure of Provision For Income Taxes.

+ References

No definition available.

+ Details

Name: fil_ProvisionForIncomeTaxesTableTextBlock

Namespace Prefix: fil_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 56 R41.htm IDEA: XBRL DOCUMENT v2.4.0.8

INCOME TAXES Undistributed Earnings And Income Tax Rates (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

INCOME TAXES Undistributed Earnings

Undistributed earnings of Helpson in millions 76.9

Investment in Helpson, a foreign subsidiary for the company in millions 23.3

Enterprise Income Tax Rates for the year 2014 15.00%

Enterprise Income Tax Rates for the year 2015 15.00%

Enterprise Income Tax Rates for the year 2016 15.00%

Enterprise Income Tax Rates for the year 2016 There after 25.00%

Net operating loss carryforwards for PRC tax purposes in millions 10.16

Net deferred tax asset, $ 6,450,846 $ 4,915,960

X

- Definition

EnterpriseIncomeTaxRatesForTheYear2014

+ References

No definition available.

+ Details

Name: fil_EnterpriseIncomeTaxRatesForTheYear2014

Namespace Prefix: fil_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

EnterpriseIncomeTaxRatesForTheYear2015

+ References

No definition available.

+ Details

Name: fil_EnterpriseIncomeTaxRatesForTheYear2015

Namespace Prefix: fil_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

EnterpriseIncomeTaxRatesForTheYear2015

+ References

No definition available.

+ Details

Name: fil_EnterpriseIncomeTaxRatesForTheYear2016

Namespace Prefix: fil_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition

Enterprise Income Tax Rates for the year 2016 There after

+ References

No definition available.

+ Details

Name: fil_EnterpriseIncomeTaxRatesForTheYear2016ThereAfter

Namespace Prefix: fil_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Details

Name: fil_INCOMETAXESUndistributedEarningsAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Investment in Helpson, a foreign subsidiary for the company in millions

+ References

No definition available.

+ Details

Name: fil_InvestmentInHelpsonAForeignSubsidiaryForTheCompanyInMillions

Namespace Prefix: fil_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: instant

X

- Definition

Net operating loss carryforwards for PRC tax purposes in millions

+ References

No definition available.

+ Details

Name: fil_NetOperatingLossCarryforwardsForPrcTaxPurposesInMillions

Namespace Prefix: fil_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: instant

X

- Definition

Undistributed earnings of Helpson in millions

+ References

No definition available.

+ Details

Name: fil_UndistributedEarningsOfHelpsonInMillions

Namespace Prefix: fil_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: instant

X

- Definition

Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

+ Details

Name: us-gaap_DeferredTaxAssetsLiabilitiesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 57 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)
9 Months Ended

Sep. 30, 2014

Sep. 30, 2013

Cash Flows from Operating Activities:

Net loss $ (17,361,167) $ (9,578,163)

Depreciation and amortization 1,014,221 1,039,716

Bad debt expense 15,280,588 7,910,583

Deferred income taxes 57,758 (1,129,506)

Inventory obsolescence reserve 3,311,926

Changes in assets and liabilities:

Trade accounts receivable (3,029,386) 1,077,182

Other receivables (342,012) (452,500)

Advances to suppliers (1,468,882) (642,850)

Inventory 7,671,072 4,138,431

Trade accounts payable 1,338,724 376,312

Accrued taxes payable (34,638) (2,486,073)

Other payables and accrued expenses (90,108) 42,847

Advances from customers (439,740) 90,159

Net Cash Provided by Operating Activities 2,596,430 3,698,064

Cash Flows from Investing Activities:

Advances for purchases of intangible assets (244,073) (496,634)

Purchases of property and equipment and construction in process (4,638,265) (9,267,088)

Net Cash Used in Investing Activities (4,882,338) (9,763,722)

Cash Flows from Financing Activities:

Proceeds from construction term loan 604,756 6,437,906

Net Cash Provided by Financing Activity 604,756 6,437,906

Effect of Exchange Rate Changes on Cash (42,950) 103,542

Net (Decrease) Increase in Cash and Cash Equivalents (1,724,102) 475,790

Cash and Cash Equivalents at Beginning of Period 5,993,139 4,029,708

Cash and Cash Equivalents at End of Period 4,269,037 4,505,498

Supplemental Cash Flow Information:

Cash paid for interest 943,251 324,117

Cash paid for income taxes 2,472,099

Supplemental Noncash Investing and Financing Activities:

Accounts payable for purchases of property and equipment 69,378 136,742

Accounts receivable collected with banker's acceptances 1,955,808 6,256,327

Inventory purchased with banker's acceptances 2,173,689 2,810,462

Advances for purchases of equipment paid with banker's acceptances 2,555,419

Advances for purchases of intangibles paid with banker's acceptances $ 715,445

X

- Definition

No authoritative reference available.

+ References

No definition available.

+ Details

Name: fil_AccountsPayableForPurchasesOfPropertyAndEquipment

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Accounts payable for purchases of property and equipment

+ References

No definition available.

+ Details

Name: fil_AccountsReceivableCollectedWithBankerSAcceptances

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Advances for purchases of equipment paid with banker's acceptances

+ References

No definition available.

+ Details

Name: fil_AdvancesForPurchasesOfEquipmentPaidWithBankerSAcceptances

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Advances for purchases of intangibles paid with banker's acceptances

+ References

No definition available.

+ Details

Name: fil_AdvancesForPurchasesOfIntangiblesPaidWithBankerSAcceptances

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of the current period expense charged against operations, the offset which is generally to the allowance for doubtful accounts for the purpose of reducing receivables, including notes receivable, to an amount that approximates their net realizable value (the amount expected to be collected).

+ References

No definition available.

+ Details

Name: fil_BadDebtExpense

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

No definition available.

+ Details

Name: fil_CashAndCashEquivalentsAtBeginningOfPeriod

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

No definition available.

+ Details

Name: fil_CashAndCashEquivalentsAtEndOfPeriod

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Advances for purchases of intangibles paid with banker's acceptances

+ References

No definition available.

+ Details

Name: fil_InventoryObsolescenceReserve

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Inventory purchased with banker's acceptances

+ References

No definition available.

+ Details

Name: fil_InventoryPurchasedWithBankerSAcceptances

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I.7)

-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section I

-Subsection 7

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Deferred Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6510177

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationDepletionAndAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

+ Details

Name: us-gaap_IncomeTaxesPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableTrade

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.

+ References

No definition available.

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedTaxesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the amount of prepayments by customers for goods or services to be provided at a later date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInCustomerAdvances

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in other amounts due to the reporting entity, which are not otherwise defined in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherReceivables

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of increase (decrease) of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name: us-gaap_IndefiniteLivedIntangibleAssetsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of cash paid for interest during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Cash received from principal payments made on loans related to operating activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name: us-gaap_ProceedsFromLoans

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 58 R10.htm IDEA: XBRL DOCUMENT v2.4.0.8

INTANGIBLE ASSETS
9 Months Ended

Sep. 30, 2014

INTANGIBLE ASSETS

INTANGIBLE ASSETS
NOTE 5 - INTANGIBLE ASSETS

Intangible assets represent the cost of medical formulas approved for production by the China Food and Drug Administration (“CFDA”) in China. During the nine months ended September 30, 2014, the Company did not obtain CFDA production approval for any medical formula and therefore there were no costs reclassified from advances to medical formulas.

Approved medical formulas are amortized from the date CFDA approval is obtained over their individually identifiable estimated useful life, which ranges from ten to thirteen years. It is at least reasonably possible that a change in the estimated useful lives of the medical formulas could occur in the near term due to changes in the demand for the drugs and medicines produced from these medical formulas. For the three and nine months ended September 30, 2014 and 2013, amortization expense relating to intangible assets was $96,382 and $131,585, $289,712 and $399,166, respectively. Medical formulas typically do not have a residual value at the end of their amortization period.



The Company evaluates each approved medical formula for impairment at the date of CFDA approval, when indications of impairment are present and at the date of each financial statement. The Company’s evaluation is based on an estimated undiscounted net cash flow model, considering currently available market data for the related drug and the Company’s estimated market share. If the carrying value of the medical formula exceeds the estimated future net cash flows, an impairment loss is recognized for the excess of the carrying value over the discounted estimated future net cash flows. As a result of the evaluation, the Company has determined that each medical formula continues to provide benefits to the Company and no impairment was recognized during the nine months ended September 30, 2014 or 2013.

As of September 30, 2014 and December 31, 2013, intangible assets consisted solely of CFDA approved medical formulas as follows:

September 30,

December 31,

2014

2013

Gross carrying amount

$

5,486,178

$

5,524,785

Accumulated amortization

(4,075,696

)

(3,812,992

)

Net carrying amount

$

1,410,482

$

1,711,793

X

- Details

Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all or part of the information related to intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16265-109275

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16373-109275

+ Details

Name: us-gaap_IntangibleAssetsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 59 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8

FAIR VALUE MEASUREMENTS (Tables)
9 Months Ended

Sep. 30, 2014

FAIR VALUE MEASUREMENTS (Tables)

Assets Fair Value
. The Company held the following assets recorded at fair value as of September 30, 2014 and December 31, 2013:

Fair Value Measurements at

Reporting Date Using

Description

September 30, 2014

Level 1

Level 2

Level 3

Banker's acceptance notes

$

116,047

$

-

$

116,047

$

-

Total

$

116,047

$

-

$

116,047

$

-

Fair Value Measurements at

Reporting Date Using

Description

December 31, 2013

Level 1

Level 2

Level 3

Banker's acceptance notes

$

336,003

$

-

$

336,003

$

-

Total

$

336,003

$

-

$

336,003

$

-

X

- Definition

Tabular disclosure of assets vair value.

+ References

No definition available.

+ Details

Name: fil_AssetsFairValuesTablETextBlock

Namespace Prefix: fil_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: fil_FairValueMeasurementsTablesAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 60 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.8 Html 10 212 1 false 0 0 false 4 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://www.chinapharmaholdings.com/20140930/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information true false R2.htm 000020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://www.chinapharmaholdings.com/20140930/role/idr_CONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) false false R3.htm 000030 - Statement - Balance Sheets Parentheticals Sheet http://www.chinapharmaholdings.com/20140930/role/idr_BalanceSheetsParentheticals Balance Sheets Parentheticals false false R4.htm 000040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED) Sheet http://www.chinapharmaholdings.com/20140930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOMEUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED) false false R5.htm 000050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Sheet http://www.chinapharmaholdings.com/20140930/role/idr_CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) false false R6.htm 000060 - Disclosure - BASIS OF PRESENTATION Sheet http://www.chinapharmaholdings.com/20140930/role/idr_DisclosureBASISOFPRESENTATION BASIS OF PRESENTATION false false R7.htm 000070 - Disclosure - LOSSES FROM NATURAL DISASTER Sheet http://www.chinapharmaholdings.com/20140930/role/idr_DisclosureLOSSESFROMNATURALDISASTER LOSSES FROM NATURAL DISASTER false false R8.htm 000080 - Disclosure - INVENTORY. Sheet http://www.chinapharmaholdings.com/20140930/role/idr_DisclosureINVENTORY INVENTORY. false false R9.htm 000090 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://www.chinapharmaholdings.com/20140930/role/idr_DisclosurePROPERTYANDEQUIPMENT PROPERTY AND EQUIPMENT false false R10.htm 000100 - Disclosure - INTANGIBLE ASSETS Sheet http://www.chinapharmaholdings.com/20140930/role/idr_DisclosureINTANGIBLEASSETS INTANGIBLE ASSETS false false R11.htm 000110 - Disclosure - ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS. Sheet http://www.chinapharmaholdings.com/20140930/role/idr_DisclosureADVANCESFORPURCHASESOFINTANGIBLEASSETS ADVANCES FOR PURCHASES OF INTANGIBLE ASSETS. false false R12.htm 000120 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://www.chinapharmaholdings.com/20140930/role/idr_DisclosureRELATEDPARTYTRANSACTIONS RELATED PARTY TRANSACTIONS false false R13.htm 000130 - Disclosure - NOTES PAYABLE Notes http://www.chinapharmaholdings.com/20140930/role/idr_DisclosureNOTESPAYABLE NOTES PAYABLE false false R14.htm 000140 - Disclosure - CONSTRUCTION LOAN FACILITY. Sheet http://www.chinapharmaholdings.com/20140930/role/idr_DisclosureCONSTRUCTIONLOANFACILITY CONSTRUCTION LOAN FACILITY. false false R15.htm 000150 - Disclosure - INCOME TAXES Sheet http://www.chinapharmaholdings.com/20140930/role/idr_DisclosureINCOMETAXES INCOME TAXES false false R16.htm 000160 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.chinapharmaholdings.com/20140930/role/idr_DisclosureFAIRVALUEMEASUREMENTS FAIR VALUE MEASUREMENTS false false R17.htm 000170 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.chinapharmaholdings.com/20140930/role/idr_DisclosureSTOCKHOLDERSEQUITY STOCKHOLDERS' EQUITY false false R18.htm 000180 - Disclosure - CONTINGENCIES Sheet http://www.chinapharmaholdings.com/20140930/role/idr_DisclosureCONTINGENCIES CONTINGENCIES false false R19.htm 000190 - Disclosure - CONCENTRATIONS Sheet http://www.chinapharmaholdings.com/20140930/role/idr_DisclosureCONCENTRATIONS CONCENTRATIONS false false R20.htm 000200 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.chinapharmaholdings.com/20140930/role/idr_DisclosureSUBSEQUENTEVENTS SUBSEQUENT EVENTS false false R21.htm 000210 - Disclosure - Accounting Policies (Policies) Sheet http://www.chinapharmaholdings.com/20140930/role/idr_DisclosureAccountingPoliciesPolicies Accounting Policies (Policies) false false R22.htm 000220 - Disclosure - BASIS OF PRESENTATION (Tables) Sheet http://www.chinapharmaholdings.com/20140930/role/idr_DisclosureBASISOFPRESENTATIONTables BASIS OF PRESENTATION (Tables) false false R23.htm 000230 - Disclosure - INVENTORY(Tables) Sheet http://www.chinapharmaholdings.com/20140930/role/idr_DisclosureINVENTORYTables INVENTORY(Tables) false false R24.htm 000240 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://www.chinapharmaholdings.com/20140930/role/idr_DisclosurePROPERTYANDEQUIPMENTTables PROPERTY AND EQUIPMENT (Tables) false false R25.htm 000250 - Disclosure - INTANGIBLE ASSETS (Tables) Sheet http://www.chinapharmaholdings.com/20140930/role/idr_DisclosureINTANGIBLEASSETSTables INTANGIBLE ASSETS (Tables) false false R26.htm 000260 - Disclosure - INCOME TAXES (Tables) Sheet http://www.chinapharmaholdings.com/20140930/role/idr_DisclosureINCOMETAXESTables INCOME TAXES (Tables) false false R27.htm 000270 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.chinapharmaholdings.com/20140930/role/idr_DisclosureFAIRVALUEMEASUREMENTSTables FAIR VALUE MEASUREMENTS (Tables) false false R28.htm 000280 - Statement - BASIS OF PRESENTATION (Details) Sheet http://www.chinapharmaholdings.com/20140930/role/idr_BASISOFPRESENTATIONDetails BASIS OF PRESENTATION (Details) false false R29.htm 000290 - Statement - BASIS OF PRESENTATION Basic and Diluted Earnings per Common Share (Details) Sheet http://www.chinapharmaholdings.com/20140930/role/idr_BASISOFPRESENTATIONBasicAndDilutedEarningsPerCommonShareDetails BASIS OF PRESENTATION Basic and Diluted Earnings per Common Share (Details) false false R30.htm 000300 - Statement - LOSSES FROM NATURAL DISASTER (DETAILS) Sheet http://www.chinapharmaholdings.com/20140930/role/idr_LOSSESFROMNATURALDISASTERDETAILS LOSSES FROM NATURAL DISASTER (DETAILS) false false R31.htm 000310 - Statement - Inventory consisted of the following (Details) Sheet http://www.chinapharmaholdings.com/20140930/role/idr_InventoryConsistedOfTheFollowingDetails Inventory consisted of the following (Details) false false R32.htm 000320 - Statement - Property and equipment consisted of the following (Details) Sheet http://www.chinapharmaholdings.com/20140930/role/idr_PropertyAndEquipmentConsistedOfTheFollowingDetails Property and equipment consisted of the following (Details) false false R33.htm 000330 - Statement - PROPERTY AND EQUIPMENT Assets Life (Details) Sheet http://www.chinapharmaholdings.com/20140930/role/idr_PROPERTYANDEQUIPMENTAssetsLifeDetails PROPERTY AND EQUIPMENT Assets Life (Details) false false R34.htm 000340 - Statement - Reconciliation of Total Interest incurred cost (Details) Sheet http://www.chinapharmaholdings.com/20140930/role/idr_ReconciliationOfTotalInterestIncurredCostDetails Reconciliation of Total Interest incurred cost (Details) false false R35.htm 000350 - Statement - ASSETS Depreciation (Details) Sheet http://www.chinapharmaholdings.com/20140930/role/idr_ASSETSDepreciationDetails ASSETS Depreciation (Details) false false R36.htm 000360 - Statement - INTANGIBLE ASSETS SFDA Approved Medical Formulas (Details) Sheet http://www.chinapharmaholdings.com/20140930/role/idr_INTANGIBLEASSETSSFDAApprovedMedicalFormulasDetails INTANGIBLE ASSETS SFDA Approved Medical Formulas (Details) false false R37.htm 000365 - Statement - Amortization expense (DETAILS) Sheet http://www.chinapharmaholdings.com/20140930/role/idr_AmortizationExpenseDETAILS Amortization expense (DETAILS) false false R38.htm 000370 - Statement - RELATED PARTY TRANSACTIONS Owings (Details) Sheet http://www.chinapharmaholdings.com/20140930/role/idr_RELATEDPARTYTRANSACTIONSOwingsDetails RELATED PARTY TRANSACTIONS Owings (Details) false false R39.htm 000380 - Statement - Revolving line of credit (Details) Sheet http://www.chinapharmaholdings.com/20140930/role/idr_RevolvingLineOfCreditDetails Revolving line of credit (Details) false false R40.htm 000390 - Statement - CONSTRUCTION LOAN FACILITY (Details) Sheet http://www.chinapharmaholdings.com/20140930/role/idr_CONSTRUCTIONLOANFACILITYDetails CONSTRUCTION LOAN FACILITY (Details) false false R41.htm 000400 - Statement - INCOME TAXES Undistributed Earnings And Income Tax Rates (Details) Sheet http://www.chinapharmaholdings.com/20140930/role/idr_INCOMETAXESUndistributedEarningsAndIncomeTaxRatesDetails INCOME TAXES Undistributed Earnings And Income Tax Rates (Details) false false R42.htm 000410 - Statement - INCOME TAXES Provision (Details) Sheet http://www.chinapharmaholdings.com/20140930/role/idr_INCOMETAXESProvisionDetails INCOME TAXES Provision (Details) false false R43.htm 000420 - Statement - FAIR VALUE MEASUREMENTS At Reporting Date Using (Details) Sheet http://www.chinapharmaholdings.com/20140930/role/idr_FAIRVALUEMEASUREMENTSAtReportingDateUsingDetails FAIR VALUE MEASUREMENTS At Reporting Date Using (Details) false false R44.htm 000430 - Statement - Preferred Common Stock And Warrants (Details) Sheet http://www.chinapharmaholdings.com/20140930/role/idr_PreferredCommonStockAndWarrantsDetails Preferred Common Stock And Warrants (Details) false false R45.htm 000440 - Statement - CONCENTRATIONS Sales And Purchases (Details) Sheet http://www.chinapharmaholdings.com/20140930/role/idr_CONCENTRATIONSSalesAndPurchasesDetails CONCENTRATIONS Sales And Purchases (Details) false false R46.htm 000450 - Statement - CONCENTRATIONS Accounts Receivable (Details) Sheet http://www.chinapharmaholdings.com/20140930/role/idr_CONCENTRATIONSAccountsReceivableDetails CONCENTRATIONS Accounts Receivable (Details) false false All Reports Book All Reports Process Flow-Through: 000020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) Process Flow-Through: 000030 - Statement - Balance Sheets Parentheticals Process Flow-Through: 000040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (UNAUDITED) Process Flow-Through: 000050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Process Flow-Through: 000280 - Statement - BASIS OF PRESENTATION (Details) Process Flow-Through: 000290 - Statement - BASIS OF PRESENTATION Basic and Diluted Earnings per Common Share (Details) Process Flow-Through: 000300 - Statement - LOSSES FROM NATURAL DISASTER (DETAILS) Process Flow-Through: 000310 - Statement - Inventory consisted of the following (Details) Process Flow-Through: 000320 - Statement - Property and equipment consisted of the following (Details) Process Flow-Through: 000330 - Statement - PROPERTY AND EQUIPMENT Assets Life (Details) Process Flow-Through: 000340 - Statement - Reconciliation of Total Interest incurred cost (Details) Process Flow-Through: 000350 - Statement - ASSETS Depreciation (Details) Process Flow-Through: 000360 - Statement - INTANGIBLE ASSETS SFDA Approved Medical Formulas (Details) Process Flow-Through: 000365 - Statement - Amortization expense (DETAILS) Process Flow-Through: 000370 - Statement - RELATED PARTY TRANSACTIONS Owings (Details) Process Flow-Through: 000380 - Statement - Revolving line of credit (Details) Process Flow-Through: 000390 - Statement - CONSTRUCTION LOAN FACILITY (Details) Process Flow-Through: 000400 - Statement - INCOME TAXES Undistributed Earnings And Income Tax Rates (Details) Process Flow-Through: 000410 - Statement - INCOME TAXES Provision (Details) Process Flow-Through: 000420 - Statement - FAIR VALUE MEASUREMENTS At Reporting Date Using (Details) Process Flow-Through: 000430 - Statement - Preferred Common Stock And Warrants (Details) Process Flow-Through: 000440 - Statement - CONCENTRATIONS Sales And Purchases (Details) Process Flow-Through: 000450 - Statement - CONCENTRATIONS Accounts Receivable (Details) cphi-20140930.xml cphi-20140930.xsd cphi-20140930_cal.xml cphi-20140930_def.xml cphi-20140930_lab.xml cphi-20140930_pre.xml true true XML 61 R38.htm IDEA: XBRL DOCUMENT v2.4.0.8

RELATED PARTY TRANSACTIONS Owings (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

RELATED PARTY TRANSACTIONS Owings

Adavances owing to board member $ 1,354,567 $ 1,354,567

Interest rate on advances from Member of BOD 1.00% 1.00%

Interest amount on advances $ 10,159 $ 10,159

X

- Definition

Adavance owing to boardmember

+ References

No definition available.

+ Details

Name: fil_AdavanceOwingToBoardmember

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Interest amount on advances

+ References

No definition available.

+ Details

Name: fil_InterestAmountOnAdvances

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Interest rate on advances from Member of BOD

+ References

No definition available.

+ Details

Name: fil_InterestRateOnAdvancesFromMemberOfBod

Namespace Prefix: fil_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Details

Name: fil_RelatedPartyTransactionMemberOwingsAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 62 R20.htm IDEA: XBRL DOCUMENT v2.4.0.8

SUBSEQUENT EVENTS
9 Months Ended

Sep. 30, 2014

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS
NOTE 15 – SUBSEQUENT EVENTS

In November 2014 the Company received the manufacturing certificate from the CFDA relating to the Company’s new manufacturing facility. This certificate enables the Company to commence production in the new facility in accordance with the new Good Manufacturing Practice standards promulgated by the CFDA effective March 1, 2011.

X

- Details

Name: fil_SubsequentEventsAbstract1

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

PROPERTY AND EQUIPMENT Assets Life (Details)	9 Months Ended
PROPERTY AND EQUIPMENT Assets Life (Details)	Sep. 30, 2014
PROPERTY AND EQUIPMENT Assets Life
Permit of land use life	40 to 70 years
Building life	20 to 35 years
Plant, machinery and equipment life	10 years
Motor vehicle life	5 to 10 years
Office equipment life	3 to 5 years

INCOME TAXES Provision (Details) (USD $)	3 Months Ended		9 Months Ended
INCOME TAXES Provision (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
INCOME TAXES Provision
Current tax provision.	$ 0	$ 0
Deferred tax provision.	19,215	(472,512)	57,758	(1,129,506)
Total income tax expense	$ 19,215	$ (472,512)	$ 57,758	$ (1,129,506)

Amortization expense (DETAILS) (USD $)	3 Months Ended		9 Months Ended
Amortization expense (DETAILS) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Amortization expense (DETAILS)
Amortization expense relating to intangible assets	$ 96,382	$ 131,585	$ 289,712	$ 399,166

FAIR VALUE MEASUREMENTS At Reporting Date Using (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
FAIR VALUE MEASUREMENTS At Reporting Date Using
Bankers acceptance notes	$ 116,047	$ 336,003
Total	116,047	336,003
Bankers acceptance notes Level 1	0	0
Total Level 1	0	0
Bankers acceptance notes Level 2	116,047	336,003
Total Level 2	116,047	336,003
Bankers acceptance notes Level 3	0	0
Total Level 3	$ 0	$ 0

BASIS OF PRESENTATION (Details)	Sep. 30, 2014
Organization and operations
Percentage of share owned by China Pharma Holdings Inc of Onny Investment Limited	100.00%
Percentage of share owned by China Pharma Holdings Inc of Helpson Medical & Biotechnology Co., Ltd.	100.00%
Percetage of acquired by Onny in Helpson	100.00%

Preferred Common Stock And Warrants (Details)	Sep. 30, 2014
Preferred Common Stock And Warrants
Common shares authorized	95,000,000
Preferred shares authorized	5,000,000
Number of common stock shares to purchase by warrants outstaning and exercisable	4,000,000
Shares of restricted stock granted and outstanding under the Plan	175,000

LOSSES FROM NATURAL DISASTER (DETAILS) (USD $)	Jul. 18, 2014
LOSSES FROM NATURAL DISASTER DETAILS
Losses comprised	$ 2,015,248
Inventory related costs	$ 260,345

Inventory consisted of the following (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Inventory consisted of the following:
Raw materials	$ 19,571,419	$ 28,259,707
Work in process		853,602
Finished goods	4,113,606	3,590,937
Inventory Gross	23,685,025	32,704,246
Inventory obsolescence reserve	(4,670,853)	(8,027,126)
Total Inventory	$ 19,014,172	$ 24,677,120

Property and equipment consisted of the following (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Property and equipment consisted of the following:
Permit of land use	$ 457,743	$ 460,964
Building	10,033,988	2,494,623
Plant, machinery and equipment	16,393,856	6,671,620
Motor vehicle	150,611	151,670
Office equipment	246,553	229,210
Construction in progress	12,537,905	25,497,600
Total Property and Equipment	39,820,656	35,505,687
Less: accumulated depreciation details	(5,951,165)	(5,264,350)
Property and Equipment, net	$ 33,869,491	$ 30,241,337

CONSTRUCTION LOAN FACILITY (Details) (USD $)	Jun. 21, 2013
Construction loan facility details
Construction loan amount in total	$ 80,000,000
Loan interest rate per annum	7.21%
Amount drawn under line of credit	$ 12,983,008

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current Assets:
Cash and cash equivalents	$ 4,269,037	$ 5,993,139
Banker's acceptances	116,047	336,003
Trade accounts receivable, less allowance for doubtful accounts of $27,912,179 and $13,301,622, respectively	30,642,878	45,147,602
Other receivables, less allowance for doubtful accounts of $70,004 and $43,064, respectively	516,095	175,739
Advances to suppliers	9,040,464	7,626,716
Inventory, less allowance for obsolescence of $4,670,853 and $8,027,126, respectively	19,014,172	24,677,120
Total Current Assets	63,598,693	83,956,319
Advances for purchases of intangible assets	41,653,862	41,701,505
Property and equipment, net of accumulated depreciation of $5,951,165 and $5,264,350, respectively	33,869,491	30,241,337
Intangible assets, net of accumulated amortization of $4,075,696 and $3,812,992, respectively	1,410,482	1,711,793
TOTAL ASSETS	140,532,528	157,610,954
Current Liabilities:
Trade accounts payable	3,131,988	1,877,437
Accrued expenses	214,740	323,651
Other payables	1,293,273	1,312,361
Advances from customers	1,773,478	2,228,238
Other payables - related parties	1,354,567	1,354,567
Current portion of construction loan facility.	1,625,118
Short-term notes payable	4,875,353	4,909,662
Total Current Liabilities	14,268,517	12,005,916
Non-current Liabilities:
Construction loan facility	11,375,825	12,484,183
Long-term deferred tax liability	232,866	176,414
Total Liabilities	25,877,208	24,666,513
Stockholders' Equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued or outstanding		0
Common stock, $0.001 par value; 95,000,000 shares authorized; 43,579,557 shares and 43,579,557 shares outstanding, respectively	43,580	43,580
Additional paid-in capital	23,590,204	23,590,204
Retained earnings	71,535,109	88,896,276
Accumulated other comprehensive income	19,486,427	20,414,381
Total Stockholders' Equity	114,655,320	132,944,441
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 140,532,528	$ 157,610,954

CONCENTRATIONS Sales And Purchases (Details)	9 Months Ended
CONCENTRATIONS Sales And Purchases (Details)	Sep. 30, 2014	Sep. 30, 2013
CONCENTRATIONS Sales And Purchases
Percentage of no customer accounted for more than sales	16.70%	0.00%
Percentage of purchases from two supplier of raw materials	31.80%	20.60%
Percentage of one customer accounted for more than sales		10.00%

ASSETS Depreciation (Details) (USD $)	3 Months Ended		9 Months Ended
ASSETS Depreciation (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Assets Depreciation
Depreciation Expense property and equipment	$ 321,020	$ 210,182	$ 724,509	$ 640,550

INTANGIBLE ASSETS SFDA Approved Medical Formulas (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
INTANGIBLE ASSETS SFDA Approved Medical Formulas
Gross carrying amount	$ 5,486,178	$ 5,524,785
Accumulated amortization Intangible assets SFDA Approved Medical Formulas	(4,075,696)	(3,812,992)
Net carrying amount	$ 1,410,482	$ 1,711,793

Balance Sheets Parentheticals (USD $)	Sep. 30, 2014	Dec. 31, 2013
BALANCE SHEETS PARENTHETICALS
Allowance for doubtful accounts ,Trade accounts receivables	$ 27,912,179	$ 13,301,622
Allowance for doubtful accounts , Other receivables	70,004	43,064
Allowance for obsolescence, Inventories	4,670,853	8,027,126
Accumulated depreciation of Property and equipment	5,951,165	5,264,350
accumulated amortization of Intangible assets	$ 4,075,696	$ 3,812,992
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	5,000,000	5,000,000
Preferred Stock, shares issued		0
Preferred Stock, shares outstanding		0
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	95,000,000	95,000,000
Common Stock, shares issued	43,579,557	43,579,557
Common Stock, shares outstanding	43,579,557	43,579,557

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2014	Nov. 10, 2014
Document and Entity Information
Entity Registrant Name	CHINA PHARMA HOLDINGS, INC.
Document Type	10-Q
Document Period End Date	Sep. 30, 2014
Amendment Flag	false
Entity Central Index Key	0001106644
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		43,579,557
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q3

INCOME TAXES Undistributed Earnings And Income Tax Rates (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
INCOME TAXES Undistributed Earnings
Undistributed earnings of Helpson in millions	76.9
Investment in Helpson, a foreign subsidiary for the company in millions	23.3
Enterprise Income Tax Rates for the year 2014	15.00%
Enterprise Income Tax Rates for the year 2015	15.00%
Enterprise Income Tax Rates for the year 2016	15.00%
Enterprise Income Tax Rates for the year 2016 There after	25.00%
Net operating loss carryforwards for PRC tax purposes in millions	10.16
Net deferred tax asset,	$ 6,450,846	$ 4,915,960

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash Flows from Operating Activities:
Net loss	$ (17,361,167)	$ (9,578,163)
Depreciation and amortization	1,014,221	1,039,716
Bad debt expense	15,280,588	7,910,583
Deferred income taxes	57,758	(1,129,506)
Inventory obsolescence reserve		3,311,926
Changes in assets and liabilities:
Trade accounts receivable	(3,029,386)	1,077,182
Other receivables	(342,012)	(452,500)
Advances to suppliers	(1,468,882)	(642,850)
Inventory	7,671,072	4,138,431
Trade accounts payable	1,338,724	376,312
Accrued taxes payable	(34,638)	(2,486,073)
Other payables and accrued expenses	(90,108)	42,847
Advances from customers	(439,740)	90,159
Net Cash Provided by Operating Activities	2,596,430	3,698,064
Cash Flows from Investing Activities:
Advances for purchases of intangible assets	(244,073)	(496,634)
Purchases of property and equipment and construction in process	(4,638,265)	(9,267,088)
Net Cash Used in Investing Activities	(4,882,338)	(9,763,722)
Cash Flows from Financing Activities:
Proceeds from construction term loan	604,756	6,437,906
Net Cash Provided by Financing Activity	604,756	6,437,906
Effect of Exchange Rate Changes on Cash	(42,950)	103,542
Net (Decrease) Increase in Cash and Cash Equivalents	(1,724,102)	475,790
Cash and Cash Equivalents at Beginning of Period	5,993,139	4,029,708
Cash and Cash Equivalents at End of Period	4,269,037	4,505,498
Supplemental Cash Flow Information:
Cash paid for interest	943,251	324,117
Cash paid for income taxes		2,472,099
Supplemental Noncash Investing and Financing Activities:
Accounts payable for purchases of property and equipment	69,378	136,742
Accounts receivable collected with banker's acceptances	1,955,808	6,256,327
Inventory purchased with banker's acceptances	2,173,689	2,810,462
Advances for purchases of equipment paid with banker's acceptances		2,555,419
Advances for purchases of intangibles paid with banker's acceptances		$ 715,445

RELATED PARTY TRANSACTIONS Owings (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
RELATED PARTY TRANSACTIONS Owings
Adavances owing to board member	$ 1,354,567	$ 1,354,567
Interest rate on advances from Member of BOD	1.00%	1.00%
Interest amount on advances	$ 10,159	$ 10,159